@article{adangLeukodystrophies2022,
  title = {Leukodystrophies},
  author = {Adang, Laura},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1194--1216},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001130},
  url = {https://journals.lww.com/10.1212/CON.0000000000001130},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the most common leukodystrophies and is focused on diagnosis, clinical features, and emerging therapeutic options.                                         RECENT FINDINGS               In the past decade, the recognition of leukodystrophies has exponentially increased, and now this class includes more than 30 distinct disorders. Classically recognized as progressive and fatal disorders affecting young children, it is now understood that leukodystrophies are associated with an increasing spectrum of neurologic trajectories and can affect all ages. Next-generation sequencing and newborn screening allow the opportunity for the recognition of presymptomatic and atypical cases. These new testing opportunities, in combination with growing numbers of natural history studies and clinical consensus guidelines, have helped improve diagnosis and clinical care. Additionally, a more granular understanding of disease outcomes informs clinical trial design and has led to several recent therapeutic advances. This review summarizes the current understanding of the clinical manifestations of disease and treatment options for the most common leukodystrophies.                                         SUMMARY               As early testing becomes more readily available through next-generation sequencing and newborn screening, neurologists will better understand the true incidence of the leukodystrophies and be able to diagnose children within the therapeutic window. As targeted therapies are developed, it becomes increasingly imperative that this broad spectrum of disorders is recognized and diagnosed. This work summarizes key advances in the leukodystrophy field.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{ailaniAcuteMigraineTreatment2021,
  title = {Acute {{Migraine Treatment}}},
  author = {Ailani, Jessica},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {597--612},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000956},
  url = {https://journals.lww.com/10.1212/CON.0000000000000956},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Migraine is a disabling disease of attacks of moderate to severe pain with associated symptoms. Every person with migraine requires treatment for acute attacks. Treatments can range from behavioral management and nonspecific medications to migraine-specific medications and neuromodulation. For many with migraine, having a combination of tools allows for effective treatment of all types of attacks.                                         RECENT FINDINGS               Over the past several years, four neuromodulation devices have been cleared by the US Food and Drug Administration (FDA) for treatment of acute migraine, and three medications with novel mechanisms of action have been FDA approved. They add to the arsenal available to people with migraine and focus on migraine-specific pathways to allow for precise care with fewer side effects.                                         SUMMARY               This article discusses acute migraine therapy, focusing on best-level evidence.},
  langid = {english},
  keywords = {Current}
}

@article{aksamitMeningitis2021,
  title = {Meningitis},
  author = {Aksamit, Allen J. and Berkowitz, Aaron L.},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {836--854},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001016},
  url = {https://journals.lww.com/10.1212/CON.0000000000001016},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the diagnosis and treatment of infectious meningitis, including updates on newer molecular diagnostic techniques for microbiological diagnosis.                                         RECENT FINDINGS               New polymerase chain reaction (PCR)-based molecular diagnostic techniques have improved the timeliness of microbiological diagnosis in meningitis, but clinicians must be aware of the limitations of such tests. Next-generation sequencing can now be applied to CSF, allowing for diagnosis of infections not identifiable by conventional means.                                         SUMMARY               Infectious meningitis can be caused by a broad range of organisms. The clinician must be aware of the test characteristics of new molecular techniques for microbiological diagnosis as well as traditional techniques to tailor antimicrobial therapy appropriately in patients with meningitis.},
  langid = {english},
  keywords = {Current}
}

@article{allenChronicDemyelinatingPolyneuropathies2017,
  title = {Chronic {{Demyelinating Polyneuropathies}}},
  author = {Allen, Jeffrey A.},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1310--1331},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000517},
  url = {https://journals.lww.com/00132979-201710000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article reviews the chronic demyelinating neuropathies, with a focus on the diagnosis and treatment of immune-mediated neuropathies and the features that can help differentiate immune-mediated neuropathies from other chronic demyelinating peripheral nerve conditions.                                         Recent Findings:               Advances in clinical phenotyping and outcomes assessment have enabled neurologists to improve disease recognition, treatment, and disease monitoring. Our understanding of the immunopathogenesis of demyelinating neuropathies is evolving. Identification of new antibodies and recognition that node of Ranvier dysfunction may be an early pathogenic feature may herald further diagnostic and treatment advancements.                                         Summary:               The chronic demyelinating polyneuropathies are heterogeneous. The clinical and diagnostic features are sometimes overlapping, and the specific disorders are variable in pathogenesis, treatment, and prognosis. This heterogeneity underscores the importance of achieving diagnostic accuracy and implementing disease-specific treatment approaches.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/9Y7I2VIW/allen2017.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/NA7V4FLT/Allen (2017) Chronic Demyelinating Polyneuropathies.pdf}
}

@article{amezcuaProgressiveMultipleSclerosis2022,
  title = {Progressive {{Multiple Sclerosis}}},
  author = {Amezcua, Lilyana},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1083--1103},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001157},
  url = {https://journals.lww.com/10.1212/CON.0000000000001157},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW                                This article provides an update on progressive forms of multiple sclerosis (MS) commonly referred to as                 primary progressive MS                 and                 secondary progressive MS                 . It discusses the importance of diagnosing and detecting progression early, the similarities between progressive forms, challenges in detecting progression, factors that could augment progression, and the importance of disease-modifying therapies in patients with evidence of active progressive MS. It also discusses the overall care of progressive MS.                                                        RECENT FINDINGS               The pathogenesis of primary progressive MS and secondary progressive MS is overlapping, and in both presentations, patients with relapses or focal MRI activity are classified as having active, progressive MS. All currently approved disease-modifying therapies are indicated for active secondary progressive MS. The therapeutic opportunity of anti-inflammatory drugs for the treatment of progressive MS is enhanced in those who are younger and have a shorter disease duration. Vascular comorbidities may contribute to progression in MS.                                         SUMMARY               Several challenges remain in the diagnosis, follow-up, and treatment of progressive MS. Early identification of active progressive MS is needed to maximize treatment benefit. The advantages of optimal comorbidity management (eg, hypertension, hyperlipidemia) in delaying progression are uncertain. Clinical care guidelines for advanced, severe MS are lacking.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{amlie-lefondEvaluationAcuteManagement2018,
  title = {Evaluation and {{Acute Management}} of {{Ischemic Stroke}} in {{Infants}} and {{Children}}},
  author = {{Amlie-Lefond}, Catherine},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {150--170},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000559},
  url = {https://journals.lww.com/00132979-201802000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of stroke in neonates, infants, and children.                                         RECENT FINDINGS               Arterial ischemic stroke and cerebral venous sinus thrombosis are increasingly recognized in childhood as important causes of lifelong morbidity and mortality. Diagnosis of arterial ischemic stroke is frequently delayed, as acute neurologic deficits can be challenging to detect in the young child, and stroke is often not considered in the differential diagnosis. Neurologic sequelae following stroke are common, and strategies to minimize stroke size and optimize recovery are being developed. Recurrent arterial ischemic stroke is not uncommon, particularly in children with cerebral arteriopathy. Cerebral venous sinus thrombosis causes obstruction of venous outflow leading to venous infarcts. Complications include hemorrhagic conversion of infarcts and increased intracranial pressure. Without treatment, thrombus extension with increased symptoms is common. Robust guidelines of care that exist for adults do not exist for children, particularly for children with arterial ischemic stroke.                                         SUMMARY               The approach to stroke in infants and children can be informed by clinical experience in pediatric stroke and cerebral venous sinus thrombosis, the extensive literature on pediatric thrombosis, and extrapolation from data from adult patients.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/BXBMPKLA/Amlie-Lefond (2018) Evaluation and Acute Management of Ischemic Stroke in Infants and Children.pdf}
}

@article{anandNeurologicInfectionsPatients2021,
  title = {Neurologic {{Infections}} in {{Patients}} on {{Immunomodulatory}} and {{Immunosuppressive Therapies}}},
  author = {Anand, Pria},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {1066--1104},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000985},
  url = {https://journals.lww.com/10.1212/CON.0000000000000985},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Both broadly immunosuppressive medications and selective immunomodulatory agents that act on particular components of the immune system are increasingly used in the treatment of neurologic and non-neurologic diseases. These therapies predispose patients to particular infections, some of which may affect the nervous system. Therefore, familiarity with the clinical and radiologic features of neurologic infections associated with specific immunomodulatory therapies is of importance for the practicing neurologist. This article reviews these neuroinfectious conditions, as well as other neurologic complications unique to transplant recipients and other patients who are immunocompromised.                                         RECENT FINDINGS               Diagnosis of infectious pathogens in patients who are immunocompromised may be particularly challenging because a decreased immune response can lead to atypical imaging or laboratory findings. Next-generation sequencing and other novel diagnostic modalities may improve the rate of early identification of neurologic infections in patients who are immunocompromised and ultimately ameliorate outcomes in this vulnerable population.                                         SUMMARY               A broad range of bacterial, viral, fungal, and parasitic infections of the nervous system can complicate solid organ and hematopoietic cell transplantation as well as other forms of immunocompromise. In addition to neurologic infections, such patients are at risk of neurotoxic and neuroinflammatory complications related to immunomodulatory and immunosuppressive therapies. Early recognition of infectious and noninfectious complications of immunocompromise is essential to guide appropriate treatment, which can include antimicrobial therapy and, in some cases, withdrawal of the predisposing medication with a transition to an alternative regimen.},
  langid = {english},
  keywords = {Current}
}

@article{andersonTreatmentLanguageMotor2011,
  title = {Treatment of {{Language}}, {{Motor Speech Impairments}}, and {{Dysphagia}}:},
  shorttitle = {Treatment of {{Language}}, {{Motor Speech Impairments}}, and {{Dysphagia}}},
  author = {Anderson, Maria and Anzalone, Jessie and Holland, Lauren and Tracey, Elvira},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {471--493},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399068.77191.12},
  url = {http://journals.lww.com/00132979-201106000-00011},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/9VXX5EQZ/anderson2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/ANRPAQAR/Anderson et al (2011) Treatment of Language, Motor Speech Impairments, and Dysphagia.pdf}
}

@article{armstrongLewyBodyDementias2019,
  title = {Lewy {{Body Dementias}}},
  author = {Armstrong, Melissa J.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {128--146},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000685},
  url = {https://journals.lww.com/00132979-201902000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes current diagnostic criteria relating to the diagnosis of Lewy body dementia, highlights diagnostic controversies, and reviews treatment approaches.                                         RECENT FINDINGS               Clinical diagnostic criteria for both Parkinson disease and dementia with Lewy bodies have been recently updated. These criteria result in overlap between individuals diagnosed with Parkinson disease and those with dementia with Lewy bodies. Although clinical features and symptomatic treatment overlap, differences remain in epidemiology and expected progression. The high prevalence of cognitive impairment in Parkinson disease supports regular screening for cognitive changes and counseling patients and families regarding what to expect. Treatment for Lewy body dementia involves avoiding medications that may cause or exacerbate symptoms; prescribing pharmacologic agents to address bothersome cognitive, behavioral, movement, and other nonmotor symptoms; recommending physical exercise and therapy; and providing education, counseling, caregiver support, and palliative care.                                         SUMMARY               Lewy body dementia includes both dementia with Lewy bodies and Parkinson disease dementia, overlapping clinicopathologic entities with differences relating to diagnosis and expected progression. Treatment is symptomatic and thus largely overlapping for the two conditions.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/EMDXDJ36/Armstrong (2019) Lewy Body Dementias.pdf}
}

@article{baldwinHerpesvirusInfectionsNervous2018,
  title = {Herpesvirus {{Infections}} of the {{Nervous System}}},
  author = {Baldwin, Kelly J. and Cummings, Christopher L.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1349--1369},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000661},
  url = {https://journals.lww.com/00132979-201810000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the spectrum of neurologic disease associated with human herpesvirus infections.                                         RECENT FINDINGS               As more patients are becoming therapeutically immunosuppressed, human herpesvirus infections are increasingly common. Historically, infections with human herpesviruses were described as temporal lobe encephalitis caused by herpes simplex virus type 1 or type 2. More recently, however, additional pathogens, such as varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 have been identified to cause serious neurologic infections. As literature emerges, clinical presentations of herpesvirus infections have taken on many new forms, becoming heterogeneous and involving nearly every location along the neuraxis. Advanced diagnostic methods are now available for each specific pathogen in the herpesvirus family. As data emerge on viral resistance to conventional therapies, newer antiviral medications must be considered.                                         SUMMARY               Infections from the herpesvirus family can have devastating neurologic outcomes without prompt and appropriate treatment. Clinical recognition of symptoms and appropriate advanced testing are necessary to correctly identify the infectious etiology. Knowledge of secondary neurologic complications of disease is equally important to prevent additional morbidity and mortality. This article discusses infections of the central and peripheral nervous systems caused by herpes simplex virus type 1 and type 2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6. The pathophysiology, epidemiology, clinical presentations of disease, diagnostic investigations, imaging characteristics, and treatment for each infectious etiology are discussed in detail.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/6W6TG7P3/Baldwin_Cummings (2018) Herpesvirus Infections of the Nervous System.pdf}
}

@article{balls-berryHealthDisparitiesDementia2022,
  title = {Health {{Disparities}} in {{Dementia}}},
  author = {{Balls-Berry}, Joyce (Joy) E. and Babulal, Ganesh M.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {872--884},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001088},
  url = {https://journals.lww.com/10.1212/CON.0000000000001088},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Causes of health disparities in Alzheimer disease and related dementias (ADRD) in the United States are multifactorial. This article contextualizes health disparities as they relate to the neurodegenerative processes of ADRD.                                         RECENT FINDINGS               Older adults' life expectancy has increased such that a 65-year-old is expected to live 19 or more years and an 85-year-old can expect to live, on average, 6 to 7 years longer. Individuals of certain ethnoracial groups (Black, Hispanic/Latino, American Indian/Alaska Native, and Native Hawaiian/Pacific Islander) may be at a higher risk of incident ADRD compared to non-Hispanic/Latino White people. These differences in a higher risk of ADRD across ethnoracial groups persist despite no statistically significant differences in the rate of cognitive decline over time. The intersectionality of social determinants of health, experiences with discrimination and oppression, and access to care are related to the issue of justice and the risk for and expression of ADRD. The theoretical frameworks of various health disparities provide organized approaches to tracking the progression of health disparities for diverse patients.                                         SUMMARY               ADRD health disparities are complex. Neurologists and their care teams must consider the main reasons for clinical ADRD evaluations of members of ethnoracial groups and the factors that may impact patient adherence and compliance with diagnostic and management recommendations.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/A3RXPMB2/Balls-Berry_Babulal (2022) Health Disparities in Dementia.pdf}
}

@article{barrettSpatialNeglectAnosognosia2021,
  title = {Spatial {{Neglect}} and {{Anosognosia After Right Brain Stroke}}},
  author = {Barrett, A. M.},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1624--1645},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001076},
  url = {https://journals.lww.com/10.1212/CON.0000000000001076},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Up to 80\% of survivors of right brain stroke leave acute care without being diagnosed with a major invisible disability. Studies indicate that a generic cognitive neurologic evaluation does not reliably detect spatial neglect, nor does it identify unawareness of deficit after right brain stroke; this article reviews the symptoms, clinical presentation, and management of these two cognitive disorders occurring after right brain stroke.                                         RECENT FINDINGS               Stroke and occupational therapy practice guidelines stress a quality standard for spatial neglect assessment and treatment to reduce adverse outcomes for patients, their families, and society. Neurologists may attribute poor outcomes associated with spatial neglect to stroke severity. However, people with spatial neglect are half as likely to return to home and community, have one-third the community mobility, and require 3 times as much caregiver supervision compared with similar stroke survivors. Multiple randomized trials support a feasible first-line rehabilitation approach for spatial neglect: prism adaptation therapy; more than 20 studies reported that this treatment improves daily life independence. Evidence-based treatment of anosognosia is not as developed; however, treatment for this problem is also available.                                         SUMMARY               This article guides neurologists' assessment of right brain cognitive disorders and describes how to efficiently assemble and direct a treatment team to address spatial neglect and unawareness of deficit.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/598EKWV4/Barrett (2021) Spatial Neglect and Anosognosia After Right Brain Stroke.pdf}
}

@article{bauerBehavioralCognitiveAspects2021,
  title = {Behavioral and {{Cognitive Aspects}} of {{Concussion}}},
  author = {Bauer, Russell M. and Jaffee, Michael S.},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1646--1669},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001057},
  url = {https://journals.lww.com/10.1212/CON.0000000000001057},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This review provides the reader with an overview of concussion and mild traumatic brain injury (TBI). Key aspects of the pathophysiology, signs, and symptoms, treatment and rehabilitation, and recovery from concussion/mild TBI are reviewed with an emphasis on the variety of factors that may contribute to cognitive concerns following injury.                                         RECENT FINDINGS                                Concussion remains a clinical diagnosis based on symptoms that occur in the immediate aftermath of an applied force and in the hours, days, and weeks thereafter. Although advances have been made in advanced diagnostics, including neuroimaging and fluid biomarkers in hopes of developing objective indicators of injury, such markers currently lack sufficient specificity to be used in clinical diagnostics. The symptoms of concussion are heterogeneous and may be seen to form subtypes, each of which suggests a targeted rehabilitation by the interdisciplinary team. Although the majority of patients with concussion recover within the first 30 to 90 days after injury, some have persistent disabling symptoms. The concept of                 postconcussion syndrome                 , implying a chronic syndrome of injury-specific symptoms, is replaced by a broader concept of                 persistent symptoms after concussion                 . This concept emphasizes the fact that most persistent symptoms have their basis in complex somatic, cognitive, psychiatric, and psychosocial factors related to risk and resilience. This framework leads to the important conclusion that concussion is a treatable injury from which nearly all patients can be expected to recover.                                                        SUMMARY               Concussion/mild TBI is a significant public health problem in civilian, military, and organized athletic settings. Recent advances have led to a better understanding of underlying pathophysiology and symptom presentation and efficacious treatment and rehabilitation of the resulting symptoms. An interdisciplinary team is well-positioned to provide problem-oriented, integrated care to facilitate recovery and to advance the evidence base supporting effective practice in diagnosis, treatment, and prevention.},
  langid = {english},
  keywords = {Current}
}

@article{baumerEvaluationManagementChild2018,
  title = {Evaluation and {{Management}} of the {{Child With Autism Spectrum Disorder}}},
  author = {Baumer, Nicole and Spence, Sarah J.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {248--275},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000578},
  url = {https://journals.lww.com/00132979-201802000-00015},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Autism spectrum disorder is a neurodevelopmental disorder defined by deficits in social communication and the presence of restricted and repetitive behaviors and interests. This article provides the tools to diagnose and manage patients with autism spectrum disorder.                                         RECENT FINDINGS               Autism spectrum disorder is a heterogeneous condition with varying presentations, multiple etiologies, and a number of comorbidities that impact the course and management of the disorder. This article defines the core features of social communication deficits, including problems with social reciprocity, decreased nonverbal communication, and difficulties in developing and maintaining relationships. The second domain of repetitive behaviors and restricted interests, which includes the presence of stereotyped behaviors or speech, insistence on sameness and behavioral rigidity, intense or out of the ordinary interests, and unusual responses to sensory stimulation, is also delineated. Comorbidities commonly seen with autism spectrum disorder include medical, neurologic, and psychiatric conditions. Despite intense research efforts, the etiology of autism spectrum disorder remains unknown in most cases, but it is clear that a strong genetic component exists that interacts with various environmental risk factors. Current research is identifying overlapping neurobiological pathways that are involved in pathogenesis. Treatment involves intensive behavioral therapy and educational programming along with traditional ancillary services, such as speech/language, occupational, and physical therapies. Psychopharmacologic treatments are also used to target certain symptoms and comorbid conditions.                                         SUMMARY               Neurologists can play an important role in diagnosing autism spectrum disorder according to clinical criteria through a comprehensive evaluation that includes a thorough medical and developmental history, behavioral and play observations, and a review of standardized cognitive and language evaluations. Neurologists are also responsible for investigating etiologies, recommending and advocating for appropriate behavioral and educational interventions, and identifying and often managing comorbidities.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/X2HMA5IZ/Baumer_Spence (2018) Evaluation and Management of the Child With Autism Spectrum Disorder.pdf}
}

@article{belagajeStrokeRehabilitation2017,
  title = {Stroke {{Rehabilitation}}},
  author = {Belagaje, Samir R.},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {238--253},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000423},
  url = {https://journals.lww.com/00132979-201702000-00017},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               Rehabilitation is an important aspect of the continuum of care in stroke. With advances in the acute treatment of stroke, more patients will survive stroke with varying degrees of disability. Research in the past decade has expanded our understanding of the mechanisms underlying stroke recovery and has led to the development of new treatment modalities. This article reviews and summarizes the key concepts related to poststroke recovery.                                         Recent Findings:               Good data now exist by which one can predict recovery, especially motor recovery, very soon after stroke onset. Recent trials have not demonstrated a clear benefit associated with very early initiation of rehabilitative therapy after stroke in terms of improvement in poststroke outcomes. However, growing evidence suggests that shorter and more frequent sessions of therapy can be safely started in the first 24 to 48 hours after a stroke. The optimal amount or dose of therapy for stroke remains undetermined, as more intensive treatments have not been associated with better outcomes compared to standard intensities of therapy. Poststroke depression adversely affects recovery across a variety of measures and is an important target for therapy. Additionally, the use of selective serotonin reuptake inhibitors (SSRIs) appears to benefit motor recovery through pleiotropic mechanisms beyond their antidepressant effect. Other pharmacologic approaches also appear to have a benefit in stroke rehabilitation.                                         Summary:               A comprehensive rehabilitation program is essential to optimize poststroke outcomes. Rehabilitation is a process that uses three major principles of recovery: adaptation, restitution, and neuroplasticity. Based on these principles, multiple different approaches, both pharmacologic and nonpharmacologic, exist to enhance rehabilitation. In addition to neurologists, a variety of health care professionals are involved in stroke rehabilitation. Successful rehabilitation involves understanding the natural history of stroke recovery and a multidisciplinary approach with judicious use of resources to identify and treat common poststroke sequelae.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/PEH2I83V/Belagaje (2017) Stroke Rehabilitation.pdf}
}

@article{benarrochPhysiologyPathophysiologyAutonomic2020,
  title = {Physiology and {{Pathophysiology}} of the {{Autonomic Nervous System}}},
  author = {Benarroch, Eduardo E.},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {12--24},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000817},
  url = {https://journals.lww.com/10.1212/CON.0000000000000817},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF THE REVIEW               This article reviews the anatomic, functional, and neurochemical organization of the sympathetic and parasympathetic outputs; the effects on target organs; the central mechanisms controlling autonomic function; and the pathophysiologic basis for core symptoms of autonomic failure.                                         RECENT FINDINGS               Functional neuroimaging studies have elucidated the areas involved in central control of autonomic function in humans. Optogenetic and other novel approaches in animal experiments have provided new insights into the role of these areas in autonomic control across behavioral states, including stress and the sleep-wake cycle.                                         SUMMARY               Control of the function of the sympathetic, parasympathetic, and enteric nervous system functions depends on complex interactions at all levels of the neuraxis. Peripheral sympathetic outputs are critical for maintenance of blood pressure, thermoregulation, and response to stress. Parasympathetic reflexes control lacrimation, salivation, pupil response to light, beat-to-beat control of the heart rate, gastrointestinal motility, micturition, and erectile function. The insular cortex, anterior and midcingulate cortex, and amygdala generate autonomic responses to behaviorally relevant stimuli. Several nuclei of the hypothalamus generate coordinated patterns of autonomic responses to internal or social stressors. Several brainstem nuclei participate in integrated control of autonomic function in relationship to respiration and the sleep-wake cycle. Disorders affecting the central or peripheral autonomic pathways, or both, manifest with autonomic failure (including orthostatic hypotension, anhidrosis, gastrointestinal dysmotility, and neurogenic bladder or erectile dysfunction) or autonomic hyperactivity, primary hypertension, tachycardia, and hyperhidrosis.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{bennettOpticNeuritis2019,
  title = {Optic {{Neuritis}}},
  author = {Bennett, Jeffrey L.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1236--1264},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000768},
  url = {https://journals.lww.com/10.1212/CON.0000000000000768},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the clinical presentation, evaluation, and management of the patient with optic neuritis. Initial emphasis is placed on clinical history, examination, diagnostic testing, and medical decision making, while subsequent focus is placed on examining specific inflammatory optic neuropathies. Clinical clues, examination findings, neuroimaging, and laboratory testing that differentiate autoimmune, granulomatous, demyelinating, infectious, and paraneoplastic causes of optic neuritis are assessed, and current treatments are evaluated.                                         RECENT FINDINGS               Advances in technology and immunology have enhanced our understanding of the pathologies driving inflammatory optic nerve injury. Clinicians are now able to interrogate optic nerve structure and function during inflammatory injury, rapidly identify disease-relevant autoimmune targets, and deliver timely therapeutics to improve visual outcomes.                                         SUMMARY               Optic neuritis is a common clinical manifestation of central nervous system inflammation. Depending on the etiology, visual prognosis and the risk for recurrent injury may vary. Rapid and accurate diagnosis of optic neuritis may be critical for limiting vision loss, future neurologic disability, and organ damage. This article will aid neurologists in formulating a systematic approach to patients with optic neuritis.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/XIIQPXQ7/Bennett (2019) Optic Neuritis.pdf}
}

@article{berkowitzApproachNeurologicInfections2021,
  title = {Approach to {{Neurologic Infections}}},
  author = {Berkowitz, Aaron L.},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {818--835},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000984},
  url = {https://journals.lww.com/10.1212/CON.0000000000000984},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the clinical approach to the diagnosis of neurologic infections, focusing on the symptoms, signs, imaging features, and laboratory findings of the major categories of neuroinfectious diseases.                                         RECENT FINDINGS               The increased use of immunosuppressive and immunomodulatory therapy to treat autoimmune diseases has led to an increase in opportunistic neurologic infections. The description of numerous causes of autoimmune antibody--mediated encephalitis over the past decade has expanded the differential diagnosis of encephalitis beyond infection. The emergence of metagenomic next-generation sequencing has led to diagnoses of rare or unexpected causes of neurologic infections and has the potential to enhance diagnostic precision in neuroinfectious diseases.                                         SUMMARY               Infections of the nervous system can affect any level of the neuraxis and present over any time course. Neurologic infections may present atypically with respect to clinical, radiologic, and CSF analysis features in immunocompromised patients or older adults. A thorough evaluation including systemic features, past medical history, travel, exposures, detailed examination, neuroimaging, and CSF analysis is often necessary to make a definitive diagnosis. It is important to be aware of the test characteristics and limitations of microbiological tests on CSF for neurologic infections to avoid being misled by false positives or false negatives.},
  langid = {english},
  keywords = {Current}
}

@article{berkowitzTetanusBotulismDiphtheria2018,
  title = {Tetanus, {{Botulism}}, and {{Diphtheria}}},
  author = {Berkowitz, Aaron L.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1459--1488},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000651},
  url = {https://journals.lww.com/00132979-201810000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the pathophysiology, epidemiology, clinical manifestations, diagnosis, and treatment of tetanus, botulism, and diphtheric neuropathy.                                         RECENT FINDINGS               Tetanus is most common in lower-income settings, but rare cases are seen in higher-income settings because of the inadequate maintenance of vaccination status. Foodborne botulism remains rare, but botulism can also be caused by IV drug use (wound botulism) and medical use of botulinum toxin (iatrogenic botulism); botulinum toxin has also been considered a potential agent of bioterrorism. Diphtheric neuropathy is rare but has been seen in recent epidemics in the former Soviet Union, and vaccination status is inadequate in a significant proportion of older individuals, creating the potential for subsequent epidemics.                                         SUMMARY               Tetanus, botulism, and diphtheric neuropathy are rare in higher-resource settings where most neurologists practice; however, familiarity with the unique clinical manifestations of and laboratory evaluation for these disorders is essential for the rapid diagnosis and treatment of patients with these conditions.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/VP5LY5IH/Berkowitz (2018) Tetanus, Botulism, and Diphtheria.pdf}
}

@article{bhattacharyyaInfectionsSpineSpinal2021,
  title = {Infections of the {{Spine}} and {{Spinal Cord}}},
  author = {Bhattacharyya, Shamik and Bradshaw, Michael J.},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {887--920},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001031},
  url = {https://journals.lww.com/10.1212/CON.0000000000001031},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Infections of the spine and spinal cord are associated with a high risk of morbidity and mortality and, therefore, require prompt clinical recognition, efficient diagnostic evaluation, and interdisciplinary treatment. This article reviews the pathophysiology, epidemiology, clinical manifestations, diagnosis, and treatment of infections of the spine and spinal cord to help practicing clinicians recognize, evaluate, and manage patients with such infections.                                         RECENT FINDINGS               Aging of the population, increasing use of immunosuppressive medications, and other factors have contributed to increasing rates of spinal infections. Although the most common agents responsible for spinal infections remain bacteria and viruses, fungal infections occur in individuals who are immunocompromised, and parasitic infections are common in endemic regions, but patterns are in evolution with migration and climate change. Recent outbreaks of acute flaccid myelitis in children have been associated with enteroviruses A71 and D68.                                         SUMMARY               Infections of the spine and spinal cord can be challenging to diagnose, requiring a thorough history and neurologic examination, laboratory studies of serum and CSF, neuroimaging (particularly MRI), and, in some instances, biopsy, to establish a diagnosis and treatment regimen. Interdisciplinary management including collaboration with experts in internal medicine, infectious disease, and neurosurgery is important to improve clinical outcomes.},
  langid = {english},
  keywords = {Current}
}

@article{bhattacharyyaSpondyloticOtherStructural2021,
  title = {Spondylotic and {{Other Structural Myelopathies}}},
  author = {Bhattacharyya, Shamik},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {163--184},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000975},
  url = {https://journals.lww.com/10.1212/CON.0000000000000975},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article highlights both common structural causes of myelopathy, such as spondylotic disease, and infrequent but treatable causes, such as syringomyelia, spinal cord herniation, arachnoid cyst, arachnoid band and web, epidural lipomatosis, Hirayama disease, and arachnoiditis.                                         RECENT FINDINGS               Neuroimaging improvements and availability have uncovered many structural abnormalities in the spines and spinal cords of patients who were asymptomatic or minimally symptomatic. Recent published clinical series have improved our knowledge of the natural history of structural abnormalities and the risks of intervention versus conservative management.                                         SUMMARY               Myelopathy from a suspected structural cause is a common reason for neurologic consultation. Correlation between the history, examination, and imaging are especially important to determine whether intervention is necessary or conservative management is the best option.},
  langid = {english}
}

@article{birchNeuromuscularDisordersIntensive2021,
  title = {Neuromuscular {{Disorders}} in the {{Intensive Care Unit}}},
  author = {Birch, Torrey Boland},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1344--1364},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001004},
  url = {https://journals.lww.com/10.1212/CON.0000000000001004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the pathophysiology, presentation, diagnosis, treatment, and prognosis of common neuromuscular disorders seen in the intensive care unit, including Guillain-Barr{\'e} syndrome, myasthenia gravis, and intensive care unit--acquired weakness.                                         RECENT FINDINGS               Guillain-Barr{\'e} syndrome can have an excellent prognosis if patients are diagnosed early, appropriately treated, and monitored for complications, including respiratory failure and dysautonomia. Intensive care unit--acquired weakness increases overall mortality in patients who are critically ill, and distinguishing between critical illness myopathy and critical illness polyneuropathy may have important prognostic implications.                                         SUMMARY               Neuromuscular disorders are not rare in the intensive care unit setting, and precise identification and treatment of these conditions can greatly impact long-term outcomes.},
  langid = {english}
}

@article{boeveBehavioralVariantFrontotemporal2022,
  title = {Behavioral {{Variant Frontotemporal Dementia}}},
  author = {Boeve, Bradley F.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {702--725},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001105},
  url = {https://journals.lww.com/10.1212/CON.0000000000001105},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews many of the complex facets of behavioral variant frontotemporal dementia (bvFTD) and frontotemporal lobar degeneration (FTLD). A particular focus is on improving diagnostic accuracy to reduce the arduous diagnostic odyssey that so many patients and families endure. Strategies to promote diagnostic accuracy and approach the management of problematic symptoms are also discussed.                                         RECENT FINDINGS               Although the International Consensus Criteria for bvFTD were published more than a decade ago and clinicopathologic studies have confirmed their utility, diagnostic confusion continues. This article presents updated data along with illustrative cases to emphasize the clinical pearls that are most useful for clinicians. Although accurate prediction of the underlying proteinopathy remains a challenge, the ability to differentiate bvFTD from atypical Alzheimer disease, psychiatric disorders, and other mimickers has improved. Knowledge about the genetic underpinnings in a significant minority of individuals with familial FTLD is enabling early and accurate diagnosis. Therapeutic optimism has also increased, particularly in familial FTLD, with a few clinical trials in progress and several more planned, some of which are designed to slow progression or delay the onset of symptoms, or both.                                         SUMMARY               The diagnosis and management of bvFTD is challenging for clinicians and particularly for patients and their families. Although much progress has been gained over recent years, several key research questions persist. Treatments that significantly improve symptoms or alter the course of FTLD remain elusive, but optimism is increasing as pathobiology is better understood and novel therapies are being developed.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/XDHXRT42/Boeve (2022) Behavioral Variant Frontotemporal Dementia.pdf}
}

@article{boireMetastasisCentralNervous2020,
  title = {Metastasis to the {{Central Nervous System}}},
  author = {Boire, Adrienne},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1584--1601},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000939},
  url = {https://journals.lww.com/10.1212/CON.0000000000000939},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Management of metastasis to the central nervous system (CNS) has evolved, and molecular characterization of metastatic disease is now routinely done. Targeted therapies, once few in number with limited penetration into the CNS, have multiplied in number and increased in CNS coverage. This article addresses recent advances in the evaluation and clinical management of patients with CNS metastasis.                                         RECENT FINDINGS                                Metastasis of cancer to the CNS can be diagnosed and characterized with novel techniques, including molecular analyses of the spinal fluid, so-called                 liquid biopsies                 . Resected parenchymal CNS metastases are now routinely subjected to genomic sequencing. For patients with CNS metastases displaying targetable mutations, a wide variety of treatment options are available, including deferral of radiation therapy in favor of a trial of an orally bioavailable targeted therapy or immunotherapy. For patients without a molecularly targetable lesion, local treatment in the form of radiation therapy, now most often stereotactic radiosurgery, is supplanting untargeted whole-brain radiation therapy.                                                        SUMMARY               Technologic advances in diagnosis and management have resulted in new diagnostic and therapeutic approaches to patients with metastasis to the CNS, with resulting improvements in progression-free and overall survival.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/HAQD5FE4/Boire (2020) Metastasis to the Central Nervous System.pdf}
}

@article{boseMigrainePostdrome2018,
  title = {The {{Migraine Postdrome}}},
  author = {Bose, Pyari and Karsan, Nazia and Goadsby, Peter J.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1023--1031},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000626},
  url = {https://journals.lww.com/00132979-201808000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The migraine postdrome is the least studied and least understood phase of migraine. This article covers the salient features of the migraine postdrome and provides insight into the history, clinical symptoms, and future implications of this phase of migraine.                                         RECENT FINDINGS               Prospective electronic diary studies have shown that patients are left disabled with various nonheadache symptoms in the migraine postdrome, and 81\% of patients report at least one nonheadache symptom in the postdrome. Hence, it is important to understand this phase better and ensure that more effective treatments become available in the future to lessen the morbidity associated with this phase. Functional imaging shows widespread reduction in brain-blood flow in the postdrome, which explains the multitudes of symptoms experienced by patients.                                         SUMMARY               The disability related to migraine is not exclusive to the headache phase but extends into the postdrome phase and is associated with several nonheadache symptoms that prolong the symptoms experienced by patients with migraine. Further research into the postdrome is crucial to improve our overall understanding of migraine mechanisms. This knowledge may also help to treat the concurrent nonheadache symptoms better in the future. Novel neuroimaging techniques provide a valuable noninvasive tool to push the frontiers in the understanding of migraine pathophysiology. These methods may help shed further light onto the possible links between key brain structures and networks that could be implicated in the pathophysiology of the various migraine phases.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/XJHPDQZ6/bose2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/ZRW56V9Z/Bose et al (2018) The Migraine Postdrome.pdf}
}

@article{bothaPrimaryProgressiveAphasias2019,
  title = {Primary {{Progressive Aphasias}} and {{Apraxia}} of {{Speech}}},
  author = {Botha, Hugo and Josephs, Keith A.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {101--127},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000699},
  url = {https://journals.lww.com/00132979-201902000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews two of the primary progressive aphasias (PPAs), disorders characterized by the early and predominant impairment of language, and primary progressive apraxia of speech, a degenerative motor speech disorder that is closely related to PPA. An outline of the history and controversy surrounding how these disorders are classified is provided before the article focuses on each disorder's clinical and imaging features.                                         RECENT FINDINGS               Over the past decade, the classification of degenerative speech and language disorders has been refined. Clinical, imaging, and pathologic evidence suggests that primary progressive apraxia of speech is a distinct degenerative disorder. Furthermore, multiple lines of evidence have highlighted issues with nonfluent/agrammatic variant PPA, which complicates the diagnosis, prognosis, and study of this disorder. Semantic variant PPA, while not without controversy, remains one of the most well-defined disorders, with good clinicopathologic correlation.                                         SUMMARY               Accurate classification and diagnosis of these degenerative speech and language disorders is crucial in clinical practice and ongoing research efforts. For nonfluent/agrammatic variant PPA, the authors suggest emphasizing agrammatism as the core inclusion criterion and taking care not to include patients with isolated or predominant apraxia of speech. Isolated apraxia of speech can be the manifestation of a degenerative disease and, based on the different prognosis, should be recognized as distinct from PPA. Finally, it is important to recognize that some patients with semantic dementia, despite sharing the same pathologic associations, may not meet criteria for PPA.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/7YX7C79V/Botha_Josephs (2019) Primary Progressive Aphasias and Apraxia of Speech.pdf}
}

@article{bouffardPupil2019,
  title = {The {{Pupil}}},
  author = {Bouffard, Marc A.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1194--1214},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000771},
  url = {https://journals.lww.com/10.1212/CON.0000000000000771},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The goal of this article is to review the anatomy and physiology of pupillary function and then employ that information to develop a comprehensive framework for understanding and diagnosing pupillary disorders.                                         RECENT FINDINGS               The contribution of rods and cones to the pupillary light reflex has long been known. A third photosensitive cell type, the intrinsically photosensitive retinal ganglion cell, has recently been discovered. This cell type employs melanopsin to mediate a portion of the pupillary light reflex independent of rods and cones (the postillumination pupillary response) and photic regulation of circadian rhythm.                                         SUMMARY               The autonomic nervous system regulates pupil size in response to stimuli. The parasympathetic nervous system causes miosis in response to light and near visual stimuli. These stimuli activate supranuclear pathways that project to the Edinger-Westphal nuclei. The sympathetic nervous system causes mydriasis in response to a variety of arousing factors, both physiologic (wakefulness) and pathologic (pain). Abnormalities of physiologic function cause disturbances of pupil size, shape, and response to stimuli. The clinical approach to pupillary abnormalities should focus on the clinical and pharmacologic assessment of the pupil's expected response to diverse stimuli.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/QEVNF96T/Bouffard (2019) The Pupil.pdf}
}

@article{brentonPediatricAcquiredDemyelinating2022,
  title = {Pediatric {{Acquired Demyelinating Disorders}}},
  author = {Brenton, J. Nicholas},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1104--1130},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001128},
  url = {https://journals.lww.com/10.1212/CON.0000000000001128},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the clinical presentation, diagnostic evaluation, treatment, and prognosis of the most common monophasic and relapsing acquired demyelinating disorders presenting in childhood.                                         RECENT FINDINGS               Our understanding of neuroimmune disorders of the central nervous system is rapidly expanding. Several clinical and paraclinical factors help to inform the diagnosis and ultimately the suspicion for a monophasic versus relapsing course, including the age of the patient (prepubertal versus postpubertal), presence or absence of clinical encephalopathy, identification of serum autoantibodies (eg, myelin oligodendrocyte glycoprotein [MOG] and aquaporin-4), presence of intrathecally unique oligoclonal bands, and location/extent of radiologic abnormalities. Collaborative international research efforts have facilitated understanding of the safety and efficacy of currently available immunotherapies in children with acquired demyelinating disorders, particularly multiple sclerosis.                                         SUMMARY               Although many of the demyelinating disorders presented in this article can affect children and adults across the age spectrum, the clinical and radiologic phenotypes, treatment considerations, and long-term prognoses are often distinct in children.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current},
  file = {/Users/nathanielyomogida/Zotero/storage/7HQMCLVZ/Brenton (2022) Pediatric Acquired Demyelinating Disorders.pdf}
}

@article{burchPreventiveMigraineTreatment2021,
  title = {Preventive {{Migraine Treatment}}},
  author = {Burch, Rebecca},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {613--632},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000957},
  url = {https://journals.lww.com/10.1212/CON.0000000000000957},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of preventive interventions for migraine, including when to start and how to choose a treatment, pharmacologic options (both older oral treatments and new monoclonal antibodies to calcitonin gene-related peptide [CGRP] or its receptor), nonpharmacologic treatment such as neuromodulation, and preventive treatment of refractory migraine.                                         RECENT FINDINGS               The migraine preventive treatment landscape has been transformed by the development of monoclonal antibodies targeting CGRP or its receptor. These treatments, which are given subcutaneously or intravenously monthly or quarterly, have high efficacy and were well tolerated in clinical trials. Emerging real-world studies have found higher rates of adverse events than were seen in clinical trials. They are currently recommended for use if two traditional preventive therapies have proven inadequate. Since the commonly cited 2012 American Headache Society/American Academy of Neurology migraine prevention guidelines were released, clinical trials supporting the preventive use of lisinopril, candesartan, and memantine have been published. Neuromodulation devices, including external trigeminal nerve stimulation and single-pulse transcranial magnetic stimulation devices, have modest evidence to support preventive use. The American Headache Society/American Academy of Neurology guidelines for the preventive treatment of migraine are currently being updated. A new class of oral CGRP receptor antagonists (gepants) is being tested for migraine prevention.                                         SUMMARY               Successful preventive treatment of migraine reduces disease burden and improves quality of life. Many pharmacologic and nonpharmacologic treatment options are available for the prevention of migraine, including newer therapies aimed at the CGRP pathway as well as older treatments with good evidence for efficacy. Multiple treatment trials may be required to find the best preventive for an individual patient.},
  langid = {english},
  keywords = {Current}
}

@article{burishClusterHeadacheOther2018,
  title = {Cluster {{Headache}} and {{Other Trigeminal Autonomic Cephalalgias}}},
  author = {Burish, Mark},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1137--1156},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000625},
  url = {https://journals.lww.com/00132979-201808000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article covers the clinical features, differential diagnosis, and management of the trigeminal autonomic cephalalgias (TACs). The TACs are composed of five diseases: cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), and hemicrania continua.                                         RECENT FINDINGS                                New classifications for the TACs have two important updates; chronic cluster headache is now defined as remission periods lasting less than 3 months (formerly less than 1 month), and hemicrania continua is now classified as a TAC (formerly classified as                 other primary headache                 ). The first-line treatments of TACs have not changed in recent years: cluster headache is managed with oxygen, triptans, and verapamil; paroxysmal hemicrania and hemicrania continua are managed with indomethacin; and SUNCT and SUNA are managed with lamotrigine. However, advancements in neuromodulation have recently provided additional options for patients with cluster headache, which include noninvasive devices for abortive therapy and invasive devices for refractory cluster headache. Patient selection for these devices is key.                                                        SUMMARY               The TACs are a group of diseases that appear similar to each other and to other headache disorders but have important differences. Proper diagnosis is crucial for proper treatment. This article reviews the pathophysiology, epidemiology, differential diagnosis, and treatment of the TACs.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/KRARF8ZF/burish2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/N83VDA9P/Burish (2018) Cluster Headache and Other Trigeminal Autonomic Cephalalgias.pdf}
}

@article{buslHospitalConsultationPatient2011,
  title = {Hospital {{Consultation}} for the {{Patient With Generalized Weakness}}},
  shorttitle = {Hospital {{Consultation}} for the {{Patient With Generalized Weakness}}},
  author = {Busl, Katharina Maria and Ropper, Allan H.},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {1040--1062},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407059.40532.b3},
  url = {http://journals.lww.com/00132979-201110000-00010},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/9DAAR8NV/busl2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/HUN2IT7F/Busl_Ropper (2011) Hospital Consultation for the Patient With Generalized Weakness.pdf}
}

@article{butterfieldCongenitalMuscularDystrophy2019,
  title = {Congenital {{Muscular Dystrophy}} and {{Congenital Myopathy}}},
  author = {Butterfield, Russell J.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1640--1661},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000792},
  url = {https://journals.lww.com/10.1212/CON.0000000000000792},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Congenital muscular dystrophies and congenital myopathies are a heterogeneous group of disorders resulting in hypotonia, muscle weakness, and dystrophic or myopathic features on muscle biopsy. This article summarizes the clinical and genetic aspects of these disorders.                                         RECENT FINDINGS               Historically, diagnoses of congenital muscular dystrophy and congenital myopathy have been made by clinical features and histopathology; however, recent advances in genetics have changed diagnostic practice by relying more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)--related (merosin deficient), collagen VI--related, and {$\alpha$}-dystroglycan--related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. With the increasing accessibility of genetic testing, the number of genes found to be associated with these disorders has increased dramatically. A wide spectrum of severity and onset (from birth to adulthood) exist across all subtypes. Progression and other features are variable depending on the subtype and severity of the specific genetic mutation.                                         SUMMARY               Congenital muscular dystrophy and congenital myopathy are increasingly recognized disorders. A growing appreciation for the breadth of phenotypic variability and overlap between established subtypes has challenged long-standing phenotypic and histopathologic classifications of these disorders but has driven a greater understanding of pathogenesis and opened the door to the development of novel treatments.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/2YFL7XUT/Butterfield (2019) Congenital Muscular Dystrophy and Congenital Myopathy.pdf}
}

@article{carlssonManagementDementia2022,
  title = {Management of {{Dementia}}},
  author = {Carlsson, Cynthia M.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {885--900},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001132},
  url = {https://journals.lww.com/10.1212/CON.0000000000001132},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes an approach to managing patients following a diagnosis of dementia, including medical management, nonpharmacologic strategies, safety interventions, caregiver support, mobilization of community resources, and advanced care planning.                                         RECENT FINDINGS               Dementia clinical syndromes are frequently caused by mixed pathologies, leading to varied clinical presentations that include memory loss, behavioral changes, communication challenges, safety concerns, and loss of independent function. Medications for treating dementia currently target cognitive and behavioral symptoms, although disease-modifying therapies for Alzheimer disease may be making their way into widespread clinical practice soon. Identification and treatment of co-occurring medical problems, such as obstructive sleep apnea, adverse medication effects, mood disorders, hearing loss, pain, alcohol misuse, and vascular risk factors, may mitigate the impact of these conditions on cognitive decline. Mobilization of clinical and community-based interprofessional teams will ensure that people with dementia and their care partners have the expertise, support, and access to resources they need. Addressing goals of care early in the disease course will allow people with dementia to contribute to their care plan by expressing their wishes.                                         SUMMARY               Developing a structured approach to treating common causes of dementia and related comorbid medical conditions, identifying a local network of interprofessional clinical and community-based referrals, and providing readily available educational resources will help clinicians provide quality dementia care management that extends beyond the clinic visit. Encouraging patients and families to engage in clinical research will advance the identification of effective therapies, preventive strategies, and quality care models for the future.},
  langid = {english},
  keywords = {Current}
}

@article{cavinessMyoclonus2019,
  title = {Myoclonus},
  author = {Caviness, John N.},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {1055--1080},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000750},
  url = {https://journals.lww.com/00132979-201908000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article offers clinicians a strategic approach for making sense of a symptom complex that contains myoclonus. The article presents an evaluation strategy that highly leverages the two major classification schemes of myoclonus. The goal of this article is to link evaluation strategy with diagnosis and treatment of myoclonus.                                         RECENT FINDINGS               The growth of medical literature has helped better define myoclonus etiologies. Physiologic study of myoclonus types and etiologies with electrophysiologic testing has provided greater clarity to the pathophysiology of the myoclonus in various diseases. Although studies have been limited, the role of newer treatment agents and methods has made progress.                                         SUMMARY               Myoclonus has hundreds of different etiologies. Classification is necessary to evaluate myoclonus efficiently and pragmatically. The classification of myoclonus etiology, which is grouped by different clinical presentations, helps determine the etiology and treatment of the myoclonus. The classification of myoclonus physiology using electrophysiologic test results helps determine the pathophysiology of the myoclonus and can be used to strategize symptomatic treatment approaches. Both basic ancillary testing (including EEG and imaging) and more comprehensive testing may be necessary. Treatment of the underlying etiology is the ideal approach. However, if such treatment is not possible or is delayed, symptomatic treatment guided by the myoclonus physiology should be considered. More controlled study of myoclonus treatment is needed. Further research on myoclonus generation mechanisms should shed light on future treatment possibilities.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/2RH3TVMZ/Caviness (2019) Myoclonus.pdf;/Users/nathanielyomogida/Zotero/storage/MYXVDU6L/10.1212@CON.0000000000000750.pdf.pdf}
}

@article{chaChronicDizziness2021,
  title = {Chronic {{Dizziness}}},
  author = {Cha, Yoon-Hee},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {420--446},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000932},
  abstract = {PURPOSE OF REVIEW: Determining the etiology of disorders that manifest with chronic dizziness can seem a daunting task, but extracting some basic elements of the patient's history can reduce the differential diagnosis significantly. This includes determining initial triggers, timing of symptoms, associated features, and exacerbating factors. This article covers distinct causes of chronic dizziness including persistent postural perceptual dizziness, mal de d{\'e}barquement syndrome, motion sickness and visually induced motion sickness, bilateral vestibulopathy, and persistent dizziness after mild concussion. RECENT FINDINGS: To date, none of the disorders above has a cure but are considered chronic syndromes with fluctuations that are both innate and driven by environmental stressors. As such, the mainstay of therapy for chronic disorders of dizziness involves managing factors that exacerbate symptoms and adding vestibular rehabilitation or cognitive-behavioral therapy alone or in combination, as appropriate. These therapies are supplemented by serotonergic antidepressants that modulate sensory gating and reduce anxiety. Besides expectation management, ruling out concurrent disorders and recognizing behavioral and lifestyle factors that affect symptom severity are critical issues in reducing morbidity for each disorder. SUMMARY: Many syndromes of chronic dizziness can be diagnosed by recognition of key features, although many symptoms overlap between these groups. Symptoms may be manageable and improve with time, but they are often incompletely relieved.},
  langid = {english},
  pmid = {34351113},
  keywords = {Brain Concussion,Continuum: Neuro-otology,Dizziness,Humans,Travel-Related Illness,Vertigo},
  file = {/Users/nathanielyomogida/Zotero/storage/3NIW86FL/Cha (2021) Chronic Dizziness.pdf}
}

@article{chahineProdromalASynucleinopathies2022,
  title = {Prodromal {$\alpha$}-{{Synucleinopathies}}},
  author = {Chahine, Lana M.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1268--1280},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001153},
  url = {https://journals.lww.com/10.1212/CON.0000000000001153},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes prodromal {$\alpha$}-synucleinopathies.                                         RECENT FINDINGS               The pathology underlying {$\alpha$}-synucleinopathies, which include Parkinson disease, multiple system atrophy, and dementia with Lewy bodies, begins years before the presence of the full syndrome that is the basis for the clinical diagnosis of each of these disorders. This ``prodromal'' phase may manifest with various signs or symptoms. In addition to individuals in the prodromal phase, some individuals are asymptomatic but are at risk for {$\alpha$}-synucleinopathies owing to genetic predisposition or other risk factors.                                         SUMMARY               Clinicians are increasingly seeing patients in the clinical setting who are prodromal or at risk for {$\alpha$}-synucleinopathies, and this article reviews the approach to these patient populations, which includes identifying clinical features, assessment, and counseling.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{changwongVascularCognitiveImpairment2022,
  title = {Vascular {{Cognitive Impairment}} and {{Dementia}}},
  author = {Chang Wong, Ellen and Chang Chui, Helena},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {750--780},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001124},
  url = {https://journals.lww.com/10.1212/CON.0000000000001124},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article gives a broad overview of vascular cognitive impairment and dementia, including epidemiology, pathophysiology, clinical approach, and management. Emphasis is placed on understanding the common underlying types of cerebrovascular disease (including atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy) and awareness of rare inherited cerebrovascular disorders.                                         RECENT FINDINGS               The pathophysiology of vascular cognitive impairment and dementia is heterogeneous, and the most recent diagnostic criteria for vascular cognitive impairment and dementia break down the diagnosis of major vascular dementia into four phenotypic categories, including subcortical ischemic vascular dementia, poststroke dementia, multi-infarct dementia, and mixed dementia. Control of cardiovascular risk factors, including management of midlife blood pressure, cholesterol, and blood sugars, remains the mainstay of prevention for vascular cognitive impairment and dementia. Cerebral amyloid angiopathy requires special consideration when it comes to risk factor management given the increased risk of spontaneous intracerebral hemorrhage. Recent trials suggest some improvement in global cognitive function in patients with vascular cognitive impairment and dementia with targeted cognitive rehabilitation.                                         SUMMARY               Thorough clinical evaluation and neuroimaging form the basis for diagnosis. As vascular cognitive impairment and dementia is the leading nondegenerative cause of dementia, identifying risk factors and optimizing their management is paramount. Once vascular brain injury has occurred, symptomatic management should be offered and secondary prevention pursued.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/SJJHU88X/Chang Wong_Chang Chui (2022) Vascular Cognitive Impairment and Dementia.pdf}
}

@article{charlesMigraineAura2018,
  title = {The {{Migraine Aura}}},
  author = {Charles, Andrew},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1009--1022},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000627},
  url = {https://journals.lww.com/00132979-201808000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the basic mechanisms of migraine aura and its clinical significance based upon evidence from human studies and animal models.                                         RECENT FINDINGS               Prospective clinical studies have reinforced the understanding that migraine aura is highly variable from one individual to the next as well as from attack to attack in an individual. While migraine with aura clearly has a higher heritability than migraine without aura, population studies have not identified specific genes that underlie this heritability for typical migraine with aura. Imaging studies reveal hypoperfusion associated with migraine aura, although the timing and distribution of this hypoperfusion is not strictly correlated with migraine symptoms. Mapping of migraine visual aura symptoms onto the visual cortex suggests that the mechanisms underlying the aura propagate in a linear fashion along gyri or sulci rather than as a concentric wave and also suggests that aura may propagate in the absence of clinical symptoms. Cortical spreading depression in animal models continues to be a translational model for migraine, and the study of spreading depolarizations in the injured human brain has provided new insight into potential mechanisms of cortical spreading depression in migraine. Migraine with aura has multiple comorbidities including patent foramen ovale, stroke, and psychiatric disorders; the shared mechanisms underlying these comorbidities remains a topic of active investigation.                                         SUMMARY               Although it occurs in the minority of patients with migraine, aura may have much to teach us about basic mechanisms of migraine. In addition, its occurrence may influence clinical management regarding comorbid conditions and acute and preventive therapy.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/L8QSDRWA/Charles (2018) The Migraine Aura.pdf;/Users/nathanielyomogida/Zotero/storage/QRQX9PSC/charles2018.pdf.pdf}
}

@article{chaturvediDiagnosisManagementLarge2023,
  title = {Diagnosis and {{Management}} of {{Large Artery Atherosclerosis}}},
  author = {Chaturvedi, Seemant},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {486--500},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001212},
  url = {https://journals.lww.com/10.1212/CON.0000000000001212},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Ischemic stroke due to large vessel atherosclerosis is a significant cause of stroke globally. With the aging population, the number of people with atherosclerotic stroke will increase in the coming decades. This article reviews the recent developments in the assessment and treatment of extracranial and intracranial atherosclerotic disease.                                         LATEST DEVELOPMENTS               More intensive dual antiplatelet therapy can now be recommended for patients with transient ischemic attack or stroke. More stringent blood pressure and lipid control is also advised. The need for carotid revascularization will likely decrease in the coming decades because of advances in multimodal medical therapy; in particular, the role of revascularization for treating asymptomatic carotid stenosis is controversial. Patients with symptomatic intracranial stenosis should receive intensive medical therapy. Interest in high-resolution carotid plaque imaging is growing.                                         ESSENTIAL POINTS               The prevention of stroke due to large vessel atherosclerosis has improved owing to advances in medical therapies. The role of carotid revascularization is unclear for many patient subgroups.},
  langid = {english},
  keywords = {Current}
}

@article{cheshireAutonomicHistoryExamination2020,
  title = {Autonomic {{History}}, {{Examination}}, and {{Laboratory Evaluation}}},
  author = {Cheshire, William P.},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {25--43},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000815},
  url = {https://journals.lww.com/10.1212/CON.0000000000000815},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Autonomic disorders offer a fascinating view of the complexity of the nervous system. Their impact on human health ranges from benign to severe. Deciphering autonomic symptoms and signs draws on the cognitive skills and personal interest in the plight of patients that first attracted many physicians to the field of neurology. This article provides tools to sharpen those skills.                                         RECENT FINDINGS                                Autonomic neuroscience and accumulated clinical knowledge have led to the categorization of autonomic disorders into specific syndromes that can be identified on the basis of clinical phenotypes and physiologic responses to standardized stimuli in the autonomic laboratory. A key development has been the ability to distinguish neurogenic orthostatic hypotension from other causes of hypotension. Quantification of sudomotor responses has proven valuable in the diagnosis of thermoregulatory disorders and small fiber neuropathies such as those related to diabetes mellitus. Increasing attention has focused on autonomic failure as a defining feature of neurodegenerative {$\alpha$}-synucleinopathies, especially multiple system atrophy. As awareness of autonomic disorders has increased, the once obscure term                 dysautonomia                 has entered into common parlance.                                                        SUMMARY               With appropriate knowledge and experience, neurologists can diagnose autonomic dysfunction accurately and with confidence. The opportunity to play an important role in caring for patients with autonomic disorders is worth the effort.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{cheshireSyncope2017,
  title = {Syncope},
  author = {Cheshire, William P.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {335--358},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000444},
  url = {https://journals.lww.com/00132979-201704000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Syncope is a prevalent syndrome with diverse causes, which have in common a sudden transient failure of the autonomic nervous system to maintain blood pressure against the force of gravity at a level sufficient for cerebral perfusion. Neurally mediated syncope is an episodic phenomenon in which autonomic nervous system function is normal the rest of the time. Although relatively benign, syncope increases the risk for injury from falling and can substantially impair patients' quality of life. Recognition of its various clinical presentations and knowledge of the underlying pathophysiology are essential for accurate diagnosis and successful management.                                         Recent Findings:               The most effective forms of treatment remain education of patients, avoidance of triggers, physical counterpressure maneuvers, and hydration or intravascular volume expansion. Pharmacologic interventions may be appropriate for some patients but, in general, have limited evidence of efficacy in preventing syncope. Based on the findings of a recent study, the possibility of pulmonary embolism should be considered in patients hospitalized for syncope, whether or not an alternative etiology for syncope is identified.                                         Summary:               This article focuses on the neurologic diagnosis, differential diagnosis, physiology, and management strategies for syncope, with an emphasis on neurally mediated syncope.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/NL4JXIZH/Cheshire (2017) Syncope.pdf;/Users/nathanielyomogida/Zotero/storage/R4UJ8N8H/cheshire2017.pdf.pdf}
}

@article{chiotaHypoxicIschemicBrainInjury2011,
  title = {Hypoxic-{{Ischemic Brain Injury}} and {{Prognosis After Cardiac Arrest}}:},
  shorttitle = {Hypoxic-{{Ischemic Brain Injury}} and {{Prognosis After Cardiac Arrest}}},
  author = {Chiota, Nicole A. and Freeman, W. David and Barrett, Kevin M.},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {1094--1118},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407062.25284.f3},
  url = {http://journals.lww.com/00132979-201110000-00013},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/35CJWPSL/chiota2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/ZGK47BRT/Chiota et al (2011) Hypoxic-Ischemic Brain Injury and Prognosis After Cardiac Arrest.pdf}
}

@article{choApproachMyelopathy2018,
  title = {Approach to {{Myelopathy}}},
  author = {Cho, Tracey A. and Bhattacharyya, Shamik},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {386--406},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000583},
  url = {https://journals.lww.com/00132979-201804000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Myelopathy is commonly encountered in clinical practice and is associated with a large number of causes. This article reviews the anatomy of the spinal cord and discusses how the clinical findings, time course, and radiographic patterns can help to identify the causes of myelopathy.                                         RECENT FINDINGS               Imaging observations such as MRI ``pancake'' gadolinium enhancement pattern with spondylotic myelopathy and subpial enhancement with neurosarcoidosis have improved diagnostic specificity. On the other hand, common diseases such as degenerative spine disease are now recognized as presenting much more variably. Improved imaging and the identification of genetic markers enhance the specificity of diagnosis. The improved identification of biomarkers has shown that the same cause, such as compressive myelopathy, can present more variably than previously appreciated.                                         SUMMARY               Spinal cord dysfunction, or myelopathy, remains a clinical diagnosis, and determining the cause requires integration of clinical, laboratory, and imaging parameters, none of which have great specificity individually. Most cases of myelopathy will require further neuroimaging, and some require CSF analysis for diagnosis. This article presents an approach to the diagnosis of myelopathy based on excluding compressive myelopathy initially and then differentiating between acute and subacute processes and chronic causes.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/I28XHCZT/Cho_Bhattacharyya (2018) Approach to Myelopathy.pdf;/Users/nathanielyomogida/Zotero/storage/R2VUZ8PM/cho2018.pdf.pdf}
}

@article{choePediatricTraumaticBrain2018,
  title = {Pediatric {{Traumatic Brain Injury}} and {{Concussion}}},
  author = {Choe, Meeryo and Barlow, Karen M.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {300--311},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000569},
  url = {https://journals.lww.com/00132979-201802000-00018},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article summarizes the impact and complications of mild traumatic brain injury and concussion in children and outlines the recent evidence for its assessment and early management. Useful evidence-based management strategies are provided for children who have a typical recovery following concussion as well as for those who have persistent postconcussion syndrome. Cases are used to demonstrate the commonly encountered pathologies of headache, cognitive issues, and mood disturbances following injury.                                         RECENT FINDINGS               A clinical risk score using risk factors for poor recovery (eg, female sex, adolescence, previous migraine, and a high degree of acute symptoms) can be used to help the clinician plan follow-up in the community. Prolonged periods of physical and cognitive rest should be avoided. Multidisciplinary treatment plans are often required in the management of persistent postconcussion syndrome.                                         SUMMARY               A paucity of research exists for the treatment of postconcussion syndrome. Current treatments target individual symptoms.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/75YD5CA2/Choe_Barlow (2018) Pediatric Traumatic Brain Injury and Concussion.pdf}
}

@article{choHelminthicInfectionsCentral2018,
  title = {Helminthic {{Infections}} of the {{Central Nervous System}}},
  author = {Cho, Tracey A.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1489--1511},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000646},
  url = {https://journals.lww.com/00132979-201810000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses select helminthic parasitic infections that may affect the central nervous system and reviews the epidemiology, neurologic presentation, recommended diagnostic testing, and treatment approach to these infections.                                         RECENT FINDINGS               Emigration from and travel to areas endemic for helminthic infections that affect the nervous system has led to increased incidence of parasitic neurologic disease in developed countries, necessitating that neurologists be familiar with the diagnostic and therapeutic approach to these diseases. Evidence is emerging on the optimal treatment for neurocysticercosis, which varies based on the form of the disease in the nervous system.                                         SUMMARY               Parenchymal neurocysticercosis is a leading cause of acquired epilepsy worldwide, and extraparenchymal neurocysticercosis is responsible for many cases of hydrocephalus. Recognition of the different stages and locations of neurocysticercosis is essential for proper management. Similarly, schistosomiasis constitutes a major cause of myelopathy in endemic areas and requires prompt diagnosis and treatment to avoid permanent deficits.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/M5XLSFVK/Cho (2018) Helminthic Infections of the Central Nervous System.pdf}
}

@article{chouSecondaryHeadacheSyndromes2018,
  title = {Secondary {{Headache Syndromes}}},
  author = {Chou, Denise E.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1179--1191},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000640},
  url = {https://journals.lww.com/00132979-201808000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article is intended to assist clinicians in distinguishing benign primary headache syndromes from serious headache presentations that arise from exogenous causes.                                         RECENT FINDINGS               Although most cases of severe headache are benign, it is essential to recognize the signs and symptoms of potentially life-threatening conditions. Patients with primary headache disorders can also acquire secondary conditions that may present as a change in their baseline headache patterns and characteristics. Clinical clues in the history and examination can help guide the diagnosis and management of secondary headache disorders. Furthermore, advances in the understanding of basic mechanisms of headache may offer insight into the proposed pathophysiology of secondary headaches.                                         SUMMARY               Several structural, vascular, infectious, inflammatory, and traumatic causes of headache are highlighted. Careful history taking and examination can enable prompt identification and treatment of underlying serious medical disorders causing secondary headache syndromes.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/LCCYCKCH/chou2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/TCMJY6Q8/Chou (2018) Secondary Headache Syndromes.pdf}
}

@article{chouSubarachnoidHemorrhage2021,
  title = {Subarachnoid {{Hemorrhage}}},
  author = {Chou, Sherry Hsiang-Yi},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1201--1245},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001052},
  url = {https://journals.lww.com/10.1212/CON.0000000000001052},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Subarachnoid hemorrhage (SAH) remains an important cause of mortality and long-term morbidity. This article uses a case-based approach to guide readers through the fundamental epidemiology and pathogenesis of SAH, the approach to diagnosis and management, the results of clinical trials and evidence to date, prognostic considerations, controversies, recent developments, and future directions in SAH.                                         RECENT FINDINGS               Historically, management of SAH focused on prevention and treatment of subsequent cerebral vasospasm, which was thought to be the primary cause of delayed cerebral ischemia. Clinical and translational studies over the past decade, including several therapeutic phase 3 randomized clinical trials, suggest that the pathophysiology of SAH-associated brain injury is multiphasic and multifactorial beyond large vessel cerebral vasospasm. The quest to reduce SAH-associated brain injury and improve outcomes is shifting away from large vessel cerebral vasospasm to a new paradigm targeting multiple brain injury mechanisms, including early brain injury, delayed cerebral ischemia, microcirculatory dysfunction, spreading cortical depolarization, inflammation, and the brain-body interaction in vascular brain injury with critical illness.               Despite multiple negative randomized clinical trials in search of potential therapeutic agents ameliorating the downstream effects after SAH, the overall outcome of SAH has improved over recent decades, likely related to improvements in interventional options for ruptured cerebral aneurysms and in critical care management. Emerging clinical evidence also suggests potential harmful impact of historic empiric treatments for SAH-associated vasospasm, such as prophylactic induction of hypertension, hypervolemia, and hemodilution (triple H therapy).               With decreasing mortality, long-term SAH survivorship and efforts to reduce chronic morbidity and to improve quality of life and patient-centered outcome are growing areas of unmet need. Despite existing guidelines, significant variabilities in local and regional practices and in scientific terminologies have historically limited advancement in SAH care and therapeutic development. Large global collaborative efforts developed harmonized SAH common data elements in 2019, and studies are under way to examine how existing variabilities in SAH care impact long-term SAH outcomes.                                         SUMMARY               Although the overall incidence and mortality of SAH is decreasing with advances in preventive and acute care, SAH remains a major cause of long-term morbidity in survivors. Significant variabilities in care settings and empiric treatment protocols and inconsistent scientific terminologies have limited advancement in patient care and therapeutic clinical studies. Large consensus efforts are under way to introduce clinical guidelines and common data elements to advance therapeutic approaches and improve patient outcome.},
  langid = {english}
}

@article{chowBrainSpinalEpidural2018,
  title = {Brain and {{Spinal Epidural Abscess}}},
  author = {Chow, Felicia},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1327--1348},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000649},
  url = {https://journals.lww.com/00132979-201810000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Brain abscesses and spinal epidural abscesses are serious, potentially life-threatening infections of the central nervous system. This article outlines the clinical presentation, evaluation, and management of brain abscesses and spinal epidural abscesses, with a specific focus on bacterial infections.                                         RECENT FINDINGS               The overall incidence of brain abscesses has declined, in part because of fewer brain abscesses associated with otogenic infections. However, emerging patient populations at high risk for brain abscess include those with a history of penetrating head trauma, neurosurgery, or immunodeficiency. Improved mortality rates for brain abscess are attributable to modern diagnostic imaging, stereotactic-guided aspiration, and newer antimicrobials that readily penetrate into the central nervous system and abscesses. Brain MRI is more sensitive than CT for brain abscess, particularly in the early stages, but CT remains more widely available and can adequately identify potential abscesses and confirm response to treatment. With the advent of minimally invasive neurosurgical techniques, surgical excision is often employed only for posterior fossa, multiloculated, or superficial well-circumscribed abscesses. In select clinical scenarios, conservative medical management may be a safe alternative to a combined surgical and medical approach. Unlike brain abscess, the incidence of spinal epidural abscess is on the rise and has been attributed to higher prevalence of predisposing factors, including spinal procedures and instrumentation.                                         SUMMARY               Successful diagnosis and management of brain abscess and spinal epidural abscess requires a collaborative approach among neurologists, neurosurgeons, radiologists, and infectious disease physicians. The foundation of management of brain abscess includes surgical intervention for diagnostic purposes if a pathogen has not been identified or for decompression of larger abscesses or those with mass effect and significant surrounding edema; appropriate dosing and adequate duration of an antimicrobial regimen tailored to the presumptive source of infection and available culture data, and eradication of the primary source of infection. For spinal epidural abscesses, neurologic status at the time of presentation is directly related to outcomes, underscoring the importance of prompt recognition and intervention.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/28X7DN2Q/Chow (2018) Brain and Spinal Epidural Abscess.pdf}
}

@article{chowNeurosyphilis2021,
  title = {Neurosyphilis},
  author = {Chow, Felicia},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {1018--1039},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000982},
  url = {https://journals.lww.com/10.1212/CON.0000000000000982},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article focuses on the epidemiology, clinical presentation, diagnosis, and management of neurosyphilis, with an emphasis on clinically relevant issues faced by the practicing neurologist.                                         RECENT FINDINGS                                The incidence of primary and secondary syphilis, the sexually transmissible stages of infection, has been on the rise for the past 2 decades. A concerning recent trend is the surge in cases of syphilis in women and of congenital syphilis. Neurosyphilis remains a relatively common complication that can occur at any stage of syphilis. Along with meningitis, meningovascular syphilis, which has been historically described as a late presentation of neurosyphilis, now frequently occurs as a manifestation of early infection. Late forms of neurosyphilis, including tabes dorsalis and general paresis, are less prevalent in the era of widespread penicillin use. As more laboratories adopt the reverse-sequence algorithm for syphilis testing, patients with serodiscordant results (ie, a reactive serum treponemal test with a nonreactive nontreponemal test) may present an increasingly encountered diagnostic challenge for neurologists. Although the CSF Venereal Disease Research Laboratory (VDRL) remains a mainstay of diagnostic testing for neurosyphilis, using a higher titer cutoff (greater than 1:320) for the                 Treponema pallidum                 particle agglutination assay (TPPA) from the CSF may improve the utility of the TPPA as a supporting criterion for the diagnosis of neurosyphilis. Penicillin G is the treatment of choice for neurosyphilis, although ceftriaxone may be a reasonable alternative therapy.                                                        SUMMARY               A high index of suspicion and awareness of the variable clinical presentations of neurosyphilis are essential to the approach to this treatable infection. Neurologists should be mindful of the limitations of serologic testing in the diagnosis of neurosyphilis and exercise clinical judgment to determine the likelihood of the diagnosis.},
  langid = {english},
  keywords = {Current}
}

@article{christensenStrokeWomen2020,
  title = {Stroke in {{Women}}},
  author = {Christensen, Hanne and Bushnell, Cheryl},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {363--385},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000836},
  url = {https://journals.lww.com/10.1212/CON.0000000000000836},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews sex differences in stroke risk and presentation, with a particular emphasis on the unique risk factors women experience throughout the lifespan.                                         RECENT FINDINGS               Although prior studies suggested women have worse outcomes after stroke, it is now clear that age, prestroke functional status, and comorbidities explain many of the differences between men and women in stroke severity, functional outcomes, and mortality. Several meta-analyses and large cohort studies have evaluated the risk factors for women related to reproductive factors and found that fewer years between menarche and menopause, pregnancy complications (preeclampsia/eclampsia, preterm delivery, and stillbirth), oophorectomy, hormone replacement therapy use, and younger age at menopause all increase the risk of stroke. Although the nonreproductive risks of stroke overlap between men and women, those with greater impact on women include age, hypertension, atrial fibrillation, socioeconomic status, and depression.                                         SUMMARY               Significant sex differences are observed in risk factors of stroke and stroke outcome. Including this information in the clinical assessment of the individual patient may support development of more effective prevention plans.},
  langid = {english}
}

@article{ciafaloniMyastheniaGravisCongenital2019,
  title = {Myasthenia {{Gravis}} and {{Congenital Myasthenic Syndromes}}},
  author = {Ciafaloni, Emma},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1767--1784},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000800},
  url = {https://journals.lww.com/10.1212/CON.0000000000000800},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes fluctuating weakness in ocular, bulbar, and limb muscles and can, in 15\% of cases, cause myasthenic crisis, a neurologic emergency characterized by respiratory failure. Although infrequent, MG needs to be promptly recognized and treated because the potential for improvement and remission is very high. The diagnosis of MG can be challenging and delayed because of the fluctuating nature of muscle weakness and the overlap of signs and symptoms with other neuromuscular diseases.               This article reviews the importance of prompt recognition of the typical signs and symptoms, best tests to confirm the diagnosis, currently available acute and chronic treatment modalities, the role of thymectomy, and the natural history of the disease. Special consideration related to the diagnosis and management in women during pregnancy and in children will also be reviewed. This article also includes an overview of congenital myasthenic syndromes.                                         RECENT FINDINGS               Recent significant efforts in standardizing and improving the care of patients with MG have occurred, as well as new momentum in developing new drugs for patients with MG who do not adequately respond to currently available treatments. The number of clinical trials and drugs in development for MG is steadily increasing. Eculizumab has been recently approved by the US Food and Drug Administration (FDA) for adult patients with generalized MG who are acetylcholine receptor--antibody positive, based on the REGAIN (Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis) study, a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. An international, multicenter, randomized trial comparing thymectomy plus prednisone with prednisone alone has demonstrated that thymectomy improves clinical outcome in patients with nonthymomatous MG. Clinical care guidelines have been published, and the recommendations for clinical research standards and the Myasthenia Gravis Foundation of America MGFA clinical classification published in 2000 have become widely accepted by the clinical and research community of MG experts.                                         SUMMARY               MG is a highly treatable disease with many effective treatment modalities available and with a natural history that continues to improve thanks to better diagnostic tests and effective drugs. The diagnosis and management of patients affected by MG can be highly rewarding for any neurologist as most patients are able to live normal lives if treated appropriately. Nevertheless, future research is needed to address unresolved clinical issues, such as when and how to discontinue immunosuppressive medications in patients in remission, the role and timing of thymectomy in children, and better treatment options for refractory patients.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/XYWNEGMN/Ciafaloni (2019) Myasthenia Gravis and Congenital Myasthenic Syndromes.pdf}
}

@article{claassenMultipleSystemAtrophy2022,
  title = {Multiple {{System Atrophy}}},
  author = {Claassen, Daniel O.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1350--1363},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001154},
  url = {https://journals.lww.com/10.1212/CON.0000000000001154},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Patients with multiple system atrophy (MSA) can present with diverse clinical manifestations, and the clinical care required is complex and requires a thoughtful approach to emerging symptoms and treatment decisions.                                         RECENT FINDINGS               Even though it is a rare disease, MSA is often encountered in clinical practice. New developments in biofluid biomarkers and diagnostic assessments offer potential for earlier and more accurate diagnosis. This article describes recent findings, such as the use of skin biopsies, neuroimaging, and novel treatment concepts (eg, central noradrenergic augmentation).                                         SUMMARY               MSA is a complex disease. This article provides a summary of treatment options for diverse symptoms that include autonomic, sleep, mood, and motor manifestations of the disease to help clinicians care for patients with MSA. Providing comprehensive care for patients with MSA requires an understanding of the diverse symptomatology that patients develop over time and should include an interdisciplinary team.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{cohenMitochondrialMetabolicMyopathies2019,
  title = {Mitochondrial and {{Metabolic Myopathies}}},
  author = {Cohen, Bruce H.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1732--1766},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000805},
  url = {https://journals.lww.com/10.1212/CON.0000000000000805},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of mitochondrial and metabolic biology, the genetic mechanisms causing mitochondrial diseases, the clinical features of mitochondrial diseases, lipid myopathies, and glycogen storage diseases, all with a focus on those syndromes and diseases associated with myopathy. Over the past decade, advances in genetic testing have revolutionized patient evaluation. The main goal of this review is to give the clinician the basic understanding to recognize patients at risk of these diseases using the standard history and physical examination.                                         RECENT FINDINGS                                Primary mitochondrial disease                 is the current designation for the illnesses resulting from genetic mutations in genes whose protein products are necessary for mitochondrial structure or function. In most circumstances, more than one organ system is involved in mitochondrial disease, and the value of the classic clinical features as originally described early in the history of mitochondrial diseases has reemerged as being important to identifying patients who may have a primary mitochondrial disease. The use of the genetic laboratory has become the most powerful tool for confirming a diagnosis, and nuances of using genetic results will be discussed in this article. Treatment for mitochondrial disease is symptomatic, with less emphasis on vitamin and supplement therapy than in the past. Clinical trials using pharmacologic agents are in progress, with the field attempting to define proper goals of treatment. Several standard accepted therapies exist for many of the metabolic myopathies.                                                        SUMMARY               Mitochondrial, lipid, and glycogen diseases are not uncommon causes of multisystem organ dysfunction, with the neurologic features, especially myopathy, occurring as a predominant feature. Early recognition requires basic knowledge of the varied clinical phenotypes before moving forward with a screening evaluation and possibly a genetic evaluation. Aside from a few specific diseases for which there are recommended interventions, treatment for the majority of  these disorders remains symptomatic, with clinical trials currently in progress that will hopefully result in standard treatments.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/6E5IB52R/Cohen (2019) Mitochondrial and Metabolic Myopathies.pdf}
}

@article{coleLargeArteryAtherosclerotic2017,
  title = {Large {{Artery Atherosclerotic Occlusive Disease}}},
  author = {Cole, John W.},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {133--157},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000436},
  url = {https://journals.lww.com/00132979-201702000-00013},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               Extracranial or intracranial large artery atherosclerosis is often identified as a potential etiologic cause for ischemic stroke and transient ischemic attack. Given the high prevalence of large artery atherosclerosis in the general population, determining whether an identified atherosclerotic lesion is truly the cause of a patient's symptomatology can be difficult. In all cases, optimally treating each patient to minimize future stroke risk is paramount. Extracranial or intracranial large artery atherosclerosis can be broadly compartmentalized into four distinct clinical scenarios based upon the individual patient's history, examination, and anatomic imaging findings: asymptomatic and symptomatic extracranial carotid stenosis, intracranial atherosclerosis, and extracranial vertebral artery atherosclerotic disease. This review provides a framework for clinicians evaluating and treating such patients.                                         Recent Findings:               Intensive medical therapy achieves low rates of stroke and death in asymptomatic carotid stenosis. Evidence indicates that patients with severe symptomatic carotid stenosis should undergo carotid revascularization sooner rather than later and that the risk of stroke or death is lower using carotid endarterectomy than with carotid stenting. Specific to stenting, the risk of stroke or death is greatest among older patients and women. Continuous vascular risk factor optimization via sustained behavioral modifications and intensive medical therapy is the mainstay for stroke prevention in the setting of intracranial and vertebral artery origin atherosclerosis.                                         Summary:               Lifelong vascular risk factor optimization via sustained behavioral modifications and intensive medical therapy are the key elements to reduce future stroke risk in the setting of large artery atherosclerosis. When considering a revascularization procedure for carotid stenosis, patient demographics, comorbidities, and the periprocedural risks of stroke and death should be carefully considered.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/RK54IJSI/Cole (2017) Large Artery Atherosclerotic Occlusive Disease.pdf}
}

@article{colmanAdultGliomas2020,
  title = {Adult {{Gliomas}}},
  author = {Colman, Howard},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1452--1475},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000935},
  url = {https://journals.lww.com/10.1212/CON.0000000000000935},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article highlights important aspects of the evaluation, diagnosis, and treatment of adult gliomas, including lower-grade astrocytomas and oligodendrogliomas, glioblastomas, and ependymomas.                                         RECENT FINDINGS               The appropriate initial evaluation and accurate diagnosis of gliomas require an understanding of the spectrum of clinical and radiographic presentations. Recent advances in the understanding of distinct molecular prognostic subtypes have led to major revisions in the diagnostic classification of gliomas. Integration of these new diagnostic and molecular classifications is an important part of the modern management of gliomas and facilitates better understanding and interpretation of the efficacy of different therapies in specific glioma subtypes.                                         SUMMARY               The management of adult gliomas is a multidisciplinary endeavor. However, despite recent molecular and treatment advances, the majority of diffuse gliomas remain incurable, and efforts aimed at the development and testing of new therapies in clinical trials are ongoing.},
  langid = {english}
}

@article{conidiUnusualSportsRelatedNeurologic2014,
  title = {Some {{Unusual Sports-Related Neurologic Conditions}}},
  shorttitle = {Some {{Unusual Sports-Related Neurologic Conditions}}},
  author = {Conidi, Frank},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1645--1656},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458969.48271.1f},
  url = {http://journals.lww.com/00132979-201412000-00014},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/F5EC77IK/conidi2014.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/USR7SZ2R/Conidi (2014) Some Unusual Sports-Related Neurologic Conditions.pdf}
}

@article{coonSweatingDisorders2020,
  title = {Sweating {{Disorders}}},
  author = {Coon, Elizabeth A. and Cheshire, William P.},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {116--137},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000813},
  url = {https://journals.lww.com/10.1212/CON.0000000000000813},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews disorders of sweating, including hyperhidrosis and anhidrosis due to central or peripheral autonomic nervous system causes.                                         RECENT FINDINGS               Disorders of thermoregulation and sweating may manifest with hyperhidrosis or hypohidrosis/anhidrosis. Primary disorders of hyperhidrosis may significantly impact quality of life yet tend to be benign. Many sweating disorders present with compensatory hyperhidrosis due to areas of anhidrosis. Anhidrosis may occur due to either central or peripheral damage to the autonomic nervous system. The thermoregulatory control of sweating involves central pathways from the hypothalamus to the brainstem and then spinal cord as well as projections to peripheral structures, including the sympathetic chain ganglia, peripheral nerves, and eccrine sweat glands. Disruption at any point of this pathway may lead to impaired sweating. Characterization of sweating dysfunction helps localize different autonomic disorders to guide diagnosis and may allow for evaluation of treatment effect.                                         SUMMARY               Sweating dysfunction manifests in myriad ways, including essential hyperhidrosis, complete anhidrosis with heat intolerance, and compensatory hyperhidrosis due to anhidrosis, and often indicates involvement of underlying central or peripheral autonomic dysfunction.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{coonSynucleinopathies2020,
  title = {Synucleinopathies},
  author = {Coon, Elizabeth A. and Singer, Wolfgang},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {72--92},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000819},
  url = {https://journals.lww.com/10.1212/CON.0000000000000819},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the {$\alpha$}-synucleinopathies pure autonomic failure, multiple system atrophy, dementia with Lewy bodies, and Parkinson disease with respect to autonomic failure.                                         RECENT FINDINGS               The pattern and severity of autonomic involvement in the synucleinopathies is related to differences in cellular deposition and neuronal populations affected by {$\alpha$}-synuclein aggregation, which influences the degree and manifestation of autonomic failure. Clinical and laboratory autonomic features distinguish the different synucleinopathies based on pattern and severity. These features also determine which patients are at risk for evolution from pure autonomic failure to the synucleinopathies with prominent motor involvement, such as multiple system atrophy, dementia with Lewy bodies, or Parkinson disease.                                         SUMMARY               Autonomic failure is a key feature of the synucleinopathies, with varying type and degree of dysfunction from predominantly peripheral involvement in the Lewy body disorders to central involvement in multiple system atrophy.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current},
  file = {/Users/nathanielyomogida/Zotero/storage/IS7VWVPR/Coon_Singer (2020) Synucleinopathies.pdf}
}

@article{cornesEvaluationPatientSpells2011,
  title = {Evaluation of the {{Patient With Spells}}},
  shorttitle = {Evaluation of the {{Patient With Spells}}},
  author = {Cornes, Susannah Brock and Shih, Tina},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {984--1009},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407056.94789.2d},
  url = {http://journals.lww.com/00132979-201110000-00007},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/6Z7LJNTY/Cornes_Shih (2011) Evaluation of the Patient With Spells.pdf;/Users/nathanielyomogida/Zotero/storage/TQQNMTIW/cornes2011.pdf.pdf}
}

@article{coslettApraxiaNeglectAgnosia2018,
  title = {Apraxia, {{Neglect}}, and {{Agnosia}}},
  author = {Coslett, H. Branch},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {768--782},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000606},
  url = {https://journals.lww.com/00132979-201806000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               In part because of their striking clinical presentations, disorders of higher nervous system function figured prominently in the early history of neurology. These disorders are not merely historical curiosities, however. As apraxia, neglect, and agnosia have important clinical implications, it is important to possess a working knowledge of the conditions and how to identify them.                                         RECENT FINDINGS               Apraxia is a disorder of skilled action that is frequently observed in the setting of dominant hemisphere pathology, whether from stroke or neurodegenerative disorders. In contrast to some previous teaching, apraxia has clear clinical relevance as it is associated with poor recovery from stroke. Neglect is a complex disorder with many different manifestations that may have different underlying mechanisms. Neglect is, in the author's view, a multicomponent disorder in which impairment in attention and arousal is a major contributor. Finally, agnosias come in a wide variety of forms, reflecting impairments ranging from low-level sensory processing to access to stored knowledge of the world (semantics).                                         SUMMARY               The classic behavioral disorders reviewed here were of immense interest to early neurologists because of their arresting clinical phenomenology; more recent investigations have done much to advance the neuroscientific understanding of the disorders and to reveal their clinical relevance.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/GGKQY9FA/Coslett (2018) Apraxia, Neglect, and Agnosia.pdf}
}

@article{costelloImagingNeuroophthalmology2019,
  title = {Imaging in {{Neuro-ophthalmology}}},
  author = {Costello, Fiona and Scott, James N.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1438--1490},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000783},
  url = {https://journals.lww.com/10.1212/CON.0000000000000783},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses an approach to imaging in patients with neuro-ophthalmologic disorders, with emphasis on the clinical-anatomic localization of lesions affecting afferent and efferent visual function.                                         RECENT FINDINGS               Advances in MRI, CT, ultrasound, and optical coherence tomography have changed how neuro-ophthalmic disorders are diagnosed and followed in the modern clinical era.                                         SUMMARY               The advantages, disadvantages, and indications for various imaging techniques for neuro-ophthalmologic disorders are discussed, with a view to optimizing how these tools can be used to enhance patient care.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/IAUILBSZ/Costello_Scott (2019) Imaging in Neuro-ophthalmology.pdf}
}

@article{costelloNeuromyelitisOpticaSpectrum2022,
  title = {Neuromyelitis {{Optica Spectrum Disorders}}},
  author = {Costello, Fiona},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1131--1170},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001168},
  url = {https://journals.lww.com/10.1212/CON.0000000000001168},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the cardinal clinical features, distinct immunopathology, current diagnostic criteria, relapse-related risk factors, emerging biomarkers, and evolving treatment strategies pertaining to neuromyelitis optica spectrum disorders (NMOSD).                                         RECENT FINDINGS               The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy have spearheaded the identification of key immunologic therapeutic targets in this disease, including but not limited to the complement system, the interleukin 6 (IL-6) receptor, and B cells. Accordingly, four recent randomized controlled trials have demonstrated the efficacy of three new NMOSD therapies, namely eculizumab, satralizumab, and inebilizumab.                                         SUMMARY               Currently, NMOSD poses both diagnostic and treatment challenges. It is debated whether individuals who are seropositive for myelin oligodendrocyte glycoprotein (MOG)-IgG belong within the neuromyelitis optica spectrum. This discussion is fueled by disparities in treatment responses between patients who are AQP4-IgG seropositive and seronegative, suggesting different immunopathologic mechanisms may govern these conditions. As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse detection and inform long-term treatment decisions. Future research focal points should include strategies to optimize relapse management, restorative treatments that augment neurologic recovery, and practical solutions that promote equitable access to approved therapies for all patients with NMOSD.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{couttsDiagnosisManagementTransient2017,
  title = {Diagnosis and {{Management}} of {{Transient Ischemic Attack}}},
  author = {Coutts, Shelagh B.},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {82--92},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000424},
  url = {https://journals.lww.com/00132979-201702000-00010},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               This article reviews the diagnosis, investigation, and recommended management after a transient ischemic attack (TIA) and discusses how to make an accurate diagnosis, including the diagnosis of mimics of TIAs.                                         Recent Findings:               Up to a 10\% risk of recurrent stroke exists after a TIA, and up to 80\% of this risk is preventable with urgent assessment and treatment. Imaging of the brain and intracranial and extracranial blood vessels using CT, CT angiography, carotid Doppler ultrasound, and MRI is an important part of the diagnostic assessment. Treatment options include anticoagulation for atrial fibrillation, carotid revascularization for symptomatic carotid artery stenosis, antiplatelet therapy, and vascular risk factor reduction strategies.                                         Summary:               TIA offers the greatest opportunity to prevent stroke that physicians encounter. A TIA should be treated as a medical emergency, as up to 80\% of strokes after TIA are preventable.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/KJKFZWIV/Coutts (2017) Diagnosis and Management of Transient Ischemic Attack.pdf}
}

@article{cramerRecoveryStroke2020,
  title = {Recovery {{After Stroke}}},
  author = {Cramer, Steven C.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {415--434},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000838},
  url = {https://journals.lww.com/10.1212/CON.0000000000000838},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes restorative therapies to improve patient outcomes after stroke. These therapies contrast with acute stroke treatments such as recombinant tissue plasminogen activator (rtPA) and thrombectomy that target clots, aim to salvage threatened brain tissue to limit injury, and have a time window measured in hours. Restorative therapies target the brain, aim to promote plasticity within surviving brain tissue, and have a time window measured in days to weeks or longer.                                         RECENT FINDINGS               A number of drugs are under study. Preclinical studies are providing attractive therapeutic candidates for translation, such as the C-C chemokine receptor 5 inhibitor maraviroc. Some drug studies have used a pragmatic approach, which is premature for the nascent field of neural repair. Substantial data support the utility of activity-dependent therapies, including constraint-induced movement therapy, with recent studies supporting the need for very high doses to generate the best functional gains. While stem cell therapies are at an early stage, mounting preclinical evidence supports the efficacy of mesenchymal stem cells; some initial human studies are supportive. Several types of brain stimulation have been examined, and in some cases initial studies are promising.                                         SUMMARY               Improved insights into stroke recovery and its treatment have the potential to reduce disability in a large segment of stroke survivors.},
  langid = {english}
}

@article{creutzfeldtPalliativeCareShared2021,
  title = {Palliative {{Care}} and {{Shared Decision Making}} in the {{Neurocritical Care Unit}}},
  author = {Creutzfeldt, Claire J.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1430--1443},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001003},
  url = {https://journals.lww.com/10.1212/CON.0000000000001003},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the evidence on integrating palliative care into the care of patients with various types of serious neurologic illness, emphasizes the importance of palliative care in the neurocritical care unit, and suggests tools for clinicians to improve their communication skills and decision making.                                         RECENT FINDINGS               Palliative care is a holistic approach to medical care that aims to relieve physical, psychological, social, and spiritual suffering. It is both a medical specialty as young as neurocritical care itself and an approach to patient care by all clinicians who manage patients with serious illness. Patients presenting to the neurocritical care unit and their families have unique palliative care needs that challenge communication and shared decision making.                                         SUMMARY               Palliative care, effective communication, and shared decision making require a set of core skills that all neurology clinicians should master.},
  langid = {english}
}

@article{crossTreatmentMultipleSclerosis2022,
  title = {Treatment of {{Multiple Sclerosis}}},
  author = {Cross, Anne and Riley, Claire},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1025--1051},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001170},
  url = {https://journals.lww.com/10.1212/CON.0000000000001170},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Given the expansion of options for the treatment of relapsing multiple sclerosis, this review outlines the framework for developing a treatment strategy, with consideration of when to switch or discontinue therapies, and a comprehensive elaboration of the mechanisms of action, efficacy, and safety considerations for each of the therapeutic classes.                                         RECENT FINDINGS               The armamentarium of immunotherapies has grown rapidly, to encompass 19 US Food and Drug Administration (FDA)-approved immunotherapies available in 2021, which are addressed in the review. The coronavirus pandemic that began in 2020 underscored existing concerns regarding vaccine efficacy in those treated with immune-suppressing immunotherapies, which are also addressed here.                                         SUMMARY               By choosing a treatment strategy before exploring the individual medications, patients and providers can focus their efforts on a subset of the therapeutic options. Although the mechanisms of action, routes of administration, efficacy, safety, and tolerability of the described agents and classes differ, all are effective in reducing relapse frequency in multiple sclerosis (MS), with most also showing a reduction in the accumulation of neurologic disability. These powerful effects are improving the lives of people with MS. Pharmacovigilance is critical for the safe use of these immune-modulating and -suppressing agents, and vaccine efficacy may be reduced by those with immune-suppressing effects.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{cruccuTrigeminalNeuralgia2017,
  title = {Trigeminal {{Neuralgia}}},
  author = {Cruccu, Giorgio},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {396--420},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000451},
  url = {https://journals.lww.com/00132979-201704000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Although trigeminal neuralgia is well known to neurologists, recent developments in classification and clinical diagnosis, new MRI methods, and  a debate about surgical options necessitate an update on the topic.                                         Recent Findings:               Currently, a worldwide controversy exists regarding the classification, diagnostic process, and surgical treatment of trigeminal neuralgia. This controversy has been caused on one side by the recognition that some 50\% of patients with trigeminal neuralgia, apart from characteristic paroxysmal attacks, also have continuous pain in the same territory, which results in greater diagnostic difficulties and is associated with a lower response to medical and surgical treatments. In contrast, recent developments in MRI methods allow differentiation between a mere neurovascular contact and an effective compression of the trigeminal root by an anomalous vessel, which implies more difficulties in the choice of surgical treatment, with the indication for microvascular decompression becoming more restricted.                                         Summary:               This article proposes that the diagnosis of trigeminal neuralgia, with or without concomitant continuous pain, must rely on clinical grounds only. Diagnostic tests are necessary to distinguish three etiologic categories: idiopathic trigeminal neuralgia (nothing is found), classic trigeminal neuralgia (an anomalous vessel produces morphologic changes of the trigeminal root near its entry into the pons), and secondary trigeminal neuralgia (due to major neurologic disease, such as multiple sclerosis or tumors at the cerebellopontine angle). Carbamazepine and oxcarbazepine (ie, voltage-gated, frequency-dependent sodium channel blockers) are still the first-choice medical treatment, although many patients experience significant side effects, and those with concomitant continuous pain respond less well to treatment. The development of sodium channel blockers that are selective for the sodium channel 1.7 (Na               v               1.7) receptor will hopefully help. Although all the surgical interventions (percutaneous ganglion lesions, gamma knife radiosurgery, and microvascular decompression) are very efficacious, precise MRI criteria for differentiating a real neurovascular compression from an irrelevant contact will be of benefit in better selecting patients for microvascular decompression.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/L9K97A38/Cruccu (2017) Trigeminal Neuralgia.pdf;/Users/nathanielyomogida/Zotero/storage/YN4CCTKR/cruccu2017.pdf.pdf}
}

@article{crutchfieldManagingPatientsNeurologic2014,
  title = {Managing {{Patients With Neurologic Disorders Who Participate}} in {{Sports Activities}}},
  shorttitle = {Managing {{Patients With Neurologic Disorders Who Participate}} in {{Sports Activities}}},
  author = {Crutchfield, Kevin E.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1657--1666},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458968.40648.6f},
  url = {http://journals.lww.com/00132979-201412000-00015},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/8WEF228B/crutchfield2014.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/PSLFEFKT/Crutchfield (2014) Managing Patients With Neurologic Disorders Who Participate in Sports Activities.pdf}
}

@article{cumblerInHospitalFallsEvaluation2011,
  title = {In-{{Hospital Falls}}: {{Evaluation}} and {{Response}}},
  shorttitle = {In-{{Hospital Falls}}},
  author = {Cumbler, Ethan and Likosky, David},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {1063--1076},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407060.48155.05},
  url = {http://journals.lww.com/00132979-201110000-00011},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/J444TZKP/Cumbler_Likosky (2011) In-Hospital Falls.pdf;/Users/nathanielyomogida/Zotero/storage/UCE3X5ZC/cumbler2011.pdf.pdf}
}

@article{cutsforth-gregoryPosturalTachycardiaSyndrome2020,
  title = {Postural {{Tachycardia Syndrome}} and {{Neurally Mediated Syncope}}},
  author = {{Cutsforth-Gregory}, Jeremy K.},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {93--115},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000818},
  url = {https://journals.lww.com/10.1212/CON.0000000000000818},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the diagnosis and management of the most common disorders of orthostatic intolerance: postural tachycardia syndrome (POTS) and neurally mediated syncope.                                         RECENT FINDINGS               POTS is a heterogeneous syndrome caused by several pathophysiologic mechanisms that may coexist (limited autonomic neuropathy, hyperadrenergic state, hypovolemia, venous pooling, joint hypermobility, deconditioning). Neurally mediated syncope occurs despite intact autonomic reflexes. Management of orthostatic intolerance aims to increase functional capacity, including standing time, performance of daily activities, and exercise tolerance. Nonpharmacologic strategies (fluid and salt loading, physical countermaneuvers, compression garments, exercise training) are fundamental for patients with POTS, occasionally complemented by medications to raise blood pressure or slow heart rate. Neurally mediated syncope is best managed by recognition and avoidance of triggers.                                         SUMMARY               Significant negative effects on quality of life occur in patients with POTS and in patients with recurrent neurally mediated syncope, which can be mitigated through targeted evaluation and thoughtful management.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{dattaMoodDisorders2021,
  title = {Mood {{Disorders}}},
  author = {Datta, Shae and Suryadevara, Uma and Cheong, Josepha},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1712--1737},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001051},
  url = {https://journals.lww.com/10.1212/CON.0000000000001051},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This comprehensive review of mood disorders brings together the past and current literature on the diagnosis, evaluation, and treatment of the depressive and bipolar disorders. It highlights the primary mood disorders and secondary neurologic causes of mood disorders that are commonly encountered in a clinical setting. As the literature and our understanding evolve, recent additions to the current literature are important to bring forth to the readers.                                         RECENT FINDINGS               Advancements in clinical medicine have strengthened our understanding of the associations of neurologic and psychiatric diseases. This article highlights the medications frequently used with newly identified mood disorders and the common side effects of these medications. A paradigm shift has moved toward newer treatment modalities, such as the use of ketamine, repetitive transcranial magnetic stimulation, and complementary and alternative medicine. The risks and benefits of such therapies, along with medications, are reviewed in this article.                                         SUMMARY               Mood disorders are extraordinarily complex disorders with significant association with many neurologic disorders. Early identification of these mood disorders can prevent significant morbidity and mortality associated with them. With further expansion of pharmacologic options, more targeted therapy is possible in improving quality of life for patients.},
  langid = {english},
  keywords = {Current}
}

@article{davisAcuteBacterialMeningitis2018,
  title = {Acute {{Bacterial Meningitis}}},
  author = {Davis, Larry E.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1264--1283},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000660},
  url = {https://journals.lww.com/00132979-201810000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW                                While acute bacterial meningitis is becoming less common in developed countries because of the widespread use of vaccines against                 Streptococcus pneumoniae, Neisseria meningitides,                 and                 Haemophilus influenzae                 , bacterial meningitis still occurs worldwide, with peak incidence in young children and the elderly. Bacterial meningitis is usually lethal unless appropriate antibiotics that cross the blood-brain barrier are given. Clinical suspicion of bacterial meningitis begins when patients present with the abrupt onset of fever, headache, and meningismus.                                                        RECENT FINDINGS               New technologies are being developed for more rapid identification of the bacterial species causing meningitis. When appropriate, administration of adjunctive dexamethasone with the antibiotics often lessens neurologic sequelae in survivors, which may include aphasia, ataxia, paresis, hearing loss, and cognitive impairment.                                         SUMMARY               Confirmation of the diagnosis of bacterial meningitis comes mainly from examination and culture of CSF obtained from a lumbar puncture. Typically, the CSF shows an elevated neutrophil count, elevated protein, depressed glucose, positive Gram stain, and growth of the bacteria on appropriate culture media. Antibiotic sensitivities of the bacteria determine the appropriate antibiotics, although an educated guess of the best antibiotics to be given promptly must be made until the antibiotic sensitivities return, usually in a few days.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/UIEYLNXB/Davis (2018) Acute Bacterial Meningitis.pdf}
}

@article{dayRapidlyProgressiveDementia2022,
  title = {Rapidly {{Progressive Dementia}}},
  author = {Day, Gregory S.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {901--936},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001089},
  url = {https://journals.lww.com/10.1212/CON.0000000000001089},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article presents a practical approach to the evaluation of patients with rapidly progressive dementia.                                         RECENT FINDINGS               The approach presented in this article builds upon the standard dementia evaluation, leveraging widely available tests and emergent specific markers of disease to narrow the differential diagnosis and determine the cause(s) of rapid progressive decline. The discovery of treatment-responsive causes of rapidly progressive dementia underscores the need to determine the cause early in the symptomatic course when treatments are most likely to halt or reverse cognitive decline.                                         SUMMARY               A pragmatic and organized approach to patients with rapidly progressive dementia is essential to mitigate diagnostic and therapeutic challenges and optimize patient outcomes.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/Q2M6B7JG/Day (2022) Rapidly Progressive Dementia.pdf}
}

@article{dayReversibleDementias2019,
  title = {Reversible {{Dementias}}},
  author = {Day, Gregory S.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {234--253},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000688},
  url = {https://journals.lww.com/00132979-201902000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the clinical features that suggest a reversible cause of dementia.                                         RECENT FINDINGS               Substantial variability exists in the presenting features and clinical course of patients with common neurodegenerative causes of dementia, but the response to available therapies and eventual outcomes are often poor. This realization has influenced the evaluation of patients with dementia, with diagnostic approaches emphasizing routine screening for a short list of potentially modifiable disorders that may exacerbate dementia symptoms or severity but rarely influence long-term outcomes. Although a standard approach to the assessment of dementia is appropriate in the vast majority of cases, neurologists involved in the assessment of patients with dementia must recognize those rare patients with reversible causes of dementia, coordinate additional investigations when required, and ensure expedited access to treatments that may reverse decline and optimize long-term outcomes.                                         SUMMARY               The potential to improve the outcome of patients with reversible dementias exemplifies the need to recognize these patients in clinical practice. Dedicated efforts to screen for symptoms and signs associated with reversible causes of dementia may improve management and outcomes of these rare patients when encountered in busy clinical practices.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/WZKIWSYZ/Day (2019) Reversible Dementias.pdf}
}

@article{devereDisordersTasteSmell2017,
  title = {Disorders of {{Taste}} and {{Smell}}},
  author = {DeVere, Ronald},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {421--446},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000463},
  url = {https://journals.lww.com/00132979-201704000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article aims to educate clinical neurologists on the importance of taste and smell disorders in clinical neurology. These disorders commonly occur in head trauma, multiple sclerosis, seizure disorders, and neurodegenerative diseases such as idiopathic Parkinson disease and dementia, mild cognitive impairment, and Alzheimer disease, just to name a few. This article covers the basic anatomy of smell and taste, notes the important points of taking a proper history, and discusses smell and taste testing, which are inexpensive, minimally time-consuming procedures. Recurrent bad smells and tastes are not uncommon in these disorders, which cause major impairment in quality of life, including loss of appetite, decreased eating, and weight loss. The diagnosis and treatment of these disorders will also be discussed.                                         Recent Findings:               Despite past widespread negative prognoses of taste and smell disorders, more recent work in the last 10 years has shown an improved prognosis for smell and taste recovery in most disorders, and recommendations for changes in food preparation have helped many patients enjoy their food and increase their appetite. Recent experimental evidence has shown that smell loss and testing can assist in separating idiopathic Parkinson disease from other parkinsonian syndromes, can suggest which patients with rapid eye movement (REM) sleep behavior disorder will more likely develop Parkinson disease, and can be predictive of the progression of cognitive impairment and Alzheimer dementia.                                         Summary:               This article discusses the common smell and taste disorders that a clinical neurologist will encounter in practice. The anatomy and function of smell and taste will be reviewed, followed by office evaluation and testing. The common disorders will be reviewed, along with their prognosis and management.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/29X7W68V/devere2017.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/UAA4N45S/DeVere (2017) Disorders of Taste and Smell.pdf}
}

@article{diehnNeuroimagingSpinalCord2021,
  title = {Neuroimaging of {{Spinal Cord}} and {{Cauda Equina Disorders}}},
  author = {Diehn, Felix E. and Krecke, Karl N.},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {225--263},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000926},
  url = {https://journals.lww.com/10.1212/CON.0000000000000926},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the neuroimaging of disorders of the spinal cord and cauda equina, with a focus on MRI. An anatomic approach is used; diseases of the extradural, intradural-extramedullary, and intramedullary (parenchymal) compartments are considered, and both neoplastic and non-neoplastic conditions are covered. Differentiating imaging features are highlighted.                                         RECENT FINDINGS               Although T2-hyperintense signal abnormality of the spinal cord can have myriad etiologies, neuroimaging can provide specific diagnoses or considerably narrow the differential diagnosis in many cases. Intradural-extramedullary lesions compressing the spinal cord have a limited differential diagnosis and are usually benign; meningiomas and schwannomas are most common. Extradural lesions can often be specifically diagnosed. Disk herniations are the most commonly encountered mass of the epidural space. Cervical spondylotic myelopathy can cause a characteristic pattern of enhancement, which may be mistaken for an intrinsic myelopathy. A do-not-miss diagnosis of the extradural compartment is idiopathic spinal cord herniation, the appearance of which can overlap with arachnoid cysts and webs. Regarding intrinsic causes of myelopathy, the lesions of multiple sclerosis are characteristically short segment but can be confluent when multiple. Postcontrast MRI can be particularly helpful, including when attempting to differentiate the long-segment myelopathy of neurosarcoidosis and aquaporin-4 (AQP4)-IgG--seropositive neuromyelitis optica spectrum disorder (NMOSD) and when characterizing spinal cord tumors such as primary neoplasms and metastases. Spinal dural arteriovenous fistula is another do-not-miss diagnosis, with characteristic MRI features both precontrast and postcontrast. Tract-specific white matter involvement can be a clue for diseases such as subacute combined degeneration, paraneoplastic myelopathy, and radiation myelitis, whereas gray matter--specific involvement can suggest conditions such as cord infarct, viral myelitis, or myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorder.                                         SUMMARY               Knowledge of the neuroimaging findings of the many causes of spinal cord and cauda equina dysfunction is critical for both neurologists and neuroradiologists. A structured approach to lesion compartmental location and imaging feature characterization is recommended.},
  langid = {english}
}

@article{diesingNeurologicManifestationsGastrointestinal2023,
  title = {Neurologic {{Manifestations}} of {{Gastrointestinal}} and {{Nutritional Disorders}}},
  author = {Diesing, T. Scott},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {708--733},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001235},
  url = {https://journals.lww.com/10.1212/CON.0000000000001235},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               A tie between nutritional or gastrointestinal and neurologic disease has been recognized for centuries. Many gastrointestinal disorders are associated with neurologic disease through nutritional, immune-mediated, or degenerative pathophysiologies. This article reviews neurologic disorders in patients with gastrointestinal disease and gastrointestinal manifestations in their own neurologic patients.                                         LATEST DEVELOPMENTS                                Development of new gastric and bariatric surgical procedures and the widespread use of over-the-counter gastric acid--reducing medications continue to create vitamin and nutritional deficiencies despite modern diet and supplementation. Some supplements, such as vitamin A, vitamin B                 6                 , and selenium, themselves are now found to cause disease. Recent work has shown extraintestinal and neurologic manifestations of inflammatory bowel disease. Chronic brain damage in liver disease has been recognized, and the opportunity to intervene may exist in the covert beginning stages. The characterization of gluten-related neurologic symptoms and differentiation from those of celiac disease is an evolving body of work.                                                        ESSENTIAL POINTS               Gastrointestinal and neurologic diseases related to common immune-mediated, degenerative, or infectious mechanisms are common and can coexist in the same patient. Furthermore, gastrointestinal disease may cause neurologic complications because of nutritional inadequacies, malabsorption, and hepatic dysfunction. In many cases, the complications are treatable but have subtle or protean presentations. Therefore, the consulting neurologist must be current in knowledge of the growing ties between gastrointestinal and neurologic disease.},
  langid = {english},
  keywords = {Current}
}

@article{dietrichNeurotoxicityCancerTherapies2020,
  title = {Neurotoxicity of {{Cancer Therapies}}},
  author = {Dietrich, Jorg},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1646--1672},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000943},
  url = {https://journals.lww.com/10.1212/CON.0000000000000943},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews neurologic complications associated with chemotherapy, radiation therapy, antiangiogenic therapy, and immunotherapy.                                         RECENT FINDINGS               Cancer therapies can cause a wide range of neurologic adverse effects and may result in significant patient morbidity and mortality. Although some treatment-associated neurologic complications manifest acutely and are often reversible and transient, others occur with delayed onset, can be progressive, and are uniquely challenging to patient management. With an increase in multimodality and combination therapies, including targeted therapies and immunotherapies, and prolonged patient survival, novel and unique patterns of neurologic complications have emerged.                                         SUMMARY               Both conventional and novel cancer therapies can adversely affect the nervous system, thereby producing a wide range of neurologic complications. Increased awareness among neurologists and early recognition of cancer therapy--induced neurotoxic syndromes is critically important to minimize patient morbidity, prevent permanent injury, and improve patient outcomes.},
  langid = {english}
}

@article{dodickDiagnosingSecondaryPrimary2021,
  title = {Diagnosing {{Secondary}} and {{Primary Headache Disorders}}},
  author = {Dodick, David W.},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {572--585},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000980},
  url = {https://journals.lww.com/10.1212/CON.0000000000000980},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a systematic diagnostic approach to the patient with headache.                                         RECENT FINDINGS               The vast majority of patients presenting with headache in clinical practice have a primary headache disorder. The most common primary headache disorder in clinical practice is overwhelmingly migraine. Unfortunately, a substantial proportion of patients with migraine do not receive an accurate diagnosis. In addition, the clinical features of migraine overlap with secondary causes of headache, making a careful history and deliberative evaluation for warning symptoms or signs of a secondary headache disorder of paramount importance.                                         SUMMARY               The approach to the patient with headache requires knowledge of the diagnostic criteria for primary headache disorders, recognition of the importance of a systematic evaluation for red flags associated with secondary headache disorders, and awareness of the pearls and pitfalls encountered in the diagnostic evaluation of a patient with headache.},
  langid = {english},
  keywords = {Current}
}

@article{dohleManagementMedicalComplications2011,
  title = {Management of {{Medical Complications}}:},
  shorttitle = {Management of {{Medical Complications}}},
  author = {Dohle, Carolin I. and Reding, Michael J.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {510--529},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399070.54320.0c},
  url = {http://journals.lww.com/00132979-201106000-00013},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/8CUDCEVF/Dohle_Reding (2011) Management of Medical Complications.pdf;/Users/nathanielyomogida/Zotero/storage/JSF9S7BW/dohle2011.pdf.pdf}
}

@article{dombovyEmergingTherapiesNeurorehabilitation2011,
  title = {Emerging {{Therapies}} in {{Neurorehabilitation}}:},
  shorttitle = {Emerging {{Therapies}} in {{Neurorehabilitation}}},
  author = {Dombovy, Mary L.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {530--544},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399071.61943.e3},
  url = {http://journals.lww.com/00132979-201106000-00014},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/99ECTVA7/Dombovy (2011) Emerging Therapies in Neurorehabilitation.pdf;/Users/nathanielyomogida/Zotero/storage/K4PN32KT/dombovy2011.pdf.pdf}
}

@article{dombovyIntroductionEvolvingField2011,
  title = {Introduction: {{The Evolving Field}} of {{Neurorehabilitation}}},
  shorttitle = {Introduction},
  author = {Dombovy, Mary L.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {443--448},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399065.23826.f0},
  url = {http://journals.lww.com/00132979-201106000-00008},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/MXKXCBPG/Dombovy (2011) Introduction.pdf;/Users/nathanielyomogida/Zotero/storage/YDPTFKIB/dombovy2011.pdf.pdf}
}

@article{dombovyNeurorehabilitationOtherNeurologic2011,
  title = {Neurorehabilitation for {{Other Neurologic Disorders}}:},
  shorttitle = {Neurorehabilitation for {{Other Neurologic Disorders}}},
  author = {Dombovy, Mary L.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {606--616},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399075.07686.3f},
  url = {http://journals.lww.com/00132979-201106000-00018},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/7E5J9TZT/dombovy2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/U5M8NQYL/Dombovy (2011) Neurorehabilitation for Other Neurologic Disorders.pdf}
}

@article{dombovyTraumaticBrainInjury2011,
  title = {Traumatic {{Brain Injury}}:},
  shorttitle = {Traumatic {{Brain Injury}}},
  author = {Dombovy, Mary L.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {584--605},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399074.07686.76},
  url = {http://journals.lww.com/00132979-201106000-00017},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/FMPNYBLA/Dombovy (2011) Traumatic Brain Injury.pdf;/Users/nathanielyomogida/Zotero/storage/KMAMCKNF/dombovy2011.pdf.pdf}
}

@article{donofrioGuillainBarreSyndrome2017,
  title = {Guillain-{{Barr{\'e} Syndrome}}},
  author = {Donofrio, Peter D.},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1295--1309},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000513},
  url = {https://journals.lww.com/00132979-201710000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article reviews the current state of Guillain-Barr{\'e} syndrome (GBS), including its clinical presentation, evaluation, pathophysiology, and treatment.                                         Recent Findings:               GBS is an acute/subacute-onset polyradiculoneuropathy typically presenting with sensory symptoms and weakness over several days, often leading to quadriparesis. Approximately 70\% of patients report a recent preceding upper or lower respiratory tract infection or gastrointestinal illness. Approximately 30\% of patients require intubation and ventilation because of respiratory failure. Nerve conduction studies in the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) form of GBS typically show evidence for a multifocal demyelinating process, including conduction block or temporal dispersion in motor nerves. Sural sparing is a common phenomenon when testing sensory nerves. CSF analysis commonly shows an elevated protein, but this elevation may not be present until the third week of the illness. Patients with AIDP are treated with best medical management and either IV immunoglobulin (IVIg) or plasma exchange.                                         Summary:               GBS is a common form of acute quadriparesis; a high level of suspicion is needed for early diagnosis. With appropriate therapy, most patients make a very good to complete recovery.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/5ALGTQ9Z/Donofrio (2017) Guillain-Barr Syndrome.pdf;/Users/nathanielyomogida/Zotero/storage/DNCM47D7/donofrio2017.pdf.pdf}
}

@article{doughtyToxicMyopathies2019,
  title = {Toxic {{Myopathies}}},
  author = {Doughty, Christopher T. and Amato, Anthony A.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1712--1731},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000806},
  url = {https://journals.lww.com/10.1212/CON.0000000000000806},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the pathogenesis, clinical features, and management of toxic myopathy related to common medications, critical illness, and illicit substances.                                         RECENT FINDINGS               Muscle symptoms are common among statin users and are usually reversible after discontinuation of the statin; rarely, however, statins trigger an immune-mediated necrotizing myopathy that persists and requires immunomodulatory therapy. Autoantibodies targeting 3-hydroxy-3-methylglutaryl coenzyme A reductase can distinguish the toxic and immune-mediated forms. Immune checkpoint inhibitors, increasingly used in the treatment of advanced cancer, have recently been associated with the development of inflammatory myositis. A reversible mitochondrial myopathy has long been associated with zidovudine, but recent reports elucidate the risk of myopathy with newer antivirals, such as telbivudine and raltegravir.                                         SUMMARY               The medications most commonly associated with myopathy include statins, amiodarone, chloroquine, hydroxychloroquine, colchicine, certain antivirals, and corticosteroids, and myopathy can occur with chronic alcoholism. Certain clinical, electrodiagnostic, and histologic features can aid in early recognition. Stopping the use of the offending agent reverses symptoms in most cases, but specific and timely treatment may be required in cases related to agents that trigger immune-mediated muscle injury.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/WKK7TBZ3/Doughty_Amato (2019) Toxic Myopathies.pdf}
}

@article{douglasAlteredMentalStatus2011,
  title = {Altered {{Mental Status}}},
  shorttitle = {Altered {{Mental Status}}},
  author = {Douglas, Vanja C. and Josephson, S. Andrew},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {967--983},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407055.17661.33},
  url = {http://journals.lww.com/00132979-201110000-00006},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/7IWK47K5/Douglas_Josephson (2011) Altered Mental Status.pdf;/Users/nathanielyomogida/Zotero/storage/G2T3ET8H/douglas2011.pdf.pdf}
}

@article{eggenbergerInfectiousOpticNeuropathies2019,
  title = {Infectious {{Optic Neuropathies}}},
  author = {Eggenberger, Eric R.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1422--1437},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000777},
  url = {https://journals.lww.com/10.1212/CON.0000000000000777},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews common infectious optic neuropathies, focusing on the more common and globally important entities.                                         RECENT FINDINGS               Novel infections continue to emerge and drift geographically over time; not infrequently, these have important neurologic or ocular features. Malarial retinal findings comprise a relatively specific set of findings and serve as an invaluable aid in the diagnosis of cerebral malaria. Therapy continues to evolve and is best formulated in concert with an infectious disease expert.                                         SUMMARY               Infectious optic neuropathies are less common than inflammatory or ischemic optic neuropathies; may present with varied, overlapping, and nonspecific clinical appearances; and comprise an important differential consideration demanding specific therapy.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/L2HSYTC7/Eggenberger (2019) Infectious Optic Neuropathies.pdf}
}

@article{eggersEpisodicSpontaneousDizziness2021,
  title = {Episodic {{Spontaneous Dizziness}}},
  author = {Eggers, Scott D. Z.},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {369--401},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000931},
  abstract = {PURPOSE OF REVIEW: Conditions causing recurrent spontaneous episodes of dizziness or vertigo span several medical specialties, making it challenging for clinicians to gain confidence in evaluating and managing the spectrum of episodic vestibular disorders. Patients are often asymptomatic and have normal examinations at the time of evaluation. Thus, diagnosis depends heavily on eliciting key features from the history. Overreliance on symptom quality descriptions commonly leads to misdiagnosis. The goal of this article is to provide the reader with a straightforward approach to the diagnosis and management of conditions that cause episodic spontaneous dizziness. RECENT FINDINGS: Consensus diagnostic criteria have been established for vestibular migraine, M{\'e}ni{\`e}re disease, vestibular paroxysmia, and hemodynamic orthostatic dizziness/vertigo. Vertigo has been recognized as a common symptom in vertebrobasilar ischemia, cardiogenic dizziness, and orthostatic hypotension. Treatment recommendations for vestibular migraine still lack high-quality evidence, but controlled trials are occurring. SUMMARY: The evaluation should start with a detailed description of the episodes from the patient and any observers. Rather than focusing first on whether the symptom quality is most consistent with vertigo, dizziness, lightheadedness, or unsteadiness, the clinician should clarify the timing (episode frequency and duration), possible triggers or circumstances (eg, position changes, upright posture), and accompanying symptoms. History should identify any auditory symptoms, migraine features, posterior circulation ischemic symptoms, vascular risk factors, clues for anxiety, and potentially relevant medications. Carefully selected testing can help secure the diagnosis, but excessive and indiscriminate testing can lead to more confusion. Treatments for these conditions are vastly different, so an accurate diagnosis is critical.},
  langid = {english},
  pmid = {34351111},
  keywords = {Anxiety Disorders,Continuum: Neuro-otology,Dizziness,Humans,Migraine Disorders,Vertigo,Vestibular Diseases},
  file = {/Users/nathanielyomogida/Zotero/storage/WXW7VBN4/Eggers (2021) Episodic Spontaneous Dizziness.pdf}
}

@article{ellisAssessmentManagementPosttraumatic2018,
  title = {Assessment and {{Management}} of {{Posttraumatic Stress Disorder}}},
  author = {Ellis, Janet and Zaretsky, Ari},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {873--892},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000610},
  url = {https://journals.lww.com/00132979-201806000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE               The goal of this article is to increase clinicians' understanding of posttraumatic stress disorder (PTSD) and improve skills in assessing risk for and diagnosing PTSD. The importance and sequelae of lifetime trauma burden are discussed, with reference to trends in prevention, early intervention, and treatment.                                         RECENT FINDINGS                                PTSD has different clinical phenotypes, which are reflected in the changes in                 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition                 (                 DSM-5                 ) criteria. PTSD is almost always complicated by comorbidity. Treatment requires a multimodal approach, usually including medication, different therapeutic techniques, and management of comorbidity. Interest is growing in the neurobiology of childhood survivors of trauma, intergenerational transmission of trauma, and long-term impact of trauma on physical health. Mitigation of the risk of PTSD pretrauma in the military and first responders is gaining momentum, given concerns about the cost and disability associated with PTSD. Interest is also growing in screening for PTSD in medical populations, with evidence of improved clinical outcomes. Preliminary research supports the treatment of PTSD with repetitive transcranial magnetic stimulation.                                                        SUMMARY               PTSD is a trauma-related disorder with features of fear and negative thinking about the trauma and the future. Untreated, it leads to ongoing disruption of life due to avoidance, impaired vocational and social functioning, and other symptoms, depending on the phenotype. Despite a theoretical understanding of underlying mechanisms, PTSD remains challenging to treat, although evidence exists for benefit of pharmacologic agents and trauma-focused therapies. A need still remains for treatments that are more effective and efficient, with faster onset.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/HGCYXBLU/Ellis_Zaretsky (2018) Assessment and Management of Posttraumatic Stress Disorder.pdf}
}

@article{englishStrokeComplicationAcute2011,
  title = {Stroke as a {{Complication}} of {{Acute Cardiac Disease}}},
  shorttitle = {Stroke as a {{Complication}} of {{Acute Cardiac Disease}}},
  author = {English, Joey D.},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {1024--1039},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407058.40532.fa},
  url = {http://journals.lww.com/00132979-201110000-00009},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/DYSD3JWQ/English (2011) Stroke as a Complication of Acute Cardiac Disease.pdf;/Users/nathanielyomogida/Zotero/storage/EYJP8T5S/english2011.pdf.pdf}
}

@article{feinsteinConversionDisorder2018,
  title = {Conversion {{Disorder}}},
  author = {Feinstein, Anthony},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {861--872},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000601},
  url = {https://journals.lww.com/00132979-201806000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a broad overview of conversion disorder, encompassing diagnostic criteria, epidemiology, etiologic theories, functional neuroimaging findings, outcome data, prognostic indicators, and treatment.                                         RECENT FINDINGS                                Two important changes have been made to the recent                 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition                 (                 DSM-5                 ) diagnostic criteria: the criteria that conversion symptoms must be shown to be involuntary and occurring as the consequence of a recent stressor have been dropped. Outcome studies show that the rate of misdiagnosis has declined precipitously since the 1970s and is now around 4\%. Functional neuroimaging has revealed a fairly consistent pattern of hypoactivation in brain regions linked to the specific conversion symptom, accompanied by ancillary activations in limbic, paralimbic, and basal ganglia structures. Cognitive-behavioral therapy looks promising as the psychological treatment of choice, although more definitive data are still awaited, while preliminary evidence indicates that repetitive transcranial magnetic stimulation could prove beneficial as well.                                                        SUMMARY               Symptoms of conversion are common in neurologic and psychiatric settings, affecting up to 20\% of patients. The full syndrome of conversion disorder, while less prevalent, is associated with a guarded prognosis and a troubled psychosocial outcome. Much remains uncertain with respect to etiology, although advances in neuroscience and technology are providing reproducible findings and new insights. Given the confidence with which the diagnosis can be made, treatment should not be delayed, as symptom longevity can influence outcome.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/ZTLKXILA/Feinstein (2018) Conversion Disorder.pdf}
}

@article{fernandez-romeroMemoryDysfunction2021,
  title = {Memory {{Dysfunction}}},
  author = {{Fernandez-Romero}, Roberto and Spica, D. Malcolm},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1562--1585},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001020},
  url = {https://journals.lww.com/10.1212/CON.0000000000001020},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF THE REVIEW               This article provides a practical overview of the diagnostic process for patients with memory dysfunction through exploration of the anatomic, physiologic, and psychological aspects of human memory.                                         RECENT FINDINGS               As updated methods become available to neurologists, the ability to accurately identify and treat patients with memory disorders evolves. An appreciation of current concepts in the anatomic, physiologic, and psychological aspects of memory, combined with a rational application of everyday tools (such as clinical examination, bedside testing, standardized cognitive screening, and formal neuropsychological examination), allows the clinician to identify possible etiologies and track longitudinal changes in functional memory status. Recent findings regarding the interactions of limbic, anterior temporal, primary sensory, parietal, and dorsal prefrontal structures shed new light on the putative classifications of procedural and declarative memory and their subfunctions.                                         SUMMARY               An understanding of memory profiles pertaining to registration, encoding, consolidation, storage, and retrieval, as well as methods to assess those functions, facilitates the clinician's identification of underlying pathology and affected cerebral territories. The memory profile must be appreciated in the context of the entire individual, including possible confounds of comorbid conditions, psychiatric disorders, and normal healthy aging.},
  langid = {english},
  keywords = {Current}
}

@article{fifeApproachHistoryEvaluation2021,
  title = {Approach to the {{History}} and {{Evaluation}} of {{Vertigo}} and {{Dizziness}}},
  author = {Fife, Terry D.},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {306--329},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000938},
  abstract = {PURPOSE OF REVIEW: This article reviews a method of obtaining the medical history of patients presenting with dizziness, vertigo, and imbalance. By combining elements of the history with examination, the goal is to identify patterns and an effective differential diagnosis for this group of patients to help lead to an accurate diagnosis. RECENT FINDINGS: Studies over the past dozen years have changed the historical approach to patients with dizziness from one based primarily on how the patient describes the sensation of dizziness. This older approach can lead to misdiagnosis, so a preferred method puts greater emphasis on whether the dizziness is acute or chronic, episodic or continuous, or evoked by or brought on by an event or circumstance so that a pattern may be derived that better narrows the differential diagnosis and focused examination can further narrow to a cause or causes. SUMMARY: Dizziness is a common symptom of many possible causes. This article will help clinicians navigate gathering the history and examination to formulate a working diagnosis in patients affected by dizziness.},
  langid = {english},
  pmid = {34351108},
  keywords = {Continuum: Neuro-otology,Diagnosis Differential,Dizziness,Humans,Vertigo},
  file = {/Users/nathanielyomogida/Zotero/storage/PUMWLX43/Fife (2021) Approach to the History and Evaluation of Vertigo and Dizziness.pdf}
}

@article{fifeDizzinessOutpatientCare2017,
  title = {Dizziness in the {{Outpatient Care Setting}}},
  author = {Fife, Terry D.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {359--395},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000450},
  url = {https://journals.lww.com/00132979-201704000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article summarizes an approach to evaluating dizziness for the general neurologist and reviews common and important causes of dizziness and vertigo.                                         Recent Findings:               Improved methods of diagnosing patients with vertigo and dizziness have been evolving, including additional diagnostic criteria and characterization of some common conditions that cause dizziness (eg, vestibular migraine, benign paroxysmal positional vertigo, chronic subjective dizziness). Other uncommon causes of dizziness (eg, superior canal dehiscence syndrome, episodic ataxia type 2) have also been better clarified. Distinguishing between central and peripheral causes of vertigo can be accomplished reliably through history and examination, but imaging techniques have further added to accuracy. What has not changed is the necessity of obtaining a basic history of the patient's symptoms to narrow the list of possible causes.                                         Summary:               Dizziness and vertigo are extremely common symptoms that also affect function at home and at work. Improvements in the diagnosis and management of the syndromes that cause dizziness and vertigo will enhance patient care and cost efficiencies in a health care system with limited resources. Clinicians who evaluate patients with dizziness will serve their patient population well by continuing to manage patients with well-focused workup and attentive care.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/JRCSJCTW/Fife (2017) Dizziness in the Outpatient Care Setting.pdf;/Users/nathanielyomogida/Zotero/storage/SG9VUJWI/fife2017.pdf.pdf}
}

@article{fifeTinnitusHyperacusisOtalgia2021,
  title = {Tinnitus, {{Hyperacusis}}, {{Otalgia}}, and {{Hearing Loss}}},
  author = {Fife, Terry D. and Tourkevich, Roksolyana},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {491--525},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000961},
  abstract = {PURPOSE OF REVIEW: This article reviews the causes of tinnitus, hyperacusis, and otalgia, as well as hearing loss relevant for clinicians in the field of neurology. RECENT FINDINGS: Important causes of unilateral and bilateral tinnitus are discussed, including those that are treatable or caused by serious structural or vascular causes. Concepts of hyperacusis and misophonia are covered, along with various types of neurologic disorders that can lead to pain in the ear. Hearing loss is common but not always purely otologic. SUMMARY: Tinnitus and hearing loss are common symptoms that are sometimes related to a primary neurologic disorder. This review, tailored to neurologists who care for patients who may be referred to or encountered in neurology practice, provides information on hearing disorders, how to recognize when a neurologic process may be involved, and when to refer to otolaryngology or other specialists.},
  langid = {english},
  pmid = {34351116},
  keywords = {Continuum: Neuro-otology,Earache,Hearing Loss,Humans,Hyperacusis,Tinnitus},
  file = {/Users/nathanielyomogida/Zotero/storage/TZN4P3BP/Fife_Tourkevich (2021) Tinnitus, Hyperacusis, Otalgia, and Hearing Loss.pdf}
}

@article{findlayGeneticBasedTreatmentStrategies2022,
  title = {Genetic-{{Based Treatment Strategies}} for {{Muscular Dystrophy}} and {{Congenital Myopathies}}},
  author = {Findlay, Andrew R. and Weihl, Conrad C.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1800--1816},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001203},
  url = {https://journals.lww.com/10.1212/CON.0000000000001203},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the foundational concepts of genetic treatment strategies employed in neuromuscular medicine, as well as the importance of genetic testing as a requirement for applying gene-based therapy.                                         RECENT FINDINGS               Gene therapies have become a reality for several neuromuscular disorders. Exon-skipping and (in Europe) ribosomal read-through approaches are currently available to a subset of patients with Duchenne muscular dystrophy. Microdystrophin gene replacement has shown promise and is nearing the final stages of clinical trials. Numerous gene-based therapies for other muscular dystrophies and congenital myopathies are progressing toward approval as well.                                         SUMMARY               Muscular dystrophies and congenital myopathies are a heterogenous group of hereditary muscle disorders. Confirming a diagnosis with genetic testing is not only critical for guiding management, but also an actual prerequisite for current and future gene therapies. Recessive loss-of-function or dominant haploinsufficiency disorders may be treated with gene replacement strategies, whereas dominant negative and toxic gain-of-function disorders are best addressed with a variety of knockdown approaches. It is important to recognize that many therapeutics are mutation specific and will only benefit a subset of individuals with a specific disease.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/4W62RQE8/Findlay_Weihl (2022) Genetic-Based Treatment Strategies for Muscular Dystrophy and Congenital.pdf}
}

@article{finkHereditaryMyelopathies2021,
  title = {Hereditary {{Myelopathies}}},
  author = {Fink, John K.},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {185--204},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000934},
  url = {https://journals.lww.com/10.1212/CON.0000000000000934},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article guides clinicians in the clinical recognition and differential diagnosis of hereditary myelopathies.                                         RECENT FINDINGS                                Rather than a disease, a disease process, or relating to specific cellular vulnerability, the term                 hereditary myelopathy                 refers to diverse inherited disorders in which major aspects of the clinical syndrome reflect disturbance of elements within the spinal cord (specifically, the dorsal columns and dorsal root ganglia, corticospinal tracts, and anterior horn cells). It is important to note that the clinical features of almost all hereditary myelopathies reflect not only disturbance of elements within the spinal cord but also disturbance of extraspinal structures (particularly, but not limited to, peripheral nerves and the cerebellum) and that these extraspinal clinical features can be very helpful in recognizing specific myelopathy syndromes. The value of classifying disorders as inherited myelopathies lies primarily in facilitating their clinical recognition and differential diagnosis. It is useful to recognize that many hereditary myelopathies conform to one of four clinical paradigms: (1) spinocerebellar ataxia, (2) motor neuron disorder, (3) leukodystrophy, or (4) distal motor-sensory axonopathy predominantly affecting the central nervous system. Although they are myelopathies, spinal dysraphisms such as spina bifida and myelomeningocele are not included in this context because they are not usually due to single-gene mutation and have low hereditability.                                                        SUMMARY               This article illustrates clinical paradigms of hereditary myelopathy with clinical examples emphasizing the spectrum, clinical recognition, and differential diagnosis of hereditary myelopathies.},
  langid = {english}
}

@article{flanaganParaneoplasticDisordersNervous2020,
  title = {Paraneoplastic {{Disorders}} of the {{Nervous System}}},
  author = {Flanagan, Eoin P.},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1602--1628},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000941},
  url = {https://journals.lww.com/10.1212/CON.0000000000000941},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews paraneoplastic neurologic disorders and includes an overview of the diagnostic approach, the role of autoantibody testing, the pathophysiology of these disorders, and treatment approaches. This article also provides an overview of the emerging clinical scenarios in which paraneoplastic and autoimmune neurologic disorders may occur.                                         RECENT FINDINGS               The number of autoantibodies associated with paraneoplastic neurologic disorders has rapidly expanded over the past 2 decades. These discoveries have improved our ability to diagnose patients with these disorders and have provided insight into their pathogenesis. It is now recognized that these antibodies can be broadly divided into two major categories based on the location of the target antigen: intracellular and cell surface/synaptic. Antibodies to intracellular antigens are almost always accompanied by cancer, respond less well to immunotherapy, and have an unfavorable outcome. In contrast, antibodies to cell surface or synaptic targets are less often accompanied by cancer, generally respond well to immunotherapy, and have a good prognosis. Paraneoplastic and autoimmune neurologic disorders are now being recognized in novel settings, including their occurrence as an immune-related adverse effect of immune checkpoint inhibitor treatment for cancer.                                         SUMMARY               This article discusses when to suspect a paraneoplastic neurologic syndrome, the diagnostic utility and pitfalls of neural autoantibody testing, how to best detect the underlying tumor, and the treatment approach that involves combinations of antineoplastic treatments, immunosuppressants, and supportive/symptomatic treatments.},
  langid = {english}
}

@article{flemmingManagementUnrupturedIntracranial2017,
  title = {Management of {{Unruptured Intracranial Aneurysms}} and {{Cerebrovascular Malformations}}},
  author = {Flemming, Kelly D. and Lanzino, Giuseppe},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {181--210},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000418},
  url = {https://journals.lww.com/00132979-201702000-00015},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               Unruptured intracranial aneurysms and vascular malformations are detected more frequently because of the increased use and availability of brain imaging. Management of these entities requires knowledge of which patients are at high risk for hemorrhage and what treatment options are available. This article summarizes the epidemiology, natural history, and management strategies for unruptured intracranial aneurysms, arteriovenous malformations, cavernous malformations, developmental venous anomalies, and capillary telangiectasias.                                         Recent Findings:               Pooled cohort studies and meta-analyses have improved the ability to predict hemorrhage for each vascular abnormality. Scores and tools have been developed to aid the practitioner in predicting hemorrhage risk for unruptured intracranial aneurysms. Advances in endovascular techniques for unruptured intracranial aneurysms have improved the ability to treat difficult wide-necked aneurysms.                                         Summary:               Unruptured intracranial aneurysms are a common incidental finding. The PHASES (population, hypertension, age, size of aneurysm, earlier subarachnoid hemorrhage from another aneurysm, site of aneurysm) score and Unruptured Intracranial Aneurysm Treatment Score may be useful tools for predicting natural history and treatment recommendations. The overall risk of hemorrhage for both arteriovenous malformations and cavernous malformations is about 2\% to 4\% per year. With both of these entities, prior hemorrhage predicts future hemorrhage. In addition, other select patient and radiologic factors influence risk of hemorrhage. The risk of future hemorrhage should be compared to the risk of treatment. Developmental venous anomalies and capillary telangiectasias are largely benign entities and rarely symptomatic.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/6JMPD7IF/Flemming_Lanzino (2017) Management of Unruptured Intracranial Aneurysms and Cerebrovascular.pdf}
}

@article{forstPalliativeSupportiveCare2020,
  title = {Palliative and {{Supportive Care}} in {{Neuro-oncology}}},
  author = {Forst, Deborah A.},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1673--1685},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000940},
  url = {https://journals.lww.com/10.1212/CON.0000000000000940},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the supportive care needs of patients with primary brain tumors and their caregivers, outlines the management of selected common symptoms of patients with brain tumors, and describes challenges and opportunities in providing palliative care for this population.                                         RECENT FINDINGS               Patients with primary malignant brain tumors generally have a poor prognosis and experience progressive neurologic decline and significant physical and psychological symptoms. Management of these symptoms, including fatigue, mood disorders, and the manifestations of cerebral edema, can be challenging. Caregivers for these patients have high rates of psychological distress and report significant caregiving burden. Although the benefit of early palliative care for patients with other advanced solid tumors is well established, our understanding of the role of palliative care in neuro-oncology is incomplete, and thus palliative care and hospice services remain underutilized.                                         SUMMARY               Patients with brain tumors and their caregivers have significant supportive care needs, which often differ from the needs of patients with cancers outside of the nervous system. Clinicians face challenges associated with managing patients' symptoms and adequately facilitating prognostic understanding and decision making. Palliative care and hospice services may offer important benefits for this population.},
  langid = {english}
}

@article{foxPediatricIschemicStroke2023,
  title = {Pediatric {{Ischemic Stroke}}},
  author = {Fox, Christine},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {566--583},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001239},
  url = {https://journals.lww.com/10.1212/CON.0000000000001239},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Pediatric cerebrovascular disease is one of the leading causes of death and disability in children. Survivors of childhood stroke and their families are often left to cope with long-lasting sequelae, such as barriers to school reentry and long-term challenges in attaining independence as adults. Because childhood stroke is rare and providers may not be familiar with the disorder, this article reviews the risk factors, acute management, and sequelae of ischemic stroke in children.                                         LATEST DEVELOPMENTS               High-quality evidence has resulted in an organized approach to emergent treatment of ischemic stroke in adults, but most front-line providers are less prepared for emergent stroke management in children. The level of evidence for reperfusion therapies in children remains low but is growing. Thrombolysis and thrombectomy are sometimes considered for hyperacute treatment of stroke in children. Readiness for pediatric stroke at regional centers should include an organized approach to pediatric stroke triage and management based on extrapolation from adult stroke trials, expert consensus, and emerging pediatric studies.                                         ESSENTIAL POINTS               This review provides up-to-date information about ischemic stroke risk factors and management in children. Preparation for rapid stroke diagnosis and management in children may improve outcomes.},
  langid = {english},
  keywords = {Current}
}

@article{freemanAutonomicPeripheralNeuropathy2020,
  title = {Autonomic {{Peripheral Neuropathy}}},
  author = {Freeman, Roy},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {58--71},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000825},
  url = {https://journals.lww.com/10.1212/CON.0000000000000825},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a summary of the autonomic neuropathies, including neuropathies associated with diabetes mellitus, neuropathies due to amyloid deposition, immune-mediated autonomic neuropathies (including those associated with a paraneoplastic syndrome), inherited autonomic neuropathies, and toxic autonomic neuropathies. The presenting features, diagnostic investigations, and natural history of these neuropathies are discussed.                                         RECENT FINDINGS               Recent findings in autonomic peripheral neuropathy include data on the epidemiology and atypical presentations of diabetic autonomic neuropathy, treatment-induced neuropathy of diabetes mellitus, the presentation of immune-mediated neuropathies, and advances in hereditary neuropathy associated with amyloidosis and other hereditary neuropathies.                                         SUMMARY               Knowledge and recognition of the clinical features of the autonomic neuropathies, combined with appropriate laboratory and electrophysiologic testing, will facilitate accurate diagnosis and management.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{friedmanHeadachesDueLow2018,
  title = {Headaches {{Due}} to {{Low}} and {{High Intracranial Pressure}}},
  author = {Friedman, Deborah I.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1066--1091},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000623},
  url = {https://journals.lww.com/00132979-201808000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Headache disorders attributed to low and high intracranial pressure are commonly encountered in specialty headache practices and may occur more frequently than realized. While the headaches resulting from intracranial pressure disorders have what are conventionally thought of as defining characteristics, a substantial minority of patients do not manifest the ``typical'' features. Moreover, patients with intracranial pressure disorders may also have a preexisting primary headache disorder. Heightening the complexity of the presentation, the headaches of intracranial pressure disorders can resemble the phenotype of a primary disorder. Lastly, patients with so-called intracranial ``hypotension'' often have normal CSF pressure and neuroimaging studies. Thus, a high index of suspicion is needed. The published literature has inherent bias as many types of specialists evaluate and treat these conditions. This article reviews the key points to emphasize the history, examination, and laboratory evaluation of patients with intracranial pressure disorders from a neurologist's perspective.                                         RECENT FINDINGS               Lumbar puncture opening pressure in patients with spontaneous intracranial hypotension was low enough to meet diagnostic criteria ({$\leq$}60 mm CSF) in only 34\% of patients in one study. Most patients had an opening pressure in the low normal to normal range, and 5\% had an opening pressure of 200 mm CSF or more. Diskogenic microspurs are a common cause of this syndrome. The Idiopathic Intracranial Hypertension Treatment Trial found that most participants had a headache phenotype resembling migraine or tension-type headache. No ``typical'' or characteristic headache phenotype was found, and headache-related disability was severe at baseline. Headache disability did not correlate with the lumbar puncture opening pressure at baseline or at the 6-month primary outcome period. Although participants who were randomly assigned to acetazolamide had a lower mean CSF opening pressure at 6 months, headache disability in that group was similar to the group who received placebo.                                         SUMMARY               Significant overlap is seen in the symptoms of high and low CSF pressure disorders and in those of primary headache disorders. Neurologists are frequently challenged by patients with headaches who lack the typical clinical signs or imaging features of the pseudotumor cerebri syndrome or spontaneous intracranial hypotension. Even when characteristic symptoms and signs are initially present, the typical features of both syndromes tend to lessen or resolve over time; consider these diagnoses in patients with long-standing ``chronic migraine'' who do not improve with conventional headache treatment. While the diagnostic criteria for pseudotumor cerebri syndrome accurately identify most patients with the disorder, at least 25\% of patients with spontaneous intracranial hypotension have normal imaging and over half have a normal lumbar puncture opening pressure. Detailed history taking will often give clues that suggest a CSF pressure disorder. That said, misdiagnosis can lead to significant patient morbidity and inappropriate therapy.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/7VUGJPFH/Friedman (2018) Headaches Due to Low and High Intracranial Pressure.pdf;/Users/nathanielyomogida/Zotero/storage/8SVNVJ2I/friedman2018.pdf.pdf}
}

@article{friedmanTardiveSyndromes2019,
  title = {Tardive {{Syndromes}}},
  author = {Friedman, Joseph H.},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {1081--1098},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000754},
  url = {https://journals.lww.com/00132979-201908000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the history, nosology, clinical features, epidemiology, and treatment of tardive syndromes.                                         RECENT FINDINGS               The major advance in the field of tardive syndromes has been the development and US Food and Drug Administration (FDA) approval of two vesicular monoamine transporter type 2 inhibitors, valbenazine and deutetrabenazine, for treating tardive syndromes. These medications are derivatives of tetrabenazine and reduce dyskinetic movements by reducing dopamine stimulation. Treatment is not curative, and the medications reduce, or ``mask,'' symptoms but presumably without adding to the long-term risk of increased involuntary movements believed to accrue from suppressive treatment with dopamine receptor--blocking drugs. A confounding advance has been the accumulation of data finding that second-generation antipsychotics, also known as atypical antipsychotics, may not be safer than first-generation antipsychotics in causing tardive syndromes. The public health risk of tardive syndromes may actually have increased as some second-generation antipsychotics, widely promoted to both doctors and patients, are increasingly used as antidepressants.                                         SUMMARY               Tardive syndromes remain a public health risk. Second-generation antipsychotics have not been proven to have less risk than first-generation drugs in causing tardive syndromes and are nevertheless being used more widely to treat depression, bipolar disease, and insomnia. Symptomatic treatment for tardive syndromes is available, although expensive.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/24W7KE4Z/Friedman (2019) Tardive Syndromes.pdf;/Users/nathanielyomogida/Zotero/storage/PYSDLG8N/10.1212@CON.0000000000000754.pdf.pdf}
}

@article{furieEpidemiologyPrimaryPrevention2020,
  title = {Epidemiology and {{Primary Prevention}} of {{Stroke}}},
  author = {Furie, Karen},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {260--267},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000831},
  url = {https://journals.lww.com/10.1212/CON.0000000000000831},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an update on the epidemiology and prevention of a first stroke. Risk factor modification plays a large role in stroke prevention. Strategies for early intervention, particularly for hypertension, are critical for reducing stroke morbidity and mortality.                                         RECENT FINDINGS               Because of the new criteria for hypertension, more people are now classified as hypertensive and can benefit from lifestyle or medical management. Direct oral anticoagulants have made it easier to safely treat patients with atrial fibrillation and are now considered first-line therapy for patients with an additional stroke risk factor.                                         SUMMARY               Primary prevention of stroke is essential for maintaining brain health throughout the life span. Adherence to a healthy lifestyle and routine screening for stroke risk factors can promote healthy, stroke-free aging.},
  langid = {english}
}

@article{gaitanisNervousSystemMalformations2018,
  title = {Nervous {{System Malformations}}},
  author = {Gaitanis, John and Tarui, Tomo},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {72--95},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000561},
  url = {https://journals.lww.com/00132979-201802000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the most common nervous system malformations and serves as a reference for the latest advances in diagnosis and treatment.                                         RECENT FINDINGS               Major advances have occurred in recognizing the genetic basis of nervous system malformations. Environmental causes of nervous system malformations, such as perinatal infections including Zika virus, are also reviewed. Treatment for nervous system malformations begins prior to birth with prevention. Folic acid supplementation reduces the risk of neural tube defects and is an important part of health maintenance for pregnant women. Fetal surgery is now available for prenatal repair of myelomeningocele and has been demonstrated to improve outcomes.                                         SUMMARY               Each type of nervous system malformation is relatively uncommon, but, collectively, they constitute a large population of neurologic patients. The diagnosis of nervous system malformations begins with radiographic characterization. Genetic studies, including chromosomal microarray, targeted gene sequencing, and next-generation sequencing, are increasingly important aspects of the assessment. A genetic diagnosis may identify an associated medical condition and is necessary for family planning. Treatment consists primarily of supportive therapies for developmental delays and epilepsy, but prenatal surgery for myelomeningocele offers a glimpse of future possibilities. Prognosis depends on multiple clinical factors, including the examination findings, imaging characteristics, and genetic results. Treatment is best conducted in a multidisciplinary setting with neurology, neurosurgery, developmental pediatrics, and genetics working together as a comprehensive team.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/LI2LCFM7/Gaitanis_Tarui (2018) Nervous System Malformations.pdf}
}

@article{garciaParasiticInfectionsNervous2021,
  title = {Parasitic {{Infections}} of the {{Nervous System}}},
  author = {Garcia, Hector H.},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {943--962},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000986},
  url = {https://journals.lww.com/10.1212/CON.0000000000000986},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews how parasites affect the human nervous system, with a focus on four parasitic infections of major public health importance worldwide, two caused by protozoa (malaria and toxoplasmosis) and two by helminths (neurocysticercosis and schistosomiasis).                                         RECENT FINDINGS               Parasitic infections in humans are common, and many can affect the central nervous system where they may survive unnoticed or may cause significant pathology that can even lead to the death of the host. Neuroparasitoses should be considered in the differential diagnosis of neurologic lesions, particularly in individuals from endemic regions or those with a history of travel to endemic regions.                                         SUMMARY               Cerebral malaria is a significant cause of mortality, particularly in African children, in whom infected red blood cells affect the cerebral vessels, causing severe encephalopathy. Neurocysticercosis is the most common cause of acquired epilepsy worldwide and has varied clinical presentations, depending on the number, size, and location of the parasites in the nervous system as well as on the host's inflammatory response. Toxoplasmosis is distributed worldwide, affecting a significant proportion of the population, and may reactivate in patients who are immunosuppressed, causing encephalitis and focal abscesses. Schistosomiasis causes granulomatous lesions in the brain or the spinal cord.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/CV5L2769/Garcia (2021) Parasitic Infections of the Nervous System.pdf}
}

@article{gelberNeurologicExaminationRehabilitation2011,
  title = {Neurologic {{Examination}} in {{Rehabilitation}}:},
  shorttitle = {Neurologic {{Examination}} in {{Rehabilitation}}},
  author = {Gelber, David A.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {449--461},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399066.31449.c5},
  url = {http://journals.lww.com/00132979-201106000-00009},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/3ZISFPG9/Gelber (2011) Neurologic Examination in Rehabilitation.pdf;/Users/nathanielyomogida/Zotero/storage/S4BRTITQ/gelber2011.pdf.pdf}
}

@article{gelfandPediatricAdolescentHeadache2018,
  title = {Pediatric and {{Adolescent Headache}}},
  author = {Gelfand, Amy A.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1108--1136},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000638},
  url = {https://journals.lww.com/00132979-201808000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides the practicing neurologist with a comprehensive, evidence-based approach to the diagnosis and management of headache in children and adolescents, with a focus on migraine.                                         RECENT FINDINGS               Four triptans are now labeled by the US Food and Drug Administration (FDA) for acute migraine treatment in adolescents, and rizatriptan is labeled for use in children age 6 and older. For preventive migraine treatment, the Childhood and Adolescent Migraine Prevention trial demonstrated that approximately 60\% of children and adolescents with migraine will improve with a three-pronged treatment approach that includes: (1) lifestyle management counseling (on sleep, exercise, hydration, caffeine, and avoidance of meal skipping); (2) optimally dosed acute therapy, specifically nonsteroidal anti-inflammatory drugs and triptans; and (3) a preventive treatment that has some evidence for efficacy. For the remaining 40\% of children and adolescents, and for those who would not have qualified for the Childhood and Adolescent Migraine Prevention trial because of having continuous headache or medication-overuse headache, the clinician's judgment remains the best guide to preventive therapy selection.                                         SUMMARY               Randomized placebo-controlled trials have been conducted to guide first-line acute and preventive migraine treatments in children and adolescents. Future research is needed to guide treatment for those with more refractory migraine, as well as for children and adolescents who have other primary headache disorders.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/G7VRCU4D/Gelfand (2018) Pediatric and Adolescent Headache.pdf;/Users/nathanielyomogida/Zotero/storage/IFVTMTU8/gelfand2018.pdf.pdf}
}

@article{ghoshalRenalElectrolyteDisorders2023,
  title = {Renal and {{Electrolyte Disorders}} and the {{Nervous System}}},
  author = {Ghoshal, Shivani},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {797--825},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001286},
  url = {https://journals.lww.com/10.1212/CON.0000000000001286},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Neurologic complications are a major contributor to death and disability in patients with renal disease. Oxidative stress, endothelial dysfunction, accelerated arteriosclerosis, and uremic inflammatory milieu affect both the central and peripheral nervous systems. This article reviews the unique contributions of renal impairment to neurologic disorders and their common clinical manifestations as the prevalence of renal disease increases in a globally aging population.                                         LATEST DEVELOPMENT                                Advances in the understanding of the pathophysiologic interplay between the kidneys and brain, also referred to as the                 kidney-brain axis                 , have led to more widespread recognition of associated changes in neurovascular dynamics, central nervous system acidification, and uremia-associated endothelial dysfunction and inflammation in the central and peripheral nervous systems. Acute kidney injury increases mortality in acute brain injury to nearly 5 times that seen in matched controls. Renal impairment and its associated increased risks of intracerebral hemorrhage and accelerated cognitive decline are developing fields. Dialysis-associated neurovascular injury is increasingly recognized in both continuous and intermittent forms of renal replacement therapy, and treatment strategies for its prevention are evolving.                                                        ESSENTIAL POINTS               This article summarizes the effects of renal impairment on the central and peripheral nervous systems with special considerations in acute kidney injury, patients requiring dialysis, and conditions that affect both the renal and nervous systems.},
  langid = {english},
  keywords = {Current}
}

@article{giacobbeDiagnosisManagementAnxiety2018,
  title = {Diagnosis and {{Management}} of {{Anxiety Disorders}}},
  author = {Giacobbe, Peter and Flint, Alastair},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {893--919},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000607},
  url = {https://journals.lww.com/00132979-201806000-00015},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW                                This article provides a synopsis of the current understanding of the pathophysiology of anxiety disorders, the biological and environmental risk factors that contribute to their development and maintenance, a review of the                 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition                 (                 DSM-5                 ) diagnostic criteria, and a practical approach to the treatment of anxiety disorders in adults.                                                        RECENT FINDINGS               Despite the ubiquity of anxiety, the evidence is that most individuals with an anxiety disorder are not identified and do not receive guideline-level care. In part, this may be because of the manifold clinical presentations of anxiety disorders and clinicians' lack of confidence in accurately diagnosing and treating these conditions, especially in nonpsychiatric settings. Anxiety disorders represent the complex interplay between biological, psychological, temperamental, and environmental factors. Converging lines of evidence point to dysfunction in regulating activity in the ``threat circuit'' in the brain as a putative common pathophysiology underlying anxiety disorders. Evidence-based treatments for anxiety disorders, such as cognitive-behavioral therapy and antidepressant medications, have been shown to regulate activity in this circuit, which consists of reciprocal connections between the dorsomedial prefrontal cortex, insula, and amygdala.                                         SUMMARY               Anxiety disorders are the most common class of emotional disorders and a leading cause of disability worldwide. A variety of effective treatment strategies are available, which may exert their therapeutic benefits from top-down or bottom-up modulation of the dysfunctional brain activity associated with anxiety disorders.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/USWPR3IK/Giacobbe_Flint (2018) Diagnosis and Management of Anxiety Disorders.pdf}
}

@article{gibbonsSkinBiopsyEvaluation2020,
  title = {Skin {{Biopsy}} in {{Evaluation}} of {{Autonomic Disorders}}},
  author = {Gibbons, Christopher H. and Wang, Ningshan and Kim, Jee Young and Campagnolo, Marta and Freeman, Roy},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {200--212},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000814},
  url = {https://journals.lww.com/10.1212/CON.0000000000000814},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an up-to-date assessment of the role of skin biopsy in the evaluation of autonomic disorders. The standard methodology for completing a skin biopsy, the anatomic structures of interest detected within a skin biopsy, and the disease states in which skin biopsies may provide valuable information are reviewed.                                         RECENT FINDINGS               Several recent advances in the studies of hereditary amyloidosis and the various degenerative synucleinopathies have demonstrated that simple skin biopsies can provide valuable pathologic evidence of neurologic disease. In addition to diagnosis of the underlying disorder, skin biopsies provide a quantitative structural measurement of the associated autonomic damage.                                         SUMMARY               Skin biopsies are making great inroads into the study of autonomic and peripheral nerve disorders. Complex immunohistochemical staining protocols are challenging to complete, but the rich data derived from these studies in the diagnosis and monitoring of different disease states suggest that the role of skin biopsies in the study of the autonomic nervous system will continue to expand in the years to come.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{gillNeurologicComplicationsCOVID192023,
  title = {Neurologic {{Complications}} of {{COVID-19}}},
  author = {Gill, Christine and Cho, Tracey A.},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {946--965},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001272},
  url = {https://journals.lww.com/10.1212/CON.0000000000001272},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               This article describes the spectrum of neurologic complications occurring in acute or postacute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as the neurologic risks and benefits of vaccination against SARS-CoV-2.                                         LATEST DEVELOPMENTS               Early in the COVID-19 pandemic, reports of neurologic complications of COVID-19 began to surface. A variety of neurologic conditions have since been reported in association with COVID-19. Understanding of the underlying mechanism of COVID-19 neurologic involvement continues to evolve; however, the evidence seems to suggest that aberrant inflammatory responses may play a role. In addition to neurologic symptoms in acute COVID-19, neurologic post--COVID-19 conditions are increasingly recognized. The development of COVID-19 vaccines has been essential in preventing the spread of COVID-19. With increasing numbers of vaccine doses administered, various neurologic adverse events have been reported.                                         ESSENTIAL POINTS               Neurologists must be aware of the potential acute, postacute, and vaccine-associated neurologic complications associated with COVID-19 and be poised to serve as integral members of multidisciplinary care teams for patients with COVID-19--related conditions.},
  langid = {english},
  keywords = {Current}
}

@article{gizaIntroductionSportsConcussions2014,
  title = {An {{Introduction}} to {{Sports Concussions}}:},
  shorttitle = {An {{Introduction}} to {{Sports Concussions}}},
  author = {Giza, Christopher C. and Kutcher, Jeffrey S.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1545--1551},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458975.78766.11},
  url = {http://journals.lww.com/00132979-201412000-00008},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/DRYLU2ZC/Giza_Kutcher (2014) An Introduction to Sports Concussions.pdf;/Users/nathanielyomogida/Zotero/storage/SNU8TAYV/Giza and Kutcher - 2014 - An Introduction to Sports Concussions.pdf}
}

@article{gizaPediatricIssuesSports2014,
  title = {Pediatric {{Issues}} in {{Sports Concussions}}:},
  shorttitle = {Pediatric {{Issues}} in {{Sports Concussions}}},
  author = {Giza, Christopher C.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1570--1587},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458973.71142.7d},
  url = {http://journals.lww.com/00132979-201412000-00010},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/4UQXYZPF/giza2014.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/NUAHLKBQ/Giza (2014) Pediatric Issues in Sports Concussions.pdf;/Users/nathanielyomogida/Zotero/storage/V3H339TH/Giza - 2014 - Pediatric Issues in Sports Concussions.pdf}
}

@article{glassHypoxicIschemicEncephalopathyOther2018,
  title = {Hypoxic-{{Ischemic Encephalopathy}} and {{Other Neonatal Encephalopathies}}},
  author = {Glass, Hannah C.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {57--71},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000557},
  url = {https://journals.lww.com/00132979-201802000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Neonatal encephalopathy is the most common condition in neonates encountered by child neurologists. The etiology is most often global hypoxia-ischemia due to failure of cerebral perfusion to the fetus caused by uterine, placental, or umbilical cord compromise prior to or during delivery. Other etiologies of neonatal encephalopathy include ischemic stroke and intracranial hemorrhage, infection, developmental anomalies, and inborn errors of metabolism.                                         RECENT FINDINGS               Therapeutic hypothermia is standard of care for the treatment of neonatal encephalopathy presumed to be caused by hypoxia-ischemia. The number needed to treat is approximately 6 to 7 to prevent one child from either death or disability at age 18 to 22 months. EEG monitoring and MRI are important tools in determining the etiology of encephalopathy and prognosis of the infant.                                         SUMMARY               Neonatal encephalopathy is a heterogeneous disorder that is characterized by alterations in mental status, hypotonia, seizures, and abnormalities in feeding and respiration. The most common cause of neonatal encephalopathy is hypoxic-ischemic encephalopathy, for which treatment with 72 hours of therapeutic hypothermia is associated with reduced death or disability.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/3659RR3A/Glass (2018) Hypoxic-Ischemic Encephalopathy and Other Neonatal Encephalopathies.pdf}
}

@article{gliebusMemoryDysfunction2018,
  title = {Memory {{Dysfunction}}},
  author = {Gliebus, G. Peter},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {727--744},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000619},
  url = {https://journals.lww.com/00132979-201806000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the current understanding of memory system anatomy and physiology, as well as relevant evaluation methods and pathologic processes.                                         RECENT FINDINGS               Our understanding of memory formation advances each year. Successful episodic memory formation depends not only on intact medial temporal lobe structures but also on well-orchestrated interactions with other large-scale brain networks that support executive and semantic processing functions. Recent discoveries of cognitive control networks have helped in understanding the interaction between memory systems and executive systems. These interactions allow access to past experiences and enable comparisons between past experiences and external and internal information. The semantic memory system is less clearly defined anatomically. Anterior, lateral, and inferior temporal lobe regions appear to play a crucial role in the function of the semantic processing system. Different but tightly interconnected cortical regions, such as the prefrontal region, may play a controlling role in this system. The presentation of clinical disease affecting memory is the result of the selective vulnerability of the memory system. An understanding of current concepts of memory anatomy, physiology, and evaluation plays a central role in establishing an accurate diagnosis.                                         SUMMARY               Different memory systems rely on separate but overlapping distributed brain networks. Certain pathologic processes preferentially affect memory systems. An understanding of memory formation stages will enable more accurate diagnosis.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/4GYEGUMF/Gliebus (2018) Memory Dysfunction.pdf}
}

@article{glissonApproachDiplopia2019,
  title = {Approach to {{Diplopia}}},
  author = {Glisson, Christopher C.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1362--1375},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000786},
  url = {https://journals.lww.com/10.1212/CON.0000000000000786},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               ``Double vision'' is a commonly encountered concern in neurologic practice; the experience of diplopia is always sudden and is frequently a cause of great apprehension and potential disability for patients. Moreover, while some causes of diplopia are benign, others require immediate recognition, a focused diagnostic evaluation, and appropriate treatment to prevent vision- and life-threatening outcomes. A logical, easy-to-follow approach to the clinical evaluation of patients with diplopia is helpful in ensuring accurate localization, a comprehensive differential diagnosis, and optimal patient care. This article provides a foundation for formulating an approach to the patient with diplopia and includes practical examples of developing the differential diagnosis, effectively using confirmatory examination techniques, determining an appropriate diagnostic strategy, and (where applicable) providing effective treatment.                                         RECENT FINDINGS               Recent population-based analyses have determined that diplopia is a common presentation in both ambulatory and emergency department settings, with 850,000 such visits occurring annually. For patients presenting to an outpatient facility, diagnoses are rarely serious. However, potentially life-threatening causes (predominantly stroke or transient ischemic attack) can be encountered. In patients presenting with diplopia related to isolated cranial nerve palsy, immediate neuroimaging can often be avoided if an appropriate history and examination are used to exclude worrisome etiologies.                                         SUMMARY               Binocular diplopia is most often due to a neurologic cause. The onset of true ``double vision'' is debilitating for most patients and commonly prompts immediate access to health care services as a consequence of functional impairment and concern for worrisome underlying causes. Although patients may seek initial evaluation through the emergency department or from their primary care/ophthalmic provider, elimination of an ocular cause will not infrequently result in the patient being referred for neurologic consultation. A logical, localization-driven, and evidence-based approach is the most effective way to arrive at the correct diagnosis and provide the best outcome for the patient.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/76B8Z25Y/Glisson (2019) Approach to Diplopia.pdf}
}

@article{goldmanCognitiveSyndromesAssociated2022,
  title = {Cognitive {{Syndromes Associated With Movement Disorders}}},
  author = {Goldman, Jennifer G. and Holden, Samantha K.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {726--749},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001134},
  url = {https://journals.lww.com/10.1212/CON.0000000000001134},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the recognition and management of cognitive syndromes in movement disorders, including those with parkinsonism, chorea, ataxia, dystonia, and tremor.                                         RECENT FINDINGS               Cognitive and motor syndromes are often intertwined in neurologic disorders, including neurodegenerative diseases such as Parkinson disease, atypical parkinsonian syndromes, Huntington disease, and other movement disorders. Cognitive symptoms often affect attention, working memory, and executive and visuospatial functions preferentially, rather than language and memory, but heterogeneity can be seen in the various movement disorders. A distinct cognitive syndrome has been recognized in patients with cerebellar syndromes. Appropriate recognition and screening for cognitive changes in movement disorders may play a role in achieving accurate diagnoses and guiding patients and their families regarding progression and management decisions.                                         SUMMARY               In the comprehensive care of patients with movement disorders, recognition of cognitive syndromes is important. Pharmacologic treatments for the cognitive syndromes, including mild cognitive impairment and dementia, in these movement disorders lag behind the therapeutics available for motor symptoms, and more research is needed. Patient evaluation and management require a comprehensive team approach, often linking neurologists as well as neuropsychologists, psychologists, psychiatrists, social workers, and other professionals.},
  langid = {english},
  keywords = {Current}
}

@article{goodmanDisordersCaudaEquina2018,
  title = {Disorders of the {{Cauda Equina}}},
  author = {Goodman, Brent P.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {584--602},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000584},
  url = {https://journals.lww.com/00132979-201804000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Conditions that affect the cauda equina are a diverse group of disorders that require timely recognition and management. This article reviews cauda equina anatomy, the diagnostic approach to disorders of the cauda equina, features of cauda equina syndrome, and diskogenic and nondiskogenic disorders of the cauda equina.                                         RECENT FINDINGS               Establishing clinical criteria for cauda equina syndrome has been a focus of a number of reviews, although the clinician must maintain a low threshold for emergent imaging in cases of suspected cauda equina syndrome because of the suboptimal reliability of various signs and symptoms in identifying this condition clinically. The timing of surgical intervention for compressive causes of cauda equina dysfunction remains a point of contention, although urgent decompression remains standard practice. A recent review that focused on outcomes in patients with cauda equina compression who underwent surgical decompression identified significant residual deficits in patients despite appropriate and timely intervention. Autoimmune conditions targeting the cauda equina have been increasingly recognized, including chronic immune sensory polyradiculopathy and chronic immune sensorimotor polyradiculopathy.                                         SUMMARY               Disorders that affect the cauda equina require thoughtful and timely clinical examination and diagnostic testing to establish a definitive cause and an appropriate treatment approach.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/CH9G4Z9R/Goodman (2018) Disorders of the Cauda Equina.pdf;/Users/nathanielyomogida/Zotero/storage/PV9ICJLY/goodman2018.pdf.pdf}
}

@article{goodStrokeRehabilitation2011,
  title = {Stroke {{Rehabilitation}}:},
  shorttitle = {Stroke {{Rehabilitation}}},
  author = {Good, David C. and Bettermann, Kerstin and Reichwein, Raymond K.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {545--567},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399072.61943.38},
  url = {http://journals.lww.com/00132979-201106000-00015},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/8W37QLPB/Good et al (2011) Stroke Rehabilitation.pdf;/Users/nathanielyomogida/Zotero/storage/JYIQ8SMH/good2011.pdf.pdf}
}

@article{gordonParaneoplasticSyndromesNeuroophthalmology2019,
  title = {Paraneoplastic {{Syndromes}} in {{Neuro-ophthalmology}}},
  author = {Gordon, Lynn and Dinkin, Marc},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1401--1421},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000788},
  url = {https://journals.lww.com/10.1212/CON.0000000000000788},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the varied types of paraneoplastic syndromes that commonly have neuro-ophthalmologic manifestations. Diagnostic considerations and therapeutic options for individual diseases are also discussed.                                         RECENT FINDINGS               Paraneoplastic syndromes can affect the afferent and efferent visual systems. Paraneoplastic syndromes may result in reduced visual acuity from retinal degeneration, alterations in melanocyte proliferation and uveal thickening, or acquired nystagmus. Ocular motor abnormalities related to paraneoplastic syndromes may present with symptoms from opsoclonus or from neuromuscular junction disease. Diagnosis remains challenging, but serologic identification of some specific antibodies may be helpful or confirmatory. Treatment, in addition to directed therapies against the underlying cancer, often requires systemic corticosteroids, plasma exchange, or immunosuppression, but some specific syndromes improve with use of targeted pharmacologic therapy.                                         SUMMARY               Diagnosis and therapy of paraneoplastic syndromes presenting with neuro-ophthalmic symptoms remain a challenge, but strategies are evolving and new approaches are on the horizon.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/3LSAKADZ/Gordon_Dinkin (2019) Paraneoplastic Syndromes in Neuro-ophthalmology.pdf}
}

@article{goutmanDiagnosisClinicalManagement2017,
  title = {Diagnosis and {{Clinical Management}} of {{Amyotrophic Lateral Sclerosis}} and {{Other Motor Neuron Disorders}}},
  author = {Goutman, Stephen A.},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1332--1359},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000535},
  url = {https://journals.lww.com/00132979-201710000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article reviews the clinical features, diagnostic pathway, therapies, and current understanding of the pathophysiology of amyotrophic lateral sclerosis (ALS). The spectrum of motor neuron diseases is reviewed, and the clinical heterogeneity of ALS is described.                                         Recent Findings:               ALS is increasingly recognized as a clinical spectrum disorder with pure upper and pure lower motor neuron presentations, supported by genetic links. The phenotypic variability is broad. Identification of ALS-related genes provides insights into disease mechanisms.                                         Summary:               ALS is a progressive fatal multisystem neurodegenerative disease primarily affecting motor neurons. Clinical recognition of suspicious symptoms and the appropriate laboratory evaluation are essential to limit diagnostic delay and avoid unnecessary testing and procedures. ALS has broad genetic and hypothesized environmental causes and phenotypic variability. Recognizing related motor neuron diseases will prevent misdiagnosis while allowing proper disease counseling. Although ALS cannot be cured, implementation of appropriate symptomatic treatment is valuable.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/6SGWJRKJ/Goutman (2017) Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other.pdf;/Users/nathanielyomogida/Zotero/storage/XRLAJJ4C/goutman2017.pdf.pdf}
}

@article{goyalImmuneMediatedMyopathies2019,
  title = {Immune-{{Mediated Myopathies}}},
  author = {Goyal, Namita A.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1564--1585},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000789},
  url = {https://journals.lww.com/10.1212/CON.0000000000000789},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article summarizes the clinical features, diagnostic evaluation, and management of the common immune-mediated myopathies: dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, and overlap myositis.                                         RECENT FINDINGS               The identification of myositis-specific autoantibodies has improved the characterization of the subtypes of myositis and associated clinical phenotypes, as the severity of muscle involvement, extramuscular manifestations, and risk of malignancy may vary among the subtypes of autoimmune myopathies.                                         SUMMARY               The understanding and diagnostic accuracy of the subtypes of autoimmune myopathies have been enhanced with careful attention to the key clinical features, the emergence of myositis-specific autoantibodies, the characterization of histopathologic hallmark features, and the aid of muscle imaging. Several immunotherapeutic options now exist that can be selected to target a specific subtype, often with a favorable prognosis, especially when treatment starts early in the disease course.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/MD6LNWAS/Goyal (2019) Immune-Mediated Myopathies.pdf}
}

@article{goyalInclusionBodyMyositis2022,
  title = {Inclusion {{Body Myositis}}},
  author = {Goyal, Namita A.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1663--1677},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001204},
  url = {https://journals.lww.com/10.1212/CON.0000000000001204},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article highlights the clinical and diagnostic features of inclusion body myositis (IBM) and provides recent insights into the pathomechanisms and therapeutic strategies of the disease.                                         RECENT FINDINGS               IBM is an often-misdiagnosed myopathy subtype. Due to the insidious onset and slow progression of muscle weakness, it can often be dismissed as a sign of aging as it commonly presents in older adults. While challenging to recognize upon initial clinical evaluation, the recent recognition of specialized stains highlighting features seen on muscle pathology, the use of diagnostic tools such as the anti-cytosolic 5'-nucleotidase 1A antibody biomarker, and the ability of muscle imaging to detect patterns of preferential muscle involvement seen in IBM has allowed for earlier diagnosis of the disease than was previously possible. While the pathogenesis of IBM has historically been poorly understood, several ongoing studies point toward mechanisms of autophagy and highly differentiated cytotoxic T cells that are postulated to be pathogenic in IBM.                                         SUMMARY               Overall advancements in our understanding of IBM have resulted in improvements in the management of the disease and are the foundation of several strategies for current and upcoming novel therapeutic drug trials in IBM.},
  langid = {english},
  keywords = {Current}
}

@article{graff-radfordNormalPressureHydrocephalus2019,
  title = {Normal {{Pressure Hydrocephalus}}},
  author = {{Graff-Radford}, Neill R. and Jones, David T.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {165--186},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000689},
  url = {https://journals.lww.com/00132979-201902000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Since it was first described in 1965, normal pressure hydrocephalus (NPH) has been a controversial subject. New studies have shed light on its epidemiology and pathogenesis and provided objective ways to measure outcome in patients with NPH. Neuroimaging has improved and allows better recognition of both NPH and the presence of overlapping diseases                                         RECENT FINDINGS                                Several recent epidemiologic studies confirm that NPH is a rare disease, but the presence of large ventricles is a common finding with aging. NPH may be multifactorial, including congenital causes, vascular disease, and impaired CSF absorption. MRI features of NPH include enlarged ventricular size and CSF fluid collection outside the ventricles not due to atrophy. The term                 disproportionately enlarged subarachnoid space hydrocephalus                 (DESH) has been used to describe prognostic MRI features in NPH, including a ``tight high convexity'' and enlargement of CSF spaces in the sylvian fissure. DESH has been included in the Japanese guideline for the diagnosis and treatment of NPH. A new NPH scale has been published that provides an objective framework for evaluating patients with NPH before and after shunt placement. Programmable shunts can noninvasively manage overdrainage complications. Surgical outcome has been improving over time. Recent studies have led to improved recognition of overlapping diseases such as Alzheimer pathology, which co-occurs in about 30\% of NPH cases. Fludeoxyglucose positron emission tomography (FDG-PET) is a promising imaging modality for diagnosing NPH and detecting concomitant degenerative disease.                                                        SUMMARY               A systematic approach to patients with possible NPH allows recognition of the subset of patients who will respond to shunt surgery and identification of those with alternative diagnoses.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/AQC8ZKIK/Graff-Radford_Jones (2019) Normal Pressure Hydrocephalus.pdf}
}

@article{graff-radfordVascularCognitiveImpairment2019,
  title = {Vascular {{Cognitive Impairment}}},
  author = {{Graff-Radford}, Jonathan},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {147--164},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000684},
  url = {https://journals.lww.com/00132979-201902000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of vascular cognitive impairment; discusses its epidemiology, subtypes, and associations with other neurodegenerative diseases; and reviews the diagnostic evaluation and management of these disorders.                                         RECENT FINDINGS               Cerebrovascular disease is a common cause of dementia and frequently coexists with neurodegenerative causes. The heterogeneity of mechanisms leading to vascular cognitive impairment makes developing unifying clinical and research criteria difficult. Recognizing the neuroimaging hallmarks of different forms of vascular cognitive impairment can allow for individualized treatment and management. In individuals with mild vascular cognitive impairment, aerobic exercise appears to be a promising treatment but requires further investigation.                                         SUMMARY               Vascular cognitive impairment can be caused by several mechanisms. While treating vascular risk factors is rational to prevent worsening of cognitive impairment, well-designed studies are needed to demonstrate efficacy.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/3LSB436Y/Graff-Radford (2019) Vascular Cognitive Impairment.pdf}
}

@article{greeneProgressiveSupranuclearPalsy2019,
  title = {Progressive {{Supranuclear Palsy}}, {{Corticobasal Degeneration}}, and {{Multiple System Atrophy}}},
  author = {Greene, Paul},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {919--935},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000751},
  url = {https://journals.lww.com/00132979-201908000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Patients who have parkinsonian features, especially without tremor, that are not responsive to levodopa, usually have one of these three major neurodegenerative disorders rather than Parkinson disease: progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD). Each of these disorders eventually develops signs and symptoms that distinguish it from idiopathic Parkinson disease, but these may not be present at disease onset. Although these conditions are not generally treatable, it is still important to correctly diagnose the condition as soon as possible.                                         RECENT FINDINGS               In recent years, it has been increasingly recognized that the symptoms of these diseases do not accurately predict the pathology, and the pathology does not accurately predict the clinical syndrome. Despite this, interest has grown in treating these diseases by targeting misfolded tau (in the case of PSP and CBD) and misfolded {$\alpha$}-synuclein (in the case of MSA).                                         SUMMARY               Knowledge of the characteristic signs and symptoms of PSP, MSA, and CBD are essential in diagnosing and managing patients who have atypical parkinsonian syndromes.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/2M22BGD5/10.1212@CON.0000000000000751.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/W5S96Y6J/Greene (2019) Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System.pdf}
}

@article{grillInfectiousMyelopathies2018,
  title = {Infectious {{Myelopathies}}},
  author = {Grill, Marie F.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {441--473},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000597},
  url = {https://journals.lww.com/00132979-201804000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews bacterial, viral, fungal, and parasitic pathogens associated with myelopathy. Infectious myelopathies may be due to direct infection or parainfectious autoimmune-mediated mechanisms; this article focuses primarily on the former.                                         RECENT FINDINGS                                Some microorganisms exhibit neurotropism for the spinal cord (eg, enteroviruses such as poliovirus and flaviviruses such as West Nile virus), while others are more protean in neurologic manifestations (eg, herpesviruses such as varicella-zoster virus), and others are only rarely reported to cause myelopathy (eg, certain fungal and parasitic infections). Individuals who are immunocompromised are at increased risk of disseminated infection to the central nervous system. Within the last few years, an enterovirus D68 outbreak has been associated with cases of acute flaccid paralysis in children, and emerging Zika virus infection has been concurrent with cases of acute flaccid paralysis due to Guillain-Barr{\'e} syndrome, although cases of myelitis have also been reported. Associated pathogens differ by geographic distribution, with myelopathies related to                 Borrelia burgdorferi                 (Lyme disease) and West Nile virus more commonly seen in the United States and parasitic infections encountered more often in Latin America, Southeast Asia, and Africa. Characteristic CSF and MRI patterns have been identified with many of these infections.                                                        SUMMARY               A myriad of pathogens are associated with infectious myelopathies. Host factors, geographic distribution, clinical features, CSF profiles, and MRI findings can assist in formulating the differential diagnosis and ultimately guide management.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/9LFZAF7Z/grill2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/QH8FPU2I/Grill (2018) Infectious Myelopathies.pdf}
}

@article{grillNeurologicComplicationsHuman2021,
  title = {Neurologic {{Complications}} of {{Human Immunodeficiency Virus}}},
  author = {Grill, Marie F.},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {963--991},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001035},
  url = {https://journals.lww.com/10.1212/CON.0000000000001035},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the neurologic complications associated with human immunodeficiency virus (HIV) infection.                                         RECENT FINDINGS                                Neurologic complications of HIV may be caused by direct virally mediated pathology, immune-mediated phenomena in response to viral infection, or opportunistic infections secondary to depletion of lymphocytes. These neurologic disorders may be influenced by the degree of immunosuppression (ie, CD4+ T-cell lymphocyte count) and stage of infection (early versus late), as well as use of antiretroviral therapy, and may manifest as a variety of central and peripheral neurologic syndromes, including the more commonly encountered HIV-associated cognitive disorders and length-dependent sensorimotor polyneuropathy, respectively. Immune dysregulation underlies the majority of these neurologic phenomena, as well as other HIV-associated conditions including immune reconstitution inflammatory syndrome (IRIS), CD8 lymphocytosis, and potentially the development of compartmentalized infection within the CSF, also referred to as                 CSF escape                 .                                                        SUMMARY               This article reviews a spectrum of clinical syndromes and related neuropathologic states associated with HIV infection.},
  langid = {english},
  keywords = {Current}
}

@article{grommesCentralNervousSystem2020,
  title = {Central {{Nervous System Lymphomas}}},
  author = {Grommes, Christian},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1476--1494},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000936},
  url = {https://journals.lww.com/10.1212/CON.0000000000000936},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Primary central nervous system (CNS) lymphoma is a rare, aggressive extranodal non-Hodgkin lymphoma confined to the brain, eyes, CSF, or spinal cord without systemic, non-CNS involvement. This article reviews the clinical presentation, imaging characteristics, diagnostic workup, novel pathophysiologic insights, and treatment of immunocompetent patients with primary CNS lymphoma.                                         RECENT FINDINGS               The prognosis of primary CNS lymphoma has significantly improved over the past few decades because of the introduction of and widespread use of high-dose methotrexate, which is now the backbone of all first-line combination chemotherapy treatments. Despite this progress, durable remission is still observed in only approximately 50\% of patients. Novel insights into the pathophysiology of primary CNS lymphoma have identified the B-cell receptor pathway as well as the suppressed tumor immune microenvironment and immune evasion as key mechanisms in the pathogenesis of primary CNS lymphoma. Novel, small molecules and agents targeting these aberrant pathways have been introduced into clinical trials of recurrent/refractory primary CNS lymphomas. Agents such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs such as lenalidomide and pomalidomide have shown promising response rates in the relapsed setting.                                         SUMMARY               Diagnosis of primary CNS lymphoma requires a high level of suspicion because clinical signs and deficits can vary and depend on the involved CNS compartments. Rapid initiation of therapy is essential for recovery and prognosis. The optimal treatment regimen has not been defined, but methotrexate-based chemotherapy regimens are considered the standard treatment approach for induction treatment. Novel, targeted agents have recently been introduced into the therapeutic arsenal.},
  langid = {english}
}

@article{grossmanPrimaryProgressiveAphasia2018,
  title = {Primary {{Progressive Aphasia}} and {{Stroke Aphasia}}},
  author = {Grossman, Murray and Irwin, David J.},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {745--767},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000618},
  url = {https://journals.lww.com/00132979-201806000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article summarizes the clinical and anatomic features of the three named variants of primary progressive aphasia (PPA): semantic variant PPA, nonfluent/agrammatic variant PPA, and logopenic variant PPA. Three stroke aphasia syndromes that resemble the PPA variants (Broca aphasia, Wernicke aphasia, and conduction aphasia) are also presented.                                         RECENT FINDINGS               Semantic variant PPA and Wernicke aphasia are characterized by fluent speech with naming and comprehension difficulty; these syndromes are associated with disease in different portions of the left temporal lobe. Patients with nonfluent/agrammatic variant PPA or Broca aphasia have nonfluent speech with grammatical difficulty; these syndromes are associated with disease centered in the left inferior frontal lobe. Patients with logopenic variant PPA or conduction aphasia have difficulty with repetition and word finding in conversational speech; these syndromes are associated with disease in the left inferior parietal lobe. While PPA and stroke aphasias resemble one another, this article also presents their distinguishing features.                                         SUMMARY               Primary progressive and stroke aphasia syndromes interrupt the left perisylvian language network, resulting in identifiable aphasic syndromes.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/BBRRI365/Grossman and Irwin - 2018 - Primary Progressive Aphasia and Stroke Aphasia.pdf}
}

@article{grottaIntravenousThrombolysisAcute2023,
  title = {Intravenous {{Thrombolysis}} for {{Acute Ischemic Stroke}}},
  author = {Grotta, James C.},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {425--442},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001207},
  url = {https://journals.lww.com/10.1212/CON.0000000000001207},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               This article reviews the history of IV thrombolysis, its current indications and implementation, the duality of the ``time is brain'' versus ``tissue clock'' approaches, the impact of endovascular thrombectomy on IV thrombolysis, the emergence of tenecteplase, and future research directions.                                         LATEST DEVELOPMENTS               The growing use of factor Xa inhibitors has increasingly caused patients with stroke to be excluded from treatment with IV thrombolysis. Important geographic, socioeconomic, sex, race, and ethnic disparities have been identified in the implementation of IV thrombolysis and need to be overcome. IV thrombolysis substantially improves outcomes when provided within the first golden hour after stroke onset in patients treated in mobile stroke units, supporting the ``time is brain'' concept and encouraging the possible value of more widespread implementation of the mobile stroke unit approach. At the same time, other studies have shown that IV thrombolysis can be successful in patients whose ``tissue clock'' is still ticking up to 9 hours after stroke onset or in patients who awaken with their stroke, as demonstrated by favorable imaging profiles. These considerations, along with the emergence of endovascular thrombectomy, have fostered examination of our care systems, including the ``drip and ship'' versus direct to comprehensive or endovascular thrombectomy stroke center approaches, as well as the possibility of skipping IV thrombolysis in certain patients treated with endovascular thrombectomy. Data suggesting that tenecteplase is at least noninferior to alteplase, as well as its more convenient dosing, has led to its increased use. Ongoing studies are evaluating newer thrombolytics and adding antithrombotic therapy to IV thrombolysis.                                         ESSENTIAL POINTS               IV thrombolysis remains the most common acute stroke treatment. Advances in acting faster to treat stroke have increased its efficacy, and advances in imaging have expanded its use. However, implementing these advances and overcoming disparities in IV thrombolysis use remain major challenges.},
  langid = {english},
  keywords = {Current}
}

@article{guidonLambertEatonMyasthenicSyndrome2019,
  title = {Lambert-{{Eaton Myasthenic Syndrome}}, {{Botulism}}, and {{Immune Checkpoint Inhibitor}}--{{Related Myasthenia Gravis}}},
  author = {Guidon, Amanda C.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1785--1806},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000807},
  url = {https://journals.lww.com/10.1212/CON.0000000000000807},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the pathophysiology, epidemiology, clinical presentation, diagnosis, and treatment of Lambert-Eaton myasthenic syndrome (LEMS) and of botulism, and immune-related myasthenia gravis (MG) occurring in the context of immune checkpoint inhibitor therapy for cancer.                                         RECENT FINDINGS               The suspicion that LEMS is rare but also likely underdiagnosed is supported by recent epidemiologic data. A validated, LEMS-specific scale now exists to assess and monitor disease, and symptomatic and immunomodulatory treatments are available. As presynaptic disorders of neuromuscular transmission, LEMS and botulism share electrodiagnostic abnormalities but have important distinguishing features. Knowledge of the clinical features of botulism is needed, particularly with continued cases of infant botulism, the opioid epidemic increasing the incidence of wound botulism, and medical use of botulinum toxin, which may cause iatrogenic botulism. Foodborne botulism remains rare. Prompt recognition of botulism and administration of antitoxin can improve outcomes. MG may be exacerbated or may present de novo in the context of immune activation from immune checkpoint inhibitor therapies for cancer. Immune-related MG commonly overlaps with myositis and myocarditis. Corticosteroids typically result in improvement. However, immune-related MG can be more fulminant than its idiopathic counterpart and may cause permanent disability or death.                                         SUMMARY               The diagnosis of LEMS, botulism, or immune-related MG can generally be made from the patient's history, supplemented with directed questions, a physical examination designed to demonstrate abnormalities, and laboratory and electrodiagnostic testing. Early diagnosis and carefully selected treatment not only improve outcomes of the neuromuscular disease but can affect the prognosis of underlying malignancy, when present.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/7S929ATR/Guidon (2019) Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint.pdf}
}

@article{guzikStrokeEpidemiologyRisk2017,
  title = {Stroke {{Epidemiology}} and {{Risk Factor Management}}},
  author = {Guzik, Amy and Bushnell, Cheryl},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {15--39},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000416},
  url = {https://journals.lww.com/00132979-201702000-00007},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               Death from stroke has decreased over the past decade, with stroke now the fifth leading cause of death in the United States. In addition, the incidence of new and recurrent stroke is declining, likely because of the increased use of specific prevention medications, such as statins and antihypertensives. Despite these positive trends in incidence and mortality, many strokes remain preventable. The major modifiable risk factors are hypertension, diabetes mellitus, tobacco smoking, and hyperlipidemia, as well as lifestyle factors, such as obesity, poor diet/nutrition, and physical inactivity. This article reviews the current recommendations for the management of each of these modifiable risk factors.                                         Recent Findings:               It has been documented that some blood pressure medications may increase variability of blood pressure and ultimately increase the risk for stroke. Stroke prevention typically includes antiplatelet therapy (unless an indication for anticoagulation exists), so the most recent evidence supporting use of these drugs is reviewed. In addition, emerging risk factors, such as obstructive sleep apnea, electronic cigarettes, and elevated lipoprotein (a), are discussed.                                         Summary:               Overall, secondary stroke prevention includes a multifactorial approach. This article incorporates evidence from guidelines and published studies and uses an illustrative case study throughout the article to provide examples of secondary prevention management of stroke risk factors.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/VJGITVK2/Guzik_Bushnell (2017) Stroke Epidemiology and Risk Factor Management.pdf}
}

@article{gwathmeySensoryPolyneuropathies2017,
  title = {Sensory {{Polyneuropathies}}},
  author = {Gwathmey, Kelly Graham},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1411--1436},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000518},
  url = {https://journals.lww.com/00132979-201710000-00016},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article describes the methods of diagnosis and management of the sensory-predominant polyneuropathies. To simplify the approach to this category of patients, sensory-predominant polyneuropathies are divided broadly into either small fiber (or pain-predominant) neuropathies and large fiber (or ataxia-predominant) neuropathies, of which the sensory neuronopathies (dorsal root ganglionopathies) are highlighted.                                         Recent Findings:               Physicians can now easily perform skin biopsies in their offices, allowing access to the gold standard pathologic diagnostic tool for small fiber neuropathies. Additional diagnostic techniques, such as corneal confocal microscopy, are emerging. Recently, small fiber neuropathies have been associated with a broader spectrum of diseases, including fibromyalgia, sodium channel mutations, and voltage-gated potassium channel antibody autoimmune disease.                                         Summary:               Despite advances in diagnosing small fiber neuropathies and sensory neuronopathies, many of these neuropathies remain refractory to treatment. In select cases, early identification and treatment may result in better outcomes. ``Idiopathic'' should be a diagnosis of exclusion and a thorough investigation for treatable causes pursued.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/8SFJH2BE/gwathmey2017.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/A9MCVV76/Gwathmey (2017) Sensory Polyneuropathies.pdf}
}

@article{hainlinePeripheralNerveInjury2014,
  title = {Peripheral {{Nerve Injury}} in {{Sports}}:},
  shorttitle = {Peripheral {{Nerve Injury}} in {{Sports}}},
  author = {Hainline, Brian W.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1605--1628},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458971.86389.9c},
  url = {http://journals.lww.com/00132979-201412000-00012},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/296R6SMD/hainline2014.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/EDXIK2KM/Hainline (2014) Peripheral Nerve Injury in Sports.pdf}
}

@article{hainVestibularTesting2021,
  title = {Vestibular {{Testing}}},
  author = {Hain, Timothy C. and Cherchi, Marcello},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {330--347},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000978},
  abstract = {PURPOSE OF REVIEW: Vestibular testing, both at the bedside and in the laboratory, is often critical in diagnosing patients with symptoms of vertigo, dizziness, unsteadiness, and oscillopsia. This article introduces readers to core concepts, as well as recent advances, in bedside and instrumented vestibular assessments. RECENT FINDINGS: Vestibular testing has improved immensely in the past 2 decades. While history and bedside testing is still the primary method of differential diagnosis in patients with dizziness, advances in technology such as the ocular vestibular-evoked myogenic potential test for superior canal dehiscence and the video head impulse test for vestibular neuritis have capabilities that go far beyond the bedside examination. Current vestibular testing now allows clinicians to test all five vestibular sensors in the inner ear. SUMMARY: Contemporary vestibular testing technology can now assess the entire vestibular periphery. Relatively subtle conditions, such as superior canal dehiscence or a subtle vestibular neuritis, can now be diagnosed with far greater certainty.},
  langid = {english},
  pmid = {34351109},
  keywords = {Continuum: Neuro-otology,Dizziness,Head Impulse Test,Humans,Vertigo,Vestibular Evoked Myogenic Potentials,Vision Disorders},
  file = {/Users/nathanielyomogida/Zotero/storage/7BK4Q3KC/Hain_Cherchi (2021) Vestibular Testing.pdf}
}

@article{halperinNeuroborreliosisNeurosyphilis2018,
  title = {Neuroborreliosis and {{Neurosyphilis}}},
  author = {Halperin, John J.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1439--1458},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000645},
  url = {https://journals.lww.com/00132979-201810000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article presents an overview of the current diagnosis and management of two spirochetal infections of the nervous system, neuroborreliosis (Lyme disease) and neurosyphilis, focusing on similarities and differences. Although neuroborreliosis was first identified almost a century ago, much confusion remains about how to accurately diagnose this quite treatable nervous system infection. Well-established diagnostic tools and therapeutic regimens exist for neurosyphilis, which has been well-known for centuries.                                         RECENT FINDINGS               Serologic testing targeting the C6 antigen may simplify diagnostic testing in neuroborreliosis while improving accuracy. Historically, screening for syphilis has used a reaginic test followed by a treponeme-specific assay; alternative approaches, including use of well-defined recombinant antigens, may improve sensitivity without sacrificing specificity. In neuroborreliosis, measurement of the chemokine CXCL13 in CSF may provide a useful marker of disease activity in the central nervous system.                                         SUMMARY               Lyme disease causes meningitis, cranial neuritis, radiculitis, and mononeuropathy multiplex. Cognitive symptoms, occurring either during (encephalopathy) or after infection (posttreatment Lyme disease syndrome) are rarely, if ever, due to central nervous system infection. Posttreatment Lyme disease syndrome is not antibiotic responsive. Syphilis causes meningitis, cranial neuritis, chronic meningovascular syphilis, tabes dorsalis, and parenchymal neurosyphilis. The organism remains highly sensitive to penicillin, but residua of chronic infection may be irreversible.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/ZU4FEVZK/Halperin (2018) Neuroborreliosis and Neurosyphilis.pdf}
}

@article{hamelMyotonicDystrophy2022,
  title = {Myotonic {{Dystrophy}}},
  author = {Hamel, Johanna I.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1715--1734},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001184},
  url = {https://journals.lww.com/10.1212/CON.0000000000001184},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are genetic disorders affecting skeletal and smooth muscle, heart, brain, eyes, and other organs. The multisystem involvement and disease variability of myotonic dystrophy have presented challenges for clinical care and research. This article focuses on the diagnosis and management of the disease. In addition, recent advances in characterizing the diverse clinical manifestations and variability of the disease are discussed.                                         RECENT FINDINGS               Studies of the multisystem involvement of myotonic dystrophy, including the most lethal cardiac and respiratory manifestations and their molecular underpinnings, expand our understanding of the myotonic dystrophy phenotype. Advances have been made in understanding the molecular mechanisms of both types of myotonic dystrophy, providing opportunities for developing targeted therapeutics, some of which have entered clinical trials in DM1.                                         SUMMARY               Continued efforts focus on advancing our molecular and clinical understanding of DM1 and DM2. Accurately measuring and monitoring the diverse and variable clinical manifestations of myotonic dystrophy in clinic and in research is important to provide adequate care, prevent complications, and find treatments that improve symptoms and life quality.},
  langid = {english},
  keywords = {Current}
}

@article{hardySpinalCordAnatomy2021,
  title = {Spinal {{Cord Anatomy}} and {{Localization}}},
  author = {Hardy, Todd A.},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {12--29},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000899},
  url = {https://journals.lww.com/10.1212/CON.0000000000000899},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article focuses on clinically relevant teaching points in spinal anatomy and localizing the lesion in myelopathy.                                         RECENT FINDINGS               The principles underlying spinal cord lesion localization are well established, but improvements in MRI and the discovery of pathologic antibodies associated with causes of transverse myelitis distinct from multiple sclerosis, such as aquaporin-4 IgG and myelin oligodendrocyte glycoprotein IgG, have assisted in diagnosis.                                         SUMMARY               The spinal cord has a highly organized neuroanatomy of ascending and descending tracts that convey sensory, motor, and autonomic information. Using integration of clues from the patient's history and neurologic examination, the effective clinician can distinguish spinal cord from peripheral nerve or brain pathology, often determine the level and parts of the spinal cord affected by a lesion, and focus on a likely diagnosis. The advent of MRI of the spine has revolutionized investigation of spinal cord disorders, but an important place for strong clinical acumen still exists in assessing the patient with a myelopathy.},
  langid = {english}
}

@article{hederaHereditaryMyelopathies2018,
  title = {Hereditary {{Myelopathies}}},
  author = {Hedera, Peter},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {523--550},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000580},
  url = {https://journals.lww.com/00132979-201804000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Hereditary myelopathies are very diverse genetic disorders, and many of them represent a widespread neurodegenerative process rather than isolated spinal cord dysfunction. This article reviews various types of inherited myelopathies, with emphasis on hereditary spastic paraplegias and spastic ataxias.                                         RECENT FINDINGS               The ever-growing number of myelopathy-causing genes and broadening of phenotype-genotype correlations makes the molecular diagnosis of inherited myelopathies a daunting task. This article emphasizes the main phenotypic clusters among inherited myelopathies that can facilitate the diagnostic process. This article focuses on newly identified genetic causes and the most important identifying clinical features that can aid the diagnosis, including the presence of a characteristic age of onset and additional neurologic signs such as leukodystrophy, thin corpus callosum, or amyotrophy.                                         SUMMARY               The exclusion of potentially treatable causes of myelopathy remains the most important diagnostic step. Syndromic diagnosis can be supported by molecular diagnosis, but the genetic diagnosis at present does not change the management. Moreover, a negative genetic test does not exclude the diagnosis of a hereditary myelopathy because comprehensive molecular testing is not yet available, and many disease-causing genes remain unknown.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/D3MQEXEA/hedera2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/WHBXQEW8/Hedera (2018) Hereditary Myelopathies.pdf}
}

@article{hehirDiagnosisManagementMyasthenia2022,
  title = {Diagnosis and {{Management}} of {{Myasthenia Gravis}}},
  author = {Hehir, Michael K. and Li, Yuebing},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1615--1642},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001161},
  url = {https://journals.lww.com/10.1212/CON.0000000000001161},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews updated diagnostic procedures and currently available treatment modalities for myasthenia gravis (MG).                                         RECENT FINDINGS               Patients with MG can be classified based on antibody status and their clinical presentation; treatment responses may differ based on disease subtypes. Improved diagnostic methods and recognition of new antigenic targets such as lipoprotein-related protein 4 have led to improved diagnostic efficiencies. Corticosteroids remain the first-line immunotherapy, but there is a trend toward minimizing their use at high doses and for long durations. Oral immunosuppressants such as mycophenolate mofetil, azathioprine, and tacrolimus remain useful. An international, multicenter randomized trial comparing thymectomy plus prednisone with prednisone alone demonstrated that thymectomy improves clinical outcomes in selected patients with nonthymomatous MG. Eculizumab, efgartigimod, and ravulizumab have recently been approved by the US Food and Drug Administration (FDA) for adult patients with generalized MG who are acetylcholine receptor--antibody positive. These drugs take advantage of novel mechanisms of action and expand treatment options for patients with MG. Data on rituximab suggest that it can be a good option, especially for patients with MG who are positive for antibodies against muscle-specific tyrosine kinase (MuSK). The number of clinical trials and drugs in development for MG is steadily increasing.                                         SUMMARY               The diagnosis of MG can generally be made from the patient's history, a neurologic examination, and laboratory and electrodiagnostic testing. Carefully selected treatment improves outcomes in MG. Additional treatment options for MG will likely be available in the near future.},
  langid = {english},
  keywords = {Current}
}

@article{heilmanUpperLimbApraxia2021,
  title = {Upper {{Limb Apraxia}}},
  author = {Heilman, Kenneth M.},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1602--1623},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001014},
  url = {https://journals.lww.com/10.1212/CON.0000000000001014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Limb apraxia is one of the most common and most disabling disorders caused by brain damage. However, apraxia is one of the least recognized disorders associated with cerebral disease. This article discusses the signs and symptoms of, means of testing for, the pathophysiology of, and possible management of upper limb apraxia.                                         RECENT FINDINGS               Upper limb apraxia has four major forms: ideomotor, limb-kinetic, conceptual, and ideational. Although recent findings are included in this article, a full understanding of these disorders, including the means of testing, their possible pathophysiology, and the diseases that may cause these disorders, requires that some older literature is also discussed.                                         SUMMARY               This article guides clinicians in testing for and diagnosing the different forms of upper limb apraxia, identifying the underlying diseases that may cause apraxia, managing the different forms of the disorder, and possible forms of rehabilitation.},
  langid = {english},
  keywords = {Current}
}

@article{henri-bhargavaClinicalAssessmentPrefrontal2018,
  title = {Clinical {{Assessment}} of {{Prefrontal Lobe Functions}}},
  author = {{Henri-Bhargava}, Alexandre and Stuss, Donald T. and Freedman, Morris},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {704--726},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000609},
  url = {https://journals.lww.com/00132979-201806000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Whereas it was previously thought that there was a single overarching frontal lobe syndrome, it is now clear that several distinct cognitive and behavioral processes are mediated by the frontal lobes. This article reviews these processes and the underlying neuroanatomy and provides an approach to the assessment of prefrontal lobe functions at the bedside.                                         RECENT FINDINGS               Cognitive and behavioral frontal lobe functions are mediated by the prefrontal regions rather than the frontal lobes as a whole. At least five separate prefrontal functions have been defined: energization, task setting, monitoring, behavioral/emotional regulation, and metacognition. Energization is mediated by the superior medial prefrontal cortices bilaterally, task setting by the left lateral frontal cortex, monitoring by the right lateral prefrontal cortex, behavioral/emotional regulation by the orbitofrontal cortex, and metacognition by the frontal poles. Only task setting and monitoring are considered executive functions.                                         SUMMARY               Distinct cognitive and behavioral processes are mediated by different parts of the frontal lobe. Lesions in these areas result in characteristic clinical deficits that are discussed in this article. Key messages are that prefrontal regions mediate the higher cortical functions (as opposed to the frontal lobes in general) and that prefrontal functions are not equivalent to executive functions.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/SIMQCJYJ/Henri-Bhargava et al (2018) Clinical Assessment of Prefrontal Lobe Functions.pdf}
}

@article{hobson-webbCommonEntrapmentNeuropathies2017,
  title = {Common {{Entrapment Neuropathies}}},
  author = {{Hobson-Webb}, Lisa D. and Juel, Vern C.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {487--511},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000452},
  url = {https://journals.lww.com/00132979-201704000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article addresses relevant peripheral neuroanatomy, clinical presentations, and diagnostic findings in common entrapment neuropathies involving the median, ulnar, radial, and fibular (peroneal) nerves.                                         Recent Findings:               Entrapment neuropathies are a common issue in general neurology practice. Early diagnosis and effective management of entrapment mononeuropathies are essential in preserving limb function and maintaining patient quality of life. Median neuropathy at the wrist (carpal tunnel syndrome), ulnar neuropathy at the elbow, radial neuropathy at the spiral groove, and fibular neuropathy at the fibular head are among the most frequently encountered entrapment mononeuropathies. Electrodiagnostic studies and peripheral nerve ultrasound are employed to help confirm the clinical diagnosis of nerve compression or entrapment and to provide precise localization for nerve injury. Peripheral nerve ultrasound demonstrates nerve enlargement at or near sites of compression.                                         Summary:               Entrapment neuropathies are commonly encountered in clinical practice. Accurate diagnosis and effective management require knowledge of peripheral neuroanatomy and recognition of key clinical symptoms and findings. Clinical diagnoses may be confirmed by diagnostic testing with electrodiagnostic studies and peripheral nerve ultrasound.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/HW8ZQEYP/Hobson-Webb_Juel (2017) Common Entrapment Neuropathies.pdf;/Users/nathanielyomogida/Zotero/storage/NLW32GRB/hobson-webb2017.pdf.pdf}
}

@article{huangPreventionManagementPoststroke2017,
  title = {Prevention and {{Management}} of {{Poststroke Complications}}},
  author = {Huang, Josephine F.},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {93--110},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000421},
  url = {https://journals.lww.com/00132979-201702000-00011},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               This article provides a synopsis of the immediate and delayed medical complications of stroke, with an emphasis on prevention and management of these complications.                                         Recent Findings:               Meta-analysis of the trials for endovascular treatment of acute stroke shows no significant increase in hemorrhagic events. Rehabilitation guidelines published by the American Heart Association and American Stroke Association in 2016 aid in providing the best clinical practice for patients with stroke, from the time of their initial hospitalization to their return to the community.                                         Summary:               Medical complications from stroke are common and are associated with poor clinical outcomes, increased length of hospital stays and higher rates of readmission, increased cost of care, delayed time to rehabilitation, and increased mortality. Being cognizant of the common complications encountered, taking appropriate measures to prevent them, and knowing how to manage them when they do occur are essential to the continued care of patients with stroke.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/YQHHIP3U/Huang (2017) Prevention and Management of Poststroke Complications.pdf}
}

@article{hussainEpilepticEncephalopathies2018,
  title = {Epileptic {{Encephalopathies}}},
  author = {Hussain, Shaun A.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {171--185},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000558},
  url = {https://journals.lww.com/00132979-201802000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the manifestations and treatment of the epileptic encephalopathies, which are a heterogeneous group of disorders characterized by both seizures and neurocognitive impairment.                                         RECENT FINDINGS               Next-generation (exome- and genome-based) sequencing technologies are revolutionizing the identification of single-gene causes of epileptic encephalopathy but have only had a modest impact on patient-specific treatment decisions. The treatment of most forms of epileptic encephalopathy remains a particularly challenging endeavor, with therapeutic decisions chiefly driven by the electroclinical syndrome classification. Most antiseizure drugs are ineffective in the treatment of these disorders, and treatments that are effective often entail significant risk and cost.                                         SUMMARY               The epileptic encephalopathies continue to pose a major challenge in diagnosis and treatment, with most patients experiencing very poor outcomes, although a significant minority of patients respond to, or are even cured by, specific therapies.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/C594R9TS/Hussain (2018) Epileptic Encephalopathies.pdf}
}

@article{ishiyamaSelectedOtologicDisorders2021,
  title = {Selected {{Otologic Disorders Causing Dizziness}}},
  author = {Ishiyama, Gail},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {468--490},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000977},
  abstract = {PURPOSE OF REVIEW: This article details updated clinical presentations and current treatment paradigms of the common otologic disorders that may present to the neurologist for vertigo, including M{\'e}ni{\`e}re disease, superior semicircular canal dehiscence syndrome, perilymphatic fistula, barotrauma, cholesteatoma, Ramsay Hunt syndrome, enlarged vestibular aqueduct syndrome, and autoimmune inner ear disease including Cogan syndrome. RECENT FINDINGS: The recent data on modern imaging techniques with three-dimensional delayed IV contrast in M{\'e}ni{\`e}re disease, findings on the clinical and testing parameters to diagnose semicircular canal dehiscence and barotrauma, and clinical findings in Ramsay Hunt syndrome, cholesteatoma, and enlarged vestibular aqueduct syndrome are discussed in the article. The most recent findings on the treatment and evaluation of autoimmune inner ear disease and Cogan syndrome are also covered. SUMMARY: This article discusses the common clinical otologic entities in patients who may present to the neurologist for vertigo, and it can be used as a guide in the diagnosis of these conditions with the use of auditory, vestibular, and imaging results.},
  langid = {english},
  pmid = {34351115},
  keywords = {Continuum: Neuro-otology,Dizziness,Hearing Loss Sensorineural,Humans,Vertigo,Vestibular Aqueduct},
  file = {/Users/nathanielyomogida/Zotero/storage/GSDWIXAT/Ishiyama (2021) Selected Otologic Disorders Causing Dizziness.pdf}
}

@article{jacobyElectrolyteDisordersNervous2020,
  title = {Electrolyte {{Disorders}} and the {{Nervous System}}},
  author = {Jacoby, Nuri},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {632--658},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000872},
  url = {https://journals.lww.com/10.1212/CON.0000000000000872},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the major electrolyte disorders and discusses in detail the homeostasis, etiologies, neurologic manifestations, and treatment of these disorders.                                         RECENT FINDINGS               The diagnosis and management of hyponatremia continue to evolve. Diagnostic accuracy is improved by assessing serum and urine osmolality as well as urinary sodium. Avoiding overcorrection of hyponatremia is crucial to avoid osmotic demyelination syndrome, although even careful correction can cause osmotic demyelination syndrome in patients who have other risk factors. The clinical presentation of osmotic demyelination syndrome has expanded, with many patients presenting with extrapontine myelinolysis in addition to central pontine myelinolysis.                                         SUMMARY               Electrolyte disorders often present with neurologic manifestations. Whereas disorders of some electrolytes, such as sodium, preferentially affect the central nervous system, disorders of others, such as potassium and calcium, have significant neuromuscular manifestations. An understanding of the pathophysiology of these disorders and recognition of these manifestations are crucial for the practicing neurologist as the symptoms are reversible with correct management.},
  langid = {english},
  keywords = {Outdated}
}

@article{jayadevGeneticsAlzheimerDisease2022,
  title = {Genetics of {{Alzheimer Disease}}},
  author = {Jayadev, Suman},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {852--871},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001125},
  url = {https://journals.lww.com/10.1212/CON.0000000000001125},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the spectrum of genetic risk in familial and sporadic forms of early- and late-onset Alzheimer disease (AD). Recent work illuminating the complex genetic architecture of AD is discussed in the context of high and low risk and what is known in different populations.                                         RECENT FINDINGS                                A small proportion of AD is autosomal dominant familial AD caused by variants in                 PSEN1, PSEN2,                 or                 APP                 , although more recently described rare genetic changes can also increase risk substantially over the general population, with odds ratios estimated at 2 to 4.                 APOE                 remains the strongest genetic risk factor for late-onset AD, and understanding the biology of                 APOE                 has yielded mechanistic insights and leads for therapeutic interventions. Genome-wide studies enabled by rapidly developing technologic advances in sequencing have identified numerous risk factors that have a low impact on risk but are widely shared throughout the population and involve a repertoire of cell pathways, again shining light on potential paths to intervention. Population studies aimed at defining and stratifying genetic AD risk have been informative, although they are not yet widely applicable clinically because the studies were not performed in people with diverse ancestry and ethnicity and thus population-wide data are lacking.                                                        SUMMARY               The value of genetic information to practitioners in the clinic is distinct from information sought by researchers looking to identify novel therapeutic targets. It is possible to envision a future in which genetic stratification joins other biomarkers to facilitate therapeutic choices and inform prognosis. Genetics already has transformed our understanding of AD pathogenesis and will, no doubt, continue to reveal the complexity of brain biology in health and disease.},
  langid = {english},
  keywords = {Current}
}

@article{jichaHippocampalSclerosisArgyrophilic2019,
  title = {Hippocampal {{Sclerosis}}, {{Argyrophilic Grain Disease}}, and {{Primary Age-Related Tauopathy}}},
  author = {Jicha, Gregory A. and Nelson, Peter T.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {208--233},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000697},
  url = {https://journals.lww.com/00132979-201902000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Hippocampal sclerosis, argyrophilic grain disease, and primary age-related tauopathy are common Alzheimer disease mimics that currently lack clinical diagnostic criteria. Increased understanding of these pathologic entities is important for the neurologist who may encounter patients with an unusually slowly progressive degenerative dementia that may appear to meet criteria for Alzheimer disease but who progress to develop symptoms that are unusual for classic Alzheimer disease                                         RECENT FINDINGS               Hippocampal sclerosis has traditionally been associated with hypoxic/ischemic injury and poorly controlled epilepsy, but it is now recognized that hippocampal sclerosis may also be associated with a unique degenerative disease of aging or may be an associated pathologic finding in many cases of frontotemporal lobar degeneration. Argyrophilic grain disease has been recognized as an enigma in the field of pathology for over 30 years, but recent discoveries suggest that it may overlap with other tau-related disorders within the spectrum of frontotemporal lobar degeneration. Primary age-related tauopathy has long been recognized as a distinct clinical entity that lies on the Alzheimer pathologic spectrum, with the presence of neurofibrillary tangles that lack the coexistent Alzheimer plaque development; thus, it is thought to represent a distinct pathologic entity.                                         SUMMARY               Despite advances in dementia diagnosis that suggest that we have identified and unlocked the mysteries of the major degenerative disease states responsible for cognitive decline and dementia in the elderly, diseases such as hippocampal sclerosis, argyrophilic grain disease, and primary age-related tauopathy demonstrate that we remain on the frontier of discovery and that our diagnostic repertoire of diseases responsible for such clinical symptoms remains in its infancy. Understanding such diagnostic confounds is important for the neurologist in assigning appropriate diagnoses and selecting appropriate therapeutic management strategies for patients with mild cognitive impairment and dementia.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/ZXMGHZBL/Jicha_Nelson (2019) Hippocampal Sclerosis, Argyrophilic Grain Disease, and Primary Age-Related.pdf}
}

@article{jinnahDystonias2019,
  title = {The {{Dystonias}}},
  author = {Jinnah, H. A.},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {976--1000},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000747},
  url = {https://journals.lww.com/00132979-201908000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a summary of the state of the art in the diagnosis, classification, etiologies, and treatment of dystonia.                                         RECENT FINDINGS               Although many different clinical manifestations of dystonia have been recognized for decades, it is only in the past 5 years that a broadly accepted approach has emerged for classifying them into specific subgroups. The new classification system aids clinical recognition and diagnosis by focusing on key clinical features that help distinguish the many subtypes. In the past few years, major advances have been made in the discovery of new genes as well as advances in our understanding of the biological processes involved. These advances have led to major changes in strategies for diagnosis of the inherited dystonias. An emerging trend is to move away from heavy reliance on the phenotype to target diagnostic testing toward a broader approach that involves large gene panels or whole exome sequencing.                                         SUMMARY               The dystonias are a large family of phenotypically and etiologically diverse disorders. The diagnosis of these disorders depends on clinical recognition of characteristic clinical features. Symptomatic treatments are useful for all forms of dystonia and include oral medications, botulinum toxins, and surgical procedures. Determination of etiology is becoming increasingly important because the number of disorders is growing and more specific and sometimes disease-modifying therapies now exist.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/CTNASSVU/10.1212@CON.0000000000000747.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/QZRZYLBC/Jinnah (2019) The Dystonias.pdf}
}

@article{johnsonLimbGirdleMuscularDystrophies2022,
  title = {The {{Limb-Girdle Muscular Dystrophies}}},
  author = {Johnson, Nicholas E. and Statland, Jeffrey M.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1698--1714},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001178},
  url = {https://journals.lww.com/10.1212/CON.0000000000001178},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The limb-girdle muscular dystrophies (LGMDs) are a group of inherited muscle disorders with a common feature of limb-girdle pattern of weakness, caused by over 29 individual genes. This article describes the classification scheme, common subtypes, and the management of individuals with LGMD.                                         RECENT FINDINGS                                Advances in genetic testing and next-generation sequencing panels containing all of the LGMD genes have led to earlier genetic confirmation, but also to more individuals with variants of uncertain significance. The LGMDs include disorders with autosomal recessive inheritance, which are often due to loss-of-function mutations in muscle structural or repair proteins and typically have younger ages of onset and more rapidly progressive presentations, and those with autosomal dominant inheritance, which can have older ages of presentation and chronic progressive disease courses. All cause progressive disability and potential loss of ability to walk or maintain a job due to progressive muscle wasting. Certain mutations are associated with cardiac or respiratory involvement. No disease-altering therapies have been approved by the US Food and Drug Administration (FDA) for LGMDs and standard treatment uses a multidisciplinary clinic model, but recessive LGMDs are potentially amenable to systemic gene replacement therapies, which are already being tested in clinical trials for sarcoglycan and                 FKRP                 mutations. The dominant LGMDs may be amenable to RNA-based therapeutic approaches.                                                        SUMMARY               International efforts are underway to better characterize LGMDs, help resolve variants of uncertain significance, provide consistent and improved standards of care, and prepare for future clinical trials.},
  langid = {english},
  keywords = {Current}
}

@article{johnsonMyotonicMuscularDystrophies2019,
  title = {Myotonic {{Muscular Dystrophies}}},
  author = {Johnson, Nicholas E.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1682--1695},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000793},
  url = {https://journals.lww.com/10.1212/CON.0000000000000793},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the clinical features, pathogenesis, prevalence, diagnosis, and management of myotonic dystrophy type 1 and myotonic dystrophy type 2.                                         RECENT FINDINGS               The prevalence of myotonic dystrophy type 1 is better understood than the prevalence of myotonic dystrophy type 2, and new evidence indicates that the risk of cancer is increased in patients with the myotonic dystrophies. In addition, descriptions of the clinical symptoms and relative risks of comorbidities such as cardiac arrhythmias associated with myotonic dystrophy type 1 have been improved.                                         SUMMARY               Myotonic dystrophy type 1 and myotonic dystrophy type 2 are both characterized by progressive muscle weakness, early-onset cataracts, and myotonia. However, both disorders have multisystem manifestations that require a comprehensive management plan. While no disease-modifying therapies have yet been identified, advances in therapeutic development have a promising future.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/296ZG9UF/Johnson (2019) Myotonic Muscular Dystrophies.pdf}
}

@article{jonesExecutiveDysfunctionPrefrontal2021,
  title = {Executive {{Dysfunction}} and the {{Prefrontal Cortex}}},
  author = {Jones, David T. and {Graff-Radford}, Jonathan},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1586--1601},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001009},
  url = {https://journals.lww.com/10.1212/CON.0000000000001009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article summarizes the cognitive and behavioral functions of the prefrontal cortex with an emphasis on executive cognitive functions and the clinical consequences associated with executive dysfunction. The clinical manifestations of lesions to the lateral prefrontal, orbitofrontal, medial prefrontal, and frontopolar cortex are reviewed.                                         RECENT FINDINGS               Traditional lesion studies have emphasized the role of a brain region in controlling a cognitive function. With advances in neurology, neuropsychology, and neuroimaging, the participation of the prefrontal cortex in large-scale networks has been established with recognition that cognitive dysfunction can arise not only from a lesion within a network but also from degenerative disease targeting these large-scale, dynamic neural networks. Although executive dysfunction can result from frontal lobe injury, this article highlights the role of distributed processes subserving executive functions. An atypical phenotype of Alzheimer disease has been described that selectively targets parietal-temporal-frontal networks important for core executive functions.                                         SUMMARY               Executive function comprises working memory, cognitive flexibility, and inhibition and depends on top-down (ie, goal-driven) control of distributed processes occurring throughout the brain. The exact behavioral output (ie, function) depends on the content of the processes being controlled. Prefrontal cortex regions serve key cognitive functions related to social, emotional, and motivational aspects of behavior. The dorsal lateral prefrontal cortex plays a role in working memory, goal-driven attention, task switching, planning, problem-solving, and novelty-seeking. The ventral lateral prefrontal cortex plays a role in inhibition, response selection, and monitoring; the medial prefrontal cortex in self-knowledge, motivation, emotional regulation, and updating goal-directed behavior; the orbitofrontal cortex in personality, inhibition, and emotional and social reasoning. Although dysexecutive syndromes have been traditionally associated with dorsolateral prefrontal cortex injury, it is now recognized that they can also result from an impaired parietal-temporal-frontal system, which is targeted in a distinct form of atypical Alzheimer disease. This dysexecutive Alzheimer phenotype is characterized by impaired task performance on a wide battery of neuropsychological tests and simple daily tasks that require executive control. In contrast, dysexecutive syndromes more localized to the frontal lobe involve impaired executive control of social, emotional, and motivational aspects of behavior.},
  langid = {english},
  keywords = {Current}
}

@article{jordanChronicTraumaticEncephalopathy2014,
  title = {Chronic {{Traumatic Encephalopathy}} and {{Other Long-term Sequelae}}:},
  shorttitle = {Chronic {{Traumatic Encephalopathy}} and {{Other Long-term Sequelae}}},
  author = {Jordan, Barry D.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1588--1604},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458972.94013.e1},
  url = {http://journals.lww.com/00132979-201412000-00011},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/76MQ3H69/Jordan (2014) Chronic Traumatic Encephalopathy and Other Long-term Sequelae.pdf}
}

@article{julayanontPsychosis2021,
  title = {Psychosis},
  author = {Julayanont, Parunyou and Suryadevara, Uma},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1682--1711},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001013},
  url = {https://journals.lww.com/10.1212/CON.0000000000001013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Psychosis can manifest in primary psychotic disorders, neurologic diseases, and medical conditions. This article reviews the definition of psychotic symptoms and the evaluation and management of psychosis in primary psychiatric and neurologic disorders frequently seen in neurologic practice.                                         RECENT FINDINGS               Emerging evidence supports significant connections between psychosis and structural and functional brain changes in both primary psychotic and neurologic disorders. In addition to antidopaminergic activity, the mechanism of new-generation antipsychotics shifts to act on serotonin receptors, which potentially contributes to their benefits in the treatment of negative symptoms of psychosis and a lesser frequency of extrapyramidal side effects compared with typical antipsychotics. This is also helpful in the treatment of psychosis in patients who have neurodegenerative diseases and are vulnerable to developing extrapyramidal side effects from typical antipsychotics.                                         SUMMARY               Even with significant overlap, management of psychosis in primary psychotic disorders differs from the approach of psychosis in neurologic diseases. This article helps clinicians learn how to practically evaluate psychosis from both psychiatric and neurologic perspectives.},
  langid = {english},
  keywords = {Current}
}

@article{kamelEvolvingConceptCryptogenic2020,
  title = {The {{Evolving Concept}} of {{Cryptogenic Stroke}}},
  author = {Kamel, Hooman},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {353--362},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000832},
  url = {https://journals.lww.com/10.1212/CON.0000000000000832},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses cryptogenic stroke and the results of recent randomized trials that can inform its evaluation and management.                                         RECENT FINDINGS                                Most cryptogenic strokes appear embolic, leading to the term                 embolic stroke of undetermined source                 . It was previously thought that embolic stroke of undetermined source was a single, therapeutically relevant entity, the underlying sources of which would respond to anticoagulant therapy; however, two large randomized trials found no benefit with anticoagulation compared to antiplatelet therapy for secondary stroke prevention after embolic stroke of undetermined source. A single antiplatelet drug remains the recommended long-term antithrombotic treatment for secondary stroke prevention in embolic stroke of undetermined source. However, three caveats should be considered with regard to cryptogenic stroke. First, those with minor stroke symptoms presenting early after onset should receive 3 weeks of dual antiplatelet therapy. Second, all patients with cryptogenic stroke should be monitored for atrial fibrillation. Third, patients 60 years of age or younger with a patent foramen ovale (PFO) should be carefully evaluated to determine whether the PFO may have caused the stroke and whether they might benefit from PFO closure.                                                        SUMMARY               More personalized strategies may soon be available to guide treatment of cryptogenic stroke. In the meantime, it is hoped that the application of recent findings from clinical trials will reduce stroke recurrence in this important population.},
  langid = {english}
}

@article{karsanMigrainePremonitoryPhase2018,
  title = {The {{Migraine Premonitory Phase}}},
  author = {Karsan, Nazia and Bose, Pyari and Goadsby, Peter J.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {996--1008},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000624},
  url = {https://journals.lww.com/00132979-201808000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The premonitory phase of migraine is defined as the presence of nonpainful symptomatology occurring hours to days before the onset of headache. Symptoms can include neck stiffness, yawning, thirst, and increased frequency of micturition. Clinical recognition of these symptoms is important to ensure early and effective attack management. Further understanding of the clinical phenotype and neurobiological mediation of these symptoms is important in the advancement of therapeutics research in both acute and preventive treatments of migraine.                                         RECENT FINDINGS               Since 2014, functional imaging studies have been conducted during the premonitory stage of migraine and have provided novel insights into the early neurobiology and anatomy of the earliest stage of the migraine attack. These studies have shown early involvement of subcortical brain areas including the hypothalamus, substantia nigra, dorsal pons, and various limbic cortical areas, including the anterior cingulate cortex during the premonitory phase. More recent work has revealed altered hypothalamic-brainstem functional connectivity during migraine, which starts before the onset of pain. These exciting findings have provided functional correlation of the symptoms experienced by patients and changes seen on functional brain imaging.                                         SUMMARY               This article focuses on the prevalence, phenotype, and proposed neurobiology of premonitory symptomatology in migraineurs as well as the scope of future research.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/C2UAMSZH/Karsan et al (2018) The Migraine Premonitory Phase.pdf;/Users/nathanielyomogida/Zotero/storage/MTNDIM8W/karsan2018.pdf.pdf}
}

@article{katzPalliativeCareMovement2022,
  title = {Palliative {{Care}} and {{Movement Disorders}}},
  author = {Katz, Maya},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1520--1529},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001162},
  url = {https://journals.lww.com/10.1212/CON.0000000000001162},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the role of palliative care in the treatment of patients with life-limiting neurodegenerative movement disorders.                                         RECENT FINDINGS               Growing evidence indicates that palliative care significantly improves quality of life and symptom burden for people with Parkinson disease and other serious movement disorders, while reducing caregiver burnout. An emphasis on advance care planning guides goal-directed treatment recommendations. Serious illness communication skills are evidence-based methods of relaying bad medical news to patients and mapping out values and goals in a way that provides comfort, emphasizes patient autonomy, and builds coping and resiliency strategies.                                         SUMMARY               Palliative care, when offered alongside primary medical and neurologic teams, provides an extra layer of support for people with serious illnesses. The goal of palliative care is to intensively treat total pain, which includes all of the physical, emotional, social, and spiritual distress caused by serious illness. Serious illness communication skills are key to providing empathic and goal-concordant care.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{kerberAcuteVestibularSyndrome2020,
  title = {Acute {{Vestibular Syndrome}}},
  author = {Kerber, Kevin A.},
  year = {2020},
  month = feb,
  journal = {Seminars in Neurology},
  volume = {40},
  number = {1},
  pages = {59--66},
  issn = {1098-9021},
  doi = {10.1055/s-0039-3402739},
  abstract = {The acute vestibular syndrome (AVS) is a label for presentations of new-onset severe dizziness, vertigo, or imbalance, with examination findings of nystagmus or gait unsteadiness. The prototypical AVS presentation is the acute unilateral vestibulopathy due to vestibular neuritis. Stroke is also a serious concern in patients with AVS. Most other peripheral vestibular disorders present as episodic or chronic syndromes. In this article, the diagnostic considerations, exam findings, and management of AVS are reviewed.},
  langid = {english},
  pmid = {31994145},
  keywords = {Acute Disease,Continuum: Neuro-otology,Humans,Stroke,Syndrome,Vestibular Diseases,Vestibular Neuronitis},
  file = {/Users/nathanielyomogida/Zotero/storage/PHI64XN3/Kerber (2020) Acute Vestibular Syndrome.pdf}
}

@article{kerberEpisodicPositionalDizziness2021,
  title = {Episodic {{Positional Dizziness}}},
  author = {Kerber, Kevin A.},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {348--368},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000909},
  abstract = {PURPOSE OF REVIEW: This article provides a summary of the evaluation and treatment of patients presenting with episodic positional dizziness. RECENT FINDINGS: Positional components are nearly ubiquitous among diagnoses of dizziness, so it can be challenging to classify patients with episodic positional dizziness simply based on the history of present illness. Overreliance on the presence of a report of positional components has likely resulted in misapplication or misinterpretation of positional testing and negative experiences with maneuvers to treat positional dizziness. The prototypical episodic positional dizziness disorder is benign paroxysmal positional vertigo (BPPV). BPPV is caused by free-floating particles in a semicircular canal that move in response to gravity. The diagnosis is made by identifying the characteristic patterns of nystagmus on the Dix-Hallpike test. Particle repositioning for BPPV is supported by randomized controlled trials, meta-analyses, and practice guidelines. Other disorders that can present with episodic positional dizziness are migraine dizziness, central lesions, and light cupula syndrome. SUMMARY: Episodic positional dizziness is a common presentation of dizziness. Neurologists should prioritize identifying and treating BPPV; doing so provides an important opportunity to deliver effective and efficient care. Providers should also recognize that positional components are common in most causes of dizziness and, therefore, should not over-rely on this part of the history of presentation when considering the diagnosis and management plan.},
  langid = {english},
  pmid = {34351110},
  keywords = {Benign Paroxysmal Positional Vertigo,Continuum: Neuro-otology,Dizziness,Humans,Nystagmus Pathologic,Semicircular Canals},
  file = {/Users/nathanielyomogida/Zotero/storage/756JA9WE/Kerber (2021) Episodic Positional Dizziness.pdf}
}

@article{kimMedicalManagementSecondary2020,
  title = {Medical {{Management}} for {{Secondary Stroke Prevention}}},
  author = {Kim, Anthony S.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {435--456},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000849},
  url = {https://journals.lww.com/10.1212/CON.0000000000000849},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the evidence base and recommendations for medical management for secondary stroke prevention.                                         RECENT FINDINGS               Recent developments for secondary stroke prevention include evidence to support the use of short-term dual antiplatelet therapy after minor stroke and transient ischemic attack, direct oral anticoagulants for nonvalvular atrial fibrillation, reversal agents for direct oral anticoagulant--associated hemorrhage, and aspirin rather than presumptive anticoagulation with a direct oral anticoagulant for embolic stroke of undetermined source.                                         SUMMARY               Most strokes are preventable. The mainstays of medical management for secondary stroke prevention include antihypertensive therapy; antithrombotic therapy, with antiplatelet agents for most stroke subtypes or anticoagulants such as warfarin or a direct oral anticoagulant for cardioembolic stroke specifically; cholesterol-lowering therapy, principally with statins, but with potential roles for ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors in selected patients; and glycemic control to prevent microvascular complications from diabetes mellitus or pioglitazone in selected patients with insulin resistance but not diabetes mellitus.},
  langid = {english}
}

@article{kincaidNeurophysiologicStudiesEvaluation2017,
  title = {Neurophysiologic {{Studies}} in the {{Evaluation}} of {{Polyneuropathy}}},
  author = {Kincaid, John C.},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1263--1275},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000521},
  url = {https://journals.lww.com/00132979-201710000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article provides core information on the clinical neurophysiology techniques available for the investigation of disorders of the peripheral nervous system.                                         Recent Findings:               The role of small fiber dysfunction in some types of polyneuropathy is being increasingly appreciated, and neurophysiologic techniques for evaluating the autonomic components of peripheral axons have enhanced our understanding of small fiber dysfunction.                                         Summary:               The principles of nerve conduction studies and needle EMG are presented in this article, along with the patterns of abnormality encountered in patients with polyneuropathy due to large and small fiber involvement.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/3Z3AH4AW/Kincaid (2017) Neurophysiologic Studies in the Evaluation of Polyneuropathy.pdf;/Users/nathanielyomogida/Zotero/storage/CYT8DT8V/kincaid2017.pdf.pdf}
}

@article{kirsch-darrowCognitiveRehabilitation2021,
  title = {Cognitive {{Rehabilitation}}},
  author = {{Kirsch-Darrow}, Lindsey and Tsao, Jack W.},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1670--1681},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001075},
  url = {https://journals.lww.com/10.1212/CON.0000000000001075},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a definition of and introduction to cognitive rehabilitation. It discusses different approaches to cognitive rehabilitation (ie, restorative, compensatory, and metacognitive). It also reviews types of memory impairment and how they can be distinguished to improve treatment design and implementation.                                         RECENT FINDINGS               Neural plasticity as a biological substrate for functional changes from cognitive rehabilitation is an exciting new area of research.                                         SUMMARY               This article provides a high-level review of cognitive rehabilitation and presents a complex case example.},
  langid = {english},
  keywords = {Current}
}

@article{kramerVascularDisordersSpinal2018,
  title = {Vascular {{Disorders}} of the {{Spinal Cord}}},
  author = {Kramer, Christopher L.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {407--426},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000595},
  url = {https://journals.lww.com/00132979-201804000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Prompt recognition and timely management of vascular disorders of the spinal cord can improve patient outcomes. This article provides contemporary and practical knowledge about the most common vascular myelopathies.                                         RECENT FINDINGS               New studies have provided additional information on the risk factors and impact of neurologic monitoring on perioperative spinal cord infarction. Additionally, recent publications have provided information on the impact of misdiagnosis, corticosteroid treatment, and postoperative prognosis in the treatment of spinal dural arteriovenous fistulas and have discussed the outcome of patients with spinal arteriovenous malformations treated with embolization, surgery, and stereotactic radiosurgery. Finally, recent studies have provided information on the natural history and postoperative prognosis of spinal cavernous malformations and on the risk factors and surgical outcome of patients with spinal epidural hematomas.                                         SUMMARY               Diagnostic and therapeutic challenges are inherent in managing patients with vascular disorders of the spinal cord, and clinicians should have a thorough understanding of these disorders to facilitate optimal outcomes for patients with these potentially devastating illnesses. This article begins by reviewing functional vascular anatomy and subsequently describes the fundamental characteristics of both ischemic and hemorrhagic vascular myelopathies to equip clinicians with the knowledge to avoid common pitfalls.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/B834RXYQ/kramer2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/LADG9R8B/Kramer (2018) Vascular Disorders of the Spinal Cord.pdf}
}

@article{kuoAtaxia2019,
  title = {Ataxia},
  author = {Kuo, Sheng-Han},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {1036--1054},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000753},
  url = {https://journals.lww.com/00132979-201908000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the symptoms, laboratory and neuroimaging diagnostic tests, genetics, and management of cerebellar ataxia.                                         RECENT FINDINGS               Recent advances in genetics have led to the identification of novel genetic causes for ataxia and a more comprehensive understanding of the biological pathways critical for normal cerebellar function. When these molecular pathways become dysfunctional, patients develop cerebellar ataxia. In addition, several ongoing clinical trials for Friedreich ataxia and spinocerebellar ataxia will likely result in novel symptomatic and disease-modifying therapies for ataxia. Antisense oligonucleotides for spinocerebellar ataxias associated with CAG repeat expansions might be a promising therapeutic strategy.                                         SUMMARY               Cerebellar ataxias include heterogeneous disorders affecting cerebellar function, leading to ataxic symptoms. Step-by-step diagnostic workups with genetic investigations are likely to reveal the underlying causes of ataxia. Some disease-specific therapies for ataxia exist, such as vitamin E for ataxia with vitamin E deficiency and thiamine for Wernicke encephalopathy, highlighting the importance of recognizing these forms of ataxia. Finally, genetic diagnosis for patients with ataxia will accelerate clinical trials for disease-modifying therapy and will have prognostic value and implications for family planning for these patients.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/49J99L8J/10.1212@CON.0000000000000753.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/5K2EK7NL/Kuo - 2019 - Ataxia.pdf;/Users/nathanielyomogida/Zotero/storage/J6BSJHPL/Kuo (2019) Ataxia.pdf}
}

@article{kutcherSportsConcussionDiagnosis2014,
  title = {Sports {{Concussion Diagnosis}} and {{Management}}:},
  shorttitle = {Sports {{Concussion Diagnosis}} and {{Management}}},
  author = {Kutcher, Jeffrey S. and Giza, Christopher C.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1552--1569},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458974.78766.58},
  url = {http://journals.lww.com/00132979-201412000-00009},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/J4ABXNRS/Kutcher_Giza (2014) Sports Concussion Diagnosis and Management.pdf;/Users/nathanielyomogida/Zotero/storage/Q5P2DR63/Kutcher and Giza - 2014 - Sports Concussion Diagnosis and Management.pdf;/Users/nathanielyomogida/Zotero/storage/X3UTAKCQ/kutcher2014.pdf.pdf}
}

@article{kwonTestingInbornErrors2018,
  title = {Testing for {{Inborn Errors}} of {{Metabolism}}},
  author = {Kwon, Jennifer M.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {37--56},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000563},
  url = {https://journals.lww.com/00132979-201802000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of genetic metabolic disorders that can be identified by metabolic tests readily available to neurologists, such as tests for ammonia, plasma amino acids, and urine organic acids. The limitations of these tests are also discussed, as they only screen for a subset of the many inborn errors of metabolism that exist.                                         RECENT FINDINGS               Advances in next-generation sequencing and the emerging use of advanced metabolomic screening have made it possible to diagnose treatable inborn errors of metabolism that are not included in current newborn screening programs. Some of these inborn errors of metabolism are especially likely to present with nonspecific neurologic phenotypes, such as epilepsy, ataxia, or intellectual disability. However, cost may be a barrier to obtaining these newer tests. It is important to keep in mind that common metabolic testing may lead to treatable diagnoses. Resources are available to guide neurologists in diagnosing genetic metabolic conditions.                                         SUMMARY               This article introduces the clinical presentations of treatable inborn errors of metabolism that are important for neurologists to consider in patients of all ages. Inborn errors of metabolism are rare, but they can present with neurologic symptoms. Newborns are now screened for many treatable metabolic disorders, but these screening tests may miss milder presentations of treatable inborn errors of metabolism that present later in life. These patients may present to adult neurologists who may be less likely to consider metabolic genetic testing.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/7U57ZD4W/Kwon (2018) Testing for Inborn Errors of Metabolism.pdf}
}

@article{leeDystrophinopathies2022,
  title = {The {{Dystrophinopathies}}},
  author = {Lee, Bo Hoon},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1678--1697},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001208},
  url = {https://journals.lww.com/10.1212/CON.0000000000001208},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the history, epidemiology, genetics, clinical presentation, multidisciplinary management, and established and emerging therapies for the dystrophinopathies.                                         RECENT FINDINGS               The multidisciplinary care of individuals with dystrophinopathies continues to improve in many ways, including early surveillance and implementation of respiratory, cardiac, and orthopedic health management. The era of genetic therapeutics has altered the treatment landscape in neuromuscular disorders, including the dystrophinopathies.                                         SUMMARY               The dystrophinopathies are a spectrum of X-linked genetic disorders characterized by childhood-onset progressive weakness and variable cardiac and cognitive involvement. Corticosteroids are the mainstay of therapy to slow disease progression. Additional strategies for disease amelioration and dystrophin restoration, including gene replacement therapy, are under investigation.},
  langid = {english},
  keywords = {Current}
}

@article{leeNeurologicComplicationsPatients2020,
  title = {Neurologic {{Complications}} in {{Patients With Cancer}}},
  author = {Lee, Eudocia Q.},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1629--1645},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000937},
  url = {https://journals.lww.com/10.1212/CON.0000000000000937},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Neurologic complications in patients with cancer can significantly impact morbidity and mortality. Although these complications can be seen in patients without cancer as well, the purpose of this review is to highlight how the presentation, etiology, and management of delirium, seizures, cerebrovascular disease, and central nervous system infections may be different in patients with cancer.                                         RECENT FINDINGS               Some of the newer anticancer therapies are associated with neurologic complications. Delirium and seizures have been described in patients receiving chimeric antigen receptor (CAR) T-cell therapy and other immune effector cell therapies. Angiogenesis inhibitors can increase the risk of bleeding and clotting, including intracranial hemorrhage and stroke. The risk of opportunistic fungal infections, including aspergillosis, is elevated with the Bruton tyrosine kinase inhibitor ibrutinib.                                         SUMMARY               Providers should familiarize themselves with neurologic complications in patients with cancer because early diagnosis and intervention can improve outcomes. The differential diagnosis should be broad, including conventional causes as seen in patients who do not have cancer, with special consideration of etiologies specific to patients with cancer.},
  langid = {english}
}

@article{lewisBrainDeathDeath2021,
  title = {Brain {{Death}}/{{Death}} by {{Neurologic Criteria Determination}}},
  author = {Lewis, Ariane and Kirschen, Matthew P.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1444--1464},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000987},
  url = {https://journals.lww.com/10.1212/CON.0000000000000987},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the prerequisites for brain death/death by neurologic criteria (BD/DNC), clinical evaluation for BD/DNC (including apnea testing), use of ancillary testing, and challenges associated with BD/DNC determination in adult and pediatric patients.                                         RECENT FINDINGS               Although death determination should be consistent among physicians and across hospitals, states, and countries to ensure that someone who is declared dead in one place would not be considered alive elsewhere, variability exists in the prerequisites, clinical evaluation, apnea testing, and use of ancillary testing to evaluate for BD/DNC. Confusion also exists about performance of an evaluation for BD/DNC in challenging clinical scenarios, such as for a patient who is on extracorporeal membrane oxygenation or a patient who was treated with therapeutic hypothermia. This prompted the creation of the World Brain Death Project, which published an international consensus statement on BD/DNC that has been endorsed by five world federations and 27 medical societies from across the globe.                                         SUMMARY               The World Brain Death Project consensus statement is intended to provide guidance for professional societies and countries to revise or develop their own protocols on BD/DNC, taking into consideration local laws, culture, and resource availability; however, it does not replace local medical standards. To that end, pending publication of an updated guideline on determination of BD/DNC across the lifespan, the currently accepted medical standards for BD/DNC in the United States are the 2010 American Academy of Neurology standard for determination of BD/DNC in adults and the 2011 Society of Critical Care Medicine/American Academy of Pediatrics/Child Neurology Society standard for determination of BD/DNC in infants and children.},
  langid = {english}
}

@article{liAxonalSensorimotorPolyneuropathies2017,
  title = {Axonal {{Sensorimotor Polyneuropathies}}},
  author = {Li, Yuebing},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1378--1393},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000514},
  url = {https://journals.lww.com/00132979-201710000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article describes clinical features of axonal sensorimotor polyneuropathies based on selected etiologies.                                         Recent Findings:               Axonal sensorimotor polyneuropathies have been well described for some time. Recent advances include the assessment of the incidence of peripheral neuropathy in the elderly, the recognition of the limited influence of electrodiagnostic testing on the clinical management of uncomplicated axonal sensorimotor polyneuropathy, the development of guidelines for treatment of painful neuropathy, the identification of risk factors predisposing patients for chemotherapy-induced neuropathy, a report on the association of metabolic syndrome and idiopathic axonal sensorimotor neuropathy, and the availability of more cost-effective genetic testing for identifying inherited polyneuropathies.                                         Summary:               Axonal sensorimotor polyneuropathies carry an extensive list of differential diagnoses. Diagnosis is based on detailed history, physical examination, recognition of associated neurologic and non-neurologic features, and appropriate testing. Disease-modifying treatments are lacking in many cases. Management focuses on modification of predisposing lifestyle and medical factors, rehabilitation, and pain relief.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/ADYQMNVR/Li (2017) Axonal Sensorimotor Polyneuropathies.pdf;/Users/nathanielyomogida/Zotero/storage/PEDLFJD5/li2017.pdf.pdf}
}

@article{libermanDiagnosisTreatmentCerebral2023,
  title = {Diagnosis and {{Treatment}} of {{Cerebral Venous Thrombosis}}},
  author = {Liberman, Ava L.},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {519--539},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001211},
  url = {https://journals.lww.com/10.1212/CON.0000000000001211},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Cerebral venous thrombosis (CVT), thrombosis of the dural sinus, cerebral veins, or both, is a rare cerebrovascular disease. Although mortality rates after CVT have declined over time, this condition can result in devastating neurologic outcomes. This article reviews the latest literature regarding CVT epidemiology, details new factors associated with the development of CVT, and describes advances in CVT treatment. It also contains a discussion of future directions in the field, including novel diagnostic imaging modalities, and potential strategies to reduce the risks associated with CVT.                                         LATEST DEVELOPMENTS               The incidence of CVT may be as high as 2 per 100,000 adults per year. It remains a difficult condition to diagnose given its variable clinical manifestations and the necessity of neuroimaging for confirmation. The COVID-19 pandemic has revealed a novel CVT trigger, vaccine-induced immune thrombotic thrombocytopenia (VITT), as well as an association between COVID-19 infection and CVT. Although VITT is a very rare event, timely diagnosis and treatment of CVT due to VITT likely improves patient outcomes. Direct oral anticoagulants are currently being used to treat CVT and emerging data suggest that these agents are as safe and effective as vitamin K antagonists. The role of endovascular therapy to treat CVT, despite a recent clinical trial, remains unproven.                                         ESSENTIAL POINTS               The incidence of CVT has increased, outcomes have improved, and the use of direct oral anticoagulants to treat CVT represents an important advance in the clinical care of these patients. Rates of CVT as a complication of COVID-19 vaccines using adenoviral vectors are very low ({$<$}5 per million vaccine doses administered), with the benefits of COVID-19 vaccination far outweighing the risks.},
  langid = {english},
  keywords = {Current}
}

@article{liottaManagementCerebralEdema2021,
  title = {Management of {{Cerebral Edema}}, {{Brain Compression}}, and {{Intracranial Pressure}}},
  author = {Liotta, Eric M.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1172--1200},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000988},
  url = {https://journals.lww.com/10.1212/CON.0000000000000988},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the pathophysiology and management of cerebral edema, brain compression, and elevated intracranial pressure (ICP). It also provides a brief introduction to the concept of the glymphatic system and select cellular contributors to cerebral edema.                                         RECENT FINDINGS               Cerebral edema and brain compression should be treated in a tiered approach after the patient demonstrates a symptomatic indication to start treatment. All patients with acute brain injury should be treated with standard measures to optimize intracranial compliance and minimize risk of ICP elevation. When ICP monitors are used, therapies should target maintaining ICP at 22 mm Hg or less. Evidence exists that serial clinical examination and neuroimaging may be a reasonable alternative to ICP monitoring; however, clinical trials in progress may demonstrate advantages to advanced monitoring techniques. Early decompressive craniectomy and hypothermia are not neuroprotective in traumatic brain injury and should be reserved for situations refractory to initial medical interventions. Medical therapies that acutely lower plasma osmolality may lead to neurologic deterioration from osmotic cerebral edema, and patients with acute brain injury and renal or liver failure are at elevated risk.                                         SUMMARY               A tiered approach to the management of cerebral edema and brain compression can reduce secondary brain injury when implemented according to core physiologic principles. However, our knowledge of the pathophysiology of acute brain injury is incomplete, and the conceptual framework underlying decades of clinical management may need to be revised in response to currently evolving discoveries regarding the pathophysiology of acute brain injury.},
  langid = {english}
}

@article{livecchiSpinalCordInjury2011,
  title = {Spinal {{Cord Injury}}:},
  shorttitle = {Spinal {{Cord Injury}}},
  author = {LiVecchi, Mark A.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {568--583},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399073.00062.9e},
  url = {http://journals.lww.com/00132979-201106000-00016},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/3WRTN87A/livecchi2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/RLF7CX6Z/LiVecchi (2011) Spinal Cord Injury.pdf}
}

@article{loArterialIschemicStroke2017,
  title = {Arterial {{Ischemic Stroke}} in {{Children}} and {{Young Adults}}},
  author = {Lo, Warren D. and Kumar, Riten},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {158--180},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000438},
  url = {https://journals.lww.com/00132979-201702000-00014},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               This article reviews risk factors, recurrence risk, evaluation, management, and outcomes of arterial ischemic stroke in children and young adults.                                         Recent Findings:               The risk for recurrence and mortality appear to be low for neonatal and childhood stroke. Most children have relatively mild deficits, but those who have greater neurologic deficits, poststroke epilepsy, or strokes early in life are at risk for lower overall cognitive function. Stroke recurrence and long-term mortality after stroke in young adults are greater than originally thought. Cognitive impairments, depression, and anxiety are associated with higher levels of poststroke unemployment and represent targets for improved poststroke care. Poststroke care in young adults involves more than medical management. Self-reported memory and executive function impairments may be more severe than what is detected by objective measures. Assessment of possible cognitive impairments and appropriate management of psychological comorbidities are key to maximizing the long-term functional outcome of stroke survivors.                                         Summary:               Childhood and young adult stroke survivors survive for many more years than older patients with stroke. To ensure that these survivors maximize the productivity of their lives, neurologists must not only optimize medical management but also recognize that impairments in cognition and mood may be remediable barriers to long-term functional independence.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/R43MFC36/Lo_Kumar (2017) Arterial Ischemic Stroke in Children and Young Adults.pdf}
}

@article{longbrakeMyelinOligodendrocyteGlycoprotein2022,
  title = {Myelin {{Oligodendrocyte Glycoprotein}}--{{Associated Disorders}}},
  author = {Longbrake, Erin},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1171--1193},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001127},
  url = {https://journals.lww.com/10.1212/CON.0000000000001127},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Anti--myelin oligodendrocyte glycoprotein (MOG) autoantibodies have become a recognized cause of a pathophysiologically distinct group of central nervous system (CNS) autoimmune diseases. MOG-associated disorders can easily be confused with other CNS diseases such as multiple sclerosis or neuromyelitis optica, but they have a distinct clinical phenotype and prognosis.                                         RECENT FINDINGS               Most patients with MOG-associated disorders exhibit optic neuritis, myelitis, or acute disseminated encephalomyelitis (ADEM) alone, sequentially, or in combination; the disease may be either monophasic or relapsing. Recent case reports have continued to expand the clinical spectrum of disease, and increasingly larger cohort studies have helped clarify its pathophysiology and natural history.                                         SUMMARY               Anti--MOG-associated disorders comprise a substantial subset of patients previously thought to have other seronegative CNS diseases. Accurate diagnosis is important because the relapse patterns and prognosis for MOG-associated disorders are unique. Immunotherapy appears to successfully mitigate the disease, although not all agents are equally effective. The emerging large-scale data describing the clinical spectrum and natural history of MOG-associated disorders will be foundational for future therapeutic trials.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current},
  file = {/Users/nathanielyomogida/Zotero/storage/DAQQM5VF/Longbrake (2022) Myelin Oligodendrocyte GlycoproteinAssociated Disorders.pdf}
}

@article{lopezchiribogaMyelitisOtherAutoimmune2021,
  title = {Myelitis and {{Other Autoimmune Myelopathies}}},
  author = {Lopez Chiriboga, Sebastian and Flanagan, Eoin P.},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {62--92},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000900},
  url = {https://journals.lww.com/10.1212/CON.0000000000000900},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an update on the clinical diagnosis and management of immune-mediated myelopathies, including the relevance of imaging, ancillary testing with an emphasis on autoantibody biomarkers, recognition of myelitis mimics, and therapeutic approach.                                         RECENT FINDINGS               The imaging characterization of immune-mediated myelopathies and the discovery of neural autoantibodies have been crucial in improving our ability to accurately diagnose myelitis. The identification of autoantibodies directed against specific central nervous system targets has led to major improvements in our understanding of the mechanisms underlying inflammation in myelitis. It has also allowed distinction of these myelopathy etiologies from noninflammatory etiologies of myelopathy and from multiple sclerosis and provided insight into their risk of recurrence, treatment response, and long-term clinical outcomes. Prompt recognition and appropriate testing in the setting of acute and subacute myelopathies is critical as timely administration of immunotherapy can help improve symptoms and prevent permanent neurologic disability. A patient should not be classified as having ``idiopathic transverse myelitis'' without a comprehensive evaluation for a more specific etiology. Achieving the correct diagnosis and learning to recognize noninflammatory myelitis mimics is crucial as they have therapeutic and prognostic implications.                                         SUMMARY               Identifying the clinical and radiographic features of immune-mediated myelitis and recognizing mimics and pitfalls will help clinicians treat confirmed autoimmune myelitis appropriately.},
  langid = {english}
}

@article{lorussoDisordersCaudaEquina2021,
  title = {Disorders of the {{Cauda Equina}}},
  author = {LoRusso, Samantha},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {205--224},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000903},
  url = {https://journals.lww.com/10.1212/CON.0000000000000903},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW                                Cauda equina dysfunction (often referred to as                 cauda equina syndrome                 ) is caused by a diverse group of disorders that affect the lumbosacral nerve roots. It is important to recognize dysfunction of the cauda equina quickly to minimize diagnostic delay and lasting neurologic symptoms. This article describes cauda equina anatomy and the clinical features, differential diagnosis, and management of cauda equina disorders.                                                        RECENT FINDINGS               The diagnosis of disorders of the cauda equina continues to be a challenge. If a compressive etiology is seen, urgent neurosurgical intervention is recommended. However, many people with clinical features of cauda equina dysfunction will have negative diagnostic studies. If the MRI is negative, it is important to understand the diagnostic evaluation and differential diagnosis so that less common etiologies are not missed.                                         SUMMARY               Cauda equina dysfunction most often occurs due to lumbosacral disk herniation. Nondiskogenic causes include vascular, infectious, inflammatory, traumatic, and neoplastic etiologies. Urgent evaluation and surgical intervention are recommended in most cases of compressive cauda equina syndrome. Other types of treatment may also be indicated depending on the etiology.},
  langid = {english}
}

@article{lorussoInfectionsPeripheralNervous2021,
  title = {Infections of the {{Peripheral Nervous System}}},
  author = {LoRusso, Samantha},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {921--942},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000981},
  url = {https://journals.lww.com/10.1212/CON.0000000000000981},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes infections that affect the peripheral nervous system, including their clinical features, differential diagnoses, and treatments.                                         RECENT FINDINGS               Rates of pyomyositis have increased recently in the United States, possibly because of an increase in risk factors such as IV drug use, obesity, and diabetes. Other peripheral nervous system infections, such as diphtheria, have become more common in older patients secondary to a lack of revaccination or waning immunity. Although recommended treatment regimens for most infections remain unchanged over recent years, debate over the ideal dosing and route of administration continues for some infections such as tetanus and leprosy (Hansen disease).                                         SUMMARY               Infections of the peripheral nervous system are varied in terms of the type of infection, localization, and potential treatment. Nerve conduction studies and EMG can help determine localization, which is key to determining an initial differential diagnosis. It is important to recognize infections quickly to minimize diagnostic delays that could lead to patient morbidity and mortality.},
  langid = {english},
  keywords = {Current}
}

@article{louisTremor2019,
  title = {Tremor},
  author = {Louis, Elan D.},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {959--975},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000748},
  url = {https://journals.lww.com/00132979-201908000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Tremor may be defined as an involuntary movement that is rhythmic (ie, regularly recurrent) and oscillatory (ie, rotating around a central plane) and may manifest in a variety of ways; accordingly, tremor has a rich clinical phenomenology. Consequently, the diagnosis of tremor disorders can be challenging, and misdiagnoses are common. The goal of this article is to provide the reader with straightforward approaches to the diagnosis and treatment of tremors.                                         RECENT FINDINGS               Focused ultrasound thalamotomy of the ventral intermediate nucleus of the thalamus is an emerging and promising therapy for the treatment of essential tremor.                                         SUMMARY               The evaluation should start with a detailed tremor history followed by a focused neurologic examination, which should attend to the many subtleties of tremor phenomenology. Among other things, the history and examination are used to establish whether the primary tremor is an action tremor (ie, postural, kinetic, or intention tremor) or a resting tremor. The clinician should then formulate two sets of diagnoses: disorders in which action tremor is the predominant tremor versus those in which resting tremor is the predominant tremor. Among the most common of the former type are essential tremor, enhanced physiologic tremor, drug-induced tremor, dystonic tremor, primary writing tremor, orthostatic tremor, and cerebellar tremor. Parkinson disease is the most common disorder of resting tremor. This article details the clinical features of each of these disorders, as well as those of additional tremor disorders.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/GRSRGI4F/10.1212@CON.0000000000000748.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/TL6CWKYA/Louis (2019) Tremor.pdf}
}

@article{lukasNonmalignantBrainTumors2020,
  title = {Nonmalignant {{Brain Tumors}}},
  author = {Lukas, Rimas V. and Mrugala, Maciej M.},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1495--1522},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000942},
  url = {https://journals.lww.com/10.1212/CON.0000000000000942},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the diagnosis and management of meningioma, pituitary adenoma, craniopharyngioma, and glioneuronal tumors.                                         RECENT FINDINGS               Both meningiomas and pituitary adenomas are common brain tumors. In many cases, these lesions are found incidentally on imaging when patients are being evaluated for a variety of symptoms and signs. While nonmalignant, these tumors are occasionally associated with significant morbidity due to location and resulting secondary symptoms. Rarely, these tumors can also transform into malignant variants. Surgical techniques allow for more complete resections with minimal complications. Significant progress is being made in understanding the molecular biology of meningioma, which may result in wider availability of targeted therapies, especially for patients who are not candidates for other therapeutic modalities. Medical therapies for secretory pituitary adenomas continue to evolve. Craniopharyngiomas are nonmalignant tumors associated with significant morbidity due to their location. Molecular subtypes exist and may respond to targeted agents. Glioneuronal tumors are low-grade neoplasms potentially cured by gross total resection; however, residual and recurrent disease may require additional therapy. Recent studies have identified potentially targetable molecular alterations in more than half of cases.                                         SUMMARY               Meningiomas and pituitary adenomas are frequently encountered in neurologic practice, and familiarity with their presentation and management is essential for a practicing neurologist. Craniopharyngiomas, meningiomas, and glioneuronal tumors are characterized by a high frequency of potentially actionable genetic alterations, and targeted therapies may eventually supplement surgical therapy of these nonmalignant tumors.},
  langid = {english}
}

@article{lyonsViralMeningitisEncephalitis2018,
  title = {Viral {{Meningitis}} and {{Encephalitis}}},
  author = {Lyons, Jennifer L.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1284--1297},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000650},
  url = {https://journals.lww.com/00132979-201810000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses meningitis and encephalitis infections caused by viruses, excluding herpes family and human immunodeficiency virus (HIV).                                         RECENT FINDINGS               The viral infections of the nervous system detailed in this article have no specific treatment other than supportive care. However, many of the viruses discussed are highly preventable by vaccination, proper skin protection against transmitting vectors, and postexposure prophylaxis.                                         SUMMARY               While meningitis and encephalitis caused by viruses may have some clinical overlap, the management and outcomes can be highly disparate, making distinction between the two imperative. Furthermore, despite their relative rarity in terms of clinical disease, many of the viral infections discussed herein are highly preventable. Given the morbidity and mortality attached to such infections, provider and patient education are the best approach available to prevent these potentially devastating illnesses.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/8DYJI6QC/Lyons (2018) Viral Meningitis and Encephalitis.pdf}
}

@article{maasCriticalMedicalIllness2020,
  title = {Critical {{Medical Illness}} and the {{Nervous System}}},
  author = {Maas, Matthew B.},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {675--694},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000869},
  url = {https://journals.lww.com/10.1212/CON.0000000000000869},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Nervous system tissues have high metabolic demands and other unique vulnerabilities that place them at high risk of injury in the context of critical medical illness. This article describes the neurologic complications that are commonly encountered in patients who are critically ill from medical diseases and presents strategies for their diagnosis, prevention, and treatment.                                         RECENT FINDINGS               Chronic neurologic disability is common after critical medical illness and is a major factor in the quality of life for survivors of critical illness. Studies that carefully assessed groups of patients with general critical illness have identified a substantial rate of covert seizures, brain infarcts, muscle wasting, peripheral nerve injuries, and other neurologic sequelae that are strong predictors of poor neurologic outcomes. As the population ages and intensive care survivorship increases, critical illness--related neurologic impairments represent a large and growing proportion of the overall burden of neurologic disease.                                         SUMMARY               Improving critical illness outcomes requires identifying and managing the underlying cause of comorbid neurologic symptoms.},
  langid = {english},
  keywords = {Outdated}
}

@article{macielNeurologicOutcomePrediction2021,
  title = {Neurologic {{Outcome Prediction}} in the {{Intensive Care Unit}}},
  author = {Maciel, Carolina B.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1405--1429},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001053},
  url = {https://journals.lww.com/10.1212/CON.0000000000001053},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The burden of severe and disabling neurologic injury on survivors, families, and society can be profound. Neurologic outcome prediction, or neuroprognostication, is a complex undertaking with many important ramifications. It allows patients with good prognoses to be supported aggressively, survive, and recover; conversely, it avoids inappropriate prolonged and costly care in those with devastating injuries.                                         RECENT FINDINGS               Striving to maintain a high prediction performance during prognostic assessments encompasses acknowledging the shortcomings of this task and the challenges created by advances in medicine, which constantly shift the natural history of neurologic conditions. Embracing the unknowns of outcome prediction and the boundaries of knowledge surrounding neurologic recovery and plasticity is a necessary step toward refining neuroprognostication practices and improving the accuracy of prognostic impressions. The pillars of modern neuroprognostication include comprehensive characterization of neurologic injury burden (primary and secondary injuries), gauging cerebral resilience and estimated neurologic reserve, and tying it all together with individual values surrounding the acceptable extent of disability and the difficulties of an arduous convalescence journey.                                         SUMMARY               Comprehensive multimodal frameworks of neuroprognostication using different prognostic tools to portray the burden of neurologic injury coupled with the characterization of individual values and the degree of cerebral reserve and resilience are the cornerstone of modern outcome prediction.},
  langid = {english}
}

@article{mainaliNeurologicComplicationsCardiac2023,
  title = {Neurologic {{Complications}} of {{Cardiac}} and {{Pulmonary Disease}}},
  author = {Mainali, Shraddha},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {684--707},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001284},
  url = {https://journals.lww.com/10.1212/CON.0000000000001284},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               The heart and lungs work as a functional unit through a complex interplay. The cardiorespiratory system is responsible for the delivery of oxygen and energy substrates to the brain. Therefore, diseases of the heart and lungs can lead to various neurologic illnesses. This article reviews various cardiac and pulmonary pathologies that can lead to neurologic injury and discusses the relevant pathophysiologic mechanisms.                                         LATEST DEVELOPMENTS               We have lived through unprecedented times over the past 3 years with the emergence and rapid spread of the COVID-19 pandemic. Given the effects of COVID-19 on the lungs and heart, an increased incidence of hypoxic-ischemic brain injury and stroke associated with cardiorespiratory pathologies has been observed. Newer evidence has questioned the benefit of induced hypothermia in patients with out-of-hospital cardiac arrest. Further, global collaborative initiatives such as the Curing Coma Campaign are underway with the goal of improving the care of patients with coma and disorders of consciousness, including those resulting from cardiac and pulmonary pathologies.                                         ESSENTIAL POINTS               The neurologic complications of cardiorespiratory disorders are common and present in various forms such as stroke or hypoxic and anoxic injury related to cardiac or respiratory failure. With the emergence of the COVID-19 pandemic, neurologic complications have increased in recent years. Given the intimate and interdependent dynamics of the heart, lungs, and brain, it is crucial for neurologists to be aware of the interplay between these organs.},
  langid = {english},
  keywords = {Current}
}

@article{majersikInheritedUncommonCauses2017,
  title = {Inherited and {{Uncommon Causes}} of {{Stroke}}},
  author = {Majersik, Jennifer Juhl},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {211--237},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000432},
  url = {https://journals.lww.com/00132979-201702000-00016},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               This article is a practical guide to identifying uncommon causes of stroke and offers guidance for evaluation and management, even when large controlled trials are lacking in these rarer forms of stroke.                                         Recent Findings:               Fabry disease causes early-onset stroke, particularly of the vertebrobasilar system; enzyme replacement therapy should be considered in affected patients. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), often misdiagnosed as multiple sclerosis, causes migraines, early-onset lacunar strokes, and dementia. Moyamoya disease can cause either ischemic or hemorrhagic stroke; revascularization is recommended in some patients. Cerebral amyloid angiopathy causes both microhemorrhages and macrohemorrhages, resulting in typical stroke symptoms and progressive dementia. Pregnancy raises the risk of both ischemic and hemorrhagic stroke, particularly in women with preeclampsia/eclampsia. Pregnant women are also at risk for posterior reversible encephalopathy syndrome (PRES), reversible cerebral vasoconstriction syndrome, and cerebral venous sinus thrombosis. Experts recommend that pregnant women with acute ischemic stroke not be systematically denied the potential benefits of IV recombinant tissue plasminogen activator.                                         Summary:               Neurologists should become familiar with these uncommon causes of stroke to provide future risk assessment and family counseling and to implement appropriate treatment plans to prevent recurrence.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/ISNJNRGH/Majersik (2017) Inherited and Uncommon Causes of Stroke.pdf}
}

@article{manousakisInflammatoryMyopathies2022,
  title = {Inflammatory {{Myopathies}}},
  author = {Manousakis, Georgios},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1643--1662},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001179},
  url = {https://journals.lww.com/10.1212/CON.0000000000001179},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.                                         RECENT FINDINGS               The classification of idiopathic inflammatory myopathies has improved with the integration of myositis-specific antibodies and histopathologic findings. Characteristic features of immune checkpoint inhibitor--related myositis have been identified, allowing early recognition and treatment of the syndrome. The COVID-19 pandemic has had a profound impact on the care of patients with idiopathic inflammatory myopathies, and several mechanisms of virus-related muscle injury have been proposed.                                         SUMMARY               A comprehensive evaluation including clinical examination, EMG, imaging, antibody testing, muscle biopsy, and cancer screening, when appropriate, can lead to an earlier accurate diagnosis and an individualized treatment approach for patients with idiopathic inflammatory myopathies.},
  langid = {english},
  keywords = {Current}
}

@article{marulandaObstetricGynecologicDisorders2023,
  title = {Obstetric and {{Gynecologic Disorders}} and the {{Nervous System}}},
  author = {Marulanda, Erika and Tornes, Leticia},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {763--796},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001237},
  url = {https://journals.lww.com/10.1212/CON.0000000000001237},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               This article discusses obstetric and gynecologic associations with common neurologic disorders.                                         LATEST DEVELOPMENTS               Neurologic complications of obstetric and gynecologic disorders can arise throughout the lifespan. Caution should be exercised when prescribing fingolimod and natalizumab to patients with multiple sclerosis who are of childbearing potential because of the risk of disease rebound when they are discontinued. OnabotulinumtoxinA is considered safe in pregnancy and lactation based on long-term observational data. Hypertensive disorders of pregnancy are associated with higher subsequent cerebrovascular risk, likely via multiple mechanisms.                                         ESSENTIAL POINTS               Neurologic disorders may present in a variety of obstetric and gynecologic contexts, with meaningful implications for recognition and treatment. These interactions must be considered when treating women with neurologic conditions.},
  langid = {english},
  keywords = {Current}
}

@article{maskiPediatricSleepDisorders2018,
  title = {Pediatric {{Sleep Disorders}}},
  author = {Maski, Kiran and Owens, Judith},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {210--227},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000566},
  url = {https://journals.lww.com/00132979-201802000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the clinical features, diagnosis, and treatment of insomnia, restless legs syndrome, periodic limb movements of sleep, parasomnias, narcolepsy, and sleep-related breathing disorders among children and adolescents.                                         RECENT FINDINGS               Pediatric presentations of sleep disorders differ from adult presentations, making diagnosis challenging. Specific clinical syndromes, such as cataplexy in children with narcolepsy type 1, can have an altogether different presentation compared to adult-onset symptoms, contributing to diagnostic delays and potential misdiagnoses. More broadly, research shows strong associations between sleep and daytime cognition, mood, and behavior among children with and without neurologic conditions and thus suggests a need to identify and treat sleep problems to optimize daytime functioning.                                         SUMMARY               Addressing sleep problems in children with neurologic conditions and neurodevelopmental disorders improves quality of life for patients and their families and, in many cases, reduces neurologic disease burden.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/P5KQB3XR/Maski_Owens (2018) Pediatric Sleep Disorders.pdf}
}

@article{mathewsObsessiveCompulsiveDisorders2021,
  title = {Obsessive-{{Compulsive Disorders}}},
  author = {Mathews, Carol},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1764--1784},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001011},
  url = {https://journals.lww.com/10.1212/CON.0000000000001011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the phenomenology and clinical presentation of obsessive-compulsive disorder (OCD), a common but underdiagnosed psychiatric disorder. Guidance for effectively identifying obsessive-compulsive symptoms is provided, and treatment options, including psychotherapy, pharmacologic management, and neuromodulation approaches for treatment-resistant OCD, are discussed.                                         RECENT FINDINGS                                OCD affects 2\% to 3\% of adults worldwide and is associated with substantial individual disability and societal costs. Lack of recognition of common OCD symptom types, in addition to shame and fear of stigma on the part of patients, has created an average delay in diagnosis by almost 10 years and a delay in effective treatment (ie, a treatment gap) of nearly 2 years. Cognitive-behavioral therapy (CBT), specifically a form of CBT that includes a type of behavioral intervention called                 exposure and response prevention                 , remains the most effective form of treatment for OCD. If CBT is not effective or not available, pharmacologic treatment with selective serotonin reuptake inhibitors (SSRIs) or clomipramine, a nonselective serotonin reuptake inhibitor, can also be of benefit. Neuromodulation approaches such as deep brain stimulation and transcranial magnetic stimulation are rapidly emerging as effective treatments for OCD, particularly for patients who have not experienced an adequate response to psychotherapy or pharmacologic management.                                                        SUMMARY               OCD affects more than one in every 50 adults in the United States but is recognized and adequately treated in fewer than half of those affected. Early intervention and appropriate treatment can substantially reduce OCD symptom severity, improve quality of life, and minimize the functional disability associated with this chronic and often debilitating illness.},
  langid = {english},
  keywords = {Current}
}

@article{mauermannHematologicDisordersNervous2023,
  title = {Hematologic {{Disorders}} and the {{Nervous System}}},
  author = {Mauermann, Michelle L. and Southerland, Andrew M.},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {826--847},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001238},
  url = {https://journals.lww.com/10.1212/CON.0000000000001238},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               This article discusses the epidemiology, diagnosis, treatment, and prevention of neurologic complications of red blood cell, platelet, and plasma cell disorders.                                         LATEST DEVELOPMENTS               Cerebrovascular complications can occur in patients with blood cell and platelet disorders. Treatment strategies to prevent stroke are available for patients with sickle cell disease, polycythemia vera, and essential thrombocythemia. A diagnosis of thrombotic thrombocytopenic purpura should be considered in patients with neurologic symptoms, hemolytic anemia, thrombocytopenia, mild renal insufficiency, and fever. Plasma cell disorders can be associated with peripheral neuropathy, and classification of the monoclonal protein type and neuropathy aid in diagnosis. Patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) syndrome can present with arterial and venous neurologic events.                                         ESSENTIAL POINTS               This article discusses the neurologic complications of blood cell disorders and the most recent advances in prevention and treatment.},
  langid = {english},
  keywords = {Current}
}

@article{mcdadeAlzheimerDisease2022,
  title = {Alzheimer {{Disease}}},
  author = {McDade, Eric M.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {648--675},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001131},
  url = {https://journals.lww.com/10.1212/CON.0000000000001131},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Alzheimer disease (AD) is the most common cause of dementia in adults (mid to late life), highlighting the importance of understanding the risk factors, clinical manifestations, and recent developments in diagnostic testing and therapeutics.                                         RECENT FINDINGS               Advances in fluid (CSF and blood-based) and imaging biomarkers are allowing for a more precise and earlier diagnosis of AD (relative to non-AD dementias) across the disease spectrum and in patients with atypical clinical features. Specifically, tau- and amyloid-related AD pathologic changes can now be measured by CSF, plasma, and positron emission tomography (PET) with good precision. Additionally, a better understanding of risk factors for AD has highlighted the need for clinicians to address comorbidities to maximize prevention of cognitive decline in those at risk or to slow decline in patients who are symptomatic. Recent clinical trials of amyloid-lowering drugs have provided not only some optimism that amyloid reduction or prevention may be beneficial but also a recognition that addressing additional targets will be necessary for significant disease modification.                                         SUMMARY               Recent developments in fluid and imaging biomarkers have led to the improved understanding of AD as a chronic condition with a protracted presymptomatic phase followed by the clinical stage traditionally recognized by neurologists. As clinical trials of potential disease-modifying therapies continue, important developments in the understanding of the disease will improve clinical care now and lead to more effective therapies in the near future.},
  langid = {english},
  keywords = {Current}
}

@article{mendezEarlyonsetAlzheimerDisease2019,
  title = {Early-Onset {{Alzheimer Disease}} and {{Its Variants}}},
  author = {Mendez, Mario F.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {34--51},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000687},
  url = {https://journals.lww.com/00132979-201902000-00005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. While early-onset AD is often overshadowed by the more common late-onset AD, recognition of the differences between early- and late-onset AD is important for clinicians.                                         RECENT FINDINGS               Early-onset AD comprises about 5\% to 6\% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics of early-onset AD in comparison to late-onset AD include a larger genetic predisposition (familial mutations and summed polygenic risk), more aggressive course, more frequent delay in diagnosis, higher prevalence of traumatic brain injury, less memory impairment and greater involvement of other cognitive domains on presentation, and greater psychosocial difficulties. Neuroimaging features of early-onset AD in comparison to late-onset AD include greater frequency of hippocampal sparing and posterior neocortical atrophy, increased tau burden, and greater connectomic changes affecting frontoparietal networks rather than the default mode network.                                         SUMMARY               Early-onset AD differs substantially from late-onset AD, with different phenotypic presentations, greater genetic predisposition, and differences in neuropathologic burden and topography. Early-onset AD more often presents with nonamnestic phenotypic variants that spare the hippocampi and with greater tau burden in posterior neocortices. The early-onset AD phenotypic variants involve different neural networks than typical AD. The management of early-onset AD is similar to that of late-onset AD but with special emphasis on targeting specific cognitive areas and more age-appropriate psychosocial support and education.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/TJGEDUNN/Mendez (2019) Early-onset Alzheimer Disease and Its Variants.pdf}
}

@article{menonNeuroimagingAcuteStroke2020,
  title = {Neuroimaging in {{Acute Stroke}}},
  author = {Menon, Bijoy K.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {287--309},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000839},
  url = {https://journals.lww.com/10.1212/CON.0000000000000839},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes how imaging can be used by physicians in diagnosing, determining prognosis, and making appropriate treatment decisions in a timely manner in patients with acute stroke.                                         RECENT FINDINGS               Advances in acute stroke treatment, including the use of endovascular thrombectomy in patients with large vessel occlusion and, more recently, of IV thrombolysis in an extended time window, have resulted in a paradigm shift in how imaging is used in patients with acute stroke. This paradigm shift, combined with the understanding that ``time is brain,'' means that imaging must be fast, reliable, and available around the clock for physicians to make appropriate clinical decisions. CT has therefore become the primary imaging modality of choice. Recognition of a large vessel occlusion using CT angiography has become essential in identifying patients for endovascular thrombectomy, and techniques such as imaging collaterals on CT angiography or measuring blood flow to predict tissue fate using CT perfusion have become useful tools in selecting patients for acute stroke therapy. Understanding the use of these imaging modalities and techniques in dealing with an emergency such as acute stroke has therefore become more important than ever for physicians treating patients with acute stroke.                                         SUMMARY               Imaging the brain and the blood vessels supplying it using modern tools and techniques is a key step in understanding the pathophysiology of acute stroke and making appropriate and timely clinical decisions.},
  langid = {english}
}

@article{merklerBloodCellDisorders2020,
  title = {Blood {{Cell Disorders}} and the {{Nervous System}}},
  author = {Merkler, Alexander E.},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {659--674},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000858},
  url = {https://journals.lww.com/10.1212/CON.0000000000000858},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            purpose of review               This article discusses the epidemiology, diagnosis, treatment, and prevention of neurologic complications of common and rare blood cell disorders.                                         recent findings               A growing number of preventive treatment options are available for stroke in sickle cell disease. Paroxysmal nocturnal hemoglobinuria and immune thrombocytopenia can lead to stroke. Thrombotic thrombocytopenic purpura frequently causes neurologic symptoms and should be considered in the differential diagnosis of a patient with neurologic symptoms, thrombocytopenia, and hemolytic anemia. Polycythemia vera and essential thrombocythemia are rare causes of stroke.                                         summary               This article discusses sickle cell disease and the most recent advances in stroke preventive therapy as well as neurologic complications of paroxysmal nocturnal hemoglobinuria, immune thrombocytopenia, thrombotic thrombocytopenic purpura, polycythemia vera, and essential thrombocythemia.},
  langid = {english},
  keywords = {Outdated}
}

@article{meschiaDiagnosticEvaluationStroke2023,
  title = {Diagnostic {{Evaluation}} of {{Stroke Etiology}}},
  author = {Meschia, James F.},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {412--424},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001206},
  url = {https://journals.lww.com/10.1212/CON.0000000000001206},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Precise therapies require precise diagnoses. This article provides an evidence-based approach to confirming the diagnosis of ischemic stroke, characterizing comorbidities that provide insights into the pathophysiologic mechanisms of stroke, and identifying targets for treatment to optimize the prevention of recurrent stroke.                                         LATEST DEVELOPMENTS               Identifying the presence of patent foramen ovale, intermittent atrial fibrillation, and unstable plaque is now routinely included in an increasingly nuanced workup in patients with stroke, even as ongoing trials seek to clarify the best approaches for treating these and other comorbidities. Multicenter trials have demonstrated the therapeutic utility of patent foramen ovale closure in select patients younger than age 60 years. Insertable cardiac monitors detect atrial fibrillation lasting more than 30 seconds in about one in ten patients monitored for 12 months following a stroke. MRI of carotid plaque can detect unstable plaque at risk of being a source of cerebral embolism.                                         ESSENTIAL POINTS               To optimize the prevention of recurrent stroke, it is important to consider pathologies of intracranial and extracranial blood vessels and of cardiac structure and rhythm as well as other inherited or systemic causes of stroke. Some aspects of the stroke workup should be done routinely, while other components will depend on the clinical circumstances and preliminary testing results.},
  langid = {english},
  keywords = {Current}
}

@article{morrisNeurologicComplicationsCritical2023,
  title = {Neurologic {{Complications}} of {{Critical Medical Illness}}},
  author = {Morris, Nicholas A. and Sarwal, Aarti},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {848--886},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001278},
  url = {https://journals.lww.com/10.1212/CON.0000000000001278},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Objective               This article reviews the neurologic complications encountered in patients admitted to non-neurologic intensive care units, outlines various scenarios in which a neurologic consultation can add to the diagnosis or management of a critically ill patient, and provides advice on the best diagnostic approach in the evaluation of these patients.                                         Latest Developments               Increasing recognition of neurologic complications and their adverse impact on long-term outcomes has led to increased neurology involvement in non-neurologic intensive care units. The COVID-19 pandemic has highlighted the importance of having a structured clinical approach to neurologic complications of critical illness as well as the critical care management of patients with chronic neurologic disabilities.                                         Essential Points               Critical illness is often accompanied by neurologic complications. Neurologists need to be aware of the unique needs of critically ill patients, especially the nuances of the neurologic examination, challenges in diagnostic testing, and neuropharmacologic aspects of commonly used medications.},
  langid = {english},
  keywords = {Current}
}

@article{morrowIschemicOpticNeuropathy2019,
  title = {Ischemic {{Optic Neuropathy}}},
  author = {Morrow, Mark J.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1215--1235},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000767},
  url = {https://journals.lww.com/10.1212/CON.0000000000000767},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Vision is often threatened or lost by acute ischemic damage to the optic nerves. Such pathology most often affects the anterior portion of the nerve and is visible on funduscopic examination. Ischemic optic neuropathy is associated with typical vascular risk factors and with one systemic disease in particular: giant cell arteritis (GCA). This article provides an overview of the three major classes of ischemic optic neuropathy, including information on risk factors, differential diagnosis, evaluation, and management.                                         RECENT FINDINGS               Optical coherence tomography provides precise anatomic imaging in ischemic optic neuropathy, showing neural loss weeks before it is visible on examination. Refinements of optical coherence tomography reveal optic nerve microvasculature and may assist in understanding pathogenesis and verifying diagnosis. New diagnostic algorithms and cranial vascular imaging techniques help define the likelihood of GCA in patients with ischemic optic neuropathy. Finally, intraocular drug and biological agent delivery holds promise for nonarteritic ischemic optic neuropathy, whereas newer immunologic agents may provide effective steroid-sparing treatment for GCA.                                         SUMMARY               It is essential to recognize ischemic optic neuropathy upon presentation, especially to determine the likelihood of GCA and the need for immediate steroid therapy. A broad differential diagnosis should be considered so as not to miss alternative treatable pathology, especially in cases with retrobulbar optic nerve involvement.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/TL2RCDTW/Morrow (2019) Ischemic Optic Neuropathy.pdf}
}

@article{mossChiasmalPostchiasmalDisease2019,
  title = {Chiasmal and {{Postchiasmal Disease}}},
  author = {Moss, Heather E.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1310--1328},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000785},
  url = {https://journals.lww.com/10.1212/CON.0000000000000785},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the anatomy, symptoms, examination findings, and causes of diseases affecting the optic chiasm, optic tracts, optic radiations, and occipital lobes.                                         RECENT FINDINGS               Modern ophthalmic imaging can be used to monitor the effects of diseases of the optic chiasm and tract on the retinal ganglion cells. It can also be used to visualize transsynaptic degeneration of the anterior visual pathway in the setting of acquired retrogeniculate lesions. Visual prostheses that directly stimulate the occipital lobe are a potential strategy for rehabilitation that is in active clinical trials.                                         SUMMARY               Detecting and characterizing visual deficits due to optic chiasm and retrochiasmal disease are important for the diagnosis, localization, and monitoring of neurologic disease; identifying patient disability; and guiding rehabilitation.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/JF622D97/Moss (2019) Chiasmal and Postchiasmal Disease.pdf}
}

@article{mulFacioscapulohumeralMuscularDystrophy2022,
  title = {Facioscapulohumeral {{Muscular Dystrophy}}},
  author = {Mul, Karlien},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1735--1751},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001155},
  url = {https://journals.lww.com/10.1212/CON.0000000000001155},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the current knowledge on the clinical characteristics and disease mechanism of facioscapulohumeral muscular dystrophy (FSHD), as well as advances in targeted therapy development.                                         RECENT FINDINGS                                FSHD has a wide range of severity, yet a distinct phenotype characterized by weakness of the facial, shoulder, and upper arm muscles, followed by weakness of the trunk and leg muscles. It can be caused by two genetic mechanisms that share a common downstream pathway, namely, the epigenetic derepression and subsequent misexpression of the myotoxic                 DUX4                 transcription factor. Treatment is currently supportive and outlined in evidence-based guidelines. Advances in the understanding of the pathogenic mechanism of FSHD are paving the way for targeted therapy development. Approaches for targeted therapies to reduce                 DUX4                 expression that are currently being explored include small molecules, antisense oligonucleotides, vector-based RNA interference, and gene therapy. In anticipation of more clinical trials, ``clinical trial preparedness,'' including the development of sensitive biomarkers and clinical outcome measures, are needed.                                                        SUMMARY               The cornerstones of the diagnosis of FSHD are clinical observation and genetic testing. Management is currently supportive, but progress in the understanding of the disease mechanism has shifted the field of FSHD toward targeted therapy development.},
  langid = {english},
  keywords = {Current}
}

@article{nadeauLanguageAphasias2021,
  title = {Language and {{Aphasias}}},
  author = {Nadeau, Stephen E.},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1549--1561},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001058},
  url = {https://journals.lww.com/10.1212/CON.0000000000001058},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reveals how it is possible for a brain composed of 100 billion highly interconnected, lipid-encased, reticular electrochemical devices to support complex functions such as language and how language disorders can be understood as a reflection of degradation of one or more domains of knowledge.                                         RECENT FINDINGS               Ongoing research, building on landmark work regarding parallel distributed processing (PDP), provides the basis for understanding cognitive functions as a manifestation of the activity of populations of millions or billions of neurons in various highly interconnected networks. Population encoding networks have the following intrinsic properties that provide an orderly explanation for normal and degraded language: (1) a capacity for settling into stable ``attractor'' states; (2) processing occurs in and knowledge (long-term memories) is stored in exactly the same network; (3) a capacity for incorporating statistical regularities of experience, frequency, and age of acquisition; (4) support of content-addressable memory; and (5) graceful degradation, such that lesions increase the probability of errors but do not fundamentally transform network operations. Knowledge in parallel distributed processing networks resides in the strength of connections between units (synapses in the brain). Aphasia, whether stemming from stroke or dementing disorders, can be understood in terms of the degradation of one or more domains of knowledge.                                         SUMMARY               Understanding the brain as a population encoding machine incorporating vast interconnectivity provides an orderly explanation for language function, both normal and abnormal.},
  langid = {english},
  keywords = {Current}
}

@article{nahasClusterHeadacheOther2021,
  title = {Cluster {{Headache}} and {{Other Trigeminal Autonomic Cephalalgias}}},
  author = {Nahas, Stephanie J.},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {633--651},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000965},
  url = {https://journals.lww.com/10.1212/CON.0000000000000965},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The trigeminal autonomic cephalalgias (TACs) are relatively rare, but they represent a distinct set of syndromes that are important to recognize. Despite their unique features, TACs often go undiagnosed or misdiagnosed for several years, leading to unnecessary pain and suffering. A significant proportion of TAC presentations may have secondary causes.                                         RECENT FINDINGS               The underlying pathophysiology of TACs is likely rooted in hypothalamic dysfunction and derangements in the interplay of circuitry involving trigeminovascular, trigeminocervical, trigeminoautonomic, circadian, and nociceptive systems. Recent therapeutic advancements include a better understanding of how to use older therapies more effectively and the identification of new approaches.                                         SUMMARY               TAC syndromes are rare but important to recognize because of their debilitating nature and greater likelihood for having potentially serious underlying causes. Although treatment options have remained somewhat limited, scientific inquiry is continually advancing our understanding of these syndromes and how best to manage them.},
  langid = {english},
  keywords = {Current}
}

@article{nakagawaEvaluationManagementIncreased2011,
  title = {Evaluation and {{Management}} of {{Increased Intracranial Pressure}}:},
  shorttitle = {Evaluation and {{Management}} of {{Increased Intracranial Pressure}}},
  author = {Nakagawa, Kazuma and Smith, Wade S.},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {1077--1093},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407061.25284.28},
  url = {http://journals.lww.com/00132979-201110000-00012},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/6BW6BMWH/nakagawa2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/RYWDDI57/Nakagawa_Smith (2011) Evaluation and Management of Increased Intracranial Pressure.pdf}
}

@article{nathNeurologicManifestationsSevere2021,
  title = {Neurologic {{Manifestations}} of {{Severe Acute Respiratory Syndrome Coronavirus}} 2 {{Infection}}},
  author = {Nath, Avindra},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {1051--1065},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000992},
  url = {https://journals.lww.com/10.1212/CON.0000000000000992},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the spectrum of neurologic complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, their underlying pathology and pathogenic mechanisms, gaps in knowledge, and current therapeutic strategies.                                         RECENT FINDINGS               COVID-19 is the clinical syndrome caused by the novel coronavirus SARS-CoV-2. It can affect the entire neuraxis, and presentations in the acute phase are variable, although anosmia is a common manifestation. Encephalopathy is common in patients who are hospitalized and is often associated with multiorgan involvement. Immune-mediated encephalitis is probably underrecognized; however, viral encephalitis is rare. Other manifestations include stroke, seizures, myelitis, and peripheral neuropathies, including Guillain-Barr{\'e} syndrome, which sometimes has atypical manifestations. Treatment is symptomatic, and immunotherapies have been used successfully in some patients. Long-term complications include dysautonomia, exercise intolerance, malaise, sleep disturbances, cognitive impairment, and mood disorders.                                         SUMMARY               Neurologic manifestations of COVID-19 may occur in the acute setting and may be independent of respiratory manifestations. Immune-mediated syndromes and cerebrovascular complications are common. Large populations of patients are expected to have long-term neurologic complications of COVID-19, many of which may emerge only after recovery from the acute illness.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/HG2PGXDZ/Nath (2021) Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2.pdf}
}

@article{nguyenManagementUnrupturedIntracranial2023,
  title = {Management of {{Unruptured Intracranial Aneurysms}} and {{Brain Arteriovenous Malformations}}},
  author = {Nguyen, Thanh Ngoc},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {584--604},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001247},
  url = {https://journals.lww.com/10.1212/CON.0000000000001247},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Managing a patient with an unruptured brain aneurysm or brain arteriovenous malformation (AVM) can lead to uncertainty about preventive treatment. While the bleeding risks are low, the morbidity or mortality associated with a hemorrhagic event is not insignificant. The objective of this article is to review the natural history of these vascular entities, the risk factors for hemorrhage, preventive treatment options, and the risks of treatment.                                         LATEST DEVELOPMENTS               Randomized trials to inform preventive treatment strategies for unruptured intracranial aneurysms and brain AVMs are ongoing. Higher angiographic obliteration rates of unruptured intracranial aneurysms have been reported with the flow-diversion technique compared with alternative standard techniques. One randomized trial for unruptured brain AVMs showed a higher rate of morbidity and mortality in patients who underwent interventional treatment compared with observation.                                         ESSENTIAL POINTS               The decision to treat a patient with a brain aneurysm should consider patient factors, the patient's life expectancy, aneurysm anatomical factors, and treatment risks. Patients with unruptured brain AVMs should be observed in light of recent clinical trial data or enrolled in an ongoing clinical trial.},
  langid = {english},
  keywords = {Current}
}

@article{noblezaIntracerebralHemorrhage2021,
  title = {Intracerebral {{Hemorrhage}}},
  author = {Nobleza, Christa O'Hana S.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1246--1277},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001018},
  url = {https://journals.lww.com/10.1212/CON.0000000000001018},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Nontraumatic intracerebral hemorrhage (ICH) is the second most common type of stroke. This article summarizes the basic pathophysiology, classification, and management of ICH and discusses the available evidence on therapy for hematoma, hematoma expansion, and perihematomal edema.                                         RECENT FINDINGS               Current available data on potential therapeutic options for ICH are promising, although none of the trials have shown improvement in mortality rate. The literature available on reversal of anticoagulation and antiplatelet agents after an ICH and resumption of these medications is also increasing.                                         SUMMARY               ICH continues to have high morbidity and mortality. Advances in therapeutic options to target secondary brain injury from the hematoma, hematoma expansion, and perihematomal edema are increasing. Data on reversal therapy for anticoagulant-associated or antiplatelet-associated ICH and resumption of these medications are evolving.},
  langid = {english}
}

@article{ocarrollCardioembolicStroke2017,
  title = {Cardioembolic {{Stroke}}},
  author = {O'Carroll, Cumara B. and Barrett, Kevin M.},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {111--132},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000419},
  url = {https://journals.lww.com/00132979-201702000-00012},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               Cardioembolic stroke is common and disproportionately more disabling than nonembolic mechanisms of stroke. Its incidence is expected to rise because of the age-related incidence of atrial fibrillation and an aging population. This article summarizes the different causes of cardioembolism and outlines current management guidelines.                                         Recent Findings:               Since cardioembolic stroke is not a single disease entity, its diagnosis requires initial clinical suspicion and a comprehensive evaluation, including ECG, echocardiography, brain imaging, and cardiac monitoring. Atrial fibrillation is the most common cause of cardioembolic stroke, and anticoagulation is usually recommended. This article reviews risk stratification models to assist in the decision-making process and highlights the increased use of novel oral anticoagulants for stroke prevention in atrial fibrillation. New data support the importance of prolonged cardiac monitoring for diagnosing occult atrial fibrillation. Current data on other mechanisms of cardioembolic stroke, such as prosthetic heart valves and aortic arch atherosclerosis, are also presented, and the available evidence regarding patent foramen ovale closure in cryptogenic stroke is summarized.                                         Summary:               Cardioembolism is an important cause of ischemic stroke, with diverse underlying mechanisms requiring a tailored approach to diagnosis, management, and prevention.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/NU45C68U/OCarroll_Barrett (2017) Cardioembolic Stroke.pdf}
}

@article{odellStrokeRehabilitationMotor2023,
  title = {Stroke {{Rehabilitation}} and {{Motor Recovery}}},
  author = {O'Dell, Michael W.},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {605--627},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001218},
  url = {https://journals.lww.com/10.1212/CON.0000000000001218},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Up to 50\% of the nearly 800,000 patients who experience a new or recurrent stroke each year in the United States fail to achieve full independence afterward. More effective approaches to enhance motor recovery following stroke are needed. This article reviews the rehabilitative principles and strategies that can be used to maximize post-stroke recovery.                                         LATEST DEVELOPMENTS               Evidence dictates that mobilization should not begin prior to 24 hours following stroke, but detailed guidelines beyond this are lacking. Specific classes of potentially detrimental medications should be avoided in the early days poststroke. Patients with stroke who are unable to return home should be referred for evaluation to an inpatient rehabilitation facility. Research suggests that a substantial increase in both the dose and intensity of upper and lower extremity exercise is beneficial. A clinical trial supports vagus nerve stimulation as an adjunct to occupational therapy for motor recovery in the upper extremity. The data remain somewhat mixed as to whether robotics, transcranial magnetic stimulation, functional electrical stimulation, and transcranial direct current stimulation are better than dose-matched traditional exercise. No current drug therapy has been proven to augment exercise poststroke to enhance motor recovery.                                         ESSENTIAL POINTS               Neurologists will collaborate with rehabilitation professionals for several months following a patient's stroke. Many questions still remain about the ideal exercise regimen to maximize motor recovery in patients poststroke. The next several years will likely bring a host of new research studies exploring the latest strategies to enhance motor recovery using poststroke exercise.},
  langid = {english},
  keywords = {Current}
}

@article{ohDiagnosisMultipleSclerosis2022,
  title = {Diagnosis of {{Multiple Sclerosis}}},
  author = {Oh, Jiwon},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1006--1024},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001156},
  url = {https://journals.lww.com/10.1212/CON.0000000000001156},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The diagnosis of multiple sclerosis (MS) can be made based on clinical symptoms and signs alone or a combination of clinical and paraclinical features. Diagnostic criteria for MS have evolved over time, and the latest version facilitates earlier diagnosis of MS in those presenting with typical clinical syndromes. This article summarizes the current diagnostic criteria for MS, typical and atypical presentations of MS, and when diagnostic criteria should be applied with caution.                                         RECENT FINDINGS               The most recent version of the MS diagnostic criteria has the benefits of simplicity and greater sensitivity in comparison to previous iterations. However, misdiagnosis remains a significant issue in MS clinical care, even at MS specialty centers. It is, therefore, evident that careful clinical application of the current version of the diagnostic criteria is necessary and that tools improving the diagnostic accuracy of MS would be of substantial clinical utility. Emerging diagnostic biomarkers that may be useful in this regard, including the central vein sign, paramagnetic rim lesions, and fluid biomarkers, are discussed.                                         SUMMARY               Current MS diagnostic criteria facilitate the early diagnosis of MS in people presenting with typical clinical syndromes but should be used cautiously in those presenting with atypical syndromes and in special populations. Clinical judgment and existing paraclinical tools, including sequential MRIs of the neuraxis and laboratory tests, are useful in minimizing misdiagnosis and facilitating the accurate diagnosis of MS. Diagnostic biomarkers that may facilitate or refute a diagnosis of MS in these settings, and emerging imaging and fluid biomarkers may eventually become available for use in clinical settings.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{oliveiraToxicMetabolicHereditaryOptic2019,
  title = {Toxic-{{Metabolic}} and {{Hereditary Optic Neuropathies}}},
  author = {Oliveira, Cristiano},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1265--1288},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000769},
  url = {https://journals.lww.com/10.1212/CON.0000000000000769},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The diagnosis of visual loss from toxic-metabolic and hereditary optic neuropathies may be delayed in some cases because of a failure to elicit important information in the clinical history or to recognize typical examination findings. An understanding of the features specific to each type of toxic-metabolic and hereditary optic neuropathy, and of the underlying mechanism of insult to the optic nerve, could lead to earlier recognition, diagnosis, and treatment (when available).                                         RECENT FINDINGS                                Understanding of the role of mitochondria in toxic-metabolic and hereditary optic neuropathies is growing, particularly regarding the mechanism of insult of certain agents (medications and toxins) and of vitamin B                 12                 deficiency. New developments in the quest for treatment for hereditary optic neuropathy, specifically Leber hereditary optic neuropathy, are being seen.                                                        SUMMARY               Toxic-metabolic and hereditary optic neuropathies present in a similar fashion, with painless, progressive, bilateral visual loss with dyschromatopsia and cecocentral visual field defects. The associated retinal ganglion cell and axonal loss is typically due to mitochondrial dysfunction caused by an exogenous agent (toxic), by insufficient or deficient substrate (metabolic or nutritional), or by abnormal proteins or mitochondrial structure determined by a genetic mutation (hereditary).},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/CZL72WLD/Oliveira (2019) Toxic-Metabolic and Hereditary Optic Neuropathies.pdf}
}

@article{omalleyDiagnosingCommonMovement2022,
  title = {Diagnosing {{Common Movement Disorders}} in {{Children}}},
  author = {O'Malley, Jennifer A.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1476--1519},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001187},
  url = {https://journals.lww.com/10.1212/CON.0000000000001187},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article is designed to help the clinician identify the most common pediatric movement disorders and recognize benign versus pathologic movements in infancy and childhood, with a particular focus on treatable conditions and those that should not be missed.                                         RECENT FINDINGS               As telehealth has become more prevalent as a means of providing health care services, the challenges of obtaining relevant examination findings during telehealth encounters for assessment of children with movement disorders have become evident.                                         SUMMARY               Although many children who present with a chief complaint of ``abnormal movements'' are found to have a benign, self-resolving etiology, it is critical that neurologists accurately recognize benign versus pathologic movements in children to ensure appropriate diagnosis and intervention.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{onealObstetricGynecologicDisorders2020,
  title = {Obstetric and {{Gynecologic Disorders}} and the {{Nervous System}}},
  author = {O'Neal, Mary Angela},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {611--631},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000860},
  url = {https://journals.lww.com/10.1212/CON.0000000000000860},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article highlights the multiple intersections between obstetric/gynecologic issues and neurologic disorders.                                         RECENT FINDINGS               Neurologic issues can arise related to contraceptive medications, infertility treatments, pregnancy, and menopause. This article explores these areas in chronologic order, beginning with women's neurologic conditions that overlap their reproductive years and those that may occur during pregnancy and continuing through menopause. For each disorder, the epidemiology, pathophysiology, complications, and best sex-based treatment are described. Recent findings and treatments are highlighted.                                         SUMMARY               Obstetric and gynecologic disorders may present with neurologic symptoms, so it is important for neurologists to understand these intersections to deliver the best care for our female patients.},
  langid = {english},
  keywords = {Outdated}
}

@article{palmaManagementOrthostaticHypotension2020,
  title = {Management of {{Orthostatic Hypotension}}},
  author = {Palma, Jose-Alberto and Kaufmann, Horacio},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {154--177},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000816},
  url = {https://journals.lww.com/10.1212/CON.0000000000000816},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the management of orthostatic hypotension with emphasis on neurogenic orthostatic hypotension.                                         RECENT FINDINGS               Establishing whether the cause of orthostatic hypotension is a pathologic lesion in sympathetic neurons (ie, neurogenic orthostatic hypotension) or secondary to other medical causes (ie, non-neurogenic orthostatic hypotension) can be achieved by measuring blood pressure and heart rate at the bedside. Whereas fludrocortisone has been extensively used as first-line treatment in the past, it is associated with adverse events including renal and cardiac failure and increased risk of all-cause hospitalization. Distinguishing whether neurogenic orthostatic hypotension is caused by central or peripheral dysfunction has therapeutic implications. Patients with peripheral sympathetic denervation respond better to norepinephrine agonists/precursors such as droxidopa, whereas patients with central autonomic dysfunction respond better to norepinephrine reuptake inhibitors.                                         SUMMARY               Management of orthostatic hypotension is aimed at improving quality of life and reducing symptoms rather than at normalizing blood pressure. Nonpharmacologic measures are the key to success. Pharmacologic options include volume expansion with fludrocortisone and sympathetic enhancement with midodrine, droxidopa, and norepinephrine reuptake inhibitors. Neurogenic supine hypertension complicates management of orthostatic hypotension and is primarily ameliorated by avoiding the supine position and sleeping with the head of the bed elevated.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current},
  file = {/Users/nathanielyomogida/Zotero/storage/279M7GD8/Palma_Kaufmann (2020) Management of Orthostatic Hypotension.pdf}
}

@article{panickerLowerUrinaryTract2020,
  title = {Lower {{Urinary Tract}} and {{Bowel Dysfunction}} in {{Neurologic Disease}}},
  author = {Panicker, Jalesh N. and Sakakibara, Ryuji},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {178--199},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000824},
  url = {https://journals.lww.com/10.1212/CON.0000000000000824},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the clinical presentation, investigations, and treatment options for lower urinary tract and bowel dysfunction in patients with neurologic diseases.                                         RECENT FINDINGS                                The site of the neurologic lesion influences the pattern of lower urinary tract dysfunction. Antimuscarinic agents are first-line management for urinary incontinence; however, the side effect profile should be considered when prescribing them. {$\beta$}                 3                 -Receptor agonists are a promising alternative oral medication. Botulinum toxin injections into the detrusor have revolutionized the management of neurogenic detrusor overactivity.                              Bowel dysfunction commonly presents as constipation and fecal incontinence. Gastrointestinal emergencies may arise, including intestinal pseudoobstruction, intussusception, volvulus, and stercoral ulcer (ulcer of the colon due to pressure and irritation resulting from severe, prolonged constipation). Bowel function tests in neurologic patients often show a combination of slow transit and anorectal dysfunction. Management for slow transit constipation includes bulking agents, softening agents, yogurt/probiotics, and prokinetic agents. Suppositories, botulinum toxin injections, and transanal irrigation are options for managing anorectal constipation.                                         SUMMARY               Functions of the lower urinary tract and bowel are commonly affected in neurologic disease. Neurologists play an important role in assessing lower urinary tract and bowel symptoms in their patients and planning treatment strategies, often in collaboration with specialist teams.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{panickerUrogenitalSymptomsNeurologic2017,
  title = {Urogenital {{Symptoms}} in {{Neurologic Patients}}},
  author = {Panicker, Jalesh N.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {533--552},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000448},
  url = {https://journals.lww.com/00132979-201704000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Lower urinary tract and sexual dysfunction are commonly reported sequelae of neurologic disease and have a significant impact on quality of life. This article presents an up-to-date summary of the clinical presentation, investigations, and treatment options for urogenital dysfunction in patients with neurologic disease.                                         Recent Findings:               The pattern of lower urinary tract dysfunction is influenced by the site of the neurologic lesion. The risk for developing upper urinary tract damage is considerably less in patients with slowly progressive nontraumatic neurologic disorders, as compared to those with spinal cord injury or spina bifida. Investigations such as urinalysis, ultrasonography, and urodynamics provide further information about the cause and nature of lower urinary tract dysfunction. Antimuscarinic agents are the first-line management of urinary incontinence; however, side effect profile and anticholinergic burden should be considered when prescribing medications. {$\beta$}               3               -Adrenergic receptor agonists are a promising alternative oral medication. Tibial and sacral neuromodulation have been shown to be effective for managing incontinence, as well as urinary retention due to Fowler syndrome. Intradetrusor injections of onabotulinumtoxinA have revolutionized the management of neurogenic detrusor overactivity.                                         Summary:               Neurologic patients reporting urogenital symptoms require a comprehensive evaluation for planning a patient-tailored approach to management. Neurologists are increasingly inquiring about lower urinary tract and sexual functions and becoming involved in the management of these disorders.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/HTZKA87F/Panicker (2017) Urogenital Symptoms in Neurologic Patients.pdf;/Users/nathanielyomogida/Zotero/storage/JC85YMBF/panicker2017.pdf.pdf}
}

@article{pantelyatProgressiveSupranuclearPalsy2022,
  title = {Progressive {{Supranuclear Palsy}} and {{Corticobasal Syndrome}}},
  author = {Pantelyat, Alexander},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1364--1378},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001158},
  url = {https://journals.lww.com/10.1212/CON.0000000000001158},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The differential diagnosis of parkinsonism (tremor, rigidity, bradykinesia, and gait difficulty/postural instability) is broad and includes two neurodegenerative conditions that exist on a clinicopathologic spectrum: progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Early in their clinical course, PSP and CBS may be difficult to distinguish from Parkinson disease and several other illnesses, but it is crucial to do so because of implications for management and prognosis.                                         RECENT FINDINGS               Early accurate diagnosis of PSP and CBS remains a challenge because of heterogeneity in presenting symptoms and high frequency of coexisting pathologies (especially Alzheimer disease and vascular disease). It is increasingly recognized that patients with PSP, CBS, and other parkinsonian disorders require multidisciplinary care for optimal outcomes. With the recent proliferation of biomarker studies and therapeutic trials for tauopathies, there is growing hope that better treatments for PSP and CBS are on the horizon.                                         SUMMARY               Although PSP and CBS currently lack disease-modifying therapies, it is important to diagnose them as early as possible so that the patient can benefit from the many available symptomatic therapies, support groups, and a growing number of clinical trials.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{partapPediatricBrainTumors2020,
  title = {Pediatric {{Brain Tumors}}},
  author = {Partap, Sonia and Monje, Michelle},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1553--1583},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000955},
  url = {https://journals.lww.com/10.1212/CON.0000000000000955},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article focuses on primary brain tumors in the pediatric population with an emphasis on molecular classifications and treatment strategies.                                         RECENT FINDINGS               Pediatric brain tumors are a heterogeneous group of tumors that differ from adult brain cancers despite similar nomenclature. With the added complexity of the developing brain, treatment regimens are tailored to protect neurocognitive outcomes without sacrificing long-term survival. The 2016 World Health Organization's classification incorporated molecular characteristics to aid in defining the diagnosis and prognosis of these tumors. These changes have enabled providers to stratify patients, thus intensifying therapies in those with high-risk diseases and modifying treatments to reduce morbidity for children and to provide better outcomes. Recent published findings from clinical trials have been especially helpful for gliomas, embryonal tumors, and ependymomas. By using this new information, molecular factors that correlate with survival have been identified in patients. In addition, genetic findings in tumor tissue have also led to revelations in predisposing germline mutations.                                         SUMMARY               New findings from clinical trials and molecular stratification will shape the next generation of therapies in hopes of improving overall outcome, identifying pathways in tumorigenesis, and aiding in genetic counseling for children and their families.},
  langid = {english}
}

@article{pasnoorApproachMuscleNeuromuscular2019,
  title = {Approach to {{Muscle}} and {{Neuromuscular Junction Disorders}}},
  author = {Pasnoor, Mamatha and Dimachkie, Mazen M.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1536--1563},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000799},
  url = {https://journals.lww.com/10.1212/CON.0000000000000799},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Muscle and neuromuscular junction disorders are a diverse group of disorders that can be difficult to diagnose. This article provides a diagnostic approach based on clinical history and neurologic examination leading to a narrow set of diagnostic tests.                                         RECENT FINDINGS               Numerous discoveries in recent years have facilitated clinician access to more advanced laboratory and genetic testing to pinpoint the exact diagnosis in patients with muscle or neuromuscular junction disorders. Large-scale genetic testing has become much less expensive, and free testing has become available for many of the rare conditions because of increased research and the availability of effective therapies for these rare disorders.                                         SUMMARY               The approach to muscle and neuromuscular junction disorders depends on the clinical pattern of muscle weakness. By classifying patients into one of 10 muscle patterns, diagnostic testing can be targeted and gene testing yield will be optimized. With the increased accessibility and reduced cost of genetic testing (eg, gene panels, whole-exome sequencing, whole-genome sequencing, and chromosomal microarray), this clinical approach to muscle weakness and targeted gene testing will ensure a cost-effective investigational plan. This clinical approach should also assist clinicians in making a timely and accurate diagnosis.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/SRSD5KNY/Pasnoor_Dimachkie (2019) Approach to Muscle and Neuromuscular Junction Disorders.pdf}
}

@article{patelCongenitalInfectionsNervous2021,
  title = {Congenital {{Infections}} of the {{Nervous System}}},
  author = {Patel, Payal},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {1105--1126},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000991},
  url = {https://journals.lww.com/10.1212/CON.0000000000000991},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of congenital infections affecting the central nervous system (CNS), discussing the epidemiology, clinical features, diagnostic tools, and preventive and treatment measures for a variety of pathogens with the potential to infect the developing fetal brain.                                         RECENT FINDINGS               Contrary to popular belief, many congenital CNS infections are preventable and treatable. Treatment options exist for congenital cytomegalovirus, human immunodeficiency virus (HIV), herpes simplex virus, toxoplasmosis, and syphilis, although the efficacy of these treatments and the populations that may benefit from treatment are variable. Zika virus has recently emerged as a pathogen affecting the fetal brain, and new data suggest that the pathogenesis of Zika virus involves direct infection of neuronal progenitor cells leading to destruction of CNS tissue. The incidence of congenital syphilis has been increasing in the United States over the past decade as a direct result of new syphilis cases among adults and poor access to adequate maternal health care.                                         SUMMARY               Congenital CNS infections often result in significant neurologic morbidity in pediatric patients. Therefore, early identification of maternal illness and implementation of preventive measures are important in improving developmental outcomes and quality of life.},
  langid = {english},
  keywords = {Current}
}

@article{pavlakisRheumatologicDisordersNervous2020,
  title = {Rheumatologic {{Disorders}} and the {{Nervous System}}},
  author = {Pavlakis, Pantelis P.},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {591--610},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000856},
  url = {https://journals.lww.com/10.1212/CON.0000000000000856},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE               This article describes the neurologic manifestations of systemic autoimmune diseases.                                         RECENT FINDINGS               Systemic autoimmune diseases can be associated with a wide spectrum of neurologic comorbidities involving the central and peripheral nervous systems. Systemic lupus erythematosus (SLE) can be associated with a number of manifestations predominantly affecting the central nervous system (CNS), whereas peripheral neuropathy is less common. Sj{\"o}gren syndrome can be associated with peripheral neuropathy in 10\% of cases and CNS disease in 2\% to 5\% of cases. The risk of stroke is increased in SLE, rheumatoid arthritis, temporal arteritis, psoriatic arthritis, and ankylosing spondylitis. Systemic vasculitides present most commonly with mononeuritis multiplex but can also affect the CNS. Cognitive dysfunction is a common symptom among patients with systemic autoimmune diseases, most commonly seen in patients with SLE or Sj{\"o}gren syndrome.                                         SUMMARY               Neurologic manifestations of systemic autoimmune disease are important to recognize, as they may often be the presenting manifestation leading to diagnosis of the systemic disease or may be associated with increased morbidity, other complications, or mortality. Timely diagnosis and institution of appropriate treatment, often requiring multidisciplinary care, is essential to minimize morbidity and decrease the risk of permanent neurologic deficits.},
  langid = {english},
  keywords = {Outdated}
}

@article{pavlovicHeadacheWomen2021,
  title = {Headache in {{Women}}},
  author = {Pavlovi{\'c}, Jelena M.},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {686--702},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001010},
  url = {https://journals.lww.com/10.1212/CON.0000000000001010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Women are greatly overrepresented among patients seeking treatment for symptoms of headache pain in general and migraine in particular. Understanding the presentation of headache in women in relation to hormonal changes both during the menstrual cycle and throughout the life span is essential for appropriate diagnosis and treatment.                                         RECENT FINDINGS               Although perimenstrual migraine attacks are generally without aura, the diagnosis of migraine with aura has been added to the headache classification for menstrual migraine to account for women with the diagnosis of migraine with aura who experience menstrual migraine attacks. Emerging knowledge regarding the differences between menstrual and nonmenstrual attacks, the variability of attack triggering within and between women, and the response of women with menstrually related migraine to new migraine drug classes is contributing to better understanding and more effective treatment of these particularly burdensome and refractory attacks. Given the burden of migraine, almost one-fourth of women with migraine avoid or delay pregnancy. Women who experience migraine during pregnancy are more likely to have a hypertensive disorder and stroke during pregnancy and/or delivery and the postpartum period. Treatment of headache in general and migraine in particular in pregnancy is challenging because of fetal and maternal risks; however, a 2021 systematic review suggests that triptans and low-dose aspirin may not be associated with fetal/child adverse effects and could be more strongly considered for headache treatment in pregnancy.                                         SUMMARY               Headache in general and migraine in particular are extraordinarily common in women of reproductive age and fluctuate with hormonal changes and phases of life. Improved knowledge of the epidemiology, pathophysiology, and response to treatment of perimenstrual attacks is essential for more effective response to this most burdensome headache type. Treatment of headache in pregnancy remains challenging.},
  langid = {english},
  keywords = {Current}
}

@article{pawateSarcoidosisNervousSystem2020,
  title = {Sarcoidosis and the {{Nervous System}}},
  author = {Pawate, Siddharama},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {695--715},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000855},
  url = {https://journals.lww.com/10.1212/CON.0000000000000855},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview and update on the neurologic manifestations of sarcoidosis.                                         RECENT FINDINGS                                The 2018 Neurosarcoidosis Consortium diagnostic criteria emphasize that biopsy is key for diagnosis and determines the level of diagnostic certainty. Thus,                 definite neurosarcoidosis                 requires nervous system biopsy and                 probable neurosarcoidosis                 requires biopsy from extraneural tissue. Without biopsy,                 possible neurosarcoidosis                 can be diagnosed if the clinical, imaging, and laboratory picture is compatible and other causes are ruled out. Recent large retrospective studies from the United States and France established that infliximab appears to be efficacious when other treatments are inadequate.                                                        SUMMARY                                Sarcoidosis is a multisystem noninfectious granulomatous disorder that is immune mediated, reflecting the response to an as-yet unidentified antigen or antigens. Neurosarcoidosis refers to neurologic involvement due to sarcoidosis that clinically manifests in 5\% of cases of sarcoidosis, with asymptomatic involvement in as many as another one in five patients with sarcoidosis. Sarcoid granulomas can occur in any anatomic substrate in the nervous system, causing protean manifestations that have earned neurosarcoidosis the sobriquet                 the great mimic                 . Nevertheless, central nervous system sarcoidosis occurs in well-defined presentations that can be classified as cranial neuropathies, meningeal disease, brain parenchymal (including pituitary-hypothalamic) disease, and spinal cord disease. In addition, the peripheral nervous system is affected in the form of peripheral neuropathy and myopathy. Glucocorticoids are the cornerstone of treatment, especially in the acute stage, whereas steroid-sparing agents such as methotrexate, mycophenolate mofetil, and azathioprine are used for prolonged therapy to minimize steroid toxicity. Anti--tumor necrosis factor agents may help in refractory cases.},
  langid = {english},
  keywords = {Outdated}
}

@article{pearlEpilepsySyndromesChildhood2018,
  title = {Epilepsy {{Syndromes}} in {{Childhood}}},
  author = {Pearl, Phillip L.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {186--209},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000568},
  url = {https://journals.lww.com/00132979-201802000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Epilepsy syndromes are an important clinical construct in pediatric epilepsy, as they encompass recognizable patterns seen in patients with epilepsies, whether of the more benign variety or associated with encephalopathy.                                         RECENT FINDINGS               Syndromes may be organized by age of onset: neonatal, infantile, childhood, or adolescent. The assignment of a syndrome has specific implications for diagnosis, management, and prognostication. The 2010 revised classification of the epilepsies by the International League Against Epilepsy preserved the syndrome approach, while progress in genetics continues to advance our understanding of the pathophysiology and overlap of the epilepsy syndromes.                                         SUMMARY               Given that mutations of the same gene may cause both encephalopathic and relatively benign epilepsies, an understanding of the pediatric epilepsy syndromes remains vital to patient care.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/NN4JQAK5/Pearl (2018) Epilepsy Syndromes in Childhood.pdf}
}

@article{pearsonMovementDisordersChildren2019,
  title = {Movement {{Disorders}} in {{Children}}},
  author = {Pearson, Toni S. and Pons, Roser},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {1099--1120},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000756},
  url = {https://journals.lww.com/00132979-201908000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the clinical features and disorders associated with movement disorders in childhood. This article discusses movement disorder phenomena and their clinical presentation in infants and children and presents a diagnostic approach to suspected genetic disorders with a focus on treatable conditions.                                         RECENT FINDINGS               Technologic advances in molecular genetic testing over the past decade continue to lead to the discovery of new diseases. This article discusses the clinical presentation and early experience with treatment for several recently described genetic forms of infantile-onset and childhood-onset dystonia and chorea.                                         SUMMARY               The clinical spectrum of pediatric movement disorders is broad and heterogeneous, ranging from acute or transient self-limited conditions to conditions that cause profound lifelong motor disability. Most movement disorders in childhood are chronic, and the large number of rare, genetic conditions associated with pediatric movement disorders can pose a significant diagnostic challenge. Recognition of distinctive diagnostic clues in the history and examination can facilitate the diagnosis of potentially treatable disorders.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/9GHFBH8S/Pearson_Pons (2019) Movement Disorders in Children.pdf;/Users/nathanielyomogida/Zotero/storage/FCUTRGXX/10.1212@CON.0000000000000756.pdf.pdf}
}

@article{pizziAcuteNeurologicManifestations2021,
  title = {Acute {{Neurologic Manifestations}} of {{Respiratory Viruses}}},
  author = {Pizzi, Michael A.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1365--1381},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001007},
  url = {https://journals.lww.com/10.1212/CON.0000000000001007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Understanding the pathophysiology of COVID-19 and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes the disease has demonstrated the complexity of acute respiratory viruses that can cause neurologic manifestations. This article describes the most common respiratory viruses that have neurologic manifestations, with a focus on SARS-CoV-2 and COVID-19.                                         RECENT FINDINGS               In vitro and in vivo studies have better elucidated the neurotropism of various respiratory viruses. Understanding host cell receptors that mediate viral binding and entry not only demonstrates how viruses enter host cells but also provides possible mechanisms for therapeutic interventions. Elucidation of SARS-CoV-2 binding and fusion with host cells expressing the angiotensin-converting enzyme 2 (ACE2) receptor may also provide greater insights into its systemic and neurologic sequelae. Respiratory virus neurotropism and collateral injury due to concurrent inflammatory cascades result in various neurologic pathologies, including Guillain-Barr{\'e} syndrome, encephalopathy, encephalitis, ischemic stroke, intracerebral hemorrhage, and seizures.                                         SUMMARY               Numerous respiratory viruses can infect the cells of the peripheral and central nervous systems, elicit inflammatory cascades, and directly and indirectly cause various neurologic manifestations. Patients with neurologic manifestations from respiratory viruses are often critically ill and require mechanical ventilation. Neurologists and neurointensivists should be familiar with the common neurologic manifestations of respiratory viruses and the unique and still-evolving sequelae associated with COVID-19.},
  langid = {english}
}

@article{polsinelliAtypicalAlzheimerDisease2022,
  title = {Atypical {{Alzheimer Disease Variants}}},
  author = {Polsinelli, Angelina J. and Apostolova, Liana G.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {676--701},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001082},
  url = {https://journals.lww.com/10.1212/CON.0000000000001082},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the clinical, neuroimaging, and biomarker profiles of sporadic atypical Alzheimer disease (AD) variants, including early-onset AD, posterior cortical atrophy, logopenic variant primary progressive aphasia, dysexecutive variant and behavioral variant AD, and corticobasal syndrome.                                         RECENT FINDINGS               Significant advances are being made in the recognition and characterization of the syndromically diverse AD variants. These variants are identified by the predominant cognitive and clinical features: early-onset amnestic syndrome, aphasia, visuospatial impairments, dysexecutive and behavioral disturbance, or motor symptoms. Although understanding of regional susceptibility to disease remains in its infancy, visualizing amyloid and tau pathology in vivo and CSF examination of amyloid-{$\beta$} and tau proteins are particularly useful in atypical AD, which can be otherwise prone to misdiagnosis. Large-scale research efforts, such as LEADS (the Longitudinal Early-Onset Alzheimer Disease Study), are currently ongoing and will continue to shed light on our understanding of these diverse presentations.                                         SUMMARY               Understanding the clinical, neuroimaging, and biomarker profiles of the heterogeneous group of atypical AD syndromes improves diagnostic accuracy in patients who are at increased risk of misdiagnosis. Earlier accurate identification facilitates access to important interventions, social services and disability assistance, and crucial patient and family education.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/6SCDKDY5/Polsinelli_Apostolova (2022) Atypical Alzheimer Disease Variants.pdf}
}

@article{porterNeurologicComplicationsCancer2023,
  title = {Neurologic {{Complications}} of {{Cancer Treatment}}},
  author = {Porter, Alyx B.},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {903--922},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001236},
  url = {https://journals.lww.com/10.1212/CON.0000000000001236},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Objective               Advances in cancer treatment have led to extended survival and increased risk of neurologic complications in an aging population. This review summarizes potential neurologic complications in patients who have undergone treatment for neurologic and systemic malignancies.                                         Latest Developments               Radiation and cytotoxic chemotherapy along with other targeted therapies continue to be the mainstay of cancer treatment. These advances in cancer care have led to improved outcomes and increased the need to understand the spectrum of neurologic complications that may arise from treatment. While radiation and older therapies including cytotoxic chemotherapies have side effect profiles that are widely known and well understood, this article serves as a review of the more commonly associated neurologic complications of both traditional and newer treatments being offered to this patient population.                                         Essential Points               Neurotoxicity is a common complication of cancer-directed treatment. In general, neurologic complications of radiation therapy are more common in central nervous system malignancies, and neurologic complications of chemotherapy are more common in non-neurologic malignancies. Attempts at prevention, early detection, and intervention remain paramount in the reduction of neurologic morbidity.},
  langid = {english},
  keywords = {Current}
}

@article{prasadHigherCorticalVisual2019,
  title = {Higher {{Cortical Visual Disorders}}},
  author = {Prasad, Sashank and Dinkin, Marc},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1329--1361},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000774},
  url = {https://journals.lww.com/10.1212/CON.0000000000000774},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the disorders that result from disruption of extrastriate regions of the cerebral cortex responsible for higher visual processing. For each disorder, a historical perspective is offered and relevant neuroscientific studies are reviewed.                                         RECENT FINDINGS               Careful analysis of the consequences of lesions that disrupt visual functions such as facial recognition and written language processing has improved understanding of the role of key regions in these networks. In addition, modern imaging techniques have built upon prior lesion studies to further elucidate the functions of these cortical areas. For example, functional MRI (fMRI) has identified and characterized the response properties of ventral regions that contribute to object recognition and dorsal regions that subserve motion perception and visuospatial attention. Newer network-based functional imaging studies have shed light on the mechanisms behind various causes of spontaneous visual hallucinations.                                         SUMMARY               Understanding the regions and neural networks responsible for higher-order visual function helps the practicing neurologist to diagnose and manage associated disorders of visual processing and to identify and treat responsible underlying disease.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/MURUX38R/Prasad_Dinkin (2019) Higher Cortical Visual Disorders.pdf}
}

@article{pruittCentralNervousSystem2018,
  title = {Central {{Nervous System Infections Complicating Immunosuppression}} and {{Transplantation}}},
  author = {Pruitt, Amy A.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1370--1396},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000653},
  url = {https://journals.lww.com/00132979-201810000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews infections associated with cancer treatments and immunosuppressive/immunomodulatory therapies used in both neoplastic and non-neoplastic conditions, including hematopoietic cell transplantation and solid organ transplantation. It provides a clinical approach to the most commonly affected patient groups based on clinicoanatomic presentation and disease-specific risks resulting from immune deficits and drugs received.                                         RECENT FINDINGS               The clinical presentations, associated neuroimaging findings, and CSF abnormalities of patients with central nervous system infections who are immunocompromised may differ from those of patients with central nervous system infections who are immunocompetent and may be confused with noninfectious processes. Triggering of brain autoimmunity with emergence of neurotropic antibodies has emerged as a recognized parainfectious complication. New unbiased metagenomic assays to identify obscure pathogens help clinicians navigate the increasing range of conditions affecting the growing population of patients with altered immunity.                                         SUMMARY               Despite evidence-based prophylactic regimens and organism-specific antimicrobials, central nervous system infections continue to cause significant morbidity and mortality in an increasing range of patients who are immunocompromised by their conditions and therapies. Multiple new drugs put patients at risk for progressive multifocal leukoencephalopathy, which has numerous imaging and clinical manifestations; patients at risk include those with multiple sclerosis, for whom infection risk is becoming one of the most important factors in therapeutic decision making. Efficient, early diagnosis is essential to improve outcomes in these often-devastating diseases.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/X25DD96P/Pruitt (2018) Central Nervous System Infections Complicating Immunosuppression and.pdf}
}

@article{putaalaIschemicStrokeYoung2020,
  title = {Ischemic {{Stroke}} in {{Young Adults}}},
  author = {Putaala, Jukka},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {386--414},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000833},
  url = {https://journals.lww.com/10.1212/CON.0000000000000833},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews current knowledge on epidemiology, risk factors and causes, diagnostic considerations, management, and prognosis of ischemic stroke in young adults (those 55 years old and younger).                                         RECENT FINDINGS               The incidence of ischemic stroke in young adults has been increasing since the 1980s, which has occurred in parallel with increasing prevalence of vascular risk factors and substance abuse among the younger population. Young adults have a considerably wider range of risk factors than older patients, including age-specific factors such as pregnancy/puerperium and oral contraceptive use. Behavioral risk factors such as low physical activity, excess alcohol consumption, and smoking are factors as well. More than 150 identified causes of early-onset ischemic stroke exist, including rare monogenic disorders. Several recent advances have been made in diagnosis and management of stroke in young adults, including molecular characterization of monogenic vasculitis due to deficiency of adenosine deaminase 2 and transcatheter closure of patent foramen ovale for secondary prevention. Compared with the background population of the same age and sex, long-term mortality in patients remains fourfold higher with cardiovascular causes underlying most of the deaths. The cumulative rate of recurrent stroke extends up to 15\% at 10 years. Patients with atherosclerosis, high-risk sources of cardioembolism, and small vessel disease underlying their stroke seem to have the worst prognosis regarding survival and recurrent vascular events. Young stroke survivors also often have other adverse outcomes in the long term, including epilepsy, pain, cognitive problems, and depression.                                         SUMMARY               Systematic identification of risk factors and causes and the motivation of patients for long-term prevention and lifestyle changes are of utmost importance to improve the prognosis of early-onset ischemic stroke.},
  langid = {english}
}

@article{rabinoviciLateonsetAlzheimerDisease2019,
  title = {Late-Onset {{Alzheimer Disease}}},
  author = {Rabinovici, Gil D.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {14--33},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000700},
  url = {https://journals.lww.com/00132979-201902000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Alzheimer disease (AD) is the most common cause of late-onset dementia. This article describes the epidemiology, genetic and environmental risk factors, clinical diagnosis, biomarkers, and treatment of late-onset AD, defined by age of onset of 65 years or older.                                         RECENT FINDINGS                                An estimated 5.7 million Americans are living with AD dementia, with the number of affected individuals growing rapidly because of an aging population. Vascular risk factors, sleep disorders, and traumatic brain injury are associated with an increased risk of AD, while increased cognitive and physical activity throughout the lifespan reduce the risk of disease. The primary genetic risk factor for late-onset AD is the apolipoprotein E (                 APOE                 ) {$\varepsilon$}4 allele. AD typically presents with early and prominent episodic memory loss, although this clinical syndrome is neither sensitive nor specific for underlying AD neuropathology. Emerging CSF and imaging biomarkers can now detect the key neuropathologic features of the disease (amyloid plaques, neurofibrillary tangles, and neurodegeneration) in living people, allowing for characterization of patients based on biological measures. A comprehensive treatment plan for AD includes use of symptomatic medications, optimal treatment of comorbid conditions and neuropsychiatric symptoms, counseling about safety and future planning, and referrals to community resources.                                                        SUMMARY               AD is very common in older neurologic patients. Neurologists should set the standard for the diagnosis and care of patients with AD and should be familiar with emerging biomarkers that have transformed AD research and are primed to enter the clinical arena.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/67HQKUWN/Rabinovici (2019) Late-onset Alzheimer Disease.pdf}
}

@article{rabinsteinAutonomicHyperactivity2020,
  title = {Autonomic {{Hyperactivity}}},
  author = {Rabinstein, Alejandro A.},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {138--153},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000811},
  url = {https://journals.lww.com/10.1212/CON.0000000000000811},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Autonomic hyperactivity is a relatively common consequence of severe acute brain injury and can also be seen with spinal cord and peripheral nerve disorders. This article reviews basic pathophysiologic concepts regarding autonomic hyperactivity, its various forms of clinical presentation, and practical management considerations.                                         RECENT FINDINGS               Paroxysmal sympathetic hyperactivity is most common after traumatic brain injury but can also occur after other forms of severe acute diffuse or multifocal brain injury. Formal criteria for the diagnosis and severity grading of paroxysmal sympathetic hyperactivity have now been proposed. A growing body of literature is beginning to elucidate the mechanisms underlying this disorder, but treatment remains based on observational data. Our mechanistic understanding of other distinct forms of autonomic hyperactivity, such as autonomic dysreflexia after traumatic spinal cord injury and dysautonomia after Guillain-Barr{\'e} syndrome, remains rudimentary, yet clinical experience shows that their appropriate management can minimize the risk of serious complications.                                         SUMMARY               Syndromes of autonomic hyperactivity can result from injury at all levels of the neuraxis. Much more research is needed to refine our understanding of these disorders and guide optimal management decisions.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{rabinsteinTraumaticSpinalCord2018,
  title = {Traumatic {{Spinal Cord Injury}}},
  author = {Rabinstein, Alejandro A.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {551--566},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000581},
  url = {https://journals.lww.com/00132979-201804000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an update on the acute and subacute management and prognostication of patients with traumatic spinal cord injury.                                         RECENT FINDINGS               Immobilization of the spine and spine clearance should be individualized depending on the ability to perform a reliable neurologic examination, the presence of neck pain, and the imaging findings. Early surgery (within 24 hours) to achieve definitive cord decompression and spine stabilization may be beneficial. Ensuring adequate oxygenation and perfusion and avoiding secondary systemic complications remain the goals of the critical care of these patients. No neuroprotective treatment has been shown to improve outcomes. In fact, the use of high-dose methylprednisolone is now generally discouraged because of its major systemic adverse effects. Survivors of severe cervical traumatic spinal cord injury typically sustain substantial long-term functional impairment. Advances in our understanding of neuroregenerative strategies, especially stem cell transplantation, can offer the future hope of functional improvement to the many patients currently living with the consequences of traumatic spinal cord injury. Yet, at present, these therapies remain strictly investigational.                                         SUMMARY               The treatment of traumatic spinal cord injury remains supportive, and prognosis is still poor for patients who are severely affected. While much remains to be learned about how to optimize the acute management of these patients, future efforts would be most useful if focused on injury prevention and the development of effective neuroregenerative therapies.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/NCJL534M/Rabinstein (2018) Traumatic Spinal Cord Injury.pdf;/Users/nathanielyomogida/Zotero/storage/RBHJSMMC/rabinstein2018.pdf.pdf}
}

@article{rabinsteinTreatmentAcuteIschemic2017,
  title = {Treatment of {{Acute Ischemic Stroke}}},
  author = {Rabinstein, Alejandro A.},
  year = {2017},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {1},
  pages = {62--81},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000420},
  url = {https://journals.lww.com/00132979-201702000-00009},
  urldate = {2023-10-28},
  abstract = {ABSTRACT                            Purpose of Review:               This article provides an update on the state of the art of the emergency treatment of acute ischemic stroke with particular emphasis on the alternatives for reperfusion therapy.                                         Recent Findings:               The results of several randomized controlled trials consistently and conclusively demonstrating that previously functional patients with disabling strokes from a proximal intracranial artery occlusion benefit from prompt recanalization with mechanical thrombectomy using a retrievable stent have changed the landscape of acute stroke therapy. Mechanical thrombectomy within 6 hours of symptom onset should now be considered the preferred treatment for these patients along with IV thrombolysis with recombinant tissue plasminogen activator (rtPA) within the first 4.5 hours for all patients who do not have contraindications for systemic thrombolysis. Patients who are ineligible for IV rtPA can also benefit from mechanical thrombectomy. Collateral status and time to reperfusion are the main determinants of outcome.                                         Summary:               Timely successful reperfusion is the most effective treatment for patients with acute ischemic stroke. Systems of care should be optimized to maximize the number of patients with acute ischemic stroke able to receive reperfusion therapy.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/DNDGTPKS/Rabinstein (2017) Treatment of Acute Ischemic Stroke.pdf}
}

@article{rabinsteinUpdateTreatmentAcute2020,
  title = {Update on {{Treatment}} of {{Acute Ischemic Stroke}}},
  author = {Rabinstein, Alejandro A.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {268--286},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000840},
  url = {https://journals.lww.com/10.1212/CON.0000000000000840},
  urldate = {2023-10-27},
  abstract = {EDITOR'S NOTE                                The article ``Update on Treatment of Acute Ischemic Stroke'' by Dr Rabinstein was first published in the February 2017 Cerebrovascular Disease issue of                 Continuum: Lifelong Learning in Neurology                 as ``Treatment of Acute Ischemic Stroke'' and has been updated by Dr Rabinstein for this issue at the request of the Editor-in-Chief.                                                        ABSTRACT               PURPOSE OF REVIEW               This article provides an update on the state of the art of the treatment of acute ischemic stroke with particular emphasis on the indications for reperfusion therapy.               RECENT FINDINGS               In addition to the previously established indications for intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) within 4.5 hours of stroke symptom onset and endovascular therapy with mechanical thrombectomy for patients with large artery occlusion who can be treated within 6 hours of symptom onset, recent randomized controlled trials have now established new indications for emergency reperfusion in patients with wake-up stroke or delayed presentation (up to 24 hours from last known well in the case of mechanical thrombectomy). Identification of patients who may benefit from acute reperfusion therapy within this extended time window requires screening with perfusion brain imaging or, in the case of IV thrombolysis for wake-up strokes, emergency brain MRI. Collateral status and time to reperfusion remain the primary determinants of outcome.               SUMMARY               Timely successful reperfusion is the most effective treatment for patients with acute ischemic stroke. Recent evidence supports the expansion of the time window for reperfusion treatment in carefully selected patients.},
  langid = {english}
}

@article{rajaLambertEatonMyasthenicSyndrome2022,
  title = {Lambert-{{Eaton Myasthenic Syndrome}} and {{Botulism}}},
  author = {Raja, Shruti M.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1596--1614},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001205},
  url = {https://journals.lww.com/10.1212/CON.0000000000001205},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the pathophysiology, epidemiology, clinical features, diagnosis, and treatment of Lambert-Eaton myasthenic syndrome (LEMS) and botulism, presynaptic disorders of neuromuscular transmission in which rapid diagnosis improves long-term outcomes.                                         RECENT FINDINGS               Therapy for LEMS has seen significant advances in recent years due to the approval of amifampridine-based compounds. LEMS is likely still underdiagnosed, particularly when no underlying malignancy is identified. Clinicians must have a strong suspicion for LEMS in any patient presenting with proximal weakness and autonomic dysfunction. Botulism is another rare disorder of presynaptic neuromuscular transmission that is most commonly associated with improper storage or preservation of food products. Over the past 2 decades, wound botulism has been increasingly reported among users of black tar heroin. A high degree of clinical suspicion and electrodiagnostic studies can be beneficial in distinguishing botulism from other acute neurologic disorders, and early involvement of state and federal health authorities may assist in confirming the diagnosis and obtaining treatment. When botulism is suspected, electrodiagnostic studies can provide clinical evidence of disordered neuromuscular transmission in advance of serologic confirmation, and providers should not wait for confirmation of the diagnosis to initiate treatment.                                         SUMMARY               A targeted clinical history and a thorough neurologic examination with support from serologic and electrodiagnostic studies are key to early diagnosis of LEMS and botulism. Early diagnosis of both conditions creates opportunities for therapy and improves outcomes.},
  langid = {english},
  keywords = {Current}
}

@article{rajiValueNeuroimagingDementia2022,
  title = {The {{Value}} of {{Neuroimaging}} in {{Dementia Diagnosis}}},
  author = {Raji, Cyrus A. and Benzinger, Tammie L. S.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {800--821},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001133},
  url = {https://journals.lww.com/10.1212/CON.0000000000001133},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses neuroimaging in dementia diagnosis, with a focus on new applications of MRI and positron emission tomography (PET).                                         RECENT FINDINGS               Although the historical use of MRI in dementia diagnosis has been supportive to exclude structural etiologies, recent innovations allow for quantification of atrophy patterns that improve sensitivity for supporting the diagnosis of dementia causes. Neuronuclear approaches allow for localization of specific amyloid and tau neuropathology on PET and are available for clinical use, in addition to dopamine transporter scans in dementia with Lewy bodies and metabolic studies with fludeoxyglucose PET (FDG-PET).                                         SUMMARY               Using computerized software programs for MRI analysis and cross-sectional and longitudinal evaluations of hippocampal, ventricular, and lobar volumes improves sensitivity in support of the diagnosis of Alzheimer disease and frontotemporal dementia. MRI protocol requirements for such quantification are three-dimensional T1-weighted volumetric imaging protocols, which may need to be specifically requested. Fluid-attenuated inversion recovery (FLAIR) and 3.0T susceptibility-weighted imaging (SWI) sequences are useful for the detection of white matter hyperintensities as well as microhemorrhages in vascular dementia and cerebral amyloid angiopathy. PET studies for amyloid and/or tau pathology can add additional specificity to the diagnosis but currently remain largely inaccessible outside of research settings because of prohibitive cost constraints in most of the world. Dopamine transporter PET scans can help identify Lewy body dementia and are thus of potential clinical value.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/FPSRET8T/Raji_Benzinger (2022) The Value of Neuroimaging in Dementia Diagnosis.pdf}
}

@article{rakofskyMoodDisorders2018,
  title = {Mood {{Disorders}}},
  author = {Rakofsky, Jeffrey and Rapaport, Mark},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {804--827},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000604},
  url = {https://journals.lww.com/00132979-201806000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the prevalence of the major mood disorders (major depressive disorder and bipolar disorder) in the community and within neurologic settings, articulates the steps taken to make a diagnosis of major depressive disorder or bipolar disorder, and reviews old and newer treatment options with proven efficacy for the treatment of these two conditions.                                         RECENT FINDINGS               New medications are available as treatment options for major depressive disorder and bipolar disorder, such as intranasal and IV ketamine, and somatic treatments, such as deep brain stimulation and vagal nerve stimulators, are being used to target treatment-resistant depression.                                         SUMMARY               Mood disorders are common in neurologic settings. They are disabling and increase morbidity and mortality. Clinicians should have a high index of suspicion if they suspect their patients seem more distressed or incapacitated than would be warranted by their neurologic disorders. If a patient does have a mood disorder, validating the patient's experience, initiating treatment, and, if necessary, referring the patient to a primary care physician or psychiatrist are appropriate steps.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/RZPSRGFC/Rakofsky_Rapaport (2018) Mood Disorders.pdf}
}

@article{ramchandrenCharcotMarieToothDiseaseOther2017,
  title = {Charcot-{{Marie-Tooth Disease}} and {{Other Genetic Polyneuropathies}}},
  author = {Ramchandren, Sindhu},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1360--1377},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000529},
  url = {https://journals.lww.com/00132979-201710000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Genetic polyneuropathies are rare and clinically heterogeneous. This article provides an overview of the clinical features, neurologic and electrodiagnostic findings, and management strategies for Charcot-Marie-Tooth disease and other genetic polyneuropathies as well as an algorithm for genetic testing.                                         Recent Findings:               In the past 10 years, many of the mutations causing genetic polyneuropathies have been identified. International collaborations have led to the development of consortiums that are undertaking careful genotype-phenotype correlations to facilitate the development of targeted therapies and validation of outcome measures for future clinical trials. Clinical trials are currently under way for some genetic polyneuropathies.                                         Summary:               Readers are provided a framework to recognize common presentations of various genetic polyneuropathies and a rationale for current diagnostic testing and management strategies in genetic polyneuropathies.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/BT4YEJLR/Ramchandren (2017) Charcot-Marie-Tooth Disease and Other Genetic Polyneuropathies.pdf;/Users/nathanielyomogida/Zotero/storage/V7UUFGBI/ramchandren2017.pdf.pdf}
}

@article{ransomOrthosesAdaptiveEquipment2011,
  title = {Orthoses and {{Adaptive Equipment}}:},
  shorttitle = {Orthoses and {{Adaptive Equipment}}},
  author = {Ransom, Cecilia Lim},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {494--509},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399069.77191.5b},
  url = {http://journals.lww.com/00132979-201106000-00012},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/SPRSE4VA/Ransom (2011) Orthoses and Adaptive Equipment.pdf;/Users/nathanielyomogida/Zotero/storage/VG7J6MG5/ransom2011.pdf.pdf}
}

@article{rawlsSurgicalTherapiesParkinson2022,
  title = {Surgical {{Therapies}} for {{Parkinson Disease}}},
  author = {Rawls, Ashley E.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1301--1313},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001160},
  url = {https://journals.lww.com/10.1212/CON.0000000000001160},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Parkinson disease (PD) is a progressive neurodegenerative disorder that is often difficult to manage with medications alone. This article reviews the current therapeutic surgical interventions for PD, patient selection criteria, timing of patient referral to surgical services, procedure overview, and future directions.                                         RECENT FINDINGS               Adaptive, or closed-loop, deep brain stimulation is a promising therapy that can detect ongoing circuit changes and deliver appropriate stimulation based on the patient's dominant symptom and level of dopaminergic medication.                                         SUMMARY               Patients with PD can benefit from surgical interventions that can be added to their medication regimen. These patients should be referred to comprehensive centers that offer complete multidisciplinary screening evaluation to ensure appropriate patient selection and intervention selection. With the appropriate surgical intervention and continued management from their care team, patients with PD can maximize their quality of life.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{recoberPathophysiologyMigraine2021,
  title = {Pathophysiology of {{Migraine}}},
  author = {Recober, Ana},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {586--596},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000983},
  url = {https://journals.lww.com/10.1212/CON.0000000000000983},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article summarizes the current understanding of the pathophysiology of migraine, including some controversial aspects of the underlying mechanisms of the disorder.                                         RECENT FINDINGS               Recent functional neuroimaging studies focusing on the nonpainful symptoms of migraine have identified key areas of the central nervous system implicated in the early phases of a migraine attack. Clinical studies of spontaneous and provoked migraine attacks, together with preclinical studies using translational animal models, have led to a better understanding of the disease and the development of disease-specific and targeted therapies.                                         SUMMARY               Our knowledge of the pathophysiology of migraine has advanced significantly in the past decades. Current evidence supports our understanding of migraine as a complex cyclical brain disorder that likely results from dysfunctional sensory processing and dysregulation of homeostatic mechanisms. This article reviews the underlying mechanisms of the clinical manifestations of each phase of the migraine cycle.},
  langid = {english},
  keywords = {Current}
}

@article{redaNeurologicComplicationsEndocrine2023,
  title = {Neurologic {{Complications}} of {{Endocrine Disorders}}},
  author = {Reda, Haatem},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {887--902},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001262},
  url = {https://journals.lww.com/10.1212/CON.0000000000001262},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               This article provides an overview of the neurologic complications of the most prevalent endocrine disorders in adults with an emphasis on relevant neurologic symptoms, signs, and laboratory and neuroimaging findings.                                         LATEST DEVELOPMENTS               Although the mechanisms of many of the neurologic complications discussed here remain unclear, our understanding of the impacts of diabetes and hypothyroidism on the nervous system and muscle, including complications of rapid correction of chronic hyperglycemia, has advanced in recent years. Recent large studies have not demonstrated a convincing association between subclinical or overt hypothyroidism and cognitive decline.                                         ESSENTIAL POINTS               Neurologists must become familiar with the neurologic complications of endocrine disorders not only because they are common and treatable (and often reversible) but also because they may be iatrogenic, as is the case with adrenal insufficiency in the setting of long-term corticosteroid therapy.},
  langid = {english},
  keywords = {Current}
}

@article{reichBellPalsy2017,
  title = {Bell's {{Palsy}}},
  author = {Reich, Stephen G.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {447--466},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000447},
  url = {https://journals.lww.com/00132979-201704000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Bell's palsy is a common outpatient problem, and while the diagnosis is usually straightforward, a number of diagnostic pitfalls can occur, and a lengthy differential diagnosis exists. Recognition and management of Bell's palsy relies on knowledge of the anatomy and function of the various motor and nonmotor components of the facial nerve. Avoiding diagnostic pitfalls relies on recognizing red flags or features atypical for Bell's palsy, suggesting an alternative cause of peripheral facial palsy.                                         Recent Findings:               The first American Academy of Neurology (AAN) evidence-based review on the treatment of Bell's palsy in 2001 concluded that corticosteroids were probably effective and that the antiviral acyclovir was possibly effective in increasing the likelihood of a complete recovery from Bell's palsy. Subsequent studies led to a revision of these recommendations in the 2012 evidence-based review, concluding that corticosteroids, when used shortly after the onset of Bell's palsy, were ``highly likely'' to increase the probability of recovery of facial weakness and should be offered; the addition of an antiviral to steroids may increase the likelihood of recovery but, if so, only by a very modest effect.                                         Summary:               Bell's palsy is characterized by the spontaneous acute onset of unilateral peripheral facial paresis or palsy in isolation, meaning that no features from the history, neurologic examination, or head and neck examination suggest a specific or alternative cause. In this setting, no further testing is necessary. Even without treatment, the outcome of Bell's palsy is favorable, but treatment with corticosteroids significantly increases the likelihood of improvement.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/BYBJAYGQ/Reich (2017) Bells Palsy.pdf;/Users/nathanielyomogida/Zotero/storage/KPFX6AYC/reich2017.pdf.pdf}
}

@article{richterObsessiveCompulsiveDisorder2018,
  title = {Obsessive-{{Compulsive Disorder}}},
  author = {Richter, Peggy M. A. and Ramos, Renato T.},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {828--844},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000603},
  url = {https://journals.lww.com/00132979-201806000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews current knowledge regarding diagnosis, pathophysiology, and treatment trends in obsessive-compulsive disorder (OCD), a severe, underrecognized, and chronic condition frequently encountered in neurologic practice.                                         RECENT FINDINGS               With a lifetime prevalence estimated at 2.5\%, OCD is a common condition that can also present comorbidly with neurologic disease. The core symptoms of OCD are obsessions and compulsions. Obsessions are intrusive repetitive thoughts, urges, images, or impulses that trigger anxiety and that the individual is not able to suppress. Compulsions are repetitive behaviors or mental acts occurring in response to an obsession with the intention of reducing the distress caused by obsessions. Neuroimaging, neuropsychological, and pharmacologic studies suggest that the expression of OCD symptoms is associated with dysfunction in a cortico-striato-thalamo-cortical circuit. Evidence-based treatments for OCD comprise pharmacotherapy and cognitive-behavioral therapy. Selective serotonin reuptake inhibitors (SSRIs) are the first-line drugs recommended for OCD, but significant differences exist in their use for OCD compared to their use for other mood and anxiety conditions, including the need for higher dosage, longer trials necessitated by a longer lag for therapeutic response, and typically lower response rates. Cognitive-behavioral therapy, based on the principles of exposure and response prevention, shows results superior to pharmacologic treatments with lower relapse rates on long-term follow-up and thus should be considered in the treatment plan of every patient with OCD.                                         SUMMARY               OCD and obsessive-compulsive symptoms are frequently encountered in the neurologic clinic setting and require a high index of suspicion to effectively screen for them and an illness-specific therapeutic approach.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/VVXM3ZH7/Richter_Ramos (2018) Obsessive-Compulsive Disorder.pdf}
}

@article{robbinsClinicbasedProceduresHeadache2021,
  title = {Clinic-Based {{Procedures}} for {{Headache}}},
  author = {Robbins, Matthew S.},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {732--745},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000959},
  url = {https://journals.lww.com/10.1212/CON.0000000000000959},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Headache disorders are common and disabling, and many therapies that are effective and safe are procedural.                                         RECENT FINDINGS               After pivotal clinical trials, onabotulinumtoxinA has become an established preventive therapy for chronic migraine; it is better tolerated than many other treatments and may be useful for other headache disorders. Peripheral nerve blocks, especially greater occipital nerve blocks, have amassed evidence from randomized trials in the acute and short-term preventive treatment of migraine and cluster headache. Trigger point injections and sphenopalatine ganglion blocks have recent trials suggesting efficacy and safety in properly selected patients. Medical education initiatives are needed to train neurologists in these procedures to help manage the large population of patients with headache disorders who need them.                                         SUMMARY               Evidence exists for the efficacy and safety of procedural therapies to be incorporated into neurology practice for the management of patients with migraine, cluster headache, and other headache disorders.},
  langid = {english},
  keywords = {Current}
}

@article{robbinsHeadachePregnancy2018,
  title = {Headache in {{Pregnancy}}},
  author = {Robbins, Matthew S.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1092--1107},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000642},
  url = {https://journals.lww.com/00132979-201808000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Headache disorders are extraordinarily common and disproportionately impact women of childbearing age. This article reviews the importance of proper diagnosis, natural history, and management of headache disorders in pregnant and postpartum women.                                         RECENT FINDINGS               Red flags for secondary headache specifically among pregnant women include elevated blood pressure and lack of a previous headache history, as well as a prolonged duration of the headache attack in those with a prior history of migraine. Migraine improvement is typical for most pregnant women, but the prognosis for women who have migraine with aura or chronic migraine is less predictable. Migraine is now an established risk factor for the development of preeclampsia. Recent data suggest hazards for compounds containing butalbital and possibly a better safety profile for triptans than previously believed during pregnancy. Peripheral nerve blocks and noninvasive neurostimulation devices are procedural and emerging therapies that have promising safety profiles for pregnant women with headache disorders.                                         SUMMARY               Acute headache occurring in pregnancy and the postpartum period is a red flag requiring diagnostic vigilance. Migraine frequency in women typically improves during pregnancy, although this trend is less certain when aura is present and after delivery. Acute and preventive treatment plans during pregnancy and lactation are plausible but may require shifts in therapeutic hierarchy. Relatively safe oral, parenteral, and procedural therapies are available for pregnant women. Noninvasive neuromodulation devices are already available and will likely play a greater role in the coming years. Migraine is associated with medical and obstetrical complications during pregnancy, and women with frequent migraine attacks may need to be considered high risk.},
  langid = {english},
  keywords = {Continuum: Headache,Headache,Outdated,Pregnancy},
  file = {/Users/nathanielyomogida/Zotero/storage/A9X3ER73/robbins2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/P5KQSJ3A/Robbins (2018) Headache in Pregnancy.pdf}
}

@article{robertsonCranialNeuralgias2021,
  title = {Cranial {{Neuralgias}}},
  author = {Robertson, Carrie},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {665--685},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000962},
  url = {https://journals.lww.com/10.1212/CON.0000000000000962},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the differential diagnosis, evaluation, and management of trigeminal neuralgia and reviews other neuralgias of the head and neck, including those that contribute to neuralgic ear pain.                                         RECENT FINDINGS               Most cases of trigeminal neuralgia are related to vascular compression, a demyelinating plaque, or a compressive mass affecting the trigeminal nerve. However, recent studies have shown that up to 11\% of patients have a family history of trigeminal neuralgia, suggesting that some patients may have a genetic predisposition to demyelination or nerve hyperexcitability. In these patients, trigeminal neuralgia may occur at a younger age, on both sides of the face, or in combination with other neuralgias.                                         SUMMARY               When a patient presents with neuralgic pain, the diagnosis is made by careful history and neurologic examination, with attention to the dermatome involved, the triggers, and the presence of any associated sensory deficit. All patients with new neuralgia or neuropathic facial pain warrant a careful evaluation for a secondary cause. The presence of sensory deficit on bedside examination is particularly concerning for an underlying secondary etiology.},
  langid = {english},
  keywords = {Current}
}

@article{robinsonModerateSevereTraumatic2021,
  title = {Moderate and {{Severe Traumatic Brain Injury}}},
  author = {Robinson, Christopher P.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1278--1300},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001036},
  url = {https://journals.lww.com/10.1212/CON.0000000000001036},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Traumatic brain injury (TBI) encompasses a group of heterogeneous manifestations of a disease process with high neurologic morbidity and, for severe TBI, high probability of mortality and poor neurologic outcomes. This article reviews TBI in neurocritical care, hence focusing on moderate and severe TBI, and includes an up-to-date review of the many variables to be considered in clinical care.                                         RECENT FINDINGS               With advances in medicine and biotechnology, understanding of the impact of TBI has substantially elucidated the distinction between primary and secondary brain injury. Consequently, care of TBI is evolving, with intervention-based modalities targeting multiple physiologic variables. Multimodality monitoring to assess intracranial pressure, cerebral oxygenation, cerebral metabolism, cerebral blood flow, and autoregulation is at the forefront of such advances.                                         SUMMARY               Understanding the anatomic and physiologic principles of acute brain injury is necessary in managing moderate to severe TBI. Management is based on the prevention of secondary brain injury from resultant trauma. Care of patients with TBI should occur in a dedicated critical care unit with subspecialty expertise. With the advent of multimodality monitoring and targeted biomarkers in TBI, patient outcomes have a higher probability of improving in the future.},
  langid = {english}
}

@article{roosMeningitisEncephalitis2011,
  title = {Meningitis and {{Encephalitis}}},
  shorttitle = {Meningitis and {{Encephalitis}}},
  author = {Roos, Karen L. and Greenlee, John E.},
  year = {2011},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {1010--1023},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000407057.02414.a9},
  url = {http://journals.lww.com/00132979-201110000-00008},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurologic Consultation in the Hospital,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/F8US7PN8/roos2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/FP3SNXDN/Roos_Greenlee (2011) Meningitis and Encephalitis.pdf}
}

@article{roosNeurologicComplicationsLyme2021,
  title = {Neurologic {{Complications}} of {{Lyme Disease}}},
  author = {Roos, Karen L.},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {1040--1050},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001015},
  url = {https://journals.lww.com/10.1212/CON.0000000000001015},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the symptomatology, diagnosis, and treatment of neuroborreliosis.                                         RECENT FINDINGS               The most recent guidelines for the diagnosis and treatment of Lyme disease were published in 2020 by the Infectious Diseases Society of America, the American Academy of Neurology, and the American College of Rheumatology.                                         SUMMARY               The most common neurologic complications of Lyme disease are cranial neuritis (most often a unilateral or bilateral facial nerve palsy), meningitis, and radiculoneuritis/mononeuropathy multiplex. Testing for Lyme disease begins with an enzyme-linked immunosorbent assay (ELISA). If the ELISA is positive or borderline, Western blots should be performed for both IgM and IgG antibodies. As a general rule, in infectious diseases, an IgM antibody response is followed by an IgG antibody response. A central nervous system infection has either a CSF pleocytosis or pathogen-specific intrathecal antibody production. Lyme meningitis, cranial neuropathy, radiculoneuropathy, or other peripheral nervous system manifestations are treated with oral doxycycline or IV ceftriaxone, cefotaxime, or penicillin G. No additional antibiotic therapy is indicated for patients with posttreatment Lyme disease syndrome or patients with concern for chronic Lyme disease with no evidence of previous or current Lyme infection.},
  langid = {english},
  keywords = {Completed,Current},
  file = {/Users/nathanielyomogida/Zotero/storage/3VS32AYH/Roos (2021) Neurologic Complications of Lyme Disease.pdf}
}

@article{rosenthalNeurodegenerativeCerebellarAtaxia2022,
  title = {Neurodegenerative {{Cerebellar Ataxia}}},
  author = {Rosenthal, Liana S.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1409--1434},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001180},
  url = {https://journals.lww.com/10.1212/CON.0000000000001180},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Neurodegenerative cerebellar ataxia is a diverse collection of diseases that are unified by gait and balance abnormalities, appendicular incoordination, and abnormalities of eye movement and speech. The differential diagnosis is broad, ranging from paraneoplastic syndromes that progress quite rapidly to unidentified genetic disorders that progress slowly over the course of decades. This article highlights the diagnostic process, including the differential diagnosis, as well as treatment approaches and symptomatic management. The pillars of treatment are physical, occupational, and speech therapy as well as counseling and discussions of disease prognosis, genetics, and reproductive choices. There are many ways to help patients with neurodegenerative cerebellar ataxia and improve their quality of life.                                         RECENT FINDINGS               Recent years have seen significant improvements in genetic testing, with reductions in cost of both Sanger sequencing and whole exome sequencing and increasing availability of the latter. These improvements increase clinicians' ability to identify the etiology of neurodegenerative cerebellar ataxia and suggest future treatments. Although no medication has been approved by the US Food and Drug Administration (FDA) for treatment of cerebellar ataxia, research and clinical trials for these diseases are increasing.                                         SUMMARY               Neurodegenerative cerebellar ataxia is characterized by dysarthria, dysmetria, oculomotor abnormalities, and ataxic gait. It has a broad differential diagnosis, and numerous options exist for managing symptoms. Although no medications have been approved specifically for cerebellar ataxia, treatment options are available to improve patients' quality of life.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{rosenthalSeizuresStatusEpilepticus2021,
  title = {Seizures, {{Status Epilepticus}}, and {{Continuous EEG}} in the {{Intensive Care Unit}}},
  author = {Rosenthal, Eric S.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1321--1343},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001012},
  url = {https://journals.lww.com/10.1212/CON.0000000000001012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the evolving definitions of seizures and status epilepticus in the critical care environment and the role of critical care EEG in both diagnosing seizure activity and serving as a predictive biomarker of clinical trajectory.                                         RECENT FINDINGS               Initial screening EEG has been validated as a tool to predict which patients are at risk of future seizures. However, accepted definitions of seizures and nonconvulsive status epilepticus encourage a treatment trial when the diagnosis on EEG is indeterminate because of periodic or rhythmic patterns or uncertain clinical correlation. Similarly, recent data have demonstrated the diagnostic utility of intracranial EEG in increasing the yield of seizure detection. EEG has additionally been validated as a diagnostic biomarker of covert consciousness, a predictive biomarker of cerebral ischemia and impending neurologic deterioration, and a prognostic biomarker of coma recovery and status epilepticus resolution. A recent randomized trial concluded that patients allocated to continuous EEG had no difference in mortality than those undergoing intermittent EEG but could not demonstrate whether this lack of difference was because of studying heterogeneous conditions, examining a monitoring tool rather than a therapeutic approach, or examining an outcome measure (mortality) perhaps more strongly associated with early withdrawal of life-sustaining therapy than to a sustained response to pharmacotherapy.                                         SUMMARY               Seizures and status epilepticus are events of synchronous hypermetabolic activity that are either discrete and intermittent or, alternatively, continuous. Seizures and status epilepticus represent the far end of a continuum of ictal-interictal patterns that include lateralized rhythmic delta activity and periodic discharges, which not only predict future seizures but may be further classified as status epilepticus on the basis of intracranial EEG monitoring or a diagnostic trial of antiseizure medication therapy. In particularly challenging cases, neuroimaging or multimodality neuromonitoring may be a useful adjunct documenting metabolic crisis. Specialized uses of EEG as a prognostic biomarker have emerged in traumatic brain injury for predicting language function and covert consciousness, cardiac arrest for predicting coma recovery, and subarachnoid hemorrhage for predicting neurologic deterioration due to delayed cerebral ischemia.},
  langid = {english}
}

@article{rosserNeurocutaneousDisorders2018,
  title = {Neurocutaneous {{Disorders}}},
  author = {Rosser, Tena},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {96--129},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000562},
  url = {https://journals.lww.com/00132979-201802000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article presents an up-to-date summary of the genetic etiology, diagnostic criteria, clinical features, and current management recommendations for the most common neurocutaneous disorders encountered in clinical adult and pediatric neurology practices.                                         RECENT FINDINGS               The phakomatoses are a phenotypically and genetically diverse group of multisystem disorders that primarily affect the skin and central nervous system. A greater understanding of the genetic and biological underpinnings of numerous neurocutaneous disorders has led to better clinical characterization, more refined diagnostic criteria, and improved treatments in neurofibromatosis type 1, Legius syndrome, neurofibromatosis type 2, Noonan syndrome with multiple lentigines, tuberous sclerosis complex, Sturge-Weber syndrome, and incontinentia pigmenti.                                         SUMMARY               Neurologists require a basic knowledge of and familiarity with a wide variety of neurocutaneous disorders because of the frequent involvement of the central and peripheral nervous systems. A simple routine skin examination can often open a broad differential diagnosis and lead to improved patient care.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/CIEEBUYB/Rosser (2018) Neurocutaneous Disorders.pdf}
}

@article{rostCerebralSmallVessel2020,
  title = {Cerebral {{Small Vessel Disease}}},
  author = {Rost, Natalia S. and Etherton, Mark},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {332--352},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000841},
  url = {https://journals.lww.com/10.1212/CON.0000000000000841},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the clinical significance and neuroimaging characteristics of cerebral small vessel disease and the impact on neurologic disease and current and potential therapeutic approaches.                                         RECENT FINDINGS               Cerebral small vessel disease is increasingly prevalent and highly heterogeneous in neuroimaging and clinical presentation. Small subcortical infarcts, lacunes, cerebral microbleeds, cortical microinfarcts, and white matter hyperintensity of presumed vascular origin represent the major neuroimaging markers of small vessel disease. Increasing small vessel disease burden is associated with risk of incident stroke and dementia, as well as other neuropsychiatric symptoms. Current research strategies are targeting elucidation of the mechanisms of small vessel disease pathogenesis and pursuing clinical trials of therapeutic agents to reduce the clinical manifestations of cerebral small vessel disease.                                         SUMMARY               Cerebral small vessel disease is common in aging adults and represents a major risk factor for multiple acute and chronic neurologic diseases. Increased awareness of cerebral small vessel disease as a modifiable risk factor holds potential for reducing neurologic disease morbidity and mortality across diverse populations in the United States and worldwide.},
  langid = {english}
}

@article{ruckerNystagmusSaccadicIntrusions2019,
  title = {Nystagmus and {{Saccadic Intrusions}}},
  author = {Rucker, Janet C.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1376--1400},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000772},
  url = {https://journals.lww.com/10.1212/CON.0000000000000772},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of nystagmus and saccadic intrusions with the goal of facilitating recognition and differentiation of abnormal eye movements to assist with accurate diagnosis of neurologic disease and evidence-based specific treatment of oscillopsia. Myriad advances have been made in the understanding of several types of nystagmus and saccadic intrusions, even in the past 5 to 10 years, especially regarding underlying pathophysiology, leading to pharmacologic advances rooted in physiologic principles.                                         RECENT FINDINGS               Specific recent advances in the study of nystagmus and saccadic intrusions include (1) improved understanding of the underlying etiologies and mechanisms of nystagmus enhanced or unmasked by provocative maneuvers such as supine position or head shaking; (2) recognition of the differences in behavior and treatment responsivity of acquired pendular nystagmus in demyelinating disease versus oculopalatal myoclonus; (3) recognition that oculopalatal myoclonus results from a dual mechanism of abnormal inferior olivary gap junction connection formation and maladaptive cerebellar learning; and (4) well-controlled clinical trials to evaluate the efficacy of pharmacologic interventions, such as memantine for acquired pendular nystagmus and 4-aminopyridine for downbeat nystagmus.                                         SUMMARY               Accurate recognition of nystagmus and saccadic intrusions, including familiarity with the subtleties of examination techniques that allow such eye movements to be unmasked, is critical to proper diagnosis and ultimate alleviation of the visual impairment these patients experience.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/JQAXT7YV/Rucker (2019) Nystagmus and Saccadic Intrusions.pdf}
}

@article{ruigrokManagementUnrupturedCerebral2020,
  title = {Management of {{Unruptured Cerebral Aneurysms}} and {{Arteriovenous Malformations}}},
  author = {Ruigrok, Ynte M.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {478--498},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000835},
  url = {https://journals.lww.com/10.1212/CON.0000000000000835},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Unruptured intracranial aneurysms and brain arteriovenous malformations (AVMs) may be detected as incidental findings on cranial imaging. This article provides a practical approach to the management of unruptured intracranial aneurysms and unruptured brain AVMs and reviews the risk of rupture, risk factors for rupture, preventive treatment options with their associated risks, and the approach of treatment versus observation for both types of vascular malformations.                                         RECENT FINDINGS               For unruptured intracranial aneurysms, scoring systems on the risk of rupture can help with choosing preventive treatment or observation with follow-up imaging. Although the literature provides detailed information on the complication risks of preventive treatment of unruptured intracranial aneurysms, individualized predictions of these procedural complication risks are not yet available. With observation with imaging, growth of unruptured intracranial aneurysms can be monitored, and prediction scores for growth can help determine the optimal timing of monitoring. The past years have revealed more about the risk of complications of the different treatment modalities for brain AVMs. A randomized clinical trial and prospective follow-up data have shown that preventive interventional therapy in patients with brain AVMs is associated with a higher rate of neurologic morbidity and mortality compared with observation.                                         SUMMARY               The risk of hemorrhage from both unruptured intracranial aneurysms and brain AVMs varies depending on the number of risk factors associated with hemorrhage. For both types of vascular malformations, different preventive treatment options are available, and all carry risks of complications. For unruptured intracranial aneurysms, the consideration of preventive treatment versus observation is complex, and several factors should be included in the decision making. Overall, it is recommended that patients with unruptured asymptomatic brain AVMs should be observed.},
  langid = {english}
}

@article{russellGeneralApproachPeripheral2017,
  title = {General {{Approach}} to {{Peripheral Nerve Disorders}}},
  author = {Russell, James A.},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1241--1262},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000519},
  url = {https://journals.lww.com/00132979-201710000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article provides a conceptual framework for the evaluation of patients with suspected polyneuropathy to enhance the clinician's ability to localize and confirm peripheral nervous system pathology and, when possible, identify an etiologic diagnosis through use of rational clinical and judicious testing strategies.                                         Recent Findings:               Although these strategies are largely time-honored, recent insights pertaining to the pathophysiology of certain immune-mediated neuropathies and to evolving genetic testing strategies may modify the way that select causes of neuropathy are conceptualized, evaluated, and managed.                                         Summary:               The strategies suggested in this article are intended to facilitate accurate bedside diagnosis in patients with suspected polyneuropathy and allow efficient and judicious use of supplementary testing and application of rational treatment when indicated.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/BRXKDX4N/Russell (2017) General Approach to Peripheral Nerve Disorders.pdf;/Users/nathanielyomogida/Zotero/storage/Y4RQPJ4S/russell2017.pdf.pdf}
}

@article{sahaVertigoRelatedCentral2021,
  title = {Vertigo {{Related}} to {{Central Nervous System Disorders}}},
  author = {Saha, Kamala},
  year = {2021},
  month = apr,
  journal = {Continuum (Minneapolis, Minn.)},
  volume = {27},
  number = {2},
  pages = {447--467},
  issn = {1538-6899},
  doi = {10.1212/CON.0000000000000933},
  abstract = {PURPOSE OF REVIEW: This article provides an overview of the numerous causes of vertigo and dizziness that are due to central nervous system (CNS) pathology and guides clinicians in formulating a differential diagnosis and treating patients with CNS causes of vertigo. RECENT FINDINGS: Specific autoimmune vestibulocerebellar syndromes may now be tested for, and this article discusses the antibodies known to cause such syndromes. Superficial siderosis can be more accurately diagnosed with imaging studies, and treatment using iron chelation has recently been studied but has not yet been established as an effective treatment. Central autonomic network damage in the brain can cause central orthostatic hypotension in some neurodegenerative diseases, and medication has been approved for treatment. SUMMARY: CNS causes of vertigo are numerous and important for clinicians to recognize. Examination findings are still an extremely valuable way to diagnose central vertigo; therefore, learning how to differentiate central from peripheral vertigo based on examination is an important skill. CNS causes of vertigo often have available treatments.},
  langid = {english},
  pmid = {34351114},
  keywords = {Central Nervous System Diseases,Continuum: Neuro-otology,Diagnosis Differential,Dizziness,Humans,Vertigo},
  file = {/Users/nathanielyomogida/Zotero/storage/QLL3N4CN/Saha (2021) Vertigo Related to Central Nervous System Disorders.pdf}
}

@article{salehiomranCervicalArteryDissection2023,
  title = {Cervical {{Artery Dissection}}},
  author = {Salehi Omran, Setareh},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {540--565},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001233},
  url = {https://journals.lww.com/10.1212/CON.0000000000001233},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Cervical artery dissection is a common cause of stroke in young adults. This article reviews the pathophysiology, etiology and risk factors, evaluation, management, and outcomes of spontaneous cervical artery dissection.                                         LATEST DEVELOPMENTS               Cervical artery dissection is believed to be a multifactorial disease, with environmental factors serving as possible triggers in patients who have a genetic predisposition to dissection formation. Cervical artery dissection can cause local symptoms or ischemic events, such as ischemic stroke or transient ischemic attack. Neuroimaging is used to confirm the diagnosis; classic findings include a long tapered arterial stenosis or occlusion, dissecting aneurysm, intimal flap, double lumen, or intramural hematoma. Patients with cervical artery dissection who present with an acute ischemic stroke should be evaluated for IV thrombolysis, endovascular therapy eligibility, or both. Antithrombotic therapy with either anticoagulation or antiplatelet treatment is used to prevent stroke from cervical artery dissection. The risk of recurrent ischemia appears low and is mostly limited to the first two weeks after symptom onset.                                         ESSENTIAL POINTS               Cervical artery dissection is a known cause of ischemic strokes. Current data show no difference between the benefits and risks of anticoagulation versus antiplatelet therapy in the acute phase of symptomatic extracranial cervical artery dissection, thereby supporting the recommendation that clinicians can prescribe either treatment. Further research is warranted to better understand the pathophysiology and long-term outcomes of cervical artery dissection.},
  langid = {english},
  keywords = {Current}
}

@article{sansoneEpisodicMuscleDisorders2019,
  title = {Episodic {{Muscle Disorders}}},
  author = {Sansone, Valeria A.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1696--1711},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000802},
  url = {https://journals.lww.com/10.1212/CON.0000000000000802},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the episodic muscle disorders, including benign cramp-fasciculation syndrome, the periodic paralyses, and the nondystrophic myotonias. The core diagnostic criteria for a diagnosis of primary periodic paralysis, including clues to distinguish between the hypokalemic and hyperkalemic forms, and the distinctive elements that characterize Andersen-Tawil syndrome are discussed. Management of patients with these disorders is also discussed.                                         RECENT FINDINGS               Childhood presentations of periodic paralysis have recently been described, including atypical findings. Carbonic anhydrase inhibitors, such as dichlorphenamide, have recently been approved by the US Food and Drug Administration (FDA) for the treatment of both hypokalemic and hyperkalemic forms of periodic paralysis. Muscle MRI may be a useful outcome measure in pharmacologic trials in periodic paralysis. Genetic research continues to identify additional gene mutations responsible for periodic paralysis.                                         SUMMARY               This article will help neurologists diagnose and manage episodic muscle disorders and, in particular, the periodic paralyses and the nondystrophic myotonias.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/G442C8TG/Sansone (2019) Episodic Muscle Disorders.pdf}
}

@article{santomassoAnticancerDrugsNervous2020,
  title = {Anticancer {{Drugs}} and the {{Nervous System}}},
  author = {Santomasso, Bianca D.},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {732--764},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000873},
  url = {https://journals.lww.com/10.1212/CON.0000000000000873},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the clinical features, prognosis, and treatment of neurotoxicity from anticancer drugs, including conventional cytotoxic chemotherapy, biologics, and targeted therapies, with a focus on the newer immunotherapies (immune checkpoint inhibitors and chimeric antigen receptor T cells).                                         RECENT FINDINGS               Whereas neurologic complications from traditional chemotherapy are widely recognized, newer cancer therapies, in particular immunotherapies, have unique and distinct patterns of neurologic adverse effects. Anticancer drugs may cause central or peripheral nervous system complications. Neurologic complications of therapy are being seen with increasing frequency as patients with cancer are living longer and receiving multiple courses of anticancer regimens, with novel agents, combinations, and longer duration. Neurologists must know how to recognize treatment-related neurologic toxicity since discontinuation of the offending agent or dose adjustment may prevent further or permanent neurologic injury. It is also imperative to differentiate neurologic complications of therapy from cancer progression into the nervous system and from comorbid neurologic disorders that do not require treatment dose reduction or discontinuation.                                         SUMMARY               Neurotoxicity from cancer therapy is common, with effects seen on both the central and peripheral nervous systems. Immune checkpoint inhibitor therapy and chimeric antigen receptor T-cell therapy are new cancer treatments with distinct patterns of neurologic complications. Early recognition and appropriate management are essential to help prevent further neurologic injury and optimize oncologic management.},
  langid = {english},
  keywords = {Outdated}
}

@article{sarwalNeurologicComplicationsPostoperative2021,
  title = {Neurologic {{Complications}} in the {{Postoperative Neurosurgery Patient}}},
  author = {Sarwal, Aarti},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1382--1404},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001039},
  url = {https://journals.lww.com/10.1212/CON.0000000000001039},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses neurologic complications encountered in the postoperative care of neurosurgical patients that are common or key to recognize in the immediate postoperative period. The major neurosurgical subspecialty procedures (cerebrovascular neurosurgery, neuro-oncology, epilepsy neurosurgery, functional neurosurgery, CSF diversion, endovascular neurosurgery, and spinal surgery) are broadly included under craniotomy procedures, endovascular/vascular procedures, and spinal procedures. This article focuses on the range of complications inherent in these approaches with specific scenarios addressed as applicable.                                         RECENT FINDINGS               The morbidity and mortality related to neurosurgical procedures remains high, necessitating ongoing research and quality improvement efforts in perioperative screening, intraoperative management, surgical approaches, and postoperative care of these patients. Emerging research continues to investigate safer and newer options for routine neurosurgical approaches, such as coiling over clipping for amenable aneurysms, endoscopic techniques for transsphenoidal hypophysectomy, and minimally invasive spinal procedures; postoperative monitoring and care of patients after these procedures continues to be a key component in the continuum of care for improving outcomes.                                         SUMMARY               Postoperative care of patients undergoing major neurosurgical procedures is an integral part of many neurocritical care practices. Neurosurgeons often enlist help from neurologists to assist with evaluation, interpretation, and management of complications in routine inpatient settings. Awareness of the common neurologic complications of various neurosurgical procedures can help guide appropriate clinical monitoring algorithms and quality improvement processes for timely evaluation and management of these patients.},
  langid = {english}
}

@article{sawlaniPeripheralNerveHyperexcitability2017,
  title = {Peripheral {{Nerve Hyperexcitability Syndromes}}},
  author = {Sawlani, Komal and Katirji, Bashar},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1437--1450},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000520},
  url = {https://journals.lww.com/00132979-201710000-00017},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article provides a review of the clinical phenotypes and evaluation of peripheral nerve hyperexcitability syndromes. These rare diagnoses include cramp-fasciculation syndrome, Isaacs syndrome, and Morvan syndrome. Recent investigations have led to an understanding of the autoimmune underpinnings of these conditions and their specific associated antibodies. As the presentation of peripheral nerve hyperexcitability syndromes includes muscle stiffness, twitches, and spasms, which are also shared with certain central nervous system and myopathic conditions, the differential diagnosis of peripheral nerve hyperexcitability syndromes is reviewed.                                         Recent Findings:               Peripheral nerve hyperexcitability syndromes share clinical and electrodiagnostic evidence of motor nerve instability; however, their clinical presentations are varied. Case reviews have helped us understand the spectrum of symptoms associated with the three peripheral nerve hyperexcitability syndromes reviewed here: cramp-fasciculation syndrome, Isaacs syndrome, and Morvan syndrome. More recently, research has focused on understanding the voltage-gated potassium channel complex antibodies as well as neoplasms associated with these conditions.                                         Summary:               The diagnosis of peripheral nerve hyperexcitability syndromes requires a high index of suspicion, support from the physical examination, familiarity with the spectrum of symptoms associated with peripheral nerve hyperexcitability syndromes, and recognition of diagnostic EMG features. Voltage-gated potassium channel complex antibodies are associated with these conditions. Optimum treatment and autoimmune pathogenesis remain areas of active research.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/WJIB42SD/Sawlani_Katirji (2017) Peripheral Nerve Hyperexcitability Syndromes.pdf;/Users/nathanielyomogida/Zotero/storage/ZVBWKLC5/sawlani2017.pdf.pdf}
}

@article{saylorNeurologicComplicationsHuman2018,
  title = {Neurologic {{Complications}} of {{Human Immunodeficiency Virus Infection}}},
  author = {Saylor, Deanna},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1397--1421},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000647},
  url = {https://journals.lww.com/00132979-201810000-00010},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Widespread use of antiretroviral therapy (ART) has led to near-normal life expectancy in people with human immunodeficiency virus (HIV) infection. However, neurologic complications of HIV remain common; can affect any part of the neuraxis; and are due to direct effects of the virus, immunosuppression because of untreated HIV infection, aberrant immune responses in the setting of ART initiation, and ART toxicities.                                         RECENT FINDINGS               HIV-associated neurocognitive disorder (HAND) remains one of the most common neurologic complications of HIV encountered today, but milder forms predominate in people on ART. No specific treatments for HAND exist, but small trials and epidemiologic evidence suggest paroxetine, intranasal insulin, and maraviroc may have utility in its treatment; further trials of these agents are ongoing. Widespread ART use has decreased the incidence of central nervous system opportunistic infections, but prognosis often remains poor in those who develop opportunistic infections. High-titer positive serum cryptococcal antigen is strongly predictive of cryptococcal meningitis and provides a tool to enhance diagnosis in areas with limited resources. HIV is an independent risk factor for stroke, and accelerated aging associated with HIV infection results in neurologic diseases of older age occurring at much younger ages in individuals infected with HIV. Ongoing HIV replication in the CSF despite peripheral virologic suppression may contribute to the development of HAND and may not improve despite adjusting the ART regimen to increase central nervous system penetrance.                                         SUMMARY               Neurologists are likely to encounter patients infected with HIV in clinical practice. This article reviews the presentation, diagnosis, and management of the most common neurologic conditions associated with HIV infection and ART.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/UETKV9WR/Saylor (2018) Neurologic Complications of Human Immunodeficiency Virus Infection.pdf}
}

@article{saylorNeurologicComplicationsTuberculosis2021,
  title = {Neurologic {{Complications}} of {{Tuberculosis}}},
  author = {Saylor, Deanna},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {992--1017},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001005},
  url = {https://journals.lww.com/10.1212/CON.0000000000001005},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the current epidemiology, common clinical characteristics, and up-to-date evidence-based approaches to the diagnosis and management of the most common neurologic complications of tuberculosis (TB): tuberculous meningitis, intracranial tuberculoma, and spinal TB.                                         RECENT FINDINGS                                Central nervous system (CNS) TB remains common and associated with significant mortality and neurologic sequelae worldwide. Human immunodeficiency virus (HIV) co-infection is strongly associated with both the development of and mortality due to CNS TB.                 Strongyloides                 co-infection is associated with reduced CNS inflammation and improved outcomes in the setting of tuberculous meningitis. Stroke remains a common complication of tuberculous meningitis, and emerging evidence suggests aspirin may be used in this context. Although a recent nucleic acid amplification test has demonstrated suboptimal sensitivity in the diagnosis of CNS TB, emerging diagnostic techniques include cell-free DNA, peripheral blood microRNA, metagenomic next-generation sequencing, and advanced imaging techniques, but these are not yet well validated. CNS TB is associated with high mortality even with current treatment regimens, although novel, promising strategies for treatment are under investigation, including a combination of IV isoniazid and ethambutol and high-dose rifampicin.                                                        SUMMARY               TB can affect the nervous system in various ways and is associated with high mortality. Diagnosis remains challenging in endemic settings, with empiric treatment often initiated without a definitive diagnosis. Furthermore, optimal treatment regimens remain uncertain because current treatment for all forms of CNS TB is extrapolated from trials of tuberculous meningitis whereas the role of steroids in people with HIV and tuberculous meningitis remains controversial.},
  langid = {english},
  keywords = {Current}
}

@article{schindlerFluidBiomarkersDementia2022,
  title = {Fluid {{Biomarkers}} in {{Dementia Diagnosis}}},
  author = {Schindler, Suzanne E.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {822--833},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001083},
  url = {https://journals.lww.com/10.1212/CON.0000000000001083},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses how fluid biomarkers can augment the routine dementia evaluation and improve diagnostic accuracy. The tests that are currently available and the indications for their use are described. Further, tests that are under development and likely to be used in the future are identified.                                         RECENT FINDINGS               Technical improvements in assay sensitivity and precision have led to the rapid development of blood-based biomarkers for Alzheimer disease (AD) over the past several years. Studies have found that the ratio of amyloid-{$\beta$} (A{$\beta$}) peptides (A{$\beta$}42/A{$\beta$}40) and concentrations of phosphorylated tau isoforms in plasma can identify individuals with AD brain pathology. Blood-based tests may enable much broader use of AD biomarkers in the evaluation of patients with cognitive impairment.                                         SUMMARY               Even after a detailed history, examination, routine laboratory testing, and brain imaging, the cause of dementia sometimes remains unclear. CSF and blood-based biomarkers can evaluate for a range of neurologic disorders that are associated with dementia, including AD. Integrating data from fluid biomarker tests and the routine dementia evaluation may improve the accuracy of dementia diagnosis.},
  langid = {english},
  keywords = {Current}
}

@article{schneiderCognitiveBehavioralDisorders2011,
  title = {Cognitive and {{Behavioral Disorders}} in {{Neurorehabilitation}}:},
  shorttitle = {Cognitive and {{Behavioral Disorders}} in {{Neurorehabilitation}}},
  author = {Schneider, William N. and Wong, Tony M.},
  year = {2011},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {17},
  pages = {462--470},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000399067.69567.f2},
  url = {http://journals.lww.com/00132979-201106000-00010},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Neurorehabilitation,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/MAB6DMTF/schneider2011.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/NMZVADNP/Schneider_Wong (2011) Cognitive and Behavioral Disorders in Neurorehabilitation.pdf}
}

@article{schneiderNeuropathologyDementiaDisorders2022,
  title = {Neuropathology of {{Dementia Disorders}}},
  author = {Schneider, Julie A.},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {834--851},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001137},
  url = {https://journals.lww.com/10.1212/CON.0000000000001137},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the neuropathology of common age-related dementing disorders, focusing on the pathologies that underlie Alzheimer disease (AD) and related dementias, including Lewy body dementias, frontotemporal dementia, vascular dementia, limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy (LATE), and mixed-etiology dementias. This article also discusses the underlying proteinopathies of neurodegenerative diseases (eg, amyloid-{$\beta$}, paired helical filament tau, {$\alpha$}-synuclein, and TDP-43 pathology) and vascular pathologies, including tissue injury (eg, infarcts, hemorrhages) with or without vessel disease.                                         RECENT FINDINGS                                New criteria for AD pathologic diagnosis highlight amyloid-{$\beta$} as the                 sine qua non                 of AD; they require molecular markers of amyloid and establish a minimum threshold of Braak neurofibrillary tangle stage 3. Pathologic diagnosis is separated from clinical disease (ie, pathologic diagnosis no longer requires dementia). TDP-43 pathology, a major pathology in a frontotemporal dementia subtype, was found as a central pathology in LATE, a newly named amnestic disorder. Multiple pathologies (often co-occurring with AD) contribute to dementia and add complexity to the clinical picture. Conversely, Lewy body, LATE, and vascular dementias often have accompanying AD pathology. Pathology and biomarker studies highlight subclinical pathologies in older people without cognitive impairment. This resilience to brain pathology is common and is known as                 cognitive reserve                 .                                                        SUMMARY               The pathologies of dementia in aging are most commonly amyloid, tangles, Lewy bodies, TDP-43, hippocampal sclerosis, and vascular pathologies. These pathologies often co-occur (mixed pathologies), which may make specific clinical diagnoses difficult. In addition, dementia-related pathologies are often subclinical, suggesting varying levels of resilience in older people.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/VPNB3C6L/Schneider (2022) Neuropathology of Dementia Disorders.pdf}
}

@article{schottPosteriorCorticalAtrophy2019,
  title = {Posterior {{Cortical Atrophy}}},
  author = {Schott, Jonathan M. and Crutch, Sebastian J.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {52--75},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000696},
  url = {https://journals.lww.com/00132979-201902000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article presents an overview of the clinical syndrome of posterior cortical atrophy (PCA), including its pathologic underpinnings, clinical presentation, investigation findings, diagnostic criteria, and management.                                         RECENT FINDINGS               PCA is usually an atypical form of Alzheimer disease with relatively young age at onset. New diagnostic criteria allow patients to be diagnosed on a syndromic basis as having a primary visual (pure) form or more complex (plus) form of PCA and, when possible, on a disease-specific basis using biomarkers or underlying pathology. Imaging techniques have demonstrated that some pathologic processes are concordant (atrophy, hypometabolism, tau deposition) with clinical symptoms and some are discordant (widespread amyloid deposition). International efforts are under way to establish the genetic underpinnings of this typically sporadic form of Alzheimer disease. In the absence of specific disease-modifying therapies, a number of practical suggestions can be offered to patients and their families to facilitate reading and activities of daily living, promote independence, and improve quality of life                                         SUMMARY               While rare, PCA is an important diagnostic entity for neurologists, ophthalmologists, and optometrists to recognize to allow for early accurate diagnosis and appropriate patient management. PCA provides an important opportunity to investigate the causes of selective vulnerability in Alzheimer disease.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/ZGVV3AHX/Schott_Crutch (2019) Posterior Cortical Atrophy.pdf}
}

@article{schrimpfPsychosis2018,
  title = {Psychosis},
  author = {Schrimpf, Lindsey A. and Aggarwal, Arpit and Lauriello, John},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {845--860},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000602},
  url = {https://journals.lww.com/00132979-201806000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Psychosis is a psychiatric condition that has significant overlap with neurologic disease. This article is intended to educate the neurologist on the psychiatric manifestations of psychosis and its evaluation, diagnosis, and treatment. How to differentiate a primary psychiatric cause of psychosis from psychosis secondary to a medical or neurologic condition is also reviewed.                                         RECENT FINDINGS               Current research in psychotic disorders has focused increasingly on negative symptoms and cognitive impairment in psychotic illness, as it is now recognized that these cause the greatest impact on functional deficits for patients. A number of new medications have also been introduced to target negative symptoms and cognitive deficits in psychotic illness. These have new implications in terms of treatment overlap with medications being prescribed by providers in psychiatry, neurology, and general practice.                                         SUMMARY               This article discusses the current methods for evaluating, diagnosing, and treating psychosis. Psychosis as a primary mental health disorder is a diagnosis of exclusion, as psychosis can be a direct symptom of underlying medical or neurologic disease. Delirium and dementia are the two most important disorders to rule out. This article will help readers be more prepared to assess and treat the patient with psychosis.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/ZAPNURAF/Schrimpf et al (2018) Psychosis.pdf}
}

@article{schwedtPreventiveTherapyMigraine2018,
  title = {Preventive {{Therapy}} of {{Migraine}}},
  author = {Schwedt, Todd J.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1052--1065},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000635},
  url = {https://journals.lww.com/00132979-201808000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the preventive therapy of migraine, including indications, strategies for use, and available treatments.                                         RECENT FINDINGS               Lifestyle modifications and migraine trigger avoidance are recommended as preventive measures for all individuals with migraine. The decision to recommend additional migraine preventive therapy should consider the frequency of migraine attacks and headaches, extent of migraine-associated disability, frequency of using acute migraine treatments and the responsiveness to such treatments, and patient preferences. Additional therapies include prescription medications, nutraceuticals, neurostimulation, and behavioral therapy. Considering evidence for efficacy and the risk of potential side effects and adverse events, treatments with the most favorable profiles include (in alphabetical order): amitriptyline, beta-blockers (several), biofeedback, candesartan, coenzyme Q10, cognitive-behavioral therapy, magnesium citrate, onabotulinumtoxinA (for chronic migraine only), relaxation therapy, riboflavin, and topiramate. In addition, erenumab, a calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, received  approval from the US Food and Drug Administration (FDA) for the prevention of migraine in May 2018.                                         SUMMARY               Successful migraine preventive therapy reduces the frequency and burden of attacks while causing limited side effects. Individual treatment recommendations are determined based upon evidence for efficacy, side effect and adverse event profiles, medication interactions, patient comorbidity, costs, and patient preferences. Patients must be counseled on reasonable expectations for their preventive therapy and the importance of adhering to the recommended treatment plan for a period of time that is sufficient to determine outcomes.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/PCZ35MB7/schwedt2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/X3JYZVBM/Schwedt (2018) Preventive Therapy of Migraine.pdf}
}

@article{schwendimannMetabolicToxicMyelopathies2018,
  title = {Metabolic and {{Toxic Myelopathies}}},
  author = {Schwendimann, Robert N.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {427--440},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000596},
  url = {https://journals.lww.com/00132979-201804000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Myelopathy may occur as a consequence of various metabolic and toxic conditions. This article provides an update on the clinical presentations, diagnostic evaluations, and management of metabolic and toxic myelopathies.                                         RECENT FINDINGS                                Myelopathy and myeloneuropathy due to vitamin B                 12                 deficiency is increasing in prevalence partly because of an aging population. Early recognition of the clinical symptoms and rapid initiation of treatment is essential. Copper deficiency is now also recognized as causing a similar clinical picture as vitamin B                 12                 deficiency. Conditions leading to copper deficiency include bariatric surgery and excessive zinc intake. Unusual conditions such as lathyrism and konzo are relevant to all neurologists because of emigration from less well-developed countries. Myelopathy can also occur from substance abuse (eg, heroin and nitrous oxide), and early diagnosis could lead to improved patient outcomes. The spinal cord may also be injured in decompression illness that occurs in sport divers and individuals who work in pressurized atmospheres.                                                        SUMMARY               Knowledge and recognition of the various metabolic and toxic causes of myelopathy is important for the practicing neurologist, as timely diagnosis and rapid initiation of therapy is essential to improve the chances for recovery.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/IF7R5Q34/schwendimann2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/PES6NI97/Schwendimann (2018) Metabolic and Toxic Myelopathies.pdf}
}

@article{seeleyBehavioralVariantFrontotemporal2019,
  title = {Behavioral {{Variant Frontotemporal Dementia}}},
  author = {Seeley, William W.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {76--100},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000698},
  url = {https://journals.lww.com/00132979-201902000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the clinical, anatomic, genetic, and pathologic features of behavioral variant frontotemporal dementia (bvFTD) and discusses strategies to improve diagnostic accuracy, emphasizing common pitfalls to avoid. Key aspects of management and the future of diagnosis and care for the disorder are highlighted.                                         RECENT FINDINGS               BvFTD is a clinical syndrome, not a disease. Patients with the syndrome share core symptoms that reflect degeneration within the most consistently affected brain regions, but accompanying features vary and reflect the precise topography of regional degeneration. The clinician must distinguish a bvFTD syndrome from psychiatric illness and other neurodegenerative syndromes that feature a prominent behavioral component. Antemortem prediction of pathologic diagnosis remains imperfect but improves with careful attention to the clinical details. Management should emphasize prevention of caregiver distress, behavioral and environmental strategies, symptom-based psychopharmacology, and genetic counseling.                                         SUMMARY               BvFTD is an important and challenging dementia syndrome. Although disease-modifying treatments are lacking, clinicians can have a profound impact on a family coping with this disorder. Treatment trials are under way for some genetic forms of bvFTD. For sporadic disease, pathologic heterogeneity remains a major challenge, and ongoing research seeks to improve antemortem molecular diagnosis to facilitate therapeutic discovery.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/9LXLDIUS/Seeley (2019) Behavioral Variant Frontotemporal Dementia.pdf}
}

@article{seifertExerciseNeurologicDisease2014,
  title = {Exercise and {{Neurologic Disease}}},
  shorttitle = {Exercise and {{Neurologic Disease}}},
  author = {Seifert, Tad},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1667--1682},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458967.63518.92},
  url = {http://journals.lww.com/00132979-201412000-00016},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/XVSCHW94/Seifert (2014) Exercise and Neurologic Disease.pdf}
}

@article{sejvarZikaVirusOther2018,
  title = {Zika {{Virus}} and {{Other Emerging Arboviral Central Nervous System Infections}}},
  author = {Sejvar, James J.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1512--1534},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000652},
  url = {https://journals.lww.com/00132979-201810000-00015},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               In recent years, we have observed the emergence and reemergence of a number of arthropod-borne viruses (arboviruses). Zika virus is the most recent addition to this group, first causing sporadic cases of uncomplicated febrile illness followed by sizeable outbreaks in the Pacific. However, the epidemiology and clinical features of Zika virus infection have changed rapidly and dramatically; it is now recognized as causing Guillain-Barr{\'e} syndrome (GBS) in children and adults and congenital abnormalities in infected fetuses. This article reviews the epidemiology, clinical features, and diagnosis of Zika virus--associated neurologic illness and briefly reviews features of West Nile virus and Japanese encephalitis virus.                                         RECENT FINDINGS               Zika virus has emerged as a significant human pathogen in recent years. In 2015, it began to cause large outbreaks of febrile rash illness in South America and the Caribbean. During these large Zika virus outbreaks, a significant increase in the incidence of GBS was also observed in multiple countries/territories. Zika virus--associated GBS has several unique features, including a relatively short interval between febrile illness and GBS onset, an unusually high incidence among older people, and prominent cranial nerve abnormalities. Congenital Zika syndrome includes a myriad of abnormalities, including microcephaly, lissencephaly, hydrocephalus, arthrogryposis, and parenchymal calcifications. Currently, no treatment has been identified for Zika virus, although work on vaccines is under way.                                         SUMMARY               Arboviruses continue to surprise us with unexpected emergence in various locations, the nature of clinical illness, and outcomes. Zika virus presents a classic example of this type of emergence. Ongoing surveillance will be needed to evaluate the long-term pattern of Zika virus and related arboviruses.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/CS9PFX4Z/Sejvar (2018) Zika Virus and Other Emerging Arboviral Central Nervous System Infections.pdf}
}

@article{sharriefDiagnosisManagementCerebral2023,
  title = {Diagnosis and {{Management}} of {{Cerebral Small Vessel Disease}}},
  author = {Sharrief, Anjail},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {501--518},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001232},
  url = {https://journals.lww.com/10.1212/CON.0000000000001232},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Cerebral small vessel disease (CSVD) is a common neurologic condition that contributes to considerable mortality and disability because of its impact on ischemic and hemorrhagic stroke risk and dementia. While attributes of the disease have been recognized for over two centuries, gaps in knowledge remain related to its prevention and management. The purpose of this review is to provide an overview of the current state of knowledge for CSVD.                                         LATEST DEVELOPMENTS                                CSVD can be recognized by well-defined radiographic criteria, but the pathogenic mechanism behind the disease is unclear. Hypertension control remains the best-known strategy for stroke prevention in patients with CSVD, and recent guidelines provide a long-term blood pressure target of less than 130/80 mm Hg for patients with ischemic and hemorrhagic stroke, including those with stroke related to CSVD. Cerebral amyloid angiopathy is the second leading cause of intracerebral hemorrhage and may be increasingly recognized because of newer, more sensitive imaging modalities.                 Transient focal neurologic episodes                 is a relatively new term used to describe ``amyloid spells.'' Guidance on distinguishing these events from seizures and transient ischemic attacks has been published.                                                        ESSENTIAL POINTS               CSVD is prevalent and will likely be encountered by all neurologists in clinical practice. It is important for neurologists to be able to recognize CSVD, both radiographically and clinically, and to counsel patients on the prevention of disease progression. Blood pressure control is especially relevant, and strategies are needed to improve blood pressure control for primary and secondary stroke prevention in patients with CSVD.},
  langid = {english},
  keywords = {Current}
}

@article{shethMechanicalThrombectomyAcute2023,
  title = {Mechanical {{Thrombectomy}} for {{Acute Ischemic Stroke}}},
  author = {Sheth, Sunil A.},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {443--461},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001243},
  url = {https://journals.lww.com/10.1212/CON.0000000000001243},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Endovascular stroke therapy has greatly improved the ability to treat the deadliest and most disabling form of acute ischemic stroke. This article summarizes some of the recent innovations in this field and discusses likely future developments.                                         LATEST DEVELOPMENTS               At present, there is robust activity to improve all facets of care for patients with large vessel occlusion stroke, including better prehospital routing, more efficient in-hospital screening, expanding indications for thrombectomy eligibility, innovating novel thrombectomy devices, and improving the effects of recanalization on clinical outcomes. In addition, the integration of endovascular stroke therapy (EVT)---an emergent and frequently off-hours procedure that requires a specialized team of nurses, technologists, and physicians---into acute stroke care has transformed referral patterns, hospital accreditation pathways, and physician practices. The eligibility for the procedure will potentially continue to grow to include patients screened without advanced imaging, larger core infarcts, and more distal occlusions.                                         ESSENTIAL POINTS               In this review, we discuss the current state of EVT and its implications for practice, and present three cases that highlight some of the directions in which the field is moving.},
  langid = {english},
  keywords = {Current}
}

@article{silvaEndovascularTreatmentAcute2020,
  title = {Endovascular {{Treatment}} of {{Acute Ischemic Stroke}}},
  author = {Silva, Gisele S. and Nogueira, Raul G.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {310--331},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000852},
  url = {https://journals.lww.com/10.1212/CON.0000000000000852},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the actual indications for mechanical thrombectomy in patients with acute ischemic stroke and how the opportunities for endovascular therapy can be expanded by using the concept of clinical-imaging or perfusion-imaging mismatch (as a surrogate for salvageable tissue) rather than time of ischemia.                                         RECENT FINDINGS               Six randomized controlled trials undoubtedly confirmed the benefits of using endovascular thrombectomy on the clinical outcome of patients with stroke with large vessel occlusion within 6 hours from symptom onset compared with those receiving only standard medical care. In a meta-analysis of individual patient data, the number needed to treat with endovascular thrombectomy to reduce disability by at least one level on the modified Rankin Scale for one patient was 2.6. Recently, the concept of ``tissue window'' versus time window has proved useful for selecting patients for mechanical thrombectomy up to 24 hours from symptom onset. The DAWN (DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention) trial included patients at a median of 12.5 hours from onset and showed the largest effect in functional outcome ever described in any acute stroke treatment trial (35.5\% increase in functional independence). In DEFUSE 3 (Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 3), patients treated with mechanical thrombectomy at a median of 11 hours after onset had a 28\% increase in functional independence and an additional 20\% absolute reduction in death or severe disability.                                         SUMMARY               For patients with acute ischemic stroke and a large vessel occlusion in the proximal anterior circulation who can be treated within 6 hours of stroke symptom onset, mechanical thrombectomy with a second-generation stent retriever or a catheter aspiration device should be indicated regardless of whether the patient received treatment with intravenous (IV) recombinant tissue plasminogen activator (rtPA) in patients with limited signs of early ischemic changes on neuroimaging. Two clinical trials completely disrupted the time window concept in acute ischemic stroke, showing excellent clinical outcomes in patients treated up to 24 hours from symptom onset. Time of ischemia is, on average, a good biomarker for tissue viability; however, the window of opportunity for treatment varies across different individuals because of a range of compensatory mechanisms. Adjusting time to the adequacy of collateral flow leads to the concept of tissue window, a paradigm shift in stroke reperfusion therapy.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/T5YRBQEE/Silva_Nogueira (2020) Endovascular Treatment of Acute Ischemic Stroke.pdf}
}

@article{silveira-moriyamaGeneticDiagnosticsNeurologists2018,
  title = {Genetic {{Diagnostics}} for {{Neurologists}}},
  author = {{Silveira-Moriyama}, Laura and Paciorkowski, Alex R.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {18--36},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000556},
  url = {https://journals.lww.com/00132979-201802000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article puts advances in the field of neurogenetics into context and provides a quick review of the broad concepts necessary for current practice in neurology.                                         RECENT FINDINGS               The exponential growth of genetic testing is due to its increased speed and decreasing cost, and it is now a routine part of the clinical care for a number of neurologic patients. In addition, phenotypic pleiotropy (mutations in the same gene causing very disparate phenotypes) and genetic heterogeneity (the same clinical phenotype resulting from mutations in different genes) are now known to exist in a number of conditions, adding an additional layer of complexity for genetic testing in these disorders.                                         SUMMARY               Although the growing complexity of technical knowledge in the ordering and interpretation of genetic tests makes it necessary for neurologists to consult medical geneticists, limitations in the availability of such professionals often means neurologists will be on the front line dealing with suspected or confirmed neurogenetic conditions. The growing availability of broad genetic testing through chromosomal microarray and next-generation sequencing and the expanded phenotypic spectrum of many conditions has implications for genetic counseling and medical management. This article discusses the various forms of genetic variability and how to test for each of them. It also provides an update on the most common forms of neurologic presentations of genetic disease and a review of testing strategies.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/4JKEP7L3/Silveira-Moriyama_Paciorkowski (2018) Genetic Diagnostics for Neurologists.pdf}
}

@article{silvestriSymptomsSignsApproach2022,
  title = {A {{Symptoms}} and {{Signs Approach}} to the {{Patient With Neuromuscular Weakness}}},
  author = {Silvestri, Nicholas J.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1580--1595},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001150},
  url = {https://journals.lww.com/10.1212/CON.0000000000001150},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Muscle weakness is a common feature of many neuromuscular disorders. This article outlines a symptoms and signs approach to the patient presenting with neuromuscular weakness, highlighting key aspects of the clinical history and examination.                                         RECENT FINDINGS               The past several years have seen a dramatic increase in the ability to test for many inherited and autoimmune neuromuscular disorders more reliably and accurately. Similarly, numerous targeted therapies have been recently approved to treat previously untreatable disorders. Therefore, timely and accurate diagnosis is essential so that patients can receive appropriate therapy, ultimately leading to better clinical outcomes.                                         SUMMARY               Muscle weakness is a common symptom resulting from dysfunction that can occur at any level of the neuraxis and is a cardinal feature of many neuromuscular disorders. An accurate and meticulous history and a thorough neurologic examination are paramount in localizing the lesion in order to generate a differential diagnosis and guide appropriate ancillary testing. The patient's age at symptom onset, any identified inciting factors, tempo of symptom progression, pattern of weakness, and associated symptoms and signs are all important diagnostic clues in the evaluation of a patient presenting with muscle weakness.},
  langid = {english},
  keywords = {Current}
}

@article{singerTicsTouretteSyndrome2019,
  title = {Tics and {{Tourette Syndrome}}},
  author = {Singer, Harvey S.},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {936--958},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000752},
  url = {https://journals.lww.com/00132979-201908000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The purpose of this article is to present current information on the phenomenology, epidemiology, comorbidities, and pathophysiology of tic disorders and discuss therapy options. It is hoped that a greater understanding of each of these components will provide clinicians with the necessary information to deliver thoughtful and optimal care to affected individuals.                                         RECENT FINDINGS               Recent advances include the finding that Tourette syndrome is likely due to a combination of several different genes, both low-effect and larger-effect variants, plus environmental factors. Pathophysiologically, increasing evidence supports involvement of the cortical--basal ganglia--thalamocortical circuit; however, the primary location and neurotransmitter remain controversial. Behavioral therapy is first-line treatment, and pharmacotherapy is based on tic severity. Several newer therapeutic agents are under investigation (eg, valbenazine, deutetrabenazine, cannabinoids), and deep brain stimulation is a promising therapy.                                         SUMMARY               Tics, defined as sudden, rapid, recurrent, nonrhythmic motor movements or vocalizations, are essential components of Tourette syndrome. Although some tics may be mild, others can cause significant psychosocial, physical, and functional difficulties that affect daily activities. In addition to tics, most affected individuals have coexisting neuropsychological difficulties (attention deficit hyperactivity disorder, obsessive-compulsive disorder, anxiety, mood disorder, disruptive behaviors, schizotypal traits, suicidal behavior, personality disorder, antisocial activities, and sleep disorders) that can further impact social and academic activities or employment.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/DA8F7DBT/Singer (2019) Tics and Tourette Syndrome.pdf;/Users/nathanielyomogida/Zotero/storage/EVWJSV36/10.1212@CON.0000000000000752.pdf.pdf}
}

@article{singhalPosteriorReversibleEncephalopathy2021,
  title = {Posterior {{Reversible Encephalopathy Syndrome}} and {{Reversible Cerebral Vasoconstriction Syndrome}} as {{Syndromes}} of {{Cerebrovascular Dysregulation}}},
  author = {Singhal, Aneesh B.},
  year = {2021},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {5},
  pages = {1301--1320},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001037},
  url = {https://journals.lww.com/10.1212/CON.0000000000001037},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the causes, clinical and imaging features, management, and prognosis of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS), in which the underlying pathophysiology is related to reversible dysregulation of the cerebral vasculature.                                         RECENT FINDINGS               PRES and RCVS are descriptive terms, each bringing together conditions with similar clinical-imaging manifestations. Headache, visual symptoms, seizures, and confusion occur in both syndromes. RCVS is usually heralded by recurrent thunderclap headaches, whereas encephalopathy and seizures are typical in PRES. In PRES, brain imaging shows reversible vasogenic edema that is typically symmetric and located in subcortical regions (mostly posterior predominant). In RCVS, brain imaging is often normal; cerebral angiography shows segmental vasoconstriction-vasodilatation affecting the circle of Willis arteries and their branches. Aside from shared clinical features, significant imaging overlap exists. Both PRES and RCVS can be complicated by ischemic and hemorrhagic brain lesions; angiographic abnormalities frequently occur in PRES and vasogenic edematous lesions in RCVS. Common triggers (eg, eclampsia, vasoconstrictive and chemotherapeutic agents) have been identified. Abnormal cerebrovascular tone and endothelial dysfunction may explain both syndromes. Management of these syndromes includes the removal of identified triggers, symptomatic treatment of headache or seizures, and moderate blood pressure control. Both syndromes are self-limited, with clinical recovery occurring within days to weeks. Long-term deficits and mortality are uncommon.                                         SUMMARY               PRES and RCVS have been well characterized and acknowledged to have significant overlap. Advances in our understanding of pathophysiology and risk factors for poor outcome are expected to optimize the management of these not uncommon syndromes.},
  langid = {english}
}

@article{smithOtherPrimaryHeadache2021,
  title = {Other {{Primary Headache Disorders}}},
  author = {Smith, Jonathan H.},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {652--664},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000960},
  url = {https://journals.lww.com/10.1212/CON.0000000000000960},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE                                This article provides an overview of a diverse group of primary headache disorders that are categorized in the                 International Classification of Headache Disorders                 ,                 3rd Edition                 (                 ICHD-3                 ), as ``other primary headache disorders.'' This article provides clinicians with a distilled understanding of the diagnoses and their epidemiology, pathophysiology, and management.                                                        RECENT FINDINGS               Cough-induced headache requires neuroimaging to exclude posterior fossa pathology and recently has been reported as a common symptom in patients with CSF-venous fistula. Clinical overlap is observed between patients with primary exercise headache and primary headache associated with sexual activity. Patients with recurrent thunderclap headache associated with sexual activity should be presumed to have reversible cerebral vasoconstriction syndrome until proven otherwise. De novo external-pressure headache is a common sequela among health care workers using personal protective equipment during the COVID-19 pandemic. New daily persistent headache is an important mimicker of chronic migraine or chronic tension-type headache and is distinguished by a daily-from-onset progression of persistent headache; a treatment-refractory course is often observed, and early involvement of a multidisciplinary team, including a psychotherapist, is advised.                                         SUMMARY               Patients with primary headache disorders that are classified as ``other primary headache disorders'' have presentations with unique diagnostic and management considerations. The disorders are highly recognizable, and an appreciation of the diagnoses will aid clinicians in providing safe and effective care for patients presenting with headache.},
  langid = {english},
  keywords = {Current}
}

@article{spainApproachSymptomManagement2022,
  title = {Approach to {{Symptom Management}} in {{Multiple Sclerosis With}} a {{Focus}} on {{Wellness}}},
  author = {Spain, Rebecca},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {1052--1082},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001140},
  url = {https://journals.lww.com/10.1212/CON.0000000000001140},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes an approach to symptom management in people with multiple sclerosis (MS), emphasizing healthy lifestyles and evidence-based treatments.                                         RECENT FINDINGS               Growing evidence supports healthy nutrition, exercise, and emotional well-being (wellness) as foundational for MS symptom management. A stepped approach starts with healthy lifestyle practices and adds nonpharmacologic, pharmacologic, and procedural-based therapies balancing levels of evidence, risks, and potential benefits. The growing availability of cannabis and widespread use of dietary supplements in self-management of MS symptoms raise both therapeutic promises and challenges.                                         SUMMARY               Wellness approaches for MS symptom management foster self-reliance and should be reinforced early and often. Recognition of symptom clusters and medical comorbidities helps limit polypharmacy.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{starlingUnusualHeadacheDisorders2018,
  title = {Unusual {{Headache Disorders}}},
  author = {Starling, Amaal Jilani},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1192--1208},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000636},
  url = {https://journals.lww.com/00132979-201808000-00015},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Unusual headache disorders are less commonly discussed and may be misdiagnosed. These headache disorders frequently have a benign natural history; however, without reassurance, therapeutic education, and treatment, they can negatively affect the health and function of patients.                                         RECENT FINDINGS               This article reviews the clinical features, diagnosis, workup, and proposed treatments for several unusual headache disorders including primary cough headache, primary headache associated with sexual activity, primary exercise headache, cold-stimulus headache, primary stabbing headache, nummular headache, hypnic headache, and headache attributed to travel in space. Exploding head syndrome is also discussed, which is a sleep disorder commonly confused with a headache disorder.                                         SUMMARY               Unusual headache disorders are usually benign, yet without the correct diagnosis can be very worrisome for many patients. Through greater awareness of these headache disorders, neurologists can evaluate and effectively manage unusual headache disorders, which offers significant benefits to patients and practice satisfaction to neurologists.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/7ZKCMUBP/starling2018.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/9I76QB7Q/Starling (2018) Unusual Headache Disorders.pdf}
}

@article{stephenDystonias2022,
  title = {The {{Dystonias}}},
  author = {Stephen, Christopher D.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1435--1475},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001159},
  url = {https://journals.lww.com/10.1212/CON.0000000000001159},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the most recent findings regarding the diagnosis, classification, and management of genetic and idiopathic dystonia.                                         RECENT FINDINGS               A new approach to classifying dystonia has been created with the aim to increase the recognition and diagnosis of dystonia. Molecular biology and genetic studies have identified several genes and biological pathways involved in dystonia.                                         SUMMARY               Dystonia is a common movement disorder involving abnormal, often twisting, postures and is a challenging condition to diagnose. The pathophysiology of dystonia involves abnormalities in brain motor networks in the context of genetic factors. Dystonia has genetic, idiopathic, and acquired forms, with a wide phenotypic spectrum, and is a common feature in complex neurologic disorders. Dystonia can be isolated or combined with another movement disorder and may be focal, segmental, multifocal, or generalized in distribution, with some forms only occurring during the performance of specific tasks (task-specific dystonia). Dystonia is classified by clinical characteristics and presumed etiology. The management of dystonia involves accurate diagnosis, followed by treatment with botulinum toxin injections, oral medications, and surgical therapies (mainly deep brain stimulation), as well as pathogenesis-directed treatments, including the prospect of disease-modifying or gene therapies.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current},
  file = {/Users/nathanielyomogida/Zotero/storage/NX8YDEX2/Stephen (2022) The Dystonias.pdf}
}

@article{stimmingChorea2022,
  title = {Chorea},
  author = {Stimming, Erin Furr and Bega, Danny},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1379--1408},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001169},
  url = {https://journals.lww.com/10.1212/CON.0000000000001169},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the diagnostic and therapeutic approach to a patient with chorea. The phenomenology of chorea is described in addition to other common hyperkinetic movements that may be mistaken for or coexist with chorea. Chorea can be acquired or hereditary. Key historical and clinical features that can aid in determining the etiology are reviewed, and pharmacologic and nonpharmacologic treatment strategies are discussed.                                         RECENT FINDINGS                                Clinical investigations are under way to target transcription and translation of the mutant huntingtin protein as a potential disease-modifying strategy in Huntington disease (HD). Additional heritable factors have been revealed through genome-wide association studies. Symptom-focused treatments for HD are are being studied, including a third vesicular monoamine transporter-2 (VMAT2) inhibitor for chorea attenuation and drugs to target irritability and cognitive impairment. Increased availability of genetic testing has led to increased awareness of HD mimics (eg,                 C9orf72                 and IgLON5).                                                        SUMMARY               Chorea is a relatively common hyperkinetic disorder with a broad differential. The first step in the approach to a patient with chorea is accurately defining the phenomenology. Once it has been determined that the patient has chorea, the investigation into determining an etiology can begin. Factors such as age of onset, time course, family history, unique clinical features, and imaging and laboratory findings can guide the diagnosis. Treatments for most causes of chorea are purely symptomatic, although it is important to recognize causes that are reversible or have disease-modifying interventions.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{stinoMyelopathiesDueStructural2018,
  title = {Myelopathies {{Due}} to {{Structural Cervical}} and {{Thoracic Disease}}},
  author = {Stino, Amro Maher and LoRusso, Samantha J.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {567--583},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000594},
  url = {https://journals.lww.com/00132979-201804000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The article discusses the current diagnostic and therapeutic approach to myelopathies occurring as a consequence of structural cervical and thoracic spine disease.                                         RECENT FINDINGS               The exact pathophysiologic basis of cervical spondylotic myelopathy remains somewhat elusive. Diffusion-tensor imaging has emerged as a useful imaging modality that correlates more closely with clinical severity than standard MRI. Baseline disease severity, symptom duration, age, presence of impaired gait, and smoking status are significant factors related to surgical outcomes.                                         SUMMARY               Advances in neuroimaging and the development of evidence-based algorithmic approaches to surgical intervention will likely further improve the outcomes of patients with spinal cord dysfunction from structural cervical and thoracic disease.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/34FK2MWW/Stino_LoRusso (2018) Myelopathies Due to Structural Cervical and Thoracic Disease.pdf;/Users/nathanielyomogida/Zotero/storage/62F74GYA/stino2018.pdf.pdf}
}

@article{stittDrugsAbuseNervous2020,
  title = {Drugs of {{Abuse}} and the {{Nervous System}}},
  author = {Stitt, Derek and Kumar, Neeraj},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {765--784},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000857},
  url = {https://journals.lww.com/10.1212/CON.0000000000000857},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the neurologic complications of traditional, nontraditional, and emerging drugs of abuse.                                         RECENT FINDINGS               The manufacture, distribution, and use of so-called designer drugs are increasing. These agents can induce dramatic neurologic manifestations and can evade identification on conventional drug-screening assays. Additionally, gabapentinoids, drug agents that are very familiar to neurologists, are being abused in the general population at increasing rates to achieve euphoric highs and potentiate the effects of opiates. Furthermore, even well-known illicit narcotics such as heroin are posing dangers above their baseline because of ``lacing'' with additives or substitutes such as fentanyl and related compounds. These clandestine agents increase the potency of what are thought to be typical dosages to lethal levels, thus leading to more unintentional overdose deaths.                                         SUMMARY               The potential for short- and long-term nervous system injury from drug abuse is well established. However, it is important for the practicing neurologist to possess awareness of the features and observed sequelae of the toxidromes of both traditional and nontraditional drugs of abuse. This is because the use of both is widespread in our society and conventional drug screening can miss detection of some powerful agents, thus forcing us to maintain a high index of suspicion based on recognition of the clinical features.},
  langid = {english},
  keywords = {Outdated}
}

@article{stittSubstanceUseNervous2023,
  title = {Substance {{Use}} and the {{Nervous System}}},
  author = {Stitt, Derek},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {923--945},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001234},
  url = {https://journals.lww.com/10.1212/CON.0000000000001234},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               This article informs and updates the practicing neurologist on the current landscape of known neurologic injuries linked to the use of illicit drugs, focusing on emerging agents.                                         LATEST DEVELOPMENTS               Synthetic opioids such as fentanyl and similar derivatives have exploded in prevalence, becoming the leading cause of overdose fatalities. The higher potency of synthetic opioids compared with semisynthetic and nonsynthetic opiates poses an increased risk for unintentional overdose when found as an adulterant in other illicit drug supplies such as heroin. Conversely, misinformation about the risk of symptomatic exposure to fentanyl through casual contact with the skin and ambient air has led to misdirected fear and stigma that threatens to impede valid harm-reduction measures for fentanyl users at risk of actual overdose. Finally, during the COVID-19 pandemic, overdose rates and deaths continued to climb, especially among those who use opioids and methamphetamine.                                         ESSENTIAL POINTS               A variety of potential neurologic effects and injuries can occur with illicit drug use owing to the diverse properties and mechanisms of action of the various classes. Many high-risk agents are not detected on standard drug screens, including so-called designer drugs, and the practicing neurologist is best served by recognizing the clinical features of the traditional toxidrome and other potential idiosyncratic effects of various illicit agents.},
  langid = {english},
  keywords = {Current}
}

@article{strowdFamilialNervousSystem2020,
  title = {Familial {{Nervous System Tumor Syndromes}}},
  author = {Strowd, Roy E. and Plotkin, Scott R.},
  year = {2020},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {6},
  pages = {1523--1552},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000950},
  url = {https://journals.lww.com/10.1212/CON.0000000000000950},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Although sporadic primary neoplasms account for the majority of nervous system tumors, familial nervous system tumor syndromes are important and clinically relevant conditions for the neurologist to understand. This article reviews common inherited nervous system tumor syndromes including neurofibromatosis type 1, neurofibromatosis type 2, schwannomatosis, tuberous sclerosis complex, and von Hippel-Lindau syndrome. The epidemiology, genetics, approach to diagnosis, neurologic and nonneurologic manifestations, and management options are reviewed.                                         RECENT FINDINGS               Awareness of the more common and clinically relevant familial nervous system tumor syndromes is important. These conditions teach us about the underlying biology that drives tumor development in the central and peripheral nervous systems including peripheral nerve sheath tumors (eg, neurofibroma, schwannoma), meningioma, vestibular schwannoma, subependymal giant cell astrocytoma, and hemangioblastoma. Knowledge of the clinical manifestations ensures that the neurologist will be able to diagnose these conditions, recommend appropriate surveillance, refer to specialists, and support optimal management. Important discoveries in the role of the underlying genetics have contributed to the launch of several novel drug trials for these tumors, which are changing therapeutic options for patients.                                         SUMMARY               Familial nervous system tumor syndromes are uncommon conditions that require specialized surveillance and management strategies. Coordination across a multidisciplinary team that includes neurologists, neuro-oncologists, radiologists, neurosurgeons, radiation oncologists, otolaryngologists, pathologists, neuropsychologists, physical medicine and rehabilitation specialists, and geneticists is necessary for the optimal treatment of these patients.},
  langid = {english}
}

@article{szperkaHeadacheChildrenAdolescents2021,
  title = {Headache in {{Children}} and {{Adolescents}}},
  author = {Szperka, Christina},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {703--731},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000993},
  url = {https://journals.lww.com/10.1212/CON.0000000000000993},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the approach to a child or adolescent with headache, the criteria for common diagnoses, and the evidence base for treatments.                                         RECENT FINDINGS               The guidelines for acute and preventive treatment of migraine were updated in 2019. These guidelines summarize the available evidence and outline the questions that should be addressed in future research. The US Food and Drug Administration (FDA) approval of several new classes of drugs and devices to treat adult migraine in the past few years has resulted in ongoing or planned pediatric trials.                                         SUMMARY               Headache is a common symptom in children, and it is important to take a detailed history and perform a thorough physical examination to make the diagnosis. Nearly 1 in 10 children experience recurrent headaches due to migraine, which cause significant impairment in school performance and quality of life. The acute and preventive treatments that are currently available will help at least two-thirds of children with migraine, and several trials of new therapies offer hope for the future.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/NQ5KLXUH/Szperka (2021) Headache in Children and Adolescents.pdf}
}

@article{tang-waiBedsideApproachMental2018,
  title = {Bedside {{Approach}} to the {{Mental Status Assessment}}},
  author = {{Tang-Wai}, David F. and Freedman, Morris},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {672--703},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000617},
  url = {https://journals.lww.com/00132979-201806000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article presents a clinically useful approach to obtaining the history and performing the mental status examination of patients with cognitive, language, or behavioral problems.                                         RECENT FINDINGS               Laboratory and imaging biomarkers are being developed for accurate diagnosis of neurobehavioral disorders, yet few are currently available for clinical use. Moreover, not all centers have access to these potential tools. Practicing clinicians are therefore left primarily with their skills of history taking and examination. Although geared for research, diagnostic criteria have been refined over the past several years and can nevertheless aid the clinician with the diagnosis of disorders such as mild cognitive impairment, Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, the primary progressive aphasias, corticobasal syndrome, vascular cognitive impairment, and posterior cortical atrophy. Regularly revised criteria reflect ongoing knowledge gained from in-depth studies of these disorders.                                         SUMMARY               The focused history and mental status examination remain essential tools for the evaluation and diagnosis of neurologic disorders affecting cognition, language, and behavior.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/CGY39VHS/Tang-Wai_Freedman (2018) Bedside Approach to the Mental Status Assessment.pdf}
}

@article{tarnopolskyMetabolicMyopathies2022,
  title = {Metabolic {{Myopathies}}},
  author = {Tarnopolsky, Mark A.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1752--1777},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001182},
  url = {https://journals.lww.com/10.1212/CON.0000000000001182},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Metabolic myopathies are disorders that affect skeletal muscle substrate oxidation. Although some drugs and hormones can affect metabolism in skeletal muscle, this review will focus on the genetic metabolic myopathies.                                         RECENT FINDINGS               Impairments in glycogenolysis/glycolysis (glycogen storage disease), fatty acid transport/oxidation (fatty acid oxidation defects), and mitochondrial metabolism (mitochondrial myopathies) represent most metabolic myopathies; however, they often overlap clinically with structural genetic myopathies, referred to as pseudometabolic myopathies. Although metabolic myopathies can present in the neonatal period with hypotonia, hypoglycemia, and encephalopathy, most cases present clinically in children or young adults with exercise intolerance, rhabdomyolysis, and weakness. In general, the glycogen storage diseases manifest during brief bouts of high-intensity exercise; in contrast, fatty acid oxidation defects and mitochondrial myopathies usually manifest during longer-duration endurance-type activities, often with fasting or other metabolic stressors (eg, surgery, fever). The neurologic examination is often normal between events (except in the pseudometabolic myopathies) and evaluation requires one or more of the following tests: exercise stress testing, blood (eg, creatine kinase, acylcarnitine profile, lactate, amino acids), urine (eg, organic acids, myoglobin), muscle biopsy (eg, histology, ultrastructure, enzyme testing), and targeted (specific gene) or untargeted (myopathy panels) genetic tests.                                         SUMMARY               Definitive identification of a specific metabolic myopathy often leads to specific interventions, including lifestyle, exercise, and nutritional modifications; cofactor treatments; accurate genetic counseling; avoidance of specific triggers; and rapid treatment of rhabdomyolysis.},
  langid = {english},
  keywords = {Current}
}

@article{taveeImmuneAxonalPolyneuropathy2017,
  title = {Immune {{Axonal Polyneuropathy}}},
  author = {Tavee, Jinny O.},
  year = {2017},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {5},
  pages = {1394--1410},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000523},
  url = {https://journals.lww.com/00132979-201710000-00015},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Immune axonal polyneuropathy is caused by a diverse group of disorders that share similar presentations and treatment regimens. This article focuses on the clinical findings, evaluation, and management of immune-mediated causes of axonal polyneuropathy, focusing primarily on large fiber sensorimotor polyneuropathy.                                         Recent Findings:               Specific characteristics of an immune-mediated polyneuropathy have been incorporated in a new diagnostic screening tool that is highly sensitive and can easily be used in the outpatient clinic setting. New insights into autoantibodies may help identify the presence of an underlying autoimmune or paraneoplastic disease as the cause of a polyneuropathy.                                         Summary:               This article provides readers with further understanding into the autoimmune causes of axonal polyneuropathy and will help the clinician recognize key clinical features that may lead to timely diagnosis and treatment.},
  langid = {english},
  keywords = {Continuum: Peripheral nerve and motor neuron disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/2A4KSFQJ/Tavee (2017) Immune Axonal Polyneuropathy.pdf;/Users/nathanielyomogida/Zotero/storage/5PDX2JGW/tavee2017.pdf.pdf}
}

@article{taveeLowBackPain2017,
  title = {Low {{Back Pain}}},
  author = {Tavee, Jinny O. and Levin, Kerry H.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {467--486},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000449},
  url = {https://journals.lww.com/00132979-201704000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               This article provides an overview of evaluating and treating low back pain in the outpatient setting.                                         Recent Findings:               As most cases of acute low back pain have a favorable prognosis, current guidelines on imaging studies recommend conservative treatment for 6 weeks prior to obtaining an MRI if no red flags are present. Of these red flags, a prior history of cancer is the strongest risk factor for a malignant etiology and requires urgent evaluation with MRI. Management of acute low back pain is mainly conservative with oral non-narcotic analgesics and mobilization as the initial recommendations. For patients with radiculopathy, epidural steroids may result in short-term pain relief, but long-term effects are still unclear.                                         Summary:               A systematic, evidence-based approach to the patient with low back pain is key to providing safe and cost-efficient care.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/EQ7CTKBB/tavee2017.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/NX96F6HV/Tavee_Levin (2017) Low Back Pain.pdf}
}

@article{tepperCranialNeuralgias2018,
  title = {Cranial {{Neuralgias}}},
  author = {Tepper, Stewart J.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1157--1178},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000637},
  url = {https://journals.lww.com/00132979-201808000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the clinical features and diagnostic criteria, pathophysiology (when known), and treatment strategies of the major cranial neuralgias.                                         RECENT FINDINGS               Abnormal vascular loops compressing cranial nerves are the most common known pathogenesis associated with the primary neuralgias.                                         SUMMARY               The most frequently encountered primary neuralgias are trigeminal neuralgia, occipital neuralgia, and, rarely, glossopharyngeal neuralgia. Nervus intermedius neuralgia is even more rare. All neuralgias merit a careful workup for secondary causes. Drug treatment generally relies on antiepileptic drugs, antidepressants, and baclofen. OnabotulinumtoxinA can be useful in treating some cranial neuralgias. Surgical and invasive treatments include ablation, gamma knife treatment, and microvascular decompression.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/LAIR8V4Y/Tepper (2018) Cranial Neuralgias.pdf;/Users/nathanielyomogida/Zotero/storage/X5ZYYKUE/tepper2018.pdf.pdf}
}

@article{termsarasabChorea2019,
  title = {Chorea},
  author = {Termsarasab, Pichet},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {1001--1035},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000763},
  url = {https://journals.lww.com/00132979-201908000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the approach to chorea in clinical practice, beginning with a discussion of the phenomenologic features of chorea and how to differentiate it from other movement disorders. The diagnostic approach, clinical features of important acquired and genetic choreas, and therapeutic principles are also discussed. Practical clinical points and caveats are included.                                         RECENT FINDINGS                                C9orf72 disease is the most common Huntington disease phenocopy, according to studies in the European population. Anti-IgLON5 disease can present with chorea. The role of immunotherapies in Sydenham chorea has increased, and further clinical studies may be useful. Benign hereditary chorea is a syndrome or phenotype due to mutations in several genes, including                 NKX2-1                 ,                 ADCY5, GNAO1,                 and                 PDE10A                 . New-generation presynaptic dopamine-depleting agents provide more options for symptomatic treatment of chorea with fewer adverse effects. Deep brain stimulation has been performed in several choreic disorders, but features other than chorea and the neurodegenerative nature should be taken into consideration. Studies on genetic interventions for Huntington disease are ongoing.                                                        SUMMARY               Clinical features remain crucial in guiding the differential diagnosis and appropriate investigations in chorea. Given the complexity of most choreic disorders, treating only the chorea is not sufficient. A comprehensive and multidisciplinary approach is required.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/3X5XAGVZ/Termsarasab (2019) Chorea.pdf;/Users/nathanielyomogida/Zotero/storage/ZD3GCLQI/10.1212@CON.0000000000000763.pdf.pdf}
}

@article{thakurChronicMeningitis2018,
  title = {Chronic {{Meningitis}}},
  author = {Thakur, Kiran T. and Wilson, Michael R.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1298--1326},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000664},
  url = {https://journals.lww.com/00132979-201810000-00006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the clinical presentation, diagnostic approach (including the use of novel diagnostic platforms), and treatment of select infectious and noninfectious etiologies of chronic meningitis.                                         RECENT FINDINGS               Identification of the etiology of chronic meningitis remains challenging, with no cause identified in at least one-third of cases. Often, several serologic, CSF, and neuroimaging studies are indicated, although novel diagnostic platforms including metagenomic deep sequencing may hold promise for identifying organisms. Infectious etiologies are more common in those at risk for disseminated disease, specifically those who are immunocompromised because of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), transplantation, or immunosuppressant medications. An important step in identifying the etiology of chronic meningitis is assembling a multidisciplinary team of individuals, including those with specialized expertise in ophthalmology, dermatology, rheumatology, and infectious diseases, to provide guidance regarding diagnostic procedures.                                         SUMMARY               Chronic meningitis is defined as inflammation involving the meninges that lasts at least 4 weeks and is associated with a CSF pleocytosis. Chronic meningitis has numerous possible infectious and noninfectious etiologies, making it challenging to definitively diagnose patients. Therefore, a multifaceted approach that combines history, physical examination, neuroimaging, and laboratory analysis, including novel diagnostic platforms, is needed. This article focuses on key aspects of the evaluation of and approach to patients with chronic meningitis. Specific infectious etiologies and differential diagnoses of subacute and chronic meningitis, including noninfectious etiologies, are addressed.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/GUJFPJVF/Thakur_Wilson (2018) Chronic Meningitis.pdf}
}

@article{thalerDiagnosisMedicalManagement2022,
  title = {Diagnosis and {{Medical Management}} of {{Parkinson Disease}}},
  author = {Thaler, Avner and Alcalay, Roy N.},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1281--1300},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001152},
  url = {https://journals.lww.com/10.1212/CON.0000000000001152},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Parkinson disease (PD) is a common neurodegenerative movement disorder, the prevalence of which is rising as the world population ages. It may present with motor and nonmotor symptoms, and symptomatic treatment significantly improves quality of life. This article provides an overview of the workup and differential diagnosis for PD and reviews genetic and environmental risk factors and current treatments.                                         RECENT FINDINGS               Novel treatments for the motor (eg, fluctuations and off times) and nonmotor (eg, hallucinations and orthostatic hypotension) complications of PD have been approved in recent years. In addition, with recent advances in our understanding of the genetics of PD, significant research is focusing on identifying at-risk populations and introducing genetically targeted interventions (precision medicine).                                         SUMMARY               PD is a heterogeneous neurodegenerative movement disorder. Affected individuals may receive substantial symptomatic relief from nonpharmacologic, pharmacologic, and surgical interventions. Although no intervention to modify the progression of PD is currently available, precision medicine and modulation of the immune system are a major focus of ongoing research.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{thangarajhDystrophinopathies2019,
  title = {The {{Dystrophinopathies}}},
  author = {Thangarajh, Mathula},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1619--1639},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000791},
  url = {https://journals.lww.com/10.1212/CON.0000000000000791},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The dystrophinopathies are among the most common neuromuscular conditions, and they include Duchenne and Becker muscular dystrophies. This article reviews the epidemiology, clinical manifestations, genetic cause, management, and new and emerging therapies for this condition.                                         RECENT FINDINGS               New studies have highlighted how oral corticosteroids have changed the natural history of the disease, prolonging ambulation in boys with Duchenne muscular dystrophy and reducing the risk of developing scoliosis and subsequent surgical correction, improving cardiac health, and increasing long-term survival. Additionally, recent publications have provided insights into how newer and emerging treatment options are becoming more common for this condition. With gene therapy being approved in the United States for the severe form, the dystrophinopathies represent model diseases to understand the personalization of genetic treatment.                                         SUMMARY               Improvement in the standardization of care and the use of oral corticosteroids have increased the life expectancy of patients with dystrophinopathy and changed the natural history of the disease. This article presents a summary of clinical features, diagnostic testing, and new and emerging treatment strategies for the dystrophinopathies.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/75EBGYF7/Thangarajh (2019) The Dystrophinopathies.pdf}
}

@article{thenganattPsychogenicFunctionalMovement2019,
  title = {Psychogenic ({{Functional}}) {{Movement Disorders}}},
  author = {Thenganatt, Mary Ann and Jankovic, Joseph},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {1121--1140},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000755},
  url = {https://journals.lww.com/00132979-201908000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews a practical approach to psychogenic movement disorders to help neurologists identify and manage this complex group of disorders.                                         RECENT FINDINGS               Psychogenic movement disorders, also referred to as functional movement disorders, describe a group of disorders that includes tremor, dystonia, myoclonus, parkinsonism, speech and gait disturbances, and other movement disorders that are incongruent with patterns of pathophysiologic (organic) disease. The diagnosis is based on positive clinical features that include variability, inconsistency, suggestibility, distractibility, suppressibility, and other supporting information. While psychogenic movement disorders are often associated with psychological and physical stressors, the underlying pathophysiology is not fully understood. Although insight-oriented behavioral and pharmacologic therapies are helpful, a multidisciplinary approach led by a neurologist, but also including psychiatrists and physical, occupational, and speech therapists, is needed for optimal outcomes.                                         SUMMARY               The diagnosis of psychogenic movement disorders is based on clinical features identified on neurologic examination, and neurophysiologic and imaging studies can provide supporting information.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/85N7H26A/Thenganatt_Jankovic (2019) Psychogenic (Functional) Movement Disorders.pdf;/Users/nathanielyomogida/Zotero/storage/NTVFZUXL/10.1212@CON.0000000000000755.pdf.pdf}
}

@article{thurtellIdiopathicIntracranialHypertension2019,
  title = {Idiopathic {{Intracranial Hypertension}}},
  author = {Thurtell, Matthew J.},
  year = {2019},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {5},
  pages = {1289--1309},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000770},
  url = {https://journals.lww.com/10.1212/CON.0000000000000770},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Idiopathic intracranial hypertension is a syndrome of increased intracranial pressure of unclear etiology that most often occurs in obese women of childbearing age but can also occur in men, children, and older adults. This article reviews the diagnostic criteria, clinical features, neuroimaging findings, differential diagnosis, and management options for this condition.                                         RECENT FINDINGS               Recent population studies have found that the annual incidence of idiopathic intracranial hypertension is increasing in association with obesity rates, whereas recent scientific studies indicate a possible role for androgen sex hormones and adipose tissue in the pathogenesis of the disease. Prospective clinical trials have demonstrated a role for weight loss, acetazolamide, and topiramate in the management of mild disease. A recently begun randomized multicenter trial of surgical interventions will provide insight into the indications for surgical intervention, optimal timing and choice of intervention, and long-term outcomes.                                         SUMMARY               Idiopathic intracranial hypertension is a disorder producing symptoms and signs of increased intracranial pressure in the absence of an alternative cause. The main goals of treatment are to preserve visual function and alleviate symptoms, which can usually be achieved with a combination of weight loss, medical therapies, and surgical interventions depending on the severity of symptoms and vision loss, response to treatment, and subsequent clinical course.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/I4YWB7QV/Thurtell (2019) Idiopathic Intracranial Hypertension.pdf}
}

@article{tiltonTransitionPediatricAdult2018,
  title = {Transition {{From Pediatric}} to {{Adult Neurologic Care}}},
  author = {Tilton, Ann H. and De Gusmao, Claudio Melo},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {276--287},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000570},
  url = {https://journals.lww.com/00132979-201802000-00016},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               With advances in medical care, the number of youths surviving with medically complex conditions has been steadily increasing. Inadequate transition planning and execution can lead to gaps in care, unexpected emergency department visits, and an increase in health care costs and patient/caregiver anxiety. Many barriers that prevent adequate transition have been identified, including insufficient time or staff to provide transition services, inadequate reimbursement, resistance from patients and caregivers, and a dearth of accepting adult providers.                                         RECENT FINDINGS               Transition is distinct from transfer of care. Transition is a planned multistage process, while transfer refers to a point in time where responsibility of care shifts from one provider to another. Key differences exist between the pediatric and adult models of care. A successful transition should empower the patient to understand and take responsibility in managing his or her condition; foster independent functioning to the extent that is possible; integrate educational, legal, and community resources in the care plan; and identify appropriate adult health care providers at the time of transfer. Different models have been proposed to streamline the transition process, with improvement in patients' knowledge of their condition, self-efficacy, and confidence.                                         SUMMARY               Neurologists have a key role in supporting their patients in the transition to adulthood. This article reviews basic tenets and provides tools to assist in navigating the complex transition process. These tenets are intended to improve quality of care and decrease clinician burden and remain an active area of research.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/E6HDTYJP/Tilton_De Gusmao (2018) Transition From Pediatric to Adult Neurologic Care.pdf}
}

@article{toledanoInfectiousMyelopathies2021,
  title = {Infectious {{Myelopathies}}},
  author = {Toledano, Michel},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {93--120},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000930},
  url = {https://journals.lww.com/10.1212/CON.0000000000000930},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews infectious etiologies of spinal cord dysfunction, emphasizing the importance of recognizing common clinicoradiographic syndromes and interpreting them in the context of exposure risk and individual host susceptibilities.                                         RECENT FINDINGS               This article discusses the shifting spectrum of neurologic infectious diseases, the growing population of patients who are immunocompromised, and the emergence of effective antiretroviral therapies. In addition, it discusses new molecular and serologic tests that have the potential to enhance our ability to rapidly and accurately diagnose infectious diseases of the spine.                                         SUMMARY               When evaluating patients with suspected infectious myelopathies, it is imperative to narrow the range of pathogens under consideration. The geography, seasonality, and clinicoradiographic presentation and immunocompetence status of the patient define the range of potential pathogens and should guide testing and initial management.},
  langid = {english}
}

@article{toledanoNeurologicManifestationsRheumatologic2023,
  title = {Neurologic {{Manifestations}} of {{Rheumatologic Disease}}},
  author = {Toledano, Michel},
  year = {2023},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {3},
  pages = {734--762},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001263},
  url = {https://journals.lww.com/10.1212/CON.0000000000001263},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Objective               This article describes the neurologic manifestations of systemic rheumatologic disorders.                                         Latest Developments               Although most have historically been classified as autoimmune disorders, rheumatologic diseases are increasingly conceptualized as distributed along a spectrum with various contributions of autoimmune (adaptive immune dysregulation) and autoinflammatory (innate immune dysregulation) mechanisms. Our evolving understanding of systemic immune-mediated disorders has been accompanied by an expansion in our differential diagnoses and therapeutic options.                                         Essential Points               Rheumatologic disease involves both autoimmune and autoinflammatory mechanisms. Neurologic symptoms can be the first manifestation of these disorders, and familiarity with the systemic manifestations of specific diseases is essential to establish the correct diagnosis. Conversely, knowledge of the neurologic syndromes that are most likely to be associated with specific systemic disorders can help narrow the differential and increase confidence when attributing a neuropsychiatric symptom to an underlying systemic disorder.},
  langid = {english},
  keywords = {Current}
}

@article{trivediMuscleChannelopathies2022,
  title = {Muscle {{Channelopathies}}},
  author = {Trivedi, Jaya R.},
  year = {2022},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {6},
  pages = {1778--1799},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001183},
  url = {https://journals.lww.com/10.1212/CON.0000000000001183},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the clinical features, diagnosis, pathophysiology, and management of nondystrophic myotonia and periodic paralysis.                                         RECENT FINDINGS               An increasing awareness exists about the genotype-phenotype overlap in skeletal muscle channelopathies, and thus genetic testing is needed to make a definitive diagnosis. Electrodiagnostic testing in channelopathies is highly specialized with significant overlap in various mutation subtypes. Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channelopathies.                                         SUMMARY               Skeletal muscle channelopathies are rare heterogeneous conditions characterized by lifelong symptoms that require a comprehensive management plan that includes pharmacologic and nonpharmacologic interventions. The significant variability in biophysical features of various mutations, coupled with the difficulties of performing clinical trials in rare diseases, makes it challenging to design and implement treatment trials for muscle channelopathies.},
  langid = {english},
  keywords = {Current}
}

@article{turkChronicTraumaticEncephalopathy2019,
  title = {Chronic {{Traumatic Encephalopathy}}},
  author = {Turk, Katherine W. and Budson, Andrew E.},
  year = {2019},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {1},
  pages = {187--207},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000686},
  url = {https://journals.lww.com/00132979-201902000-00012},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a discussion on the current state of knowledge of chronic traumatic encephalopathy (CTE), with an emphasis on clinical features and emerging biomarkers of the condition.                                         RECENT FINDINGS               The results of several large brain bank case series among subjects with a history of contact sports or repetitive head trauma have indicated that a high frequency of CTE may exist in this population. However, the true prevalence of CTE among individuals with a history of head trauma remains unknown, given that individuals who experienced cognitive, behavioral, and mood symptoms during life are more likely to have their brains donated for autopsy at death and epidemiologic studies of the condition are lacking. Neuropathologic consensus criteria have been published. Research-based clinical criteria have been proposed and are beginning to be applied, but the definitive diagnosis of CTE in a living patient remains impossible without effective biomarkers for the condition, which is an active area of study.                                         SUMMARY               The field of CTE research is rapidly growing and parallels many of the advances seen for other neurodegenerative conditions, such as Alzheimer disease decades ago.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/GH3XUMXY/Turk_Budson (2019) Chronic Traumatic Encephalopathy.pdf}
}

@article{vankarnebeekEvaluationChildDevelopmental2018,
  title = {Evaluation of the {{Child With Developmental Impairments}}},
  author = {Van Karnebeek, Clara D. M.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {228--247},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000564},
  url = {https://journals.lww.com/00132979-201802000-00014},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the diagnostic evaluation of intellectual developmental disorder, comprising global developmental delay and intellectual disability in children.                                         RECENT FINDINGS               With a prevalence of 1\% to 3\% and substantial comorbidity, high lifetime costs, and emotional burden, intellectual developmental disorder is characterized by limitations in both intellectual functioning (IQ less than 70) and adaptive behavior starting before 18 years of age. Pinpointing the precise genetic cause is important, as it allows for accurate genetic counseling, avoidance of unnecessary testing, prognostication, and tailored  management, which, for an increasing number of genetic conditions, targets the pathophysiology and improves outcomes.                                         SUMMARY               The etiology of intellectual developmental disorder is heterogeneous, which mandates a structured approach that considers family situation, test costs, yield, and potential therapeutic tractability of the identified condition. Diagnosis of an underlying genetic cause is increasingly important with the advent of new treatments. Still, in many cases, the cause remains unknown, and research is needed to elucidate its complex molecular basis.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/Z7R8AUXA/Van Karnebeek (2018) Evaluation of the Child With Developmental Impairments.pdf}
}

@article{vargasAcuteTreatmentMigraine2018,
  title = {Acute {{Treatment}} of {{Migraine}}},
  author = {Vargas, Bert B.},
  year = {2018},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {4},
  pages = {1032--1051},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000639},
  url = {https://journals.lww.com/00132979-201808000-00007},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a framework to help providers formulate a plan for the acute treatment of migraine. Topics covered include the cost-effective patient-centered approach known as stratified care and a summary of evidence-based treatment options that are currently available. Strategies for improving treatment response, troubleshooting suboptimal results, and addressing the needs of special populations are also reviewed.                                         RECENT FINDINGS               Both the American Headache Society and the Canadian Headache Society have released evidence-based assessments and reviews of acute treatments for migraine that can be used to help guide treatment decisions. Although several older medications have been re-released with new formulations or new delivery systems, several new medications have also become available or are in the final phases of study, further increasing the number of options available for patients.                                         SUMMARY               The acute management of migraine should incorporate a stratified care model in concert with evidence-based treatment options. The response to treatment should be monitored regularly, and measures should be taken to identify suboptimal tolerability or efficacy.},
  langid = {english},
  keywords = {Continuum: Headache,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/C3V5UXT9/Vargas (2018) Acute Treatment of Migraine.pdf;/Users/nathanielyomogida/Zotero/storage/JM7VIBG2/vargas2018.pdf.pdf}
}

@article{venkatesanEncephalitisBrainAbscess2021,
  title = {Encephalitis and {{Brain Abscess}}},
  author = {Venkatesan, Arun},
  year = {2021},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {4},
  pages = {855--886},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001006},
  url = {https://journals.lww.com/10.1212/CON.0000000000001006},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews infections of the brain parenchyma and includes an overview of the epidemiology, pathogenesis, diagnostic approach, and management of infectious encephalitis and brain abscess.                                         RECENT FINDINGS               The epidemiology of infectious encephalitis and brain abscess has changed in recent years. Vaccination has reduced the incidence of certain viruses associated with encephalitis, while a decrease in fulminant otogenic infections has led to fewer brain abscesses associated with otitis media. However, changes in climate and human population density and distribution have enabled the emergence of newer pathogens and expanded the geographic range of others, and greater adoption of intensive immunosuppressive regimens for autoimmune conditions has increased the risk of opportunistic infections of the brain. The widespread use of early neuroimaging, along with improved diagnostic methodologies for pathogen detection, newer antimicrobial therapies with better brain penetration, and less invasive neurosurgical techniques, has resulted in better outcomes for patients with infectious encephalitis and brain abscess. Novel technologies including metagenomic next-generation sequencing are increasingly being applied to these conditions in an effort to improve diagnosis. Nevertheless, both infectious encephalitis and brain abscess continue to be associated with substantial mortality.                                         SUMMARY               Infectious encephalitis and brain abscess can present as neurologic emergencies and require rapid assessment, thorough and appropriate diagnostic testing, and early initiation of empiric therapies directed against infectious agents. Close clinical follow-up, proper interpretation of diagnostic results, and appropriate tailoring of therapeutic agents are essential to optimizing outcomes. Diagnosis and management of parenchymal brain infections are complex and often best achieved with a multidisciplinary care team involving neurologists, neurosurgeons, neuroradiologists, infectious disease physicians, and pathologists.},
  langid = {english},
  keywords = {Current}
}

@article{verninoAutoimmuneAutonomicDisorders2020,
  title = {Autoimmune {{Autonomic Disorders}}},
  author = {Vernino, Steven},
  year = {2020},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {1},
  pages = {44--57},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000812},
  url = {https://journals.lww.com/10.1212/CON.0000000000000812},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Autonomic disorders sometimes occur in the context of systemic autoimmune disease or as a direct consequence of autoimmunity against the nervous system. This article provides an overview of autonomic disorders with potential autoimmune etiology.                                         RECENT FINDINGS               Recent evidence highlights a close association between the autonomic nervous system and inflammation. The autonomic nervous system regulates immune function, and autonomic manifestations may occur in a number of systemic autoimmune diseases. In a few instances, autoimmunity directly influences autonomic function. Autoimmune autonomic ganglionopathy is the prototypic antibody-mediated autonomic disorder. Over time, a better understanding of the clinical spectrum of autoimmune autonomic ganglionopathy, the significance of ganglionic nicotinic acetylcholine receptor antibodies, other immune-mediated autonomic neuropathies, and autonomic manifestations of other systemic or neurologic autoimmune disorders has emerged.                                         SUMMARY               Autoimmune autonomic disorders may be challenging, but correct identification of these conditions is important. In some cases, potential exists for effective immunomodulatory treatment.},
  langid = {english},
  keywords = {Continuum: Autonomic Disorders,Current}
}

@article{voCommonlyUsedDrugs2020,
  title = {Commonly {{Used Drugs}} for {{Medical Illness}} and the {{Nervous System}}},
  author = {Vo, Mary L.},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {716--731},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000854},
  url = {https://journals.lww.com/10.1212/CON.0000000000000854},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of the neurologic side effects of commonly prescribed medications, some of which can result in significant impairment if not addressed. This article aims to help clinicians recognize neurologic adverse drug reactions of a range of medication classes.                                         RECENT FINDINGS               Adverse drug reactions are a source of significant morbidity and rising health care costs. Failure to recognize neurologic adverse drug reactions may prompt unnecessary testing to identify a primary neurologic condition and expose the patient to continued adverse effects of a medication. Familiarity with the side effect profiles of newer medications, timing of side effects, pattern of reaction, medication rechallenge, and concurrent medical issues and awareness of significant medication interactions may aid in the identification of a medication side effect.                                         SUMMARY               Early recognition of neurologic adverse medication reactions can be challenging but is essential to prompt discontinuation of the offending medication or administration of specific symptomatic treatments in select cases. A high index of suspicion is needed to arrive at the correct diagnosis promptly, initiate a treatment plan, limit unnecessary testing, and reduce overall health care cost burden.},
  langid = {english},
  keywords = {Outdated}
}

@article{wagleshuklaDiagnosisTreatmentEssential2022,
  title = {Diagnosis and {{Treatment}} of {{Essential Tremor}}},
  author = {Wagle Shukla, Aparna},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1333--1349},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001181},
  url = {https://journals.lww.com/10.1212/CON.0000000000001181},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Essential tremor is a chronic, progressive syndrome that primarily presents with an action tremor involving the arms and hands. This article reviews the history and physical examination features pertinent for diagnosis, differential diagnoses, and treatments and approaches for optimal control of symptoms.                                         RECENT FINDINGS                                Essential tremor is a syndrome with symptoms extending beyond tremor to involve disturbances in gait, speech, cognition, and mood. Although the new guidelines on the definition and biaxial classification scheme have provided clarity, some tremor experts have critiqued the recently coined term                 essential tremor plus                 . For treatment, new orthotic devices and peripheral stimulation devices are now available in addition to pharmacologic and surgical options.                                                        SUMMARY               Essential tremor has a rich clinical phenomenology with many subtleties and nuances. A detailed history with open-ended questions and focused questions encompassing medical history, social history, and family history is key for establishing the diagnosis. The presence of bilateral action tremor for 3 years and absence of isolated head and voice tremor and absence of task- and position-dependent tremor are necessary for diagnosis. Dystonic tremor, Parkinson disease tremor, physiologic tremor, and drug-induced tremor are common differential diagnoses. Differentiating these tremor disorders from essential tremor based on phenomenology and physical examination alone could be challenging; thus, clinicians should seek additional clues from a detailed history. Treatment could begin with noninvasive and nonpharmacologic therapies, especially in mild cases. As the severity increases, they can advance stepwise to include pharmacotherapies and surgical interventions. With the growing recognition that essential tremor is not a monosymptomatic disorder, management should involve a multidisciplinary team. Furthermore, treatment selection should be based on shared decision making between patients and providers that gives due consideration to severity of symptoms, level of functional disability, impact on social interactions, patient preferences, and patient expectations.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{wagnerFacioscapulohumeralMuscularDystrophies2019,
  title = {Facioscapulohumeral {{Muscular Dystrophies}}},
  author = {Wagner, Kathryn R.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1662--1681},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000801},
  url = {https://journals.lww.com/10.1212/CON.0000000000000801},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Facioscapulohumeral muscular dystrophy (FSHD) is a common muscular dystrophy affecting both pediatric and adult patients. This article reviews the phenotype and pathophysiology of the disease as well as the recent efforts in clinical outcome measures and clinical trials.                                         RECENT FINDINGS                                As the name implies, FSHD involves weakness of facial muscles, muscles that fix the scapula, and muscles overlying the humerus (biceps and triceps). The distinctive phenotype of FSHD occurs secondary to two different genetic mechanisms. FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of                 DUX4                 . FSHD type 2 (FSHD2) is due to mutations in                 SMCHD1                 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of                 DUX4                 . Understanding the central role of                 DUX4                 has opened up the possibility of disease-modifying treatments. In preparation for clinical trials of novel agents, researchers are in the process of validating a number of clinical trial outcome measures including MRI, the 6-minute walk test, the FSHD Composite Outcome Measure, reachable workspace, electrical impedance myography, and the FSHD Health Index.                                                        SUMMARY               The treatment of FSHD is currently supportive only. While past clinical trials in FSHD have been largely disappointing, novel agents in development, including antisense oligonucleotides, gene therapy, and small molecules, hold promise for future meaningful therapies.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/U8CJU4LC/Wagner (2019) Facioscapulohumeral Muscular Dystrophies.pdf}
}

@article{wainwrightNeurologicComplicationsPediatric2018,
  title = {Neurologic {{Complications}} in the {{Pediatric Intensive Care Unit}}},
  author = {Wainwright, Mark S.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {288--299},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000565},
  url = {https://journals.lww.com/00132979-201802000-00017},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               All critical care is directed at maintaining brain health, but recognizing neurologic complications of critical illness in children is difficult, and limited data exist to guide practice. This article discusses an approach to the recognition and management of seizures, stroke, and cardiac arrest as complications of other critical illnesses in the pediatric intensive care unit.                                         RECENT FINDINGS               Convulsive and nonconvulsive seizures occur frequently in children after cardiac arrest or traumatic brain injury and during extracorporeal membrane oxygenation. Seizures may add to neurologic morbidity, and continuous EEG monitoring is needed for up to 24 hours for detection. Hypothermia has not been shown to improve outcome after cardiac arrest in children, but targeted temperature management with controlled normothermia and prevention of fever is a mainstay of neuroprotection.                                         SUMMARY               Much of brain-directed pediatric critical care is empiric. Recognition of neurologic complications of critical illness requires multidisciplinary care, serial neurologic examinations, and an appreciation for the multiple risk factors for neurologic injury present in most patients in the pediatric intensive care unit. Through attention to the fundamentals of neuroprotection, including maintaining or restoring cerebral perfusion matched to the metabolic needs of the brain, combined with anticipatory planning, these complications can be prevented or the neurologic injury mitigated.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/5EPIAZY2/Wainwright (2018) Neurologic Complications in the Pediatric Intensive Care Unit.pdf}
}

@article{waldmanLeukodystrophies2018,
  title = {Leukodystrophies},
  author = {Waldman, Amy T.},
  year = {2018},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {1},
  pages = {130--149},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000560},
  url = {https://journals.lww.com/00132979-201802000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               The leukodystrophies, typically considered incurable neurodegenerative disorders, are often diagnosed after irreversible central and peripheral nervous system injury has occurred. Early recognition of these disorders is imperative to enable potential therapeutic interventions. This article provides a summary of the symptoms of and diagnostic evaluation for leukodystrophies, along with the currently available therapies and recent advances in management.                                         RECENT FINDINGS               The leukodystrophies are a rapidly expanding field because of advances in neuroimaging and genetics; however, recognition of the clinical and biochemical features of a leukodystrophy is essential to accurately interpret an abnormal MRI or genetic result. Moreover, the initial symptoms of leukodystrophies may mimic other common pediatric disorders, leading to a delay in the recognition of a degenerative disorder.                                         SUMMARY               This article will aid the clinician in recognizing the clinical features of leukodystrophies and providing accurate diagnosis and management.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/UQPV6BTI/Waldman (2018) Leukodystrophies.pdf}
}

@article{wangSpontaneousIntracranialHypotension2021,
  title = {Spontaneous {{Intracranial Hypotension}}},
  author = {Wang, Shuu-Jiun},
  year = {2021},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {3},
  pages = {746--766},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000979},
  url = {https://journals.lww.com/10.1212/CON.0000000000000979},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Spontaneous intracranial hypotension is a disorder caused by spinal CSF leakage. This article reviews the clinical presentation, diagnosis, and treatment of spontaneous intracranial hypotension.                                         RECENT FINDINGS               The hallmark symptom of spontaneous intracranial hypotension is acute orthostatic headache; however, clinical presentations can be heterogeneous. New evidence shows that lumbar puncture is not always necessary or sufficient to establish the diagnosis. Some patients may have normal opening pressure, which suggests that insufficiency of CSF volume (hypovolemia) rather than CSF pressure might be the underlying mechanism. Several neuroimaging modalities can aid in diagnosis and localization of the CSF leakage, including brain MRI, spinal MRI, CT myelography, digital subtraction myelography, and radionuclide cisternography. Complications, such as subdural hematoma, can lead to a change in the headache pattern and potentially life-threatening consequences. Conservative treatments, such as fluid supplementation, can provide temporary relief; however, epidural blood patches, especially targeted ones, are more effective and definitive. For patients with refractory spontaneous intracranial hypotension, surgical repair of spinal CSF leakages should be considered.                                         SUMMARY               Brain and spinal MRIs are important for the diagnosis and treatment of patients with spontaneous intracranial hypotension. Early treatment with epidural blood patches may be considered to shorten the disease duration and minimize the potential risk of complications.},
  langid = {english},
  keywords = {Current}
}

@article{wardEpidemiologyPathophysiologyMultiple2022,
  title = {Epidemiology and {{Pathophysiology}} of {{Multiple Sclerosis}}},
  author = {Ward, Melanie and Goldman, Myla D.},
  year = {2022},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {4},
  pages = {988--1005},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001136},
  url = {https://journals.lww.com/10.1212/CON.0000000000001136},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides an overview of genetic, environmental, and lifestyle risk factors affecting the disease course of multiple sclerosis (MS) and reviews the pathophysiologic characteristics of both relapsing and progressive MS.                                         RECENT FINDINGS               The prevalence of MS has increased in recent decades, and costs of care for patients with MS have risen dramatically. Black, Asian, and Hispanic individuals may be at risk for more severe MS-related disability. Multiple genetic MS risk factors have been identified. Factors such as low vitamin D levels and a history of Epstein-Barr virus, smoking, and obesity, especially during childhood, also influence MS risk. Traditionally thought to be a T-cell--mediated disease, recent research has highlighted the additional roles of B cells and microglia in both relapsing and progressive MS.                                         SUMMARY               Complex interactions between genetic, environmental, and lifestyle factors affect the risk for MS as well as the disease course. People of color have historically been underrepresented in both MS clinical trials and literature, but current research is attempting to better clarify unique considerations in these groups. MS pathology consists of the focal inflammatory lesions that have been well characterized in relapsing MS, as well as a more widespread neurodegenerative component that is posited to drive progressive disease. Recent advances in characterization of both the inflammatory and neurodegenerative aspects of MS pathophysiology have yielded potential targets for future therapeutic options.},
  langid = {english},
  keywords = {Continuum: Demyelinating Disorders,Current}
}

@article{watersSurgicalApproachesStroke2020,
  title = {Surgical {{Approaches}} to {{Stroke Risk Reduction}}},
  author = {Waters, Michael F.},
  year = {2020},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {2},
  pages = {457--477},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000837},
  url = {https://journals.lww.com/10.1212/CON.0000000000000837},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Surgical vascular intervention is an important tool in reducing the risk of stroke. This article examines the evidence for using the available options.                                         RECENT FINDINGS               Carotid endarterectomy is an effective treatment option for reducing the risk of stroke in appropriately selected patients. Patients should be stratified for future stroke risk based on both the degree of stenosis and the presence of symptoms referable to the culprit lesion. Carotid stenting is also useful in reducing stroke risk, again in carefully selected patients. Because of the publication of significant data regarding both carotid endarterectomy and carotid artery stenting in the last several years, selection can be far more personalized and refined for individual patients based on demographics, sex, patient preference, and medical comorbidities. Routine extracranial-intracranial bypass surgery remains unproven as a therapeutic option for large vessel occlusion in reducing the incidence of ischemic stroke although some carefully screened patient populations remaining at high risk may benefit; procedural risks and pathology related to alterations in blood flow dynamics are challenges to overcome. Indirect revascularization remains an appropriate solution for carefully selected patients with cerebral large vessel steno-occlusive disease, and multiple variations of surgical technique are patient specific. Indirect revascularization may benefit from clinical trials with larger patient populations for validation in specific pathologies and offers the advantages of lower surgical complication rates and reduced risk of pathologic responses to altered cerebral flow dynamics.                                         SUMMARY               Surgical solutions to reduce stroke risk provide important alternatives in appropriately selected patients and should be considered in addition to medical management and lifestyle modification for optimizing patient outcomes.},
  langid = {english}
}

@article{weatheredCardiacPulmonaryDisorders2020,
  title = {Cardiac and {{Pulmonary Disorders}} and the {{Nervous System}}},
  author = {Weathered, Natalie R.},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {556--576},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000859},
  url = {https://journals.lww.com/10.1212/CON.0000000000000859},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the neurologic complications encountered with cardiac and pulmonary disorders, specifically focusing on endocarditis, cardiac arrest, heart failure, hypercapnia, hypoxia, and cystic fibrosis. As neurologic dysfunction is one of the most frequent complications of these diseases and may even be the presenting symptom, it is important to be familiar with these complications to foster early recognition and intervention.                                         RECENT FINDINGS               Advances have been made in the identification of which patients can safely undergo valvular surgery for treatment of infective endocarditis in the setting of stroke, which, ideally, will minimize the risk of recurrent stroke in these patients. Additionally, technologic advances are improving our ability to use a multimodal approach for prognostication after cardiac arrest.                                         SUMMARY               The neurologic complications from the described disorders range from cerebrovascular complications to encephalitis, cognitive impairment, sleep-disordered breathing, headache, and increased intracranial pressure leading to coma or even death. Given the severity of these symptoms, it is paramount that neurologists be closely involved in the care of patients with neurologic complications from cardiac and pulmonary disorders.},
  langid = {english},
  keywords = {Outdated}
}

@article{weihlSporadicInclusionBody2019,
  title = {Sporadic {{Inclusion Body Myositis}} and {{Other Rimmed Vacuolar Myopathies}}},
  author = {Weihl, Conrad C.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1586--1598},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000790},
  url = {https://journals.lww.com/10.1212/CON.0000000000000790},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the clinical, laboratory, and histopathologic features of sporadic inclusion body myositis (IBM) and explores its pathogenic overlap with inherited myopathies that have IBM-like pathology.                                         RECENT FINDINGS               Sporadic IBM is the most common acquired muscle disease in patients older than 50 years of age and is becoming more prevalent because of the increasing age of the population, the emerging development of more inclusive diagnostic criteria, and the advent of a diagnostic autoantibody. No effective therapy is known, and the pathogenic mechanism remains unclear. Some pathogenic insight can be gleaned from other myopathies with pathologic similarities or hereditary inclusion body myopathies. Although clinically distinct from sporadic IBM, preclinical models of hereditary inclusion body myopathy have offered an opportunity to move some therapies toward clinical development.                                         SUMMARY               Patients with sporadic IBM experience significant morbidity, and the disease is associated with a large unmet medical need. As therapies are developed, improved diagnosis will be essential. Early diagnosis relies on awareness, clinical history, physical examination, laboratory features, and appropriate muscle biopsy processing. Future research is needed to understand the natural history, identify genetic risk factors, and validate biomarkers to track disease progression. These steps are essential as we move toward therapeutic interventions.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/PXH4MH44/Weihl (2019) Sporadic Inclusion Body Myositis and Other Rimmed Vacuolar Myopathies.pdf}
}

@article{weintraubDiagnosisTreatmentCognitive2022,
  title = {Diagnosis and {{Treatment}} of {{Cognitive}} and {{Neuropsychiatric Symptoms}} in {{Parkinson Disease}} and {{Dementia With Lewy Bodies}}},
  author = {Weintraub, Daniel and Irwin, David},
  year = {2022},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {5},
  pages = {1314--1332},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001151},
  url = {https://journals.lww.com/10.1212/CON.0000000000001151},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article summarizes the underlying biology and current diagnostic and treatment strategies for the cognitive and neuropsychiatric features of Parkinson disease (PD) and dementia with Lewy bodies (DLB).                                         RECENT FINDINGS               Cognitive impairment and neuropsychiatric symptoms have been increasingly recognized in PD and DLB, leading to improved diagnosis and treatment strategies. While PD is most associated with and diagnosed by the presence of motor symptoms, nonmotor symptoms can often be the most debilitating for patients. Neuropsychiatric symptoms are highly prevalent nonmotor features and include cognitive impairment, depression, anxiety, psychosis, impulse control disorders, and apathy. Neuropsychiatric symptoms can be difficult to recognize and diagnose in patients with PD, in part because of comorbidity and symptom overlap with core PD features. Treatment strategies are a combination of pharmacologic and nonpharmacologic interventions used in the general population and those specific to PD. DLB is a clinical dementia syndrome, often with similar cognitive, behavioral, autonomic, and motor features as PD. Moreover, DLB has shared underlying pathophysiology with PD, as both are associated with postmortem findings of {$\alpha$}-synuclein neuropathology at autopsy and have shared genetic risk and prodromal symptoms. DLB is clinically differentiated from PD by the presenting features of cognitive impairment in DLB, compared with the variable onset of cognitive impairment occurring 1 year or more after established motor onset in PD. Thus, diagnosis and treatment of cognitive impairment and neuropsychiatric symptoms in DLB are similar to that of PD and have important implications for maintaining patient independence and providing support for caregivers because motor, cognitive, and neuropsychiatric symptoms have an additive effect on patient functional disability.                                         SUMMARY               A careful history and physical examination are often needed to accurately diagnose and treat the heterogeneous cognitive and behavioral symptoms of PD and DLB. Accurate diagnosis and treatment of neuropsychiatric symptoms and cognitive impairment in PD and DLB are important, as these are a considerable source of patient disability and caregiver burden.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Current}
}

@article{weintraubNeuropsychologicalAssessmentDementia2022,
  title = {Neuropsychological {{Assessment}} in {{Dementia Diagnosis}}},
  author = {Weintraub, Sandra},
  year = {2022},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {28},
  number = {3},
  pages = {781--799},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001135},
  url = {https://journals.lww.com/10.1212/CON.0000000000001135},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the application of neuropsychological evaluation to the workup of individuals with age-related cognitive impairment and suspected dementia. Referral questions, principles of evaluation, and common instruments to detect abnormalities in cognition and behavior in this population are reviewed. The integration of neuropsychological test findings with other clinical and biomarker information enhances early detection, differential diagnosis, and care planning.                                         RECENT FINDINGS               Life expectancy is increasing in the United States, and, accordingly, the prevalence and incidence of dementia associated with age-related neurodegenerative brain disease are rising. Age is the greatest risk factor for the dementia associated with Alzheimer disease, the most common neurodegenerative cause of dementia in people over 65 years of age; other etiologies, such as the class of frontotemporal lobar degenerations, are increasingly recognized in individuals both younger and older than 65 years of age. The clinical dementia diagnosis, unfortunately, is imperfectly related to disease etiology; however, probabilistic relationships can aid in diagnosis. Further, mounting evidence from postmortem brain autopsies points to multiple etiologies. The case examples in this article illustrate how the neuropsychological evaluation increases diagnostic accuracy and, most important, identifies salient cognitive and behavioral symptoms to target for nonpharmacologic intervention and caregiver education and support. Sharing the diagnosis with affected individuals is also discussed with reference to prognosis and severity of illness.                                         SUMMARY               The clinical neuropsychological examination facilitates early detection of dementia, characterizes the level of severity, defines salient clinical features, aids in differential diagnosis, and points to a pathway for care planning and disease education.},
  langid = {english},
  keywords = {Current},
  file = {/Users/nathanielyomogida/Zotero/storage/D5VMPBT4/Weintraub (2022) Neuropsychological Assessment in Dementia Diagnosis.pdf}
}

@article{whiteGastrointestinalDisordersNervous2020,
  title = {Gastrointestinal {{Disorders}} and the {{Nervous System}}},
  author = {White, Halina},
  year = {2020},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {26},
  number = {3},
  pages = {577--590},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000871},
  url = {https://journals.lww.com/10.1212/CON.0000000000000871},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article describes the neurologic sequelae of various nutritional micronutrient deficiencies, celiac disease, inflammatory bowel disease, and liver disease. Where relevant, appropriate treatments for these conditions are also discussed. The developing field of the microbiome and nervous system interaction is also outlined.                                         RECENT FINDINGS               Pathology in the gastrointestinal system can affect the nervous system when it causes micronutrient deficiency, when immune responses created by the gastrointestinal system affect the nervous system, when toxins caused by gastrointestinal organ failure harm the nervous system, and when treatments aimed at a gastrointestinal medical condition cause damage to the nervous system as a side effect.                                         SUMMARY               This article addresses familiar concepts and new developments in the treatment and understanding of diseases that affect the gut and nervous system simultaneously.},
  langid = {english},
  keywords = {Outdated}
}

@article{wicklundClinicalApproachCognitive2021,
  title = {Clinical {{Approach}} to {{Cognitive}} and {{Neurobehavioral Symptoms}}},
  author = {Wicklund, Meredith},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1518--1548},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001008},
  url = {https://journals.lww.com/10.1212/CON.0000000000001008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a framework for the approach to patients with cognitive or neurobehavioral concerns.                                         RECENT FINDINGS               Recent advances in structural neuroimaging, functional neuroimaging, and disease biomarkers have greatly expanded knowledge of brain-behavior relationships, neural networks and functional connectivity, and pathophysiologic processes leading to cognitive and neurobehavioral disorders. However, any one of these studies is subject to misinterpretation if not applied in the appropriate clinical context.                                         SUMMARY               A systematic approach to the history and examination in patients with cognitive and neurobehavioral symptoms is important in marrying clinical assessments with contemporary diagnostic studies and treatments.},
  langid = {english},
  keywords = {Current}
}

@article{wicklundLimbGirdleMuscularDystrophies2019,
  title = {The {{Limb-Girdle Muscular Dystrophies}}},
  author = {Wicklund, Matthew P.},
  year = {2019},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {6},
  pages = {1599--1618},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000809},
  url = {https://journals.lww.com/10.1212/CON.0000000000000809},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            purpose of review               As a group, the limb-girdle muscular dystrophies (LGMDs) are the fourth most prevalent genetic muscle disease, yet they are still not well known or understood. This article defines and describes LGMDs, delineates a diagnostic strategy, and discusses treatment of the LGMDs.                                         recent findings               In 2018, the definition of the LGMDs was further refined, and a new nomenclature was proposed. Diagnosis of the LGMDs was long guided by the distinctive clinical characteristics of each particular subtype but now integrates use of genetics---with next-generation sequencing panels, exomes, and full genome analysis---early in the diagnostic assessment. Appreciation of the phenotypic diversity of each LGMD subtype continues to expand. This emphasizes the need for precision genetic diagnostics to better understand each subtype and formulate appropriate management for individual patients. Of significant relevance, the explosion of research into therapeutic options accentuates the need for accurate diagnosis, comprehensive disease characterization, and description of the natural histories of the LGMDs to move the field forward and to mitigate disease impact on patients with LGMD.                                         summary               The LGMDs are genetic muscle diseases that superficially appear similar to one another but have important differences in rates of progression and concomitant comorbidities. Definitive diagnoses are crucial to guide management and treatment now and in the future. As targeted treatments emerge, it will be important for clinicians to understand the nomenclature, diagnosis, clinical manifestations, and treatments of the LGMDs.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/4QXVWTRP/Wicklund (2019) The Limb-Girdle Muscular Dystrophies.pdf}
}

@article{williamsNeurologicEmergenciesSports2014,
  title = {Neurologic {{Emergencies}} in {{Sports}}},
  shorttitle = {Neurologic {{Emergencies}} in {{Sports}}},
  author = {Williams, Vernon B.},
  year = {2014},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {20},
  pages = {1629--1644},
  issn = {1080-2371},
  doi = {10.1212/01.CON.0000458970.48271.c9},
  url = {http://journals.lww.com/00132979-201412000-00013},
  urldate = {2023-10-27},
  langid = {english},
  keywords = {Continuum: Sports Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/LJC9DFLB/Williams (2014) Neurologic Emergencies in Sports.pdf}
}

@article{williamsonPosttraumaticStressDisorder2021,
  title = {Posttraumatic {{Stress Disorder}} and {{Anxiety-Related Conditions}}},
  author = {Williamson, John B. and Jaffee, Michael S. and Jorge, Ricardo E.},
  year = {2021},
  month = dec,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {6},
  pages = {1738--1763},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001054},
  url = {https://journals.lww.com/10.1212/CON.0000000000001054},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article provides a synopsis of current assessment and treatment considerations for posttraumatic stress disorder (PTSD) and related anxiety disorder characteristics. Epidemiologic and neurobiological data are reviewed as well as common associated symptoms, including sleep disruption, and treatment approaches to these conditions.                                         RECENT FINDINGS                                PTSD is no longer considered an anxiety-related disorder in the                 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition                 classification and instead is associated with trauma/stressor-related disorders. PTSD symptoms are clustered into four domains including intrusive experiences, avoidance, mood, and arousal symptoms. Despite this reclassification, similarities exist in consideration of diagnosis, treatment, and comorbidities with anxiety disorders. PTSD and anxiety-related disorders are heterogeneous, which is reflected by the neural circuits involved in the genesis of symptoms that may vary across symptom domains. Treatment is likely to benefit from consideration of this heterogeneity.                              Research in animal models of fear and anxiety, as well as in humans, suggests that patients with PTSD and generalized anxiety disorder have difficulty accurately determining safety from danger and struggle to suppress fear in the presence of safety cues.               Empirically supported psychotherapies commonly involved exposure (fear extinction learning) and are recommended for PTSD. Cognitive-behavioral therapy has been shown to be effective in other anxiety-related disorders. Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are commonly used in the treatment of PTSD and anxiety disorders in which pharmacologic intervention is supported. Treating sleep disruption including sleep apnea (continuous positive airway pressure [CPAP]), nightmares, and insomnia (preferably via psychotherapy) may improve symptoms of PTSD, as well as improve mood in anxiety disorders.                                         SUMMARY               PTSD has a lifetime prevalence that is close to 10\% and shares neurobiological features with anxiety disorders. Anxiety disorders are the most common class of mental conditions and are highly comorbid with other disorders; treatment considerations typically include cognitive-behavioral therapy and pharmacologic intervention. Developing technologies show some promise as treatment alternatives in the future.},
  langid = {english},
  keywords = {Current}
}

@article{wingerchukImmuneMediatedMyelopathies2018,
  title = {Immune-{{Mediated Myelopathies}}},
  author = {Wingerchuk, Dean M.},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {497--522},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000582},
  url = {https://journals.lww.com/00132979-201804000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the clinical presentation, diagnostic evaluation, and management of immune-mediated myelopathies.                                         RECENT FINDINGS               The discovery of several neural autoantibodies and their antigenic targets has revolutionized the investigation and treatment of immune-mediated myelopathies. Detection of these serologic biomarkers can support or establish a diagnosis of an autoimmune myelopathy, and, in the case of paraneoplastic syndromes, indicate the likely presence of an underlying malignancy. Distinctive lesion patterns detected on spinal cord or brain MRI narrow the differential diagnosis in patients with acute or subacute inflammatory myelopathies, including those not associated with autoantibody markers.                                         SUMMARY               Immune-mediated myelopathies usually present acutely or subacutely and have a broad differential diagnosis. A systematic diagnostic approach using data from the clinical setting and presentation, MRI lesion patterns, CSF data, and autoantibody markers can differentiate these disorders from noninflammatory myelopathies, often with precise disease classification. This, in turn, provides prognostic information, especially whether the disorder is likely to relapse, and facilitates therapeutic decision making. Diagnostic accuracy informs selection of acute immunotherapy aimed at arresting and reversing recent neurologic injury and, when necessary, selection of long-term treatment for prevention of disease progression or relapse.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/8UTUQKCT/Wingerchuk (2018) Immune-Mediated Myelopathies.pdf;/Users/nathanielyomogida/Zotero/storage/ENNXVKZB/wingerchuk2018.pdf.pdf}
}

@article{wolfAggressionAgitationDementia2018,
  title = {Aggression and {{Agitation}} in {{Dementia}}},
  author = {Wolf, M. Uri and Goldberg, Yael and Freedman, Morris},
  year = {2018},
  month = jun,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {3},
  pages = {783--803},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000605},
  url = {https://journals.lww.com/00132979-201806000-00009},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article reviews the treatment of aggression and agitation in dementia. Both nonpharmacologic and pharmacologic approaches to responsive behaviors are discussed. Practical treatment strategies are applied to common behavioral symptoms.                                         RECENT FINDINGS               Aggressive and agitated behavior is common in dementia. Behavioral symptoms lead to reduced quality of life and distress for both patients and caregivers. They can also lead to poor outcomes and are associated with significant financial implications for the individual and health care system. A wide range of difficult behaviors exists, with limited evidence for deciding on treatment. Clinicians should integrate the available evidence with practical and commonsense strategies to target these difficult-to-treat behaviors.                                         SUMMARY               Treating aggression and agitation in dementia is challenging. Viewing behaviors as a response to either internal or external stimuli can help guide treatment. Treatment should emphasize nonpharmacologic approaches as an initial step, using practical and commonsense strategies. Caregivers and family should be actively involved in the planning and implementation of behavioral plans. It is essential to minimize both medical and nonmedical factors that may be contributing to behaviors. When pharmacologic options are required, it is important to choose medications that will target specific behavioral goals, having both practical consideration and the best evidence in mind.},
  langid = {english},
  keywords = {Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/SV69Y7S3/Wolf et al (2018) Aggression and Agitation in Dementia.pdf}
}

@article{wuNeoplasticMyelopathies2018,
  title = {Neoplastic {{Myelopathies}}},
  author = {Wu, Jing and Ranjan, Surabhi},
  year = {2018},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {2},
  pages = {474--496},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000585},
  url = {https://journals.lww.com/00132979-201804000-00008},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article discusses the diagnosis and management of neoplasms that affect the spinal cord as well as spinal cord disorders that can occur due to cancer treatments.                                         RECENT FINDINGS                                Neoplastic myelopathies are uncommon neurologic disorders but cause significant morbidity when they occur. Primary spinal cord tumors can be classified into intramedullary, intradural extramedullary, or extradural tumors. Diffuse gliomas and ependymal tumors are the most common intramedullary tumors. Diffuse gliomas include the World Health Organization (WHO) grade II and grade III astrocytomas, the grade II and grade III oligodendrogliomas, the grade IV glioblastomas, and newly recognized pediatric diffuse midline gliomas with H3 K27M mutation. The majority of diffuse and anaplastic astrocytomas are                 IDH                 -mutant tumors, whereas only 10\% of glioblastomas are                 IDH                 -mutant. Oligodendrogliomas are typically                 IDH                 -mutant and are characterized by the molecular signature of 1p/19q codeletion. Nine distinct molecular subgroups of ependymomas have been identified based on their genetic features and location.                 NF2                 mutations are frequently found in spinal cord ependymomas. Metastatic tumors are the most common tumors of the spine and can be extradural, leptomeningeal, or, rarely, intramedullary. Extradural metastatic spinal cord compression is a neurologic emergency and should be promptly diagnosed as pretreatment neurologic status dictates the posttreatment outcome.                                                        SUMMARY               Neoplastic myelopathies encompass many diagnoses ranging from benign and malignant spinal tumors to paraneoplastic syndromes heralding cancers. The knowledge of the clinical features and management of neoplastic myelopathies is essential to practicing neurologists as early diagnosis and treatment can prevent devastating neurologic sequelae.},
  langid = {english},
  keywords = {Continuum: Spinal Cord Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/QXHSUED6/Wu_Ranjan (2018) Neoplastic Myelopathies.pdf;/Users/nathanielyomogida/Zotero/storage/ZL88BHCU/wu2018.pdf.pdf}
}

@article{yaghiDiagnosisManagementCardioembolic2023,
  title = {Diagnosis and {{Management}} of {{Cardioembolic Stroke}}},
  author = {Yaghi, Shadi},
  year = {2023},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {29},
  number = {2},
  pages = {462--485},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000001217},
  url = {https://journals.lww.com/10.1212/CON.0000000000001217},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            OBJECTIVE               Cardioembolic stroke accounts for nearly 30\% of ischemic strokes. Prompt diagnosis of the underlying mechanism may improve secondary prevention strategies. This article reviews recent randomized trials, observational studies, case reports, and guidelines on the diagnosis and treatment of cardioembolic stroke.                                         LATEST DEVELOPMENTS               Several pathologies can lead to cardioembolic stroke, including atrial fibrillation, aortic arch atheroma, patent foramen ovale, left ventricular dysfunction, and many others. Secondary stroke prevention strategies differ across these heterogeneous mechanisms. In addition to medical treatment advances such as the use of direct oral anticoagulants in patients with atrial fibrillation, surgical treatments such as closure of patent foramen ovale have been shown to reduce the risk of recurrent stroke in select patients. Furthermore, left atrial appendage occlusion is a promising strategy for patients with atrial fibrillation who are candidates for short-term oral anticoagulation therapy but not long-term oral anticoagulation therapy.                                         ESSENTIAL POINTS               A thorough diagnostic evaluation is essential to determine cardioembolic causes of stroke. In addition to risk factor management and lifestyle modifications, identification and targeting of the underlying cardioembolic stroke mechanisms will lead to improved stroke prevention strategies in patients with cardioembolic stroke.},
  langid = {english},
  keywords = {Current}
}

@article{zalewskiVascularMyelopathies2021,
  title = {Vascular {{Myelopathies}}},
  author = {Zalewski, Nicholas L.},
  year = {2021},
  month = feb,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {27},
  number = {1},
  pages = {30--61},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000905},
  url = {https://journals.lww.com/10.1212/CON.0000000000000905},
  urldate = {2023-11-07},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Neurologists should be able to identify clinical and neuroimaging features that distinguish vascular disorders from other causes of myelopathy.                                         RECENT FINDINGS               Although certain clinical features suggest a vascular etiology in acute and chronic myelopathy settings, accurate MRI interpretation within the clinical context is key. Recent studies have shown vascular myelopathies are frequently misdiagnosed as transverse myelitis, and recognition of this diagnostic pitfall is important. Many different vascular mechanisms can cause myelopathy; this article provides a comprehensive review that simplifies disease categories into arterial ischemia, venous congestion/ischemia, hematomyelia, and extraparenchymal hemorrhage.                                         SUMMARY               It is important to recognize and manage vascular disorders of the spinal cord as significant causes of acute, subacute, and progressive myelopathy.},
  langid = {english}
}

@article{zesiewiczParkinsonDisease2019,
  title = {Parkinson {{Disease}}},
  author = {Zesiewicz, Theresa A.},
  year = {2019},
  month = aug,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {25},
  number = {4},
  pages = {896--918},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000764},
  url = {https://journals.lww.com/00132979-201908000-00004},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               Parkinson disease is a common neurodegenerative disorder that affects millions of people worldwide. Important advances in the treatment, etiology, and the pathogenesis of Parkinson disease have been made in the past 50 years. This article provides a review of the current understanding of Parkinson disease, including the epidemiology, phenomenology, and treatment options of the disease.                                         RECENT FINDINGS               Parkinson disease is now recognized to be a heterogeneous condition marked by both motor and nonmotor symptoms. It is composed of preclinical, prodromal, and clinical phases. New medications with improved ease of administration have been approved for its treatment. Innovative surgical therapies for Parkinson disease may be used when motor symptoms persist despite optimal medical management.                                         SUMMARY               Parkinson disease is a complex, heterogeneous neurodegenerative disorder. Considerable progress has been made in its treatment modalities, both pharmacologic and surgical. While its cure remains elusive, exciting new research advances are on the horizon.},
  langid = {english},
  keywords = {Continuum: Movement Disorders,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/9LP7C6NJ/10.1212@CON.0000000000000764.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/USBEIDJT/Zesiewicz (2019) Parkinson Disease.pdf}
}

@article{zillioxNeuropathicPain2017,
  title = {Neuropathic {{Pain}}},
  author = {Zilliox, Lindsay A.},
  year = {2017},
  month = apr,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {23},
  number = {2},
  pages = {512--532},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000462},
  url = {https://journals.lww.com/00132979-201704000-00013},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            Purpose of Review:               Neuropathic pain is a frequently encountered condition that is often resistant to treatment and is associated with poor patient satisfaction of their treatment. Several medications have been shown to be effective in treating neuropathic pain associated with diabetic neuropathy and postherpetic neuralgia, and these medications are often used to treat neuropathic pain associated with other conditions as well. This article summarizes the diagnosis and assessment of patients with neuropathic pain as well as available pharmacologic and interventional treatment options.                                         Recent Findings:               Evidence-based recommendations for the treatment of neuropathic pain have been published, and first-line medications include antidepressants, anticonvulsants, topical agents, as well as opioid analgesics. Interventional options include anesthetic and steroid injections, nerve blocks, and spinal cord stimulation. Essential to the treatment algorithm of neuropathic pain is the assessment and treatment of psychosocial comorbidities and the utilization of a multidisciplinary team approach, including cognitive-behavioral and rehabilitative therapies. Questions remain about the comparative effectiveness of various medications and combination therapies. Increasing interest also exists in the optimization and personalization of pharmacotherapy based upon the underlying mechanism(s) of neuropathic pain according to the quality of the patient's symptoms.                                         Summary:               The management of chronic neuropathic pain is challenging and is best achieved with the use of a multidisciplinary team. Pain is a subjective experience, and it is important to validate a patient's pain, address psychosocial comorbidities, and set realistic treatment goals. Evidence-based guidelines are available to guide treatment, but frequently, high-quality evidence-based recommendations are lacking.},
  langid = {english},
  keywords = {Continuum: Outpatient Neurology,Outdated},
  file = {/Users/nathanielyomogida/Zotero/storage/EQ3MBGIW/zilliox2017.pdf.pdf;/Users/nathanielyomogida/Zotero/storage/GYNJ45RD/Zilliox (2017) Neuropathic Pain.pdf}
}

@article{zuntTuberculosisCentralNervous2018,
  title = {Tuberculosis of the {{Central Nervous System}}},
  author = {Zunt, Joseph R.},
  year = {2018},
  month = oct,
  journal = {CONTINUUM: Lifelong Learning in Neurology},
  volume = {24},
  number = {5},
  pages = {1422--1438},
  issn = {1538-6899, 1080-2371},
  doi = {10.1212/CON.0000000000000648},
  url = {https://journals.lww.com/00132979-201810000-00011},
  urldate = {2023-10-27},
  abstract = {ABSTRACT                            PURPOSE OF REVIEW               This article details the epidemiology and clinical manifestations of central nervous system (CNS) tuberculosis (TB), provides guidance for diagnostic imaging and CSF testing, and recommends treatment strategies for tuberculous meningitis and other forms of CNS TB, illustrating key aspects of diagnosis and management with case presentations.                                         RECENT FINDINGS                                Although improvements in our understanding of the pathogenesis and management of CNS TB have occurred over the past 50 years, the emergence of multidrug-resistant and extensively drug-resistant TB, the advent of acquired immunodeficiency syndrome (AIDS), and the subsequent availability of highly active antiretroviral therapy that can produce the immune reconstitution inflammatory syndrome have complicated the diagnosis and treatment of CNS TB. Advances in diagnostic assays promise to increase the speed of diagnosis as well as the percentage of people with a confirmed rather than a presumptive diagnosis. Advances in precision medicine have identified polymorphisms in the                 LTA4H                 gene that influence the risk for inflammation in patients with tuberculous meningitis.                                                        SUMMARY               CNS TB continues to be a major cause of morbidity and mortality, with the majority of people affected living in low-income and middle-income countries. Newer diagnostic assays promise to increase the speed of diagnosis and improve appropriate selection of antituberculous therapy and anti-inflammatory medications. Despite these advances, CNS TB remains difficult to diagnose, and clinicians should have a low threshold for initiating empiric therapy in patients with presumptive infection.},
  langid = {english},
  file = {/Users/nathanielyomogida/Zotero/storage/TJJ9UZ43/Zunt (2018) Tuberculosis of the Central Nervous System.pdf}
}
